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UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES 
DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE 
Doctor of Philosophy 
Effects of Fatty Acids on Inflammatory Markers Studied in vitro and in vivo 
By Hayati Mohd Yusof 
 
Inflammation involves interactions amongst many different cell types as a defense mechanism of the body. 
Inflammation is also involved in cardiovascular disease (CVD). The role of long chain n-3 polyunsaturated 
fatty acids (LC n-3 PUFAs) in modulating the inflammatory response has been proposed. The aim of these 
studies is to investigate the effects of modest intakes of n-3 PUFAs on CVD risk factors especially 
inflammatory markers, including soluble adhesion molecules, in adult humans with and without CVD and 
to identify the effects of selected fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), on inflammatory responses, especially adhesion molecule expression in cultured human 
endothelial cells of different origin (fetal vs. adults; vein vs. artery).  
In the first in vivo study, healthy middle-aged men aged 35-60 years were randomized to 1.8 g/d 
EPA plus 0.23 g/d DHA (n = 9) or placebo oil (2.6 g/day medium-chain saturated fatty acids; n = 11) for 8 
weeks. In a second in vivo study, patients awaiting carotid endarterectomy were randomised to 0.8 g/d EPA 
plus 0.67 g/d DHA (Omacor; n = 47) or olive oil (n = 53) as placebo for between 7 and 102 days until 
surgery. Supplementation with fish oil in healthy men resulted in a 363% increase in EPA and only a 13% 
increase in DHA in plasma phosphatidylcholine (PC). On the other hand, Omacor supplementation resulted 
in significantly increased EPA and DHA in plasma PC by 161% and 70%, respectively. In healthy subjects, 
there was very little effect of n-3 fatty acids on the risk factors measured (lipid profiles and inflammatory 
markers), apart from a reduction in plasma soluble intercellular molecule-1 (sICAM-1) concentration 
compared with placebo (P = 0.05). The change in plasma sICAM-1 concentration was significantly 
inversely associated with the change in DHA in plasma PC (r = -0.675; P = 0.001). Supplementation with 
Omacor, however, significantly decreased total plasma cholesterol, triacylglycerol (TAG) and LDL-
cholesterol concentrations (P < 0.001) by 13%, 14%, and 5% respectively. In terms of inflammatory 
markers, supplementation with Omacor significantly decreased sE-selectin by 23% (P = 0.006) and 
sVCAM-1 by 25% (P < 0.0001), and had no significant effects on other plasma inflammatory markers 
including sICAM-1 even though trends toward decreases in these markers were observed. This study 
suggests some anti-inflammatory actions of moderate dose of Omacor in carotid endarterectomy patients. 
Based on correlation analysis between mRNA expression of inflammatory markers in plaque and plasma 
concentrations, it seems that soluble inflammatory markers cannot be used to reflect the expression of these 
molecules at the cell surface, i.e. in the vasculature or in the plaque.  
In the in vitro experiments the inflammatory stimulus lipopolysaccharide (LPS) up-regulated all 
three adhesion molecules studied at the protein (as assessed by ELISA) and the mRNA (as assessed by 
reverse transcription and real-time PCR) levels. VCAM-1 was affected by fatty acids to a greater extent 
than ICAM-1 or E-selectin. Amongst the fatty acids, DHA has the greatest and the most consistent effects 
on adhesion molecule protein expression. EPA was also a potent fatty acid inhibitor of adhesion molecule 
expression at the mRNA level. Some effects of stearic, oleic and arachidonic acids on adhesion molecules 
were also seen. The effects of fatty acids on the adhesion molecule expression were fatty acid, adhesion 
molecule and endothelial cell specific. The inhibitory effects of fatty acids were more pronounced in vein 
endothelial cells than arterial endothelial cells. The precise underlying mechanism on how fatty acids affect 
adhesion molecule expression remains to be clarified.  
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Chapter 1 
 
Introduction 
 
1.1 Cardiovascular Disease 
 
   Cardiovascular disease (CVD) refers to disease of the arterial wall that restricts blood flow 
to the heart (coronary heart disease; CHD), or to the brain (cerebrovascular disease), or to 
other regions of the body, such as the legs (peripheral vascular disease; PVD) or the kidneys. 
From the clinical perspective, CVD has become a major contributor to the causes of death all 
over the world, accounting for over half and one-third of all deaths in most developed 
countries in middle and old age groups, respectively. 
 
 
1.1.1  Pathophysiology 
 
      There are two principal components of CVD, namely atherosclerosis and thrombosis. 
Atherosclerosis refers to the building up and subsequent hardening of fatty streaks in the 
arterial wall. This process further develops into the occlusion of blood vessels (thrombosis) 
and therefore prevents the blood flow to the heart or corresponding organs. 
 
As a chronic inflammatory disease that affects large-and medium-sized arteries, 
atherosclerosis is characterized by the formation of fibrotic, lipid-containing plaques (Ross 
1999). In the early stage of atherosclerosis, the process involves the interaction between 
blood lipids, endothelial cells and inflammatory cells (Figure 1.1). Low density lipoprotein 
(LDL) has an essential physiological role as a vehicle for the delivery of cholesterol to 
peripheral tissue. Since it is a relatively small molecule, LDL easily enters into the tissue Chapter 1 Introduction                                                                                                                  19 
 
 
space of the vascular endothelium. When LDL particles become trapped in the arterial wall, 
they can undergo a progressive oxidation to produce oxidized LDL in
the presence of proatherogenic enzymes of 15-lipoxygenase (15-LO) and inducible nitric 
oxide (iNOS). It has been suggested that the LDL particles must be chemically modified in 
some way before they are taken up the macrophages receptors. Uptake of this oxidized LDL 
converts macrophages, which are initially derived from monocytes by differentiation, into 
foam cells. Several proteins may contribute to the overall process of oxidized LDL uptake; 
however, it has been demonstrated that scavenger receptors A (SR-A) and CD36 play 
quantitatively significant roles (Febbraio et al. 2000). The removal of modified LDL and its 
sequestration in macrophages are an important part of the initial, protective role of the 
macrophage in the inflammatory response to minimize the effects of modified LDL on 
endothelial smooth muscle cells (SMCs). However, the process of recruitment of 
macrophages and their subsequent uptake of oxidized LDL in response to inflammatory 
stimuli are the major cellular events which lead to fatty streak (plaque) formation. Foam 
cells secrete various types of growth factors and cytokines, resulting in promotion of SMC 
migration from the medial portion of the arterial wall towards the intima.  
 
 
FIGURE 1.1: Initiating Events in the Development of Fatty Streak Lesion 
LDL is a relatively small, dense molecule which easily enters into the intima and 
subsequently becomes oxidized (ox LDL). Adherent monocytes migrate into the intima and 
differentiate into macrophages. Macrophages take up oxidized LDL and are transformed 
into foam cells. (Source: Glass & Witztum 1995) Chapter 1 Introduction                                                                                                                  20 
The process of migration of SMCs is then followed by their proliferation and release of 
extracellular matrix proteins that create a fibrous cap over the growing of fatty lesion 
(Figure 1.2).  
 
 
FIGURE 1.2: The Progression of the Plaque Lesion 
Interactions between macrophage-derived foam cells and T cells establish a chronic 
inflammatory process whereby lesional T cells appear to be activated, expressing both Th1 
and Th2 cytokines. Smooth muscle cells migrate from the medial portion of the arterial 
wall, proliferate and secrete extracellular matrix proteins that form a fibrous plaque. 
(Source: Glass & Witztum 1995) 
 
 
Over time, the plaque continues to attract cholesterol, white blood cells and other fatty 
substances, resulting in plaque growth and formation of a relatively thick cap, due to either 
fibrosis (plaque scarring) or calcification. This particular type of plaque is considered to be 
stable, with a thick calcified cap and a smaller fatty core. Stable plaques are known as the 
primary cause of hardened (loss of elasticity) and narrowed arteries (atherosclerosis). On 
the other hand, another type of plaque is referred to as unstable; unstable plaques have a 
thin calcified cap covering a relatively larger fatty core. Unstable (thin) plaques are more 
likely to rupture, releasing fatty particles (from plasma LDL that enters the injured vascular 
wall) and other non-soluble substances into the bloodstream. The site of plaque rupture may 
be rapidly covered as blood platelets congregate at the site of the injury (non-occlusive 
thrombosis) or subsequently can further initiate the process of blood clotting (occlusive 
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thrombosis), forming a larger blockage (thrombosis) at that site. Thrombosis is associated 
with angina or myocardial infarction (MI) and sudden death. These pathophysiological 
observations lead to the ‘response to injury’ hypothesis of atherosclerosis which emphasizes 
endothelial dysfunction 
 
The American Heart Association (AHA) has suggested a classification of plaques based 
upon their morphologic appearance (Stary et al. 1995). Type I, II and III are known as 
initial lesion, fatty streak and intermediate lesions or preatheroma, respectively. Indeed, 
type I and II lesions are sometimes combined under early lesions, which generally occur 
only in infants and children, although they also may occur in adults. On the other hand, type 
III lesions may further progress after puberty which forms the bridge between early and 
advanced lesions. In type IV lesions, characterised by lipid accumulation into a lipid core 
(atheroma), are the first lesion type referred to as advanced in this classification due to the 
severe intimal disorganization caused by lipid core. Type IV lesions commonly occur from 
the third decade of life. In type V lesions whereby fibrous connective tissue has formed, are 
known as fibroatheroma or fibrotic lesions. Type VI lesions are generally characterized by 
surface disruption, haemorrhage and thrombosis or combination of these, and are also 
known as complicated lesions. Type V and VI lesions most often occur in middle-aged and 
older people. 
  
 
1.1.2  Endothelial Dysfunction 
 
   The endothelium is the thin layer of cells lining the interior surface of blood vessels 
including arteries, veins and also the inner lining of the heart and lymphatics. The 
endothelium plays a crucial role in the regulation of vascular tone, and inhibition of 
leukocyte adhesion and platelet aggregation via the action of chemical mediators such as 
nitric oxide (NO) and prostacyclin (Vane et al. 1990; Moncada & Higgs 1993). Endothelial 
dysfunction refers to the disturbance of the normal biochemical processes which are carried 
out by the endothelium. Endothelial dysfunction is believed to be a key event in signaling 
the occurrence of atherosclerosis, and is characterized by abnormalities in vasomotor 
control (constriction versus dilation). It associates with impaired fibrinolysis and enhanced 
thrombosis, and subsequently induces the inflammatory response of leukocyte and platelet 
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adhesion, along with growth of SMCs (Paterick & Fletcher 2001). Due to its role, the 
endothelium also forms a selective barrier between the blood and the underlying tissue, 
allowing oxygen and nutrients, but not dangerous substances, to cross. Therefore, any 
damage can lead to serious consequences to the vascular system, including the formation of 
fatty streaks and potentially myocardial infarction, stroke and heart disease.  
 
There are several possible causes of endothelial dysfunction, such as an elevation in 
circulating oxidized LDL, free radicals caused by cigarette smoking, hypertension and 
diabetes, genetic alterations, high concentration of plasma homocysteine, infectious 
organisms such as herpes viruses and Chlamydia pneumonia, and a combination of these or 
other factors. The endothelial dysfunction that results from different forms of injury 
increases the adhesiveness and also the permeability of the endothelium with respect to 
leukocytes or platelets, and therefore leads to compensatory responses that alter the normal 
homeostatic properties of the endothelium. Thus, the injury promotes the endothelium to 
exhibit procoagulant activity instead of anticoagulant properties and subsequently to form 
vasoactive molecules, cytokines, and growth factors. However, in the case of an 
inflammatory response which ineffectively neutralizes or removes the offending/foreign 
agents, this process continues indefinitely and induces migration and proliferation of SMCs 
to form an intermediate lesion.  
 
Continuous responses can thicken the arterial wall, which compensates by gradual dilation, 
and results in the lumen remaining unaltered (Glagov et al. 1987), a phenomenon called 
‘remodelling’.  The response is, however, mediated by monocyte-derived macrophages and 
specific subtypes of T lymphocytes at every stage of the disease (Jonasson et al. 1986; van 
der Wal et al. 1989). Increased number of macrophages and lymphocytes emigrate from the 
blood, and subsequently proliferate within the lesion. Activation of these cells stimulates 
the release of cytokines, chemokines, hydrolytic enzymes, and growth factors (Libby & 
Ross 1996; Raines et al. 1996), which eventually can induce further damage, and therefore, 
lead to focal necrosis (Falk et al. 1996). Cycles of accumulation of mononuclear cells, 
migration and proliferation of SMCs, and formation of fibrous tissues lead to further 
enlargement and restructuring of the lesion, so that it becomes covered by a fibrous cap that 
overlies a core lipid and necrotic tissues, known as an advanced, complicated lesion. At 
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some point, the artery loses its elasticity which subsequently results in a disturbance in the 
blood flow.  
 
Not all observations of SMCs of atherosclerotic plaque can be described by the ‘response to 
injury’ hypothesis because the proliferation of SMCs is also known as the monoclonal 
process. Following this finding, Benditt & Benditt (1973) refer to this theory as the 
‘monoclonal hypothesis’. The theory is supported by several studies (Parkes et al. 1991; 
Penn et al. 1986) which show the transforming mutational capacity of the c-myc gene and 
other proto-oncogens in the development of atherosclerotic lesions (Marin et al. 1993; 
Parkes et al. 1991). Indeed, there is strong experimental evidence for mutation theory of 
atherosclerosis, one of which underlines the similarity of atherosclerotic and carcinogenic 
processes (Ross et al. 2001), and subsequently supports the role of genetic alterations in the 
disease (Andreassi & Botto 2003). Moreover, it has been demonstrated that microsatalellite 
instability (Spandidos et al. 1996; Hatzistamou et al. 1996) and loss of heterozygosity in 
SMCs of human plaque suggesting that genomic destabilization also plays an important role 
in atherosclerotic mechanisms (Grati et al. 2001; Flouris et al. 2000; McCaffrey et al. 1997; 
Hatzistamou et al. 1996). Thus, in conjunction with this theory, DNA damage may provide 
new insight as an emerging risk factor in the development of atherosclerosis. Figure 1.3 
illustrates the schematic combination of atherosclerosis hypotheses, comprising of 
‘response to injury’ and the ‘monoclonal hypothesis’.  
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FIGURE 1.3: Scheme of a Unifying Hypothesis of Atherosclerosis 
The figure shows that one of the earliest events in atherosclerosis is altered endothelial 
function (dysfunction) causing increased permeability to lipids. In addition, the endothelial 
dysfunction and the plaque environment also may induce DNA modification of smooth 
muscle cells by action of exogenous and endogenous mutagens. (Source: Andreassi & Botto 
2003) 
 
 
1.1.3 Cardiovascular Risk Factors  
 
  A risk factor is a measurable characteristic that is predictively related to the subsequent 
occurrence of a disease. This definition includes modifiable lifestyle, biochemical and 
physiological characteristics, as well as unmodifiable personal characteristics such as age, 
sex and family history. The American College of Cardiology has categorized risk factors 
into four categories (Table 1.1) that match the intensity of risk factor management based on 
evidence for association with CVD, clinical usefulness, and response to therapy (Pasternak 
et al. 1996).  Category I risk factors are those in which interventions have been proven to 
lower CVD risk. Category II risk factors are those that interventions are likely to lower 
CVD risk, whereas Category III risk factors are those in which additional evidence is 
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required to determine whether interventions can lower risk. However, Category IV risk 
factors are those that cannot be modified. Alternatively, the British Nutrition Foundation 
(2005) suggested two categories of risk factors for CVD, namely classical (conventional) 
and emerging risk factors.  
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TABLE 1.1: Cardiovascular Risk Factors: Evidence to Support Interventions 
Evidence for association with CVD  Clinical 
measurement 
Response to:  Risk factor 
Epidemiologic Clinical  trials  Usefulness  Nonpharmacologic 
therapy 
Pharmacologic 
therapy 
Category I (Risk factors for which interventions have been proven to lower CVD risk) 
Cigarette smoking 
LDL-c 
High-fat/cholesterol diet 
Hypertension 
 
Left ventricular hypertrophy 
Thrombogenesis factor 
+ + + 
+ + + 
+ + + 
+ + + 
 
+ + + 
+ + + 
(fibrinogen) 
+ + 
+ + + 
+ + 
+ + + 
(stroke) 
+ 
+ + + 
(aspirin, warfarin) 
+ + + 
+ + + 
+ + 
+ + + 
 
+ + 
+ 
(fibrinogen) 
+ + + 
+ + 
+ + 
+ 
 
- 
+ 
+ + 
+ + + 
- 
+ + + 
 
+ + 
+ + + 
(aspirin, warfarin) 
Category II (Risk factors for which interventions are likely to lower CVD risk) 
Diabetes mellitus 
Physical inactivity 
HDL-c 
Triglycerides; small, dense LDL 
Obesity 
Postmenopausal status (women) 
+ + + 
+ + + 
+ + + 
+ + 
+ + + 
+ + + 
+ 
+ + 
+ 
+ + 
- 
- 
+ + + 
+ + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + 
+ + 
+ + 
+ + 
+ + 
- 
+ + + 
- 
+ 
+ + + 
+ 
+ + + 
Category III (Risk factors associated with increased CVD risk that, if modified, might lower risk) 
Psychosocial factors 
Lipoprotein (a) 
Homocysteine 
Oxidative stress 
No alcohol consumption 
+ + 
+ 
+ + 
+ 
+ + + 
+ 
- 
- 
- 
- 
+ + + 
+ 
+ 
- 
+ + 
+ 
- 
+ + 
+ 
+ + 
- 
+ 
+ + 
+ + 
- 
Category IV (Risk factors associated with increased CVD risk that cannot be modified) 
Age 
Male gender 
Family history of early-onset 
CVD 
+ + + 
+ + + 
+ + + 
- 
- 
- 
+ + + 
+ + + 
+ + + 
- 
- 
- 
- 
- 
- 
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1.1.3.1 Classical Risk Factors 
 
   Classical or conventional risk factors (Table 1.2) include unmodifiable characteristics, 
such as age, gender, genetic predisposition, and regional, social and ethnic differences. 
These unmodifiable risk factors are paralleled with modifiable risk factors, such as cigarette 
smoking, raised blood cholesterol, high blood pressure, obesity and physical inactivity. 
Modifiable risk factors not only predict the occurrence of the disease in healthy adults, but 
also contribute to the disease process in those who already have atherosclerosis. 
 Chapter 1 Introduction                                                                                                                  28 
TABLE 1.2: Conventional Risk Factors for Cardiovascular Disease 
Risk factor 
 
Direction of association  Modifiable by dietary factors?  Relevance to cardiovascular disease 
Age 
 
Gender 
 
 
 
Socioeconomic status 
 
 
 
Ethnic group 
 
 
 
 
Smoking 
 
Serum total cholesterol concentration 
 
 
Serum LDL-cholesterol concentration 
 
 
Serum HDL-cholesterol concentration 
 
 
Serum triglyceride concentration 
 
 
 
Blood pressure 
 
 
 
Diabetes 
 
 
Physical inactivity 
 
Obesity 
 
↑ with age 
 
Males at ↑ risk 
 
 
 
Lower socioeconomic status ↑ the risk 
 
 
 
People from the Indian subcontinent are at 
particularly ↑ risk of CHD. 
People of African-Caribbean descent in the 
UK are at greater risk of stroke 
 
Smoking ↑ risk 
 
↑ blood cholesterol level ↑ risk 
 
 
↑ LDL-c level ↑ risk 
 
 
Lower HDL-c ↑ risk, particularly amongst 
women  
 
↑ TG level ↑ risk 
 
 
 
↑ BP increases risk 
 
 
 
Diabetes ↑ risk 
 
 
Being inactive ↑ risk 
 
Overweight and obesity ↑ risk partly via 
other CVD risk factors (e.g. blood 
pressure, diabetes, blood cholesterol) 
No 
 
No 
 
 
 
Some dietary changes may 
help to reduce the higher risk 
in lower socioeconomic groups 
 
No 
 
 
 
 
Yes (fruits & vegetables rich in 
antioxidant are helpful) 
Yes (limit fat, cholesterol  & 
alcohol intake) 
 
Yes (limit fat, cholesterol & 
alcohol intake) 
 
Yes 
 
 
Yes (limit fat, carbohydrate & 
alcohol intake) 
 
 
Yes (potassium rich food is 
helpful, limit fatty food and 
sodium intake)  
 
Partly 
 
 
No 
 
 
Yes 
↑ prevalence as population ages 
 
Risk in men and women is equalized after the menopause, possibly due 
to protection by estrogens in the younger women or to increases in male 
pattern (central obesity) amongst post-menopausal women 
 
Highly related to other factors (e.g. diet, smoking, physical inactivity) 
 
 
 
May reflect abdominal obesity and insulin resistance 
 
Possibly reflects genetic predisposition to hypertension. Rates are 
falling as the result of better detection and treatment of hypertension 
 
Increases oxidative stress and impairs endothelial function 
 
Uptake of cholesterol by macrophages is the origin of the core of the 
atherosclerotic plaque 
 
LDL particles carry cholesterol that may be deposited in arterial walls 
 
 
HDL may transport excess cholesterol to the liver for excretion 
 
 
Strongly inversely related to HDL-c although serum TG is also an 
independent risk factor, perhaps reflecting more subtle alterations in 
lipid metabolism 
 
Hypertension ↑ the risk of haemorrhagic/ ischaemic stroke, induces 
endothelial dysfunction, exacerbates the atherosclerosis process and 
contributes to the instability of the atherosclerotic plaque 
 
Causes a unique pattern of microvascular complications and the ↑ 
frequency of macrovascular disease. 
 
Physical fitness has been demonstrated to be a powerful predictor of 
low rates of subsequent vascular disease. 
 
Some of the co-morbidities of obesity are strong risk factors for CVD. 
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1.1.3.1.1 Age and Gender 
 
   Evidence shows that with increasing age, higher mortality rates from CVD are observed 
in both genders. Indeed, the risk of CVD increases markedly with ageing, which may be 
facilitated by adiposity and increased inflammatory reactions. Fat accumulation or 
deposition peaks in middle-age and substantially declines in advanced old age.  Whilst the 
total body fat is reduced, the percentage of body fat remains unchanged or even increases in 
old age because of fat redistribution (British Nutrition Foundation 2005). Importantly, more 
fat is lost from subcutaneous than visceral fat storage after middle-age due to a decrease in 
physical activity level, which therefore, increases the risk of atherosclerosis and type 2 
diabetes.  
 
On the other hand, gender is one of the risk factors that is prominent for the assessment of 
risk. It has been reported that the incidence of death from premature CHD in men aged 35 
to 44 years is three times higher compared with women of the same age. For women, 
however, the increased risk usually occurs after the menopause. Endogenous estrogen has 
been speculated to confer an important protective role against CVD in pre-menopausal 
women, probably by preventing vascular injury (Krummel 2004). In contrast, Davison and 
Davis (2003) reported that oral estrogen had a negative role in primary and secondary 
prevention trials of cardiovascular events. Van Beresteijn et al. (1993) revealed that average 
serum cholesterol levels increased by 19% in peri-menopausal women. For instance, during 
the menopausal period, total cholesterol, LDL cholesterol and triglyceride levels increase, 
whereas level of HDL cholesterol decreases, especially in women who gain weight 
(Krummel 1996). However, rates of CHD amongst women increase between the ages of 
fifty and sixty, indicating that the hormonal protective effect is lost after this period. 
Undoubtedly, this may be correlated with changes in body fat distribution as longitudinal 
data supports an increase in central adiposity after menopause (Barrett-Connor 1997). 
 
 
1.1.3.1.2 Genetic Predisposition 
 
   Genetic factors refer to the fact that one individual will be more prone or susceptible to a 
disease than another, whatever environment they share. A family history of premature CVD 
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is a strong risk factor, even when other risk factors are considered. This genetic 
predisposition is suggested to be correlated when myocardial infarction (MI) or sudden 
death occurs before the age of 55 years in a male first-degree (close) relative or the age of 
65 years in a female first-degree relative (parents, siblings, offspring). Studies in mice show 
that susceptibility to atherosclerosis depends on strain background (Dansky et al. 1999) and 
most of this variation is unlikely to be due to changes in known risk factors, such as 
lipoprotein concentrations, suggesting the involvement of genetic differences. 
 
Current study of newly emerging risk factors may associate with understanding changes in 
the environment and the genes that determine which individuals are likely to be most 
affected, which is known as a gene-environment interaction. Studies have shown that 
regulation of metabolic consequences and risk of CVD in relation to food intake is 
genetically regulated. Interaction between genes and diet can occur when some dietary 
component switches on genes; for example certain fatty acids or their derivatives stimulate 
genes that are involved in adipocyte differentiation and behaviour (British Nutrition 
Foundation 2005). New technology that is capable of profiling the expression of thousands 
of genes in one experiment leads to in-depth understanding of developmental, homeostatic 
and pathological changes of gene expression (Lockhart & Winzeler 2000; Young 2000). 
Thus, this approach leads to identification of new candidate genes that can be tested for 
their roles in atherosclerotic development and further generates discovery of new 
antiatherogenic drugs, for instance, a specific therapy using gene expression profiles. 
  
 
1.1.3.1.3 Socioeconomic and Ethnic Group 
 
   In terms of socioeconomic status, CVD within the UK and other developed countries is 
consistently more common among less affluent groups. Studies show that amongst male 
manual workers, the premature CHD mortality rate is 58% higher than that of trained 
professionals (Frayn 2005).  Moreover, evidence demonstrates that the socioeconomic 
gradient in CVD mortality appears to be widening. For example, the difference in CHD risk 
between men in social classes V and I for sudden death due to heart attack was two-fold in 
the 1970s; however, this had risen to three-fold by the 1990s (Department of Health 2000). 
One component of this may be the smoking pattern which is higher in lower socioeconomic 
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groups for both genders compared with the more privileged ones. However, there are other 
factors that may influence the impact of socioeconomic status, such as diet, obesity, blood 
pressure and geographical differences. In addition, other suggested explanations for the 
social class differences include early life factors, physiological elements and access to 
health care services (Marmot et al. 1991). Therefore, no single factor accounts for the 
socioeconomic status since there are inter-relationships between one risk factor and another.  
 
Ethnic group additionally plays an important role in determining disease incidence and 
prevalence. For example, studies reveal that South Asian men, such as Indians, 
Bangladeshis, Pakistanis and Sri Lankans living in the UK, have higher premature death 
rates from CHD and stroke compared with the national average (Department of Health 
2001). Moreover, the difference in the death rates between South Asian men and the rest of 
population is rising due to the fact that this death rate in South Asians is not falling as fast 
as in the rest of the population. These studies have suggested that the high rates of CHD, 
simultaneously with a high rate of type 2 diabetes, are primarily explained by the existence 
of an insulin resistance syndrome. Insulin resistance syndrome is prevalent in South Asian 
populations and is also related to a pronounced susceptibility to central obesity in this group 
(Wild & McKeigue 1997). Conversely, premature death rates from CHD in Caribbeans and 
West Africans living is the UK are much lower than those of the average population, which 
are approximately half and two-thirds of the rate in the general population, for men and 
women, respectively. Notwithstanding, those of African-Caribbean ancestry have an 
increased risk of stroke, hypertension and diabetes. The underlying reasons for this 
phenomenon are not fully understood; however, genetic predisposition or other novel stroke 
risk factors are believed to contribute. On the other hand, it was found that early detection 
and control of hypertension can be attributed to the decline in stroke mortality in this group 
(Wild & McKeigue 1997).  
 
 
1.1.3.1.4 Cigarette Smoking 
 
   Smoking is the number one cause of preventable death; one in five CVD deaths is related 
to smoking (AHA 2001). The increased risk of CVD from smoking has been identified for 
more than 30 years, with conclusive evidence presented in numerous reports.  Furthermore, 
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smoking is synergistic with other risk factors and directly influences acute coronary events 
such as formation of the thrombus, plaque instability and arrhythmias. This risk also 
increases with the number of cigarettes smoked each day, and low-tar brands do not reduce 
the risk. Any exposure, including passive smoking also increases the risk (Howard & Thun 
1999). Based on the Framingham Offspring/Spouse Study (FOS), it was found that women 
who consumed a heart-healthy diet and never smoked, demonstrated the overall lowest odds 
of sub-clinical heart disease (Millen et al. 2004). Cigarette smoke consists of complex 
mixture, and only a few components have been studied extensively. Nicotine and carbon 
monoxide appear less damaging than whole smoke, although nicotine up-regulates the 
expression of several pro-inflammatory and pro-oxidative molecules (Pitillo 2000).  
 
Studies in animals suggest that the acetylcholine relaxation, which is dependent on 
endothelial function, is impaired by smoking (Celermajer et al. 1996; Pittilo 2000; Wang et 
al. 2001) an effect which may be attenuated by the antioxidant vitamin C (Mays et al. 
1998). Furthermore, Wang et al. (2001) postulate that excessive endothelial apoptosis may 
contribute to endothelial injury that is induced by cigarette smoke. On the other hand, 
cigarette smoke also contains large amounts of nitric oxide, which subsequently is mainly 
converted to a powerful oxidant of nitrogen dioxide radical during the respiratory process in 
the lungs (transfer through the alveoli). Once the oxidation takes place, the level of 
antioxidant will drop simultaneously. Tappia et al. (1995) reported a 21% lower plasma 
vitamin C concentration was observed in smokers despite a similar intake of this vitamin C 
as compared to non-smokers. 
 
 
1.1.3.1.5 Total Cholesterol (TC) 
 
   A total cholesterol (TC) determination measures cholesterol comprised in all lipoprotein 
fractions; of this TC 60-70% is carried on low density lipoprotein (LDL), 20-30% on high 
density lipoprotein (HDL) and 10-15% on very low density lipoprotein (VLDL). It has been 
reported that a 10% reduction in total cholesterol could decrease CHD incidence by up to 
30% (CDC 2001). However, there are several factors that affect the level of serum 
cholesterol, for example age, dietary fat intake, genetics, endogenous and exogenous 
hormones or steroids, body weight, glucose tolerance and physical activity. Therefore, 
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although total cholesterol was previously recommended as a screening tool, recently Adult 
Treatment Panel III (ATP-III) has endorsed a complete lipoprotein profile for screening 
purposes.  
 
Dietary cholesterol increases the ratio of total cholesterol to HDL, and higher ratios are 
associated with CHD (Dawber et al. 1982). The effects of dietary fats on total:HDL 
cholesterol ratio may differ markedly from their effects on LDL. Still, these effects on CVD 
risk markers should not be considered to reflect changes in risk and further conclusion 
needs to be confirmed by prospective observational studies or clinical trials (Katan et al. 
2003). By that standard, risk is reduced most effectively when trans fatty acids and 
saturated fatty acids are replaced with cis unsaturated fatty acids (Katan et al. 2003). Since 
trans fatty acids are only a minor proportion of the diet, even marked relative reductions in 
intake will probably have less effect on LDL compared with a reduction in saturated fatty 
acids and cholesterol (Mensink & Katan 1993). However, in the long term or after several 
years, it was found that dietary intervention with different fatty acid types is ineffective in 
substantially lowering TC (Okuyama et al. 2007). This is because serum lipoproteins 
change shortly after dietary changes, but enzymes adapt to new dietary conditions. Thus, 
based on data from several studies (Suzuki et al. 1970; MRFIT 1982; Strandberg et al. 
1991; Keys et al. 1950), the consequences of short- and long-term nutritional manipulations 
differ markedly. Even though it can be argued that the effectiveness of long-term dietary 
interventions due to progressively decreased compliance, other studies showed that a lack 
of compliance is not likely to be a major cause for the failure to lower TC values. In terms 
of cholesterol ratio, LDL/HDL balance is better than total cholesterol as a predictor of 
atherosclerosis. Although TC and LDL-c are highly directly correlated, the causal 
relationship between them and CHD is unclear. TC is probably a measure of CHD risk in 
groups with relatively large proportions of familial hypercholesterolemia (Okuyama et al. 
2007). Moreover, even positive associations are noted between the TC and CHD events, but 
not all populations behave the same since CHD events differ approximately 4 to 8 fold at 
the same TC value. 
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1.1.3.1.6 LDL-cholesterol (LDL-c) 
 
   LDL-c is essentially a cholesterol carrier in the blood; therefore, total cholesterol and 
LDL-c levels are highly correlated. In humans, the majority of serum cholesterol is carried 
by LDL particles. LDL has an important physiological role as a vehicle for the delivery of 
cholesterol to the peripheral tissues. Therefore, increased LDL-c levels are associated with 
increased risk of CVD. There are a large number of case-control studies which demonstrate 
strong relationships between LDL-c and atherosclerosis (Crouse et al. 1985; Austin et al. 
1988; Tornwall et al. 1991; Campos et al. 1992; Coresh et al. 1993; Stampfer et al. 1993; 
Griffin et al. 1994; Gardner et al. 1996; Stampfer et al. 1996; Lamarche et al. 1997; 
Skoglund-Andersson et al. 1999). Studies found that 95% of the apolipoproteins in LDL are 
apo B-100, known as apo B. It has been argued that apo B might exhibit as an even better 
risk marker than LDL-c (Sniderman et al. 1992; Lamarche et al. 1998; Walldius et al. 2001; 
Sniderman et al. 2003). However, issues of standardization and the fact that apolipoproteins 
have not been employed in large-scale studies restrain the use of apolipoproteins for these 
purposes.  
 
Two LDL subclasses with different risks for CVD have been identified. Phenotype A is 
manifested by very large LDL particles, which are not associated with CVD risk. 
Meanwhile, phenotype B is characterized by small and dense LDL particles which are 
triglyceride rich and cholesterol depleted, that are predictive of CHD risk in both genders. 
The formation of phenotype B is almost exclusively demonstrated when the plasma level of 
TAG is mildly to moderately elevated. Therefore, this process is apparently slow when only 
few TAG-rich lipoproteins are available. The subsequent changes in chemical 
characteristics of the small, dense LDL particle trigger binding to the subendothelial matrix, 
resulting in easy oxidative modification thereby leading to foam cell formation (Tribble et 
al. 1992; Anber et al. 1996) (also see Section 1.1.1).  Postmenopausal women have a greater 
prevalence of phenotype B than pre-menopausal women at the same age (Campos et al.  
1988). In addition, phenotype B that is seen in 30% of general population tends to occur 
with low HDL-c and high levels of triglyceride, VLDL and intermediate-density lipoprotein 
(IDL).  
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1.1.3.1.7 HDL-cholesterol (HDL-c) 
 
   HDL  particles  contain  more  protein  than any other lipoprotein. Apo A-I, the main 
apolipoprotein in HDL, is involved in tissue cholesterol removal by activating lecithin-
cholesteryl ester acyl-transferase (LCAT). Therefore, HDL-c is also used as a predictor of 
lower CVD risk.  Both apo C and apo E are minor apolipoprotein components, synthesized 
by the liver and are transferred to chylomicrons. Apo E allows receptors to recognize 
chylomicron remnants facilitating their removal from the circulation and metabolism. 
Elevated HDL levels are therefore associated with low levels of chylomicrons, VLDL 
remnants, and small, dense LDL. 
 
Like LDL, HDL can also be divided into sub-fractions. There are two classifications of 
HDL by which is often described based on size and/ or density. HDL2-c, which is relatively 
large and lipid rich, and HDL3-c (subdivided in to HDL2a, HDL2b, HDL3a, HDL3b, HDL3c), 
which is small and comparatively dense, that predominates in human plasma. The presence 
of HDL2-c is critically dependent on low concentrations of triglyceride. Therefore, either 
HDL-c or HDL2-c is strongly inversely related to plasma triglyceride concentrations. Only a 
limited number of studies designed to explore the relationship between HDL sub-fractions 
and CVD are available due to methodological difficulties involved in assessing the HDL 
sub-fraction concentrations accurately. Studies found that the effects of low fat diets on the 
plasma concentration of HDL2 are inconsistent (Ehnholm et al. 1984; William et al. 1994), 
whereas physical activities are important strategies raising the HDL2 concentration 
(William et al. 1994) or to improve the HDL inflammatory index from pro- to anti-
inflammatory (Roberts et al. 2006). The Quebec Cardiovascular Study, however, concludes 
that HDL sub-fractions do not provide additional information on the risk of CHD compared 
with HDL-c per se (Lamarche et al. 1997); hence, total HDL-c remains the best predictor.  
 
 
1.1.3.1.8 Triglyceride (TG) 
 
   The  triglyceride  rich  lipoproteins include chylomicrons, VLDL and any remnants or 
intermediary products formed in catabolism of chylomicrons or VLDL. Chylomicrons 
provide the primary means of transport of dietary lipid, while VLDL functions to transport 
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endogenous lipids. In addition, the function of TG-rich VLDL particles that also contain 
apo B-100 and apo E, is to transport fatty acids to adipose tissue and muscle. There are 
some studies which suggest that postprandial triglyceride measurements may be more likely 
to predict the CHD risk compared with fasting levels (Ginsberg 1994). It was also found 
that although patients with CHD have higher fasting and postprandial levels of triglycerides 
compared with controls, the response based on percent increase to a fat-rich meal is similar 
in both groups (Schaefer et al. 2001). Endothelial dysfunction observed after consumption 
of a high-fat meal indicates one possible explanation for this proposition of higher levels of 
postprandial triglycerides. There is, however, no doubt that circulating triglyceride levels in 
fasting and postprandial states are related to the severity and advancement of atherosclerosis 
(Hodis 1999) and are recognized as independent risk factors for CHD (Hokanson & Austin 
1996; Karpe 1997).  
 
1.1.3.1.9 Hypertension 
 
   Hypertension is defined as an average blood pressure of over 140/90 mm Hg, or use of 
antihypertensive drugs (AHA 2001). It has been documented that higher systolic and 
diastolic blood pressure coincides with an increased incidence of ishaemic and hemorrhagic 
stroke (MacMahon 1996). In conjunction with this finding, salt (sodium), for instance, is 
viewed as the most important dietary intervention for controlling blood pressure. Sodium is 
the principal cation in the extracellular fluid and plays a pivotal role in maintaining the 
body homeostasis. Nevertheless, there is a maximum level of intake above which excretion 
of excess sodium cannot occur. This phenomenon, therefore, causes an increase in body 
sodium content and water retention and ultimately promotes the development of raised 
blood pressure.  
 
The Committee on Medical Aspects of Food Policy (COMA) has recommended a reduction 
in salt intake to the average of 6 g/day for the adult population (Department of Health 
1994). Based on the review of the available studies, more recently, the UK’s Government of 
Scientific Advisory Committee on Nutrition (SACN 2003) concluded that the strong 
association between salt intake and elevated blood pressure strongly supports the 
recommendation. The convincing evidence comes from the Dietary Approaches to Stop 
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Hypertension (DASH) Sodium Trial, in which stepwise reductions in blood pressure were 
demonstrated in response to lowering of dietary salt levels (Sacks et al. 2001). 
 
The relationship between hypertension and atherosclerosis can be explained by means of 
endothelial dysfunction. This mechanism may lead to changes in the production of local 
vasodilators, such as nitric oxide (NO) and of vasoconstrictors, such as endothelin-1 and 
vasoactive endothelial growth factor, VEGF. Hypertension also has pro-inflammatory 
action, a potential to increase the formation of hydrogen peroxide and free radicals, such as 
anions and hydroxyl radicals in plasma (Griendling 1997; Lacy et al. 1998; Swei et al. 
1997). These substances, consequently, reduce the formation of NO (Vanhoutte et al. 1995), 
and thus the function of the endothelial layer may be impaired (British Nutrition Foundation 
2005). Furthermore, leukocyte adhesion and peripheral resistance are also increased in 
response to these pro-inflammatory mediators (Swei et al. 1997). 
 
Chobanian & Dzau (1996) found that concentrations of angiotensin II, a potent 
vasoconstrictor and the prominent product of renin-angiotensin system, are often elevated in 
hypertensive patients. In addition to causing hypertension, this vasoconstrictor can activate 
atherogenesis by inducing the growth of smooth muscle. Furthermore, angiotensin II binds 
to specific receptors on the smooth muscle, resulting in activation of phospholipase C. This 
process, subsequently, can lead to increases in intracellular calcium concentrations and in 
smooth-muscle contraction (Chobanian & Dzau 1996), and increased protein synthesis and 
smooth-muscle hypertrophy (Gibbons et al. 1992). Moreover, the activity of smooth-muscle 
lipoxygenase also increases and this can promote inflammation and oxidation of LDL. 
 
 
1.1.3.1.10 Diabetes  
 
   Diabetes, defined as a dysregulation of glucose metabolism, is both a disease in its own 
right and a risk factor for CVD. Studies demonstrated that rates of CVD are four times 
higher in diabetic women aged 18 to 44 years compared with women without the disease 
(CDC 2001; Hu et al. 2001). After age-adjustment, prevalence of CVD in women with 
diabetes is twice that in women without diabetes. Diabetes is also responsible for the 
increased frequency of macrovascular disease, with the relative risk being around two-to-
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three fold and three-to-five fold for men and women, respectively (Kannel & McGee1979; 
Morish et al. 2001). Some of the increased risk for CHD observed in diabetic patients is 
attributable to the concurrent presence of other risk factors, such as dyslipidemia, 
hypertension and obesity.  
 
 
1.1.3.1.11 Physical Inactivity 
 
      Physical inactivity, or low level of fitness, is the most prevalent modifiable and 
independent risk factor for CVD. It is generally believed that physical activity levels have 
declined in the UK over the past 20 years (Department of Health 1999; Ruston et al. 2004). 
Incidence of obesity can only occur when energy intake is not harmonized by energy 
utilisation, thus reflecting a decline in average physical activity. Despite public health 
recommendations of thirty minutes of moderate-intensity daily activity (Pate et al. 1995), 
29% to 38% of adults in national surveys reported to be physically inactive (Schoenborn & 
Barnes 2002). Physical activity minimizes CHD risk factor by hindering atherogenesis 
(Austin et al. 1990), increasing the vascularity of the myocardium, promoting fibrinolysis 
(Clarkson et al. 1999; Higashi et al. 1999) and modifying other risk factors, such as raising 
HDL cholesterol (Durstine et al. 2001), improving glucose tolerance and insulin sensitivity 
(Hsueh et al. 2004), supporting in weight management (Department of Health and Human 
Services 1996; Esposito et al. 2003; Nicklas et al. 2004) and reducing blood pressure 
(Whelton et al. 2002). 
 
 
1.1.3.1.12 Obesity 
 
   Body mass index (BMI) and CVD are well documented to be positively related; as the 
BMI goes up, the risk of CVD also increases. The WHO has adopted a definition of adult 
obesity, this being a BMI over 30 kg/m
2 (WHO 1998). This method of defining obesity, 
however, cannot differentiate between muscle mass and adiposity. Thus, heavily muscled 
individuals may be categorized as obese even though their total body fat percentage is low. 
It is quite certain that obesity is a risk factor for CVD and weight loss has been associated 
with lower fibrinogen (Ditschuneit et al. 1995) and C-reactive protein levels (Tchernof et al. 
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2002), both of which are indicators for atherosclerosis. Interestingly, adipose tissue mass 
which is below what is categorized as obese, is still found to associate with raised 
inflammatory mediators (Kazumi et al. 2003), reflecting a role of adipose tissue in the 
inflammatory processes involved in CVD.  
 
In some circumstances, visceral obesity, which is usually determined by the waist/hip ratio 
or waist circumference, is closely related to excess morbidity (Rexrode et al. 1998). A waist 
circumference of less than 35 and 40 inches for women and men, respectively, is therefore, 
recommended (NIH 1998). The relationship between morbidity and high waist/hip ratio is 
believed to be because visceral fat has especially unfavorable metabolic actions, such as 
mobilization of non-esterified fatty acid (NEFA) directly to the liver. Apparently, a 
complex mechanism is involved in this association since high waist/hip ratio is also 
accounted for by low physical inactivity, weight gain and high alcohol intake (Seidell & 
Bouchard 1997). Hence, studies correcting for these factors will be required before 
acknowledging that visceral fat per se has some adverse metabolic effect. 
 
 
1.1.3.2 Emerging Risk Factors 
 
   Emerging risk factors have been initiated because it was found that existing risk factors 
for CVD do not completely explain the risk. For example, the distribution of serum 
cholesterol levels, believed to be one of the important classical risk factors, does not clearly 
distinguish those with from those without the disease. Indeed even some individuals with 
low cholesterol levels CVD is still manifested. Therefore, other factors must underlie the 
risk of CHD and it is also likely that other novel risk factors may play a substantial role and 
also account for a significant proportion of CVD cases. Moreover, new investigations on 
the underlying mechanism of atherosclerosis have identified the presence of other 
independent risk factors, such as inflammatory markers and oxidative stress, in the 
aetiology of CHD. Table 1.3 summarizes the parameters which are considered as emerging 
risk factors. 
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TABLE 1.3: Emerging Risk Factors for CVD 
Risk factor  Relevance to CHD 
Individual factors 
Lipid-related factors  
(apart from cholesterol concentrations) 
 
 
Endothelial dysfunction 
 
 
 
 
Oxidative stress 
 
Inflammation 
 
Coagulation-related factors 
 
Homocysteine 
 
Adipose tissue-derived factors 
 
Common mechanism 
Insulin resistance 
 
 
Maternal and/or fetal undernutrition 
 
Abdominal obesity 
 
Associates with plaque development and possibly 
thrombosis. Factors other than LDL-c may play a role in 
atherosclerosis 
 
Impaired endothelial dysfunction may allow entry of 
monocytes and LDL particles to subendothelial space. 
Mechanical stress on blood vessels due to high blood 
pressure is likely to be an important factor. 
 
LDL oxidation may be involved in atherosclerosis. 
 
May reflect atherosclerosis and inflammatory process. 
 
Formation of thrombus leads to MI or stroke. 
 
Not clear 
 
Not clear 
 
 
Related to dyslipidaemia, pro-coagulant state and 
endothelial dysfunction 
 
May relate to insulin resistance and hypertension 
 
Related to insulin resistance 
 
 
1.1.3.2.1 Lipid-related Factors 
 
   Lipid-related  risk  factors,  essentially,  are  related to the classical risk factors of high 
plasma TC and LDL-c, low plasma HDL-c and elevated plasma TG (Woods et al. 1988). 
Interestingly, studies found that many of the emerging risk factors are directly related to 
plasma TG, a conventional risk factor for which it has been essentially difficult to exhibit 
independent associations with CVD. There are also interrelationships between post-prandial 
lipaemia, remnant-like particles, small dense LDL-c and HDL-c and the levels of 
triglycerides in plasma. Post-pradial (non-fasting) lipaemia is a condition in which 
atherogenic lipoproteins are generated, such as chlymicron and VLDL remnants. After 
meals, in the presence of TG-rich lipoproteins as substrates, LDL is likely to form due to 
the action of hepatic lipase activity that becomes prevalent whereas HDL depletes. If the 
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removal of post-prandial lipoproteins is slow, therefore, less de novo synthesis of HDL 
components are formed. It has been documented that a large number of case-control studies 
have shown excessive post-prandial lipaemia in people with CHD compared with controls 
(Karpe 1999). Moreover, positive relationships between markers of post-prandial 
lipoproteins and degree of CVD have been consistently shown in cohort studies (British 
Nutrition Foundation 2005).  
 
 
1.1.3.2. Endothelial Function 
 
   It is postulated that the size of the lipid particles determines the degree by which the 
endothelium can be penetrated; small particles are more easily accumulated in the arterial 
wall compared with the larger ones. This point is already discussed under the sub-topic of 
endothelial dysfunction (see section 1.1.2). 
 
 
1.1.3.2.3 Oxidative Stress 
 
   Oxidative stress is usually implicated in the aetiology of chronic diseases that are related 
to inflammatory markers. Certainly, this is true in the progression of atherosclerosis, where 
there is a participation of monocytes and macrophages in plaque formation. This invasion, 
subsequently, results in the release of reactive oxygen and nitrogen species which are 
believed to be a key process linked with many pathological events. Involvement of 
oxidative stress in the development of atherosclerosis, for example, can be ascribed in LDL 
oxidation.  LDL also contains esterified polyunsaturates from dietary intake, and these 
polyunsaturates are prone to oxidative attack by free radicals. On the other hand, many 
studies support the protective nature of antioxidants, especially in the form of foods rich in 
these nutrients upon various types of CVD. However, since LDL also carries a high 
proportion of fat-soluble antioxidants, such as tocopherols and carotenoids, oxidation and 
propagation of fatty acid oxidation can be prevented in normal circumstances (British 
Nutrition Foundation 2005). 
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1.1.3.2.4 Inflammation 
 
   Cardiovascular  disease  is  increasingly  being recognised as a disease with a major 
immune-inflammatory component in its pathogenesis (Witztum & Steinberg 2001). There 
are various stimuli which can up-regulate the expression of number of genes in the 
endothelium and circulating blood mononuclear cells that are responsible for the reaction of 
the tissues to stress such as oxidative stress, oxidised lipids, haemodynamic flow and 
inflammatory cytokines. These genes include those encoding for adhesion molecules, 
inflammatory cytokines, heat-shock proteins, eicosanoids and redox enzymes (Yaqoob 
1998; Wahle & Rotondo 1999; Witztum & Steinberg 2001).  
 
Since atherogenesis is an inflammatory process, markers of inflammation such as C-
reactive protein, have been measured.  From epidemiological studies, CRP was found to be 
associated with angina, risk of cardiac events, stroke and peripheral vascular disease, 
independent of other risk factors (Wood 2001). Tchernof et al. (2002) demonstrated that 
weight loss lowers CRP, which suggests another physiological benefit of weight 
management as a preventative strategy for CHD control.  
 
In relation to changes in endothelial cell function and inflammation, much attention has 
been devoted to the role of cellular adhesion molecules (CAMs) in CVD risk. Indeed, this 
focus has generated considerable evidence for altered endothelial CAM expression in 
animal models of CVD (Krieglstein & Granger 2001; Libby et al. 2002); identified levels of 
circulating soluble intercellular ICAM-1 (sICAM-1) as a marker of inflammation severity 
in clinical setting (Mulvihill et al. 2002); CAM expression as a critical determinant of the 
stage of organ damage and vascular dysfunction associated with experimental CVD 
(Krieglstein & Granger 2001; Tailor et al. 2000; Libby et al. 2002) and the relation between 
CAM expression and other factors involved in the development of CVD (Cai & Harrison 
2000; Cooper et al. 2002). 
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1.1.3.2.5 Homocysteine 
    
   Homocysteine, a sulphur-containing amino acid exists in all cells.  The mechanism by 
which high circulating homocysteine concentration is initially thought to be associated with 
the CVD risk factor is incompletely understood. Homocysteine is proposed as a risk factor 
when it was observed that children who were deficient in the essential catabolic enzymes 
for homocysteine, cystathionine β-synthase or methylenetetrahydrofolate reductase, were 
found to have premature atherosclerosis, albeit in veins and not arteries, and mortality. 
 
In vitro and in vivo studies suggest that homocysteine may accelerate plaque formation by 
enhancing the process of lipid oxidation, exerting procoagulant activity and promoting 
collagen synthesis and smooth muscle cell proliferation (Mangoni & Jackson 2002; Faraci 
2003). Homocysteine is also responsible for determination of acute and chronic endothelial 
dysfunction by promoting the production of hydrogen peroxide and other highly reactive 
oxygen compounds, upregulating cell adhesion molecules and inhibiting the release of nitric 
oxide or reducing nitric oxide availability (Faraci 2003; Upchurch et al. 1997).  Researchers 
have also focused on the relationship between homocysteine and inflammation. Evidence 
shows that concentrations of acute phase reactants, such as fibrinogen, CRP and ∝-1 
chymotrypsin, are closely related with circulating concentrations of homocysteine (Bates et 
al. 1997; Evans et al. 1997; de Jong et al. 1997; Rohde et al. 1999). Preclinical studies 
indicate that interleukin 6 (IL-6) may interact with vitamin B6 metabolism and compromise 
cystathionine  β-synthase activity (McCarty 2000). Interestingly, high concentrations of 
proinflammatory cytokines are associated with a high risk of medical conditions that have 
also been associated with the hyperhomocysteinemia, such as ischemic stroke, myocardial 
infarction and more recently, osteoporosis. Thus, it may be hypothesized that 
hyperhomocysteinemia and cardiovascular risk may be both mediated by inflammatory 
state.   
 
Conversely, previous studies that addressed the association between inflammation and 
homocysteine also reported conflicting findings. Therefore, homocysteine as a risk factor 
for cardiovascular disease is now controversial for several reasons (Braattstrom 2000). 
First, elevated plasma homocysteine is strongly and positively related to the other major 
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risk factors for CVD (i.e., age, smoking, blood pressure, high blood cholesterol, and lack of 
exercise) (Bots 1997). Second, serum creatinine as an indicator of renal function is a strong 
predictor for plasma homocysteine levels. Thus, poor renal function due to atherosclerosis 
raises homocysteine levels, not vice versa. Third, whereas low serum or red cell folate or 
vitamin B12, cause elevations in plasma homocysteine levels, deficiency of either of these 
vitamins does not produce vascular disease. In conclusion, homocysteine is categorized as a 
modest independent risk factor for cardiovascular disease and more research in this area is 
warranted. 
 
 
1.1.3.2.6 Adipose Tissue-derived Factors 
 
   As discussed earlier (See Section 1.1.3.1.12), obesity associates with increased risk of 
CVD morbidity and mortality, and is becoming an expanding dilemma in developing 
countries (Kushner 2002). This link involves a complex of diverse elements that can be 
partially explained by novel signaling molecules (adipokines), formed in adipose tissue. It 
has been suggested that the secretion of these molecules, such as, leptin, IL-6 and 
adiponectin, together with the expression of TNF-α in obese individuals, possibly underlies 
the association of insulin-resistance with endothelial dysfunction and coagulopathy, which 
ultimately lead to the progression of CHD (Mohamed-Ali et al. 1998). Furthermore, the 
relationship between obesity and CVD can be illustrated by popular intermediaries such as 
hypertension, type 2 diabetes and dyslipidaemia, as well as the less well-known mediators, 
such as chronic inflammation and hypercoagulation. Apparently, these proteins, synthesized 
by adipose tissue are synchronized with energy balance and metabolism. In obesity, 
peripheral tissue resistance to leptin, together with the deficiency of adiponectin, may result 
in decreased fat oxidation in skeletal muscle, macrophages and liver, thus leading to 
increased fat accumulation within these tissues.  
 
Acylation stimulating protein (ASP) or adipsin, is a small serum protein that may function 
mainly as an adipocyte autocrine factor and plays a significant role in adipose tissue 
metabolism. Studies show that adipsin is positively related to various CVD risk factors 
including, insulin glycated hemoglobin (HbA1c), leptin, CRP, plasminogen activator 
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inhibitor 1 (PAI-1) and tissue plasminogen activator (tPA) (Mavri et al. 1999; Ebeling et al. 
2001; Ylitalo et al. 2001). 
 
 
1.1.3.2.7 Maternal/Fetal Undernutrition 
 
   The roots of cardiovascular disease can be tracked back to fetal life and infancy, and also 
to the effects of poverty on mothers, as first proposed by Barker (1998). Previous, studies 
have shown that lower birth weight and weight at one year are associated with an increased 
risk of death in adult life from CHD and stroke (Barker et al. 1989; Osmond et al. 1993), 
and also are independent of socioeconomic status (Frankel et al. 1996; Rich-Edwards et al. 
1997). However, there is some evidence in Finland that the proportions of body at birth 
exhibit a stronger relationship, for example, low ponderal index (weight/ length
3) predicts 
CHD better than birth weight per se (Forsen et al. 1997; Eriksson et al. 1999), whereas, in 
UK, low birth weight/head circumference ratio predicts stroke mortality (Martyn et al. 
1996).  
 
Figure 1.4 shows the association between small size at birth and CVD risk factors that 
reflects a permanent effect of fetal undernutrition, called the ‘Fetal Origins of Adult Disease 
(FOAD)’ Hypothesis (Barker 1998), also known as ‘thrifty phenotype’ hypothesis (Hales & 
Barker 1992). Low birth weight babies tend to catch up, and the rapidity of post-natal 
growth may simply indicate the severity of growth retardation at birth (Leon et al. 1996). 
Indeed, it is also postulated that the catch-up growth hormones have adverse cardiovascular 
and metabolic effects (Lever & Harrap 1992). In contrast, the ‘thrifty phenotype’ hypothesis 
proposes ‘fetal programming’, that the undernourished fetus develops insulin resistance and 
other metabolic changes as a strategy for immediate survival, to down-regulate and 
prioritize growth, for which it pays a price later in life, generally after the reproductive 
period. However, evidence is insufficient to make recommendations about catch-up growth 
during infancy in low birth weight babies. Therefore, monitoring childhood BMI should be 
a public health concern, since accelerated weight and BMI gain in childhood is reported as a 
clear risk factor.  
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Nutrient demand >>>supply 
 
 
FETAL UNDERNUTRITION 
Hyperlipidemia 
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Down regulation of 
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                                     blood flow                  transfer                        genome 
 
 
 
          Type 2 diabetes and CHD 
FIGURE 1.4: The Fetal Origins Hypothesis 
(Adapted with modification from British Nutrition Foundation 2005) 
 
 
1.2 Fatty Acids and Cardiovascular Disease  
 
   Fatty acids are hydrocarbon chains varying in total chain length from 2 to 30 or more 
carbons, with a methyl group at one end of the chain and carboxyl group at the other 
(Calder 2005). A vast number of fatty acids occur in nature and they differ in chain length, 
and in number, type and position of double bonds. Figure 1.5 shows the molecular structure 
of some fatty acids. Stearic acid containing 18 carbon atoms and no double bonds is 
referred as a saturated fatty acid (SFA); the term ‘saturated’ refers to hydrogen, in that all 
carbons, apart from the carboxylic acid (-COOH) group, are linked to as many hydrogen 
atoms as possible. On the other hand, fatty acids with at least with one double bond between 
adjacent carbon atoms are called unsaturated. There are two types of unsaturated fatty acids; 
monounsaturated fatty acids (MUFA) contain a single double bond and polyunsaturated 
fatty acids (PUFAs) with at least two double bonds. Double bonds can be either in cis- or 
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trans- conformation and also occur in different positions within the chain.  The 
corresponding unsaturated fatty acids for stearic acid are oleic acid, linoleic acid and 
linolenic acid which contain one, two and three double bonds, respectively, as shown in 
Figure 1.5. In the commonly used fatty acid nomenclature, the double bonds are counted 
from the methyl (CH3) end of the molecule, noted by n-x (x is the position of double bond) 
or ω-x (ω for the terminal carbon). For example, oleic acid in the nomenclature is written as 
18:1n-9 or 18:1ω-9, since has 18 carbon atoms and one double bond with the double bond 
on carbon nine counting from terminal methyl group. For n-3 fatty acids, the first double 
bond is located between the third and fourth carbons from the methyl end of the chain.  
 
CH3-(CH2)16-COOH 
Stearic acid (18:0) 
 
CH3-(CH2)7-CH=CH-(CH2)7-COOH 
Oleic acid (18:1n-9) 
 
CH3-(CH2)4-CH=CH-CH2-CH=CH-(CH2)7-COOH 
Linoleic acid (18:2n-6) 
 
CH3-CH2-CH=CH-CH2-CH=CH-CH2-CH=CH-(CH2)7-COOH 
Linolenic acid (18:3n-3) 
 
FIGURE 1.5: Molecular Structures and Names of Some 18 Carbon Fatty Acids 
 
There are probably less than twenty fatty acids that are quantitatively important in the 
human diet. Table 1.4 presents the most common occurring fatty acids, grouped as SFA, 
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TABLE 1.4: Common Dietary Fatty Acids 
 
Fatty acid  Systemic name  Formula  Common food source 
Saturated 
  Caprylic 
  Capric 
  Lauric 
  Myristic 
  Palmitic 
  Stearic  
Monounsaturated 
  Oleic 
  Elaidic 
  Gadoleic 
  Erucic 
  Nervonic 
N-6 polyunsaturated 
  Linoleic (LA) 
  γ-linolenic (GLA) 
  Dihomo-γ-linolenic   (DGLA) 
  Arachidonic 
N-3 polyunsaturated 
  α-linolenic (ALA) 
  Eicosapentaenoic  (EPA) 
  Docosapentaenoic (DPA) 
  Docosahexaenoic (DHA) 
 
 
Octanoic 
Decanoic 
Dodecanoic 
Tetradecanoic 
Hexadecanoic 
Octadecanoic 
 
9-Octadecanoic 
Trans 9-Octadecanoic 
11-Eicosaenoic 
13-Docasaenoic 
15-Tetracosaenoic 
 
9,12-Octadecanoic 
6,9,12-Octadecatrienoic 
8,11,14,17-Eicosatetraenoic 
5,8,11,14-Eicosatetraenoic 
 
9,12,15-Octadecatraenoic 
5,8,11,14,17-Eicosapentaenoic 
4,7,10,13,16-Docosapentaenoic 
4,7,10,13,16,19-Docosahexaenoic 
 
8:0 
10:0 
12:0 
14:0 
16:0 
18:0 
 
18:1n-9 
t-18:1 
20:1n-9 
22:1n-9 
24:1n-9 
 
18:2n-6 
18:3n-6 
20:3n-6 
20:4n-6 
 
18:3n-3 
20:5n-3 
22:5n-3 
22:6n-3 
 
Human breast milk, coconut oil 
Animal fats. Coconut oil 
Coconut oil, palm kernel oil 
Coconut oil, palm kernel oil, dairy products 
Dairy products, meat, palm oil 
Cocoa butter, palm oil, meat 
 
Olive oil, rapeseed oil, palm oil, meat 
Partially hydrogenated fats 
 
Mustard oil 
 
 
Sunflower, maize, safflower and soybean oils 
Borage and evening primrose oils 
 
Ruminant meats (low levels) 
 
Linseed, walnut and soybean oils, walnuts, vegetables 
Fish oil, oil-rich fish, marine mammals 
Fish oil, oil-rich fish, marine mammals,  
Fish oil, oil-rich fish, marine mammals 
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Most fatty acids can be synthesised in the body. However humans and mammalian cells, but 
not plants, lack the desaturase enzymes required to produce two fatty acids: α-linolenic acid 
(n-3) and linoleic acid (n-6). These are known as essential fatty acids which must be 
acquired from the diet. The body can convert one n-3 fatty acid to another n-3 fatty acid; for 
example α-linolenic acid can be elongated and subsequently desaturated to the long chain 
n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Figure 1.6), but 
the conversion rate may not be sufficient to meet requirements and only occurs when the n-
6/n-3 ratio is low. For example, less than 8% of ALA is metabolised to EPA and the 
capacity for the body to synthesise DHA appears to be limited. It is estimated that only 
between 0.02% and 4% of dietary ALA is metabolised to DHA (Vermunt et al. 2000; 
Pawlosky et al. 2001; Burdge et al. 2002), with women having greater capacity for DHA 
synthesis than men (Budge & Wootton 2002). Thus, it is recommended that good sources of 
these fatty acids, for example oil-rich fish, need to be included in the diet.  
 
H3
C
COO
H
Linoleic acid (18:2n-6)
H3
C
COO
H
-Linoleic acid (18:3n-6)
6-desaturase
H3
C
COO
H
Dihomo linoleic acid 
(20:3n-6)
-desaturase
H3
C
COO
H Arachidonic acid 
(20:4n-6)
Elongase
H3
C COO
H
-Linoienic acid (18:3n-3)
H3C
COOH
Stearidonic acid (18:4n-
3)
H3C
COOH
20:4n-3
-desaturase
H3C
COOH
Eicosapentaenoic acid 20:5n-3
COO
H
Elongase
Elongase
-desaturase
-oxidation
Docosahexaenoic acid 22:6n-3
Elongase
6-desaturase
 
FIGURE 1.6: Metabolism of n-6 and n-3 PUFAs in Mammals 
 
The pathway in Figure 1.6 shows that there is a competition between n-6 and n-3 fatty acid 
families due to sharing of the same series of enzymes in their conversion. Although the 
preferred substrate for Δ6-desaturase is α-linolenic acid (ALA), due to linoleic acid being 
much more prevalent in most human diets as compared to ALA, the metabolism of n-6 fatty 
acids is quantitatively more important (Calder 2005). Morover, excessive n-6 fatty acids in 
 Chapter 1 Introduction                                                                                                                  50 
the diet saturates the enzymes and prevents conversion of ALA into EPA and DHA (Kris-
Etherton 2000). In mammals, this pathway occurs mainly in the liver. 
  
     
1.2.1  Long Chain n-3 Polyunsaturated Fatty Acids 
 
  LC n-3 PUFAs refer to fatty acids with chain length of 18 carbons or more, with the first 
double bond located between the third and the fourth carbons counted from the methyl end. 
For example, EPA (20:5n-3) is an omega(ω)-3 or (n-3) fatty acid with 20 carbon atoms in 
the entire chain and with five double bonds, with the first double bond located at the third 
carbon atom from the methyl end of the chain (n-3).  
 
Dietary EPA and DHA primarily come from marine sources by which algae as prime 
source: mackerel, salmon and sardines, as well as crab, shrimp and oysters and also fish oils 
and some fish liver oils like cod liver oil (Table 1.5). The content of n-3 PUFAs varies 
between species, and also depends on the location, diet, season of capture and cooking 
methods. 
 
TABLE 1.5: n-3 PUFAs Contents in 3-oz Serving Seafood 
 EPA+DHA  content,  g/3-
oz serving seafood 
(edible portion) or g/g oil 
Amount required to provide 
≈ 1g of EPA+DHA/d, oz 
(seafood) or g (oil) 
Seafood 
   Sardines 
   Mackerel 
   Halibut 
   Haddock 
   Flounder/sole 
   Lobster 
   Crab, Alaskan King 
   Shrimp, mixed species 
   Clam 
   Scallop 
   Tuna 
      Light, canned in water, drained 
      White, canned in water, drained 
      Fresh 
   Salmon 
      Chum 
      Sockeye 
      Pink 
 
0.98-1.70 
0.34-1.57 
0.4-1.0 
0.2 
0.42 
0.07-0.41 
0.35 
0.27 
0.24 
0.17 
 
0.26 
0.73 
0.24-1.28 
 
0.68 
0.68 
1.09 
 
2-3 
2-8.5 
3-7.5 
15 
7 
7.5-42.5 
8.5 
11 
12.5 
17.5 
 
12 
4 
2.5-12 
 
4.4 
4.5 
2.5 
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1.48        Chinook 
      Atlantic, farmed 
      Atlantic, wild 
   Herring 
      Pacific  
      Atlantic 
   Trout, rainbow 
      Farmed 
      Wild 
   Cod 
      Pacific 
      Atlantic 
   Catfish 
      Farmed 
      Wild 
   Oyster 
      Pacific 
      Eastern 
      Farmed 
Capsules 
   Cod liver oil 
   Standard fish body oil  
   Omega-3 fatty acid concentrate 
   Omacor (Pronova Biocare/Solvay) 
1.09-1.83 
0.9-1.56 
 
1.81 
1.71 
 
0.98 
0.84 
 
0.13 
0.24 
 
0.15 
0.2 
 
1.17 
0.47 
0.37 
 
0.19 
0.30 
0.50 
0.85 
2 
1.5-2.5 
2-3.5 
 
1.5 
2 
 
3 
3.5 
 
23 
12.5 
 
20 
15 
 
2.5 
6.5 
8 
 
5 
3 
2 
1 
The intakes of fish given above are very rough estimates because oil content can vary markedly 
(>300%) with species, season, diet, and packaging and cooking methods. 
Adapted from USDA Nutrient Data Laboratory. 
 
 
1.2.2  Fish Consumption and Risk of CVD 
 
   It is increasingly recognized that regular fish consumption is associated with a reduced 
risk of sudden cardiac death and of cardiovascular disease (von Schacky 2003; Harris 
2005). Table 1.6 illustrates that epidemiological studies consistently show that consumption 
of at least one serving of fish per week may reduce the risk of CHD death by approximately 
40% compared with no consumption of fish (Kromhout et al. 1985; Rodriguez et al. 1996; 
Daviglus et al. 1997; Albert et al. 1998). In the US Physicians’ Health Study of 20,551 US 
male physicians (aged 40-85 years) free from CVD, who were followed-up for 11 years, it 
was found that weekly fish consumption (up to one meal) was associated with a lower risk 
of sudden cardiac death and a 30% reduction in total mortality as compared to consumption 
of less than one fish meal per month (Morris et al. 1995). Similarly, Hu et al. (2002) 
concluded in the Nurses’ Health Study of 84,688 healthy women (aged 34-59 years) with 
16-year follow-up that a higher intake of fish, was associated with a lower risk of CHD and 
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CHD mortality. In a 30-year follow-up of the Chicago Western Electric Study (N=1822, 
aged 40-55 years), men who consumed more than 35 g fish daily as compared to those who 
consumed none had a relative risk of death from CHD of 0.62 (Daviglus et al. 1997). In a 
case-controlled study in the elderly (> 65 y), the beneficial association between marine-
derived n-3 PUFAs and CHD was shown for fatal CHD, but not for non-fatal MI (Lemaitre 
et al. 2003). In another study, Iso et al. (2006) in a 10-year follow-up on a large cohort 
study comprising of 41,575 Japanase men and women (aged 40-59 years) reported that a 
higher consumption as compared to modest intake of fish once a week of 20 g/day was 
associated with a substantially reduced risk of CVD, primarily of nonfatal cardiac events 
among middle-aged people. Moreover, a meta-analysis of prospective studies counted a 
total of 116,764 individuals has confirmed the association, and again only in high-risk for 
CVD groups (Marckmann & Gronbaek 1999). In this analysis, it was estimated that 
consumption of 40-60 g of fish daily could reduce the risk of CHD death by 40-60% in 
these groups.  
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TABLE 1.6: Evidence of Cardio-protective Effect of Fish and N-3 PUFAs from Epidemiological Studies 
Studies Population 
 (n) 
Follow up 
(y) 
Association between fish or n-3 PUFA intake and risk of 
CHD death 
Main conclusion-protectio
against CHD death 
(Yes/No)  
Kromhout et al. 1985 
(Zutphen Elderly Study) 
 
n=852, men, age 57-76 y  
 
20  Consumption of ≥ 30 g fish/day was associated with 50% 
lower mortality for CHD compared with those who did not eat 
fish. 
Yes 
Rodriguez et al. 1996 
(The Honolulu Heart Program) 
n=7513, men, 45-65 y, 
heavy smokers 
23  Mortality among high smoking group with high fish intake 
was half that those with low fish consumption. 
No inverse relationship between fish intake and CHD in the 
overall population 
No 
Daviglus et al. 1997 
(Chicago Western Electric) 
 
n=1822, men,  
40-55 y 
30  Consumption of > 35 g fish/d compared was associated with 
38% lower risk of death from CHD compared with those who 
did not eat fish. 
Yes 
Albert et al. 1998/ Morris et al. 
1995 
(US Physicians’ Health Study) 
 
 
n=43757, men, 40-75 y 
n=20551, men, 40-84 y 
11  Compared with < 1x fish/mo, relative risk for sudden death 
was 0.64 for those consuming 1-3x/mo and 0.48 for those 
consuming  ≥ 1x/wk 
Consumption of ≥ 1 fish meal/wk was associated with lower 
risk of sudden cardiac death and a 30% reduction in total 
mortality as compared with < 1 fish meal/mo. 
Yes 
Lemaitre et al. 2003 
(Cardiovascular Heart Study)  
n=4778 men and women 
> 65 y 
Up to 10-y  Inverse association between marine n-3 PUFAs and CHD for 
fatal CHD but not for non-fatal MI 
Yes 
Iso et al. 2006 
(JPHC-Japan Public Health 
Centre-Based Study Cohort 1) 
n=41575, 40-59 y 
 
10  Higher consumption as compared to modest intake of fish 
1x/wk of 20 g/d was associated with reduced risk of CVD 
primarily non fatal cardiac events. 
Yes 
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TABLE 1.7: Evidence of Cardio-protective Effect of N-3 PUFAs from Clinical Trials 
Studies Population 
 (n) 
Follow up 
(y) 
Outcome Main 
conclusion-
protection 
against 
CHD death
(Yes/No)  
Burr et al. 1989 
(DART; Diet and 
Reinfarction Trial) 
 
n=2033 men with recent MI, 
advised to increase their oily fish 
intake to twice a week or 
received 3 fish oil capsules/day 
if they could not tolerate the fish 
2  The fish advice resulted in a 29% reduction in total mortality, 32% decrease in 
fatal myocardial reinfarction. Based on assumption that EPA contributes ≈ 40% 
of the total EPA and DHA in oily fish, daily intake of EPA plus DHA was 
estimated ≈ 900 mg/d. 
No significant reduction in the incidence of recurrent non-fatal MI. 
 
Yes 
Sacks  et  al.  1995  n=59, 4.8 g/day EPA + DHA 
(n=31) vs olive oil (n=28) 
 
2.4  Fish oil supplementation does not promote major favourable changes in the 
diameter of atherosclerotic coronary arteries. 
No 
Singh et al. 1997 (Indian 
Study on Infarct 
Survival) 
n=360, 1.8 g/day EPA + DHA 
(n=122)  vs 2.9 g/day ALA 
(n=120) or non-oil placebo 
(n=118) 
 
1  Total cardiac events (sudden cardiac death, total cardiac death, non-fatal 
reinfarction) were reduced by 25% in the fish oil group. 
Yes 
Leng et al.  1998  n=120, 0.27 g/day EPA (n=60) 
vs sunflower seed oil 3 g/day 
(n=60) 
 
2    N-3 PUFAs significantly reduced a systolic blood pressure, but no other 
significant benefits on risk factors. 
No 
von Shacky et al. 1999  n=223 patients with CAD, 3.3 x 
mo, then 1.65 g/day EPA + 
DHA (n=112) vs  vegetable oil 
blend (n=111) 
 
2  Fish oil supplementation modestly reduces the course of coronary 
atherosclerosis. 
Yes 
De Lorgeril et al. 1999 
(The Lyon Heart Study) 
n=233 survivors of first MI, 
Mediterranean diet (rich in 
ALA)  vs prudent Western-type 
diet. 
 
4  50-70% lower risk of recurrent risk cardiac death and non-fatal MI in group 
who had Mediterranean diet supplemented with ALA 
Yes 
Nilsen et al. 2001  n=300 hospitalized patients, 3.36 
g/day n-3 PUFAs vs corn oil. 
1.5  No clinical benefit from fish oil was demonstrated, but participants lived in a 
coastal area of Norway where they consumed a baseline diet rich in n-3 PUFAs. 
 
No 
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Studies Population 
 (n) 
Follow up 
(y) 
Outcome Main 
conclusion-
protection 
against 
CHD death
(Yes/No)  
GISSI, 2001; Marchioli 
et al. 2002 
(GISSI-Prevenzione 
Trial) 
 
n=11323 persons having 
survived a MI for a median of 16 
days; a factorial design of 850-
882 mg/d EPA and DHA 
(n=5665)  vs 300 mg vitamin 
E/usual care (n=5658) 
 
3.5  A significant reduction for all-cause mortality, cardiac death and sudden death 
by 21%, 35% and 45% respectively. 
No significant reduction in the incidence of recurrent non-fatal MI. 
 
 
Yes 
Bemelmans et al. 2002 
(MARGARIN; The 
Mediterranean ALA 
Enriched Groningen 
Dietary Intervention) 
n=266, 6.3 g/day ALA (n=109) 
vs control-ALA 1.0 g/day 
(n=157) 
2  The effect of ALA supplementation on estimated IHD risk was at least similar 
to, or even greater than, that of a standard LA-rich diet 
No 
Burr et al. 2003 
(DART-2) 
DART-2 
n=3114 men with angina, advice 
to eat fish or providing fish oil 
capsules, estimated of 1.07 g/day 
EPA + DHA (n=1571) vs control 
(n=1543) 
12-16  Less sudden death in control (under-funded, thus not properly conducted or 
reported study, compliance was checked in only 2% of the cohort and only at 6 
months) 
 
No 
Raitt et al. 2005  n=200  patient  with  implantable 
cardioverter defibrilator (ICD) 
and a recent episode of sustained 
ventricular tachycardia (VT) or 
ventricular fibrillation (VF), 1.8 
g/day EPA + DHA (n=100) vs 
olive oil (n=100) 
 
2  Fish oil supplementation does not reduce the risk of VT/VF and may be pro-
arrhythmic in some patients. 
No, fo
reducing th
risk  o
VT/VF. 
Leaf et al. 2005  n=402 of ICD patients, 2.6 g/day 
EPA + DHA (n=200) vs 4 g/ day 
olive oil (n=202) 
1  Fish oil supplementation may significantly reduce fatal ventricular arrhythmias 
in individuals at high risk fatal ventricular arrhythmias although no significance 
was achieved for the primary end point (ICD events for VT/VF and/ or death 
from any cause) 
 
Yes, in high
risk 
individuals.
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Studies Population 
 (n) 
Follow up 
(y) 
Outcome Main 
conclusion-
protection 
against 
CHD death
(Yes/No)  
Brouwer et al. 2006 
(SOFA; The Study on 
Omega-3 FA and 
Ventricular 
Tachyarrhythmia) 
n=546 ICD patients, 2g/ day 
EPA + DHA (n=273) vs 3.4 
g/day sunflower oil  (n=273) 
1  Fish oil supplementation does not indicate a strong protective effect against 
ventricular arrhythmia in patients with ICD 
No, on lif
threatening 
cardiac 
arrhythmia 
Yokoyama et al. 2007 
(JELIS; Japan EPA Lipid 
Intervention Study) 
 
n=18645 patients with 
hyperlipidemia of which 3664 
had already established CAD, 
1.8 g/day EPA vs usual care 
4.6  The primary endpoint was ‘major coronary events’- sudden cardiac death, fatal 
and non- fatal MI, unstable angina, events of angioplasty/stenting or CBG. This 
primary endpoint was reduced by 19% compared with control. 
** All hyperlipidemia patients was treated with statins 
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1.2.3  n-3 PUFAs and CVD 
 
   Observational findings of a lower incidence of CVD in Inuits of Greenland despite a high 
saturated fat intake (about 40% from total energy intake) (Dyerberg & Bang 1979) were 
believed to be related to the high LC n-3 PUFAs consumption. Further experiments showed 
that the cardio-protective effects were derived from EPA and DHA (Billman et al. 1999). 
However, in a cross-sectional study involving 454 Alaskan Eskimos, Ebbesson et al. (2005) 
found that there was no association between current n-3 fatty acid consumption/blood 
concentrations and the presence of CHD. The authors suggested that the so-called ‘Eskimos 
paradox’ should be replaced with more modest hypotheses based on the information 
currently available: high consumption of n-3 PUFAs does not protect against the 
development of CHD if other risk factors are present.  
 
Table 1.7 shows a compilation of clinical studies of the effect of n-3 PUFAs on CVD risk. 
Burr et al. (1989) reported a 29% reduction in all-cause mortality over a 2-year period in 
male MI survivors who were advised to increase their oily fish intake (200 to 400 g of oily 
fish per week), equivalent to 500-800 mg/d of n-3 PUFAs.  Subsequently, Singh et al. 
(1997) reported a 25% reduction in total cardiac events with 1.8 g/d of EPA plus DHA. The 
pioneer large randomized controlled trial before JELIS to test the efficacy of n-3 PUFAs 
was the GISSI-Prevention Study. It was found that after 3.5 years of follow-up, there was a 
20% reduction in all-cause mortality and a 45% reduction in sudden death in post-MI 
patients receiving 850-882 mg/d EPA plus DHA (GISSI 2001). An effect of EPA per se 
(1.8 g/day) is suggested in a large study involving more than 18,000 patients with 
hyperlipidemia, of which 3664 had established CAD; there was a significant reduction in 
unstable angina, non-fatal coronary events and major coronary events (Yokoyama et al. 
2007) (Table 1.7). 
 
Some meta-analyses conclude that n-3 PUFAs reduce overall mortality, mortality caused by 
myocardial infarction (MI) and sudden cardiac death in patients with CHD by 30% (Bucher 
et al. 2002). In contrast, Hooper et al. (2006) concluded in a recent meta-analysis, which 
reviewed 48 randomised controlled trials and 41 cohort studies, that no strong evidence of a 
reduced risk of: total mortality, CVD events or cancer. This finding however has been 
debated and caused considerable controversy since the finding of no demonstrable 
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protective effect of n-3 PUFAs on CVD contrasts with other meta-analyses and the 
outcomes appear to be influenced by the inclusion of the DART 2 study involving more 
than 3000 men with angina. In this DART 2 study, an unexpected 26% increase in cardiac 
deaths in men taking the long chain n-3 PUFAs supplements was reported (Burr et al. 2003) 
but this finding was not explained by the authors. Among several recent reviews of the 
relationship between fish or fish consumption and CHD, that by Wang (2006) appears to be 
the most thorough and comprehensive. Indeed, the authors stated that most studies reported 
that n-3 PUFAs significantly reduce all-cause mortality, MI, cardiac and sudden death or 
stroke. Primary prevention of CVD was reported in one randomised controlled trial, in 25 
prospective cohort studies and in seven case-controlled studies. In this review, it was 
concluded that the evidence fish oil beneficial is stronger in secondary-prevention than in 
primary-prevention setting. 
 
 
1.2.3.1  Possible Mechanism: Arrhythmias 
 
   Cell culture and animal models, observational studies and human intervention trials all 
suggest that the major effect these fatty acids may protect against is fatal arrhythmias (Burr 
et al. 1989; Charnock 1994; Nair et al. 1997) rather than being anti-atherothrombotic. The 
underlying mechanism involved may due to a stabilizing effect on the myocardium itself 
(Nair et al. 1997; Kris-Etherton et al. 2002; Lee & Lip 2003) and n-3 PUFAs are suggested 
to alter the electrical properties of the surface membrane of the cell, causing a raising 
threshold for the generation of an action potential. Consequently, any stimulus that could 
lead to arrhythmia would have to be larger in order to exceed the increased threshold 
(McLennan et al. 1992) and therefore these fatty acids exert a protective effect; DHA is 
recognised as the most potent agent (McLennan et al. 1992; Demaison et al. 2002). Leaf 
(2007) concluded that even though the evidence that EPA and DHA are able to prevent fatal 
ventricular arrhythmias in humans is probable, this is not yet totally convincing.  
 
Heart-rate variability and absolute heart rates have been associated with altered risk for 
sudden cardiac death. This was investigated by Mozaffarian et al. (2006) in a meta-analysis 
of randomised trials; it was found that n-3 PUFAs decreased heart rate significantly by 2.5 
beats/min compared with placebo in trials with baseline heart rate of more than 69 
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beats/min. In trials with heart rate less than 69 beats/min only a small effect was seen. 
Furthermore, fish oil reduced heart rate by 2.5 beats/min in trials with duration greater than 
12 weeks compared with 0.7 beats/min reduction in trials less than 12 weeks.  Therefore it 
is concluded that based on randomised, controlled trials in humans, fish oil reduces heart 
rate, particularly in those with higher baseline heart rates and longer treatment duration. 
 
The intake of 1 g/day of EPA and DHA for CVD prevention, treatment after a MI, 
prevention of sudden death, and as a secondary prevention of CVD is recommended by 
cardiac societies (von Schacky & Harris 2007). In accordance to this scientific evidence,  a 
new risk factor has been proposed to be considered for sudden cardiac death, the omega-3 
index which is measured in red blood cells and presented as a percentage of EPA + DHA of 
total fatty acids. An index of > 8% is associated with 90% less risk for sudden cardiac 
death, as compared to an omega-3 index of < 4% and this index has striking similarity to 
LDL as a risk factor for CAD (von Schacky & Harris 2007).  
 
 
1.2.4 n-3 PUFAs and Blood Pressure 
 
   n-3 PUFAs appear to have a small dose-dependent hypotensive effect (Howe 1997), and 
the ability to reduce the blood pressure appears to be dependent on the initial extent of 
hypertension (Howe 1997). It has been reported that consuming a high dose of 5.6 g n-3 
PUFAs daily, a reduction in blood pressure of 3.4/2.0 mm Hg in hypertensive subjects was 
observed (Morris et al. 1993). Moreover, Geleijne et al. (2002), in a meta-analysis of 36 
randomised trials showed that blood pressure was reduced by -2.1/1.6 mm Hg following n-3 
PUFAs supplementation and the effects were greater in older (> 45 years; -3.5/-2.4) and 
hypertensive (≥ 140/90; -4.0/-2.5) subjects. On the other hand, in 11 trials involving 
normotensive subjects, Appel et al (1993) estimated a reduction by -1.0/-0.5 mm Hg and by 
-5.5/-3.5 mm Hg in untreated hypertensives (6 trials) following an average intake > 3 g/day 
n-3 PUFAs.  
 
It was still unclear until recently whether EPA and DHA are similarly important in blood 
pressure lowering. Mori et al. (1999) demonstrated that high doses (4 g/day) of DHA, but 
not EPA, significantly reduced blood pressure (-5.8/-3.3 mm Hg) in mildly 
 Chapter 1 Introduction                                                                                                                  60 
hypercholesterolemic patients. Conversely, in a similar study design, neither EPA nor DHA 
was able to demonstrate this effect (Woodman et al. 2002). Further research is needed to 
determine the effect of low doses of n-3 PUFAs which are achievable by normal dietary 
intake, on blood pressure since those studies reported blood pressure lowering tended to use 
high doses in region > 4 g/day. 
 
 
1.2.4  n-3 PUFAs and Lipid Profile 
 
   The hypotriglyceridemic effects of n-3 PUFAs from fish oils are well established. This 
effect is reported to be dose-dependent. Harris (1997) in a comprehensive review of human 
studies reported that approximately 4 g/day of n-3 PUFAs from fish oil decreased serum 
triglyceride levels by 25-30% with an accompanying increase in LDL-c of 5%-10% and in 
HDL-c of 1%-3% In terms of different type of n-3 PUFAs, EPA has been reported to have 
little impact on total cholesterol, LDL-c and HDL-c levels. One study, however, revealed a 
small but significant 2.5% decrease in total cholesterol with EPA (Grimsgaard et al. 1997). 
Despite HDL-c not being changed by EPA supplementation, HDL3-c decreased and HDL2-c 
increased in dyslipidaemic (Mori et al. 2000) and HDL3-c decreased in type 2 diabetic 
(Woodman et al. 2002) patients. Supplementation with DHA, on the other hand, reduced 
triglycerides in most controlled studies by approximately 17-33% (Woodman et al. 2002; 
Nestel et al. 2002; Mori et al. 2000; Grimsgaard et al. 1997; Agren et al. 1996; Conquer et 
al. 1996) with the largest decrease occurring in subjects with the highest baseline 
triglycerides (1.6 mmol/L) (Mori et al. 2000). Moreover, unchanged triglycerides were 
observed in studies using lower purity DHA (Conquer et al. 1998; Hamazaki et al. 1996), a 
relatively low dose (< 2 g/day) (Conquer et al. 1998) and in normotriglyceridemic subjects.  
 
 
1.2.5  n-3 PUFAs and Inflammation 
 
   Inflammation is part of the complex immunological response of host tissues to injury or 
infection and is characterized by pain, swelling, redness and heat. This reaction is a normal 
and protective mechanism in order to remove the harmful stimuli and also to initiate the 
healing process for the host. However, when inflammation occurs excessively or in 
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inappropriate manner, it can lead to the development of acute and chronic diseases 
characterised by the production of inflammatory cytokines, arachidonic acid (ARA)-derived 
eicosanoids, other inflammatory agents such as reactive oxygen species (ROS) and 
expression of adhesion molecules.   
 
The relationship between PUFAs and inflammation is based on the fact that a high intake of 
LC n-3 PUFAs results in decreased production of cytokines, inflammatory eicosanoids, 
ROS and also adhesion molecule expression (Calder 2006). The eicosanoids, which are 
among the most potent mediators and regulators of inflammation, are derived from 20-
carbon PUFAs. Since inflammatory cells typically contain a high proportion of n-6 PUFA 
ARA and low proportions of n-3 PUFAs, particularly EPA and DHA, ARA is the main 
substrate for eicosanoid synthesis (Calder 2006). For example, PGs (prostaglandins), TXs 
(thromboxanes), LTs (leukotrienes), HETEs (hydroxyeicosatetraenoic acid) and other 
derivatives as summarized in Fig 1.7, are among ARA-derived eicosanoids which are 
generated from free ARA derived from cell membrane phosphatidylcholine.  
 
Free arachidonic acid
PGG2
15-
HPETE
12-
HPETE 5-HPETE
15-HETE 12-HETE PGH2 LTA4 5-HETE
PGD2
PGE2
PGI2 TXA2
PGF2
COX 15-LOX 12-LOX 5-LOX
LTC4
LTD4
LTE4
LTB4
ARA in cell membrane 
phosphatidylcholine
Lipoxin A4
PGJ2
 
FIGURE1.7: Synthesis of Eicosanoids from ARA 
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It has been reported that eicosanoids are responsible for modulating the intensity and 
duration of inflammatory responses (Lewis et al. 1990; Tilley et al. 2001), with those from 
ARA most commonly have pro-inflammatory actions. Bagga et al. (2003) have 
demonstrated the effects of PGE2 as pro-inflammatory mediators whereby PGE2 stimulates 
cyclooxygenase 2 (COX-2) which is induced in inflammatory conditions, in fibroblasts 
cells and thus up-regulates its own production and also induces the production of IL-6 by 
macrophages. Indeed, increased rates of ARA-derived eicosanoids production are found 
under inflammatory states in blood and tissues from patients with acute and chronic 
inflammatory conditions. On the other hand, PGE2 suppresses 5-lipoxygenase (5-LOX) and 
thus decreases the production of the 4-series LTs (Levy et al. 2001) and stimulates 15-LOX 
and thus leads to the formation of lipoxins (Levy et al. 2001; Vachier et al. 2002), which 
have been shown to have anti-inflammatory effects (Gewirtz et al. 2002; Serhan et al. 
2003). Therefore, PGEs has both pro- and anti-inflammatory actions. 
 
In order to suppress the generation of pro-inflammatory mediators from ARA-derived 
eicosanoids, increased n-3 PUFAs intake should be considered. Supplementation with fish 
oil has been shown to result in decreased production of PGE2 (Endres et al. 1989; Caughey 
et al. 1996; Meydani et al. 1991; Trebble et al. 2003), TXB2 (Caughey et al. 1996), LTB4 
(Lee et al. 1985; Sperling et al. 1993), 5-HETE (Lee et al. 1985; Sperling et al. 1993) and 
LTE4 (von Shacky et al. 1993) by inflammatory cells. Studies showed that 6 g DHA/day 
resulted in decreased production of PGE2 and LTB4 by 60% and 75%, respectively in 
endotoxin-stimulated mononuclear cells (Kelley et al. 1998). Furthermore, DHA-derived 
mediators, known as D-series resolvins, docosatrienes and neuroprotectins, produced by 
COX-2 have been identified and these have anti-inflammatory actions (Hing et al. 2003; 
Marcheselli et al. 2003; Mukherjee et al. 2004).  
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FIGURE 1.8: EPA-derived Eicosanoid Synthesis 
 
On the other hand, Figure 1.8 shows EPA can also acts as substrate for both COX and 5-
LOX which leads to increases in EPA-derived eicosanoids, which have a slightly different 
structure from those generated from ARA (Figure 1.7). Accordingly, increased production 
of the less inflammatory LTB5, LTE5 and 5-hydroxyeicosapentaenoic acids (5-HEPE) by 
inflammatory cells with fish oil supplementation have been shown (Lee et al. 1985; 
Sperling et al. 1993; von Shacky et al. 1993), although production of PGE3 has been more 
difficult to demonstrate (Hawkes et al.1991). The EPA-derived eicosanoids are believed to 
be less potent than those generated from ARA (Goldman et al. 1983; Lee et al. 1984). 
Resolvins (resolution phase interaction products) are introduced for the bioactive 
compounds that demonstrate potent anti-inflammatory and immunoregulatory actions. The 
compounds derived from EPA carrying potent biological actions are designated as E series, 
given their EPA precursor, and denoted as Resolvins of the E series (Resolvin E1 or RvE1), 
and those biosynthesized from the precursor DHA are Resolvins of the D series (Resolvin 
D1 or RvD1) (Serhan et al. 2000; Serhan et al. 2002; Hong et al. 2003). Thus, not only 
decreased production of ARA-derived mediators following fish oil supplementation is 
important in understanding the modulation of immune system by EPA and DHA, but also 
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the production of D- and E-series resolvins have led to the  idea that fish oil is anti-
inflammatory (Fig 1.9).  
 
 
FIGURE 1.9: Mechanism of the Anti-inflammatory Action of DHA and EPA. (Source: 
Calder 2005) 
 
Of note, the anti-inflammatory effects of n-3 PUFAs might also be independent of 
eicosanoids production. For example, studies have been shown that n-3 PUFAs from fish 
oil result in decreased leukocyte chemotaxis, decreased production of reactive oxygen 
species and proinflammatory cytokines and decreased adhesion molecule expression (See 
Section 1.3.7). However, although some data suggest a beneficial effect of n-3 PUFAs on 
endothelial function (Schmidt et al. 2005; Kris-Etherton et al. 2002; Seierstad et al. 2005), 
there are few indications that n-3 PUFAs reduce CRP levels (Madsen et al. 2003; Geelen et 
al. 2004). The association between n-3 PUFAs and inflammatory markers remains unclear. 
For instance, some studies reported no effect of high doses of EPA and DHA (4 g/d) on 
CRP, IL-6 and  TNF-α (Mori et al. 2003), whereas other studies have found that intake of 
ALA about five times higher than average reduced levels of inflammatory marker such as 
sICAM-1 and sE-selectin (Zhou et al. 2004). Moreover, Hjerkinn et al. (2005) found that 
relatively high intake of EPA plus DHA reduced serum thrombomodulin and adhesion 
molecule levels in elderly, hyperlipidemic Norwegian men treated for 3 years.  
 
In vitro studies showed that DHA reduces endothelial expression of VCAM-1, E-selectin, 
ICAM-1, IL-6 and IL-8 in response to exposure to IL-1, IL-4, tumor necrosis factor or 
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bacterial endotoxin (De Caterina 2000). Conversely, no inhibitory effects were observed 
with saturated fatty acids. They also concluded that n-3 PUFAs seem to have the greatest 
inhibitory effect, with n-6 fatty acids being intermediate, followed by MUFAs. The effect of 
n-3 PUFAs particularly EPA and DHA on adhesion molecule expression is further 
discussed in Section 1.3.7. 
    
 
1.3 Cellular Adhesion Molecules and Atherosclerosis 
 
   Cellular adhesion molecules (CAMs) are trans-membrane proteins that mediate cell-cell 
or cell-matrix interactions. In the early pathogenesis of atherosclerosis, CAMs participate in 
leukocyte-endothelial interactions and infiltration of monocytes; thus suppression of their 
expression protects against atherosclerosis (Nageh et al. 1997). A variety of these, named 
endothelial-leukocyte adhesion molecules, participate in the process of selective attachment 
of leukocytes to the blood vessel wall, which is involved in tissue inflammation (Gonzalez-
Amaro et al. 1998), atherogenesis (Cotran et al. 1998) and immune function (Wang et al. 
1998). 
 
 
1.3.1  Adhesion Molecules of the Selectin Family 
 
   The selectin family includes: L-selectin (also known as leukocyte adhesion molecule-1, 
(LAM-1) and CD62L), E-selectin (also known as endothelial leukocyte adhesion molecule-
1 (ELAM-1) and CD62E) and P-selectin (also known as granule membrane protein 140 
(GMP-140) and CD62P). The expression of L-selectin is limited to haematopoietic cells, 
with most leukocytes expressing L-selectin at some stage of differentiation. E-selectin plays 
a central role in the binding and infiltration of neutrophils and a subset of leukocytes from 
the bloodstream into sites of inflammation (Kaszubska et al. 1993). Expression of E-selectin 
is both cell specific since it is only expressed on endothelial cells and also stimulus specific 
since it is expressed in response to induction by the cytokines interleukin-1 (IL-1), TNF-α, 
lipopolysaccaride (LPS) and phorbol myristate acetate (PMA) (Bevilacqua et al. 1989). P-
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selectin, on the other hand, is constitutively found in Weibal-Plade bodies of endothelial 
cells and in alpha granules of platelets (Table 1.8). 
 
The molecular mass of selectins varies between 75-140 kDa and these receptors are 
composed of single-chain transmembrane glycoproteins with a calcium dependent amino-
terminal lectin-binding domain, an epidermal growth factor (EGF)-like domain and varying 
numbers of domains known as short consensus repeats (SCR). Each selectin has a 
membrane-spanning region and a short cytoplasmic region of 2, 6 and 9 amino acids for L, 
E and P- selectin, respectively. The roles of each of these domains, however, remain unclear 
since monoclonal antibodies (mAB) to the lectin domain block selectin mediated adhesion 
but a mAb to the SCR also blocks L- and E-selectin mediated adhesion (Hogg & Landis 
1993). However, if the EGF domain is deleted, cell adhesion is also abolished (Pigott et al. 
1991).  
 
 
1.3.2  Adhesion Molecules of the Immunoglobulin-like Superfamily (IgSF) 
 
   Most of these proteins are located as cell surface molecules with the exception of some 
intracellular and secreted proteins. The IgSF can be divided into groups based on their 
functions. For example, the C1-type receptors participate in antigen recognition and include 
the T cell receptor (CD3), CD4 and CD8 or in complementary binding include major 
histocompatibility complex (MHC) class 1 and class 2. The C2-type receptors are involved 
with CD56 and CD58. Five receptors of this subclass have been demonstrated to be 
involved in leukocyte adhesion: ICAM-1, ICAM-2, VCAM-1, platelet-endothelial cell 
adhesion molecule (PECAM-1) and the mucosal addressin (MAdCAM-1) (Krieglstein & 
Granger 2001). 
 
ICAM-1 (also known as CD54) has a core protein of 55 kD with five extracellular Ig-like 
domains. The main ligands for ICAM-1 include LFA-1, Mac-1 and CD43 (Carlos & Harlan 
1994; Diamond et al. 1991). The main binding site for LFA-1 is located in the NH2-terminal 
first domain of ICAM-1, meanwhile the second binding site for Mac-1 is located in the third 
domain. In all, eight possible sites for N-linked glycosylation have been found in the Ig-like 
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domains. ICAM-1 is expressed by epithelial cells, fibroblasts, leukocytes and endothelial 
cells. 
 
VCAM-1 has a core protein of 81 kDa with seven extracellular Ig-like domains expressed 
in the dominant form and six in the other sites. Ligand binding sites have been located in 
the NH2-terminal first and fourth domains of seven Ig-like domains (7D) VCAM-1. The 
major ligands are VLA-4 (integrin α4/β1) (Elices et al. 1990) and α4/β7 (Ruegg et al. 1992). 
VCAM-1 is expressed by endothelial cells, tissue macrophages, dendritic cells, bone 
marrow fibroblasts and myoblasts.  
 
 
1.3.3  The role of Adhesion Molecules in Normal Physiology 
 
   Adhesion molecules mediate the processes of cell activation, migration, proliferation and 
differentiation which require direct cellular and cell-matrix interactions (Mousa & Cheresh 
1997). This discovery has been a key factor in understanding the underlying mechanisms of 
inflammation and immune system activity. Even though CAMs are expressed mainly on the 
vascular endothelium, their density is greatest in post capillary venules. Larson and 
Springer (1990) reported that engagement of these receptors to ligands on leukocytes results 
in intracellular signals which can affect the phenotype and gene expression, movement or 
activation of a cell. Consequently, this process may be partly mediated through intracellular 
transcripts of several genes associated with transcriptional control, such as IκBα and 
activator protein-1 (AP-1) which are altered after monocyte adhesion to an endothelial cell 
or by stimulation with cytokines such as TNF-α or IL-1. Activation of the cell leads to 
phosphorylation and proteolysis of IκBα, the cytoplasmic inhibitor of nuclear factor-κB 
(NF-κB). Ultimately, this activation allows NF-κB to be translocated to the nucleus where it 
binds to elements in gene promoters. Moreover, it was found that NF-κB and AP-1 can be 
modulated by redox-sensitive signal tranducers such as PKC, α-tocopherol and glutathione 
(Mondal et al. 1995; Lum & Roebuck 2001). 
 
Members of the selectin family have been implicated in mediating adhesion to endothelial 
cells while E- and P-selectin participate in coagulation (Springer 1990). When selectins 
mediate the initial weak interactions between the vascular endothelium and leukocytes as 
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shown in Figure 1.10, this process is known as rolling since the leukocytes decelerate from 
the blood stream by rolling along the endothelium. Rolling causes other CAMs to be 
activated by chemokines which are produced by cells in the tissue and attached to the 
endothelium and subsequently leading to firm adhesion and transmigration. Anti-L-selectin 
mAb decreases the adherence of monocytes and neutrophils to cytokine-stimulated 
endothelium and reduces recruitment of leukocytes in vivo (Abassi et al. 1991). Anti-E-
selectin mAb blocked neutrophil accumulation in the inflamed peritoneum and lung of 
normal animals (Mulligan et al. 1991), anti-P-selectin mAb decreased leukocyte rolling in 
vivo, whereas P-selectin activates neutrophil adhesion to endothelial cells. In accordance 
with this finding, spontaneous rolling was almost absent in mesenteric venules of P-selectin 
deficient mice (Carlos & Harlan 1994) and leukocyte rolling was found to be exclusively 
mediated by P-selectin in colonic venules (Wan et al. 2002). Therefore, it is concluded that 
differences in expression and utilization of CAMs in different parts of the body are 
depending on the ligands and regulators of L-, P- and E-selectin, such as listed in Table 1.8. 
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TABLE 1.8: Examples of Adhesion Molecule Ligands, Distributions and Regulators of 
Expression 
Adhesion 
molecule 
Ligands  Cellular distribution  Regulation and expression 
Selectin family: 
E-selectin  
(ELAM-1,  
LECAM-2) 
 
Sialyl-Lewis X and A 
antigen, CLA 
 
 
Endothelium 
 
 
 
Upregulated by inflammatory 
diseases, cytokines (TNF-α/LPS/IL-
1β), thrombin, phorbol esters. 
L-selectin  
(LAM-1, 
 LECAM-1) 
 
CD34, MadCAM-1, 
GlyCAM-1 
 
Haematopoietic cells 
 
Upregulated by phorbol esters, 
cytokines or chemoattractants. Down 
regulated by shedding after activation 
of Mac-1 receptor. 
P-selectin 
(LECAM-3) 
 
Sialyl-Lewis X and A 
antigen 
 
Platelets, EC, 
megakaryocytes 
Upregulated by thrombin, histamine, 
PMA, LTC4, bradykinin or peroxides. 
 
Integrin family: 
β1 VLA-1 α1β1 
 
Laminin, collagen 
Upregulated by retinoic acid causing 
differentiation of SY5Y and IMR32 
neuroblastoma cell lines. 
      VLA-2 α2β1  Laminin, collagen  Upregulated by mitogen or antigen on 
lymphocytes, serum on fibroblasts, 
TGFβ. 
      VLA-3  
       
α3Aβ1,α3Bβ1 
Laminin, collagen, 
fibronectin 
 
T cells, monocytes, neuronal 
cells, smooth muscle cells 
B & T cells, platelets, 
fibroblasts, EC & cell lines. 
 
 
 
 
Upregulated by attachment of some 
cells to the extracelular matrix. TGFβ 
can down regulate in some cell types. 
      VLA-4 α4β1  Fibronectin, VCAM-1  Broad, not lymphoid cell 
lines 
Expression on T cells slowly 
increased after activation. 
      VLA-5 α5β1  Fibronectin Constitutively  expressed  and 
regulated during B cell development. 
      VLA-6 α6β1   Laminin 
Broad leukocytes, 
fibroblasts, platelets, muscle 
cells platelets, monocytes, T 
cells, thymocytes, EC, 
eosinophils 
 
Constitutively expressed. Activity 
depends on Mg
2+ dependent 
activation, not quantitative changes 
triggered by TCR/CD3 complex. 
β2 LFA-1 αLβ2  ICAM-1, ICAM-2, 
ICAM-3 
Leukocytes 
 
Upregulated by inflammatory stimuli 
e.g. fMLP, C5a, leukotreine B4. 
Increased expression in maturation 
and differentiation of monocytes. 
     Mac-1 αMβ2   ICAM-1, C3bi, factor 
X, LPS, fibrinogen 
Monocytes, macrophages, 
granulocytes, NK cells 
 
Upregulated by inflammatory 
mediators, phorbol esters on B cells, 
on activation of B cells, 
differentiation of monocytes to 
macrophages. 
     p150,95 αXβ2   C3bi, fibrinogen  Macrophages, granulocytes, 
activated B lymphocytes. 
Constitutively expressed. Can only 
bind fibrinogen when platelet 
unstimulated.  
β3 GpIIb/IIIa β3 
α11bβ3, 
Fibrinogen, factor VIII, 
thrombospondin, 
vitronectin 
EC, osteoclasts, platelets, 
some B/ macrophages/ 
tumour cells 
Activated by thrombin, collagen, 
ADP. 
    CD51/CD61  
    αvβ3  
Vitronectin, factor VIII, 
fibrinogen, 
thrombospondin, 
collagen 
Epithelial.  Upregulated by phorbol esters. 
β4 
α6Aβ4/α6Bβ4, 
α4β7  
Laminin   Activated B & T cells, 
intraepithelial lymphocytes. 
Constitutively expressed. Laminin 
binding requires activation. 
Ig-like 
superfamily 
ICAM-1  
(CD54) 
 
LFA-1, Mac-1 
 
Upregulated by inflammatory 
diseases, cytokines (IFNγ, IL-1β, 
TNF-α), LPS, phorbol esters, 
activated platelets and decreased 
shear stress in vitro. 
ICAM-2, LFA-1 
 
Broad, most prominently 
expressed on vascular 
endothelium 
EC, subpopulations of 
lymphocytes, monocytes,  Constitutively expressed on EC, T 
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ICAM-3    cells 
VCAM-1  VLA-4, α4β7  
 
Upregulated by inflammatory 
diseases, cytokines (IFNγ, IL-1β, 
TNF-α), LPS. 
PECAM-1 
(CD31) 
Unknown 
 
dendritic cells, fibroblasts, 
myoblasts, myotubes 
platelets, EC, monocytes, 
granulocytes and some T 
cells 
Developmentally regulated during 
myogenesis. Constitutively expressed. 
Down regulated on active 
granulocytes with fMLP treatment 
and active T cells. 
Abbreviations: ICAM-, intercellular adhesion molecule-; C3bi, inactivated complement component C3; VCAM-, vascular 
cell adhesion molecule-; VLA, very late antigen; fMLP, fMet-Leu-Phe; PECAM-, platelet endothelial cell adhesion 
molecule-; IL-, interleukin-1; TNF-, tumour necrosis factor-; IFN-, interferon-EC, endothelial cell; TGF-
transforming growth factor; LPS, lipopolysaccaride; NK, natural killer; MadCAM, mucosal addressin cell 
adhesion molecule; TCR, Transfer-Cluster Restricted; CD, cluster differentiation. 
 
 
In the adhesion cascade (Fig 1.10), integrins mediate firm adhesion of leukocytes to the 
endothelium and subsequently assist in transmigration. Chin et al. (1992) reported that 
integrins are first expressed during differentiation of hematopoietic stem cells and are 
involved in lymphocyte trafficking to peripheral lymph nodes and Peyer’s Patches.  
 
FIGURE 1.10: The Adhesion Molecules Cascade 
This figure shows the process of leukocyte adhesion cascade beginning with 1) capturing 
and subsequently rolling of leukocytes to the blood vessel by selectins, 2) chemotactic 
factors such as chemokines on the endothelial cell surface leads to the activation of 
leukocytes, 3) firm adhesion of the leukocytes at endothelial cells before transmigration, 4) 
finally leukocytes migrate through endothelial cells into the underlying tissue. (Source: 
Wild 2008)  
 
 
 
Beta-2 integrins play a critical role in inflammation, mediating leukocyte adhesion, 
migration and diapedesis. LFA-1 is important in lymphocyte adhesion to CNS derived 
endothelial cells (Greenwood et al. 1995) and mediates a wide range of antigen-dependent 
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and independent reactions. Moreover, LFA-1 may be required for thymic development of 
lymphocytes whereby LFA-1/ICAM-1 interactions were revealed to be important in 
differentiation of CD4
+8
+ cells from CD4
-8
- cells (Fine & Kruisbeek 1991). 
 
The IgSF is also important in cell activation, differentiation and cell-cell interactions. Anti-
ICAM-1 mAb partially decreased the recruitment and adhesion of neutrophils in phorbol 
ester-induced inflammation (Barton et al. 1989) and it was found that ICAM-1 deficiency 
led to marked granulocytosis and impaired neutrophil migration and subsequently caused in 
utero fatality due to the developmental of heart abnormalities in mice (Albelda et al. 1994). 
Carlos and Harlan (1992) reported that VCAM-1 binds mononuclear cells, but not 
neutrophils. PECAM-1 is vital in regulating diapedesis and further transmigration via the 
basal lamina, whereby blocking studies demonstrated that cells remained bound to 
endothelial cells over cell junctions (Muller & Randolph 1999). In this process, the known 
regulatory mechanisms are again listed in Table 1.8.  
 
Referring to Table 1.8, of relevance to this discussion, it is clear that ICAM-1, VCAM-1 
and E-selectin are all upregulated by inflammatory mediators. NF-κB binding sites have 
been identified in the promoter region genes for each of these and AP-1 binding sites in the 
genes for E-selectin and ICAM-1 (Connor & Connor 1997). 
 
 
1.3.4  The Role of Adhesion Molecules in Pathological Conditions 
 
   From a clinical point of view, a deficiency state is needed to confirm the importance or 
role of these molecules. In this case, leukocyte adhesion deficiency-1 (LAD-1), a lack of β2 
integrins caused by a heterogenous mutation in the CD18 subunits, leads to marked 
neutrophilia and inability of neutrophils and monocytes to migrate across the endothelial 
cells. However, it was found that lymphocytes, eosinophils and plasma cells are still able to 
migrate, and so cell-mediated immunity remains intact. In LAD-2, a congenital defect in 
endogenous fucose metabolism that leads to an inability to synthesis fucosylated 
carbohydrate molecules and a crippled selectin system, leukocytes show marked defects in 
rolling and adherence (Albelda et al. 1994).  
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Adhesion molecules play an important role in protozoal, fungal, bacterial and viral 
infection. Plasmodium falciparum, for example, causes infected cells to sequester in deep 
tissue by binding to endothelial cells and subsequently leads to cerebral malaria which is 
mediated by CD36, ICAM-1 and VCAM-1. Mycobacterium tuberculosis binds to CR3 and 
CR4 receptor, whereby CR3 binding reduces IL-2 production and inhibits the macrophage 
response and in the end leads to phagocytosis. Viruses often bind to CAMs as well, for 
example, rhinoviruses (91 serotypes) bind to ICAM-1 and HIV-1 binds to CD4 and IgSF 
members. Kerr (1999) comprehensively reviewed the role of CAMs in infection.  
 
In chronic inflammatory conditions such as rheumatoid arthritis, E-selectin, VCAM-1 and 
ICAM-1 are expressed on the microvasculature and synovial lining cells. PECAM-1 is 
expressed on lining cells and macrophages (Cronstein 1994) whereas integrins, on the other 
hand, mediate the adhesion of lymphocytes to synovial endothelial cells (Haskard 1995). 
Graft rejection is another inflammatory state where CAMs play a central role, whereby 
VCAM-1 and ICAM-1 are found to be upregulated in rejecting renal allografts (Eriksson et 
al. 2001). In allergic conditions, VLA-1/VCAM-1 and LFA-1/ICAM-1 interactions 
contribute to eosinophil migration (Albelda et al. 1994). Mononuclear cells from asthmatics 
show upregulation of LFA-1 and VLA-1 (Tomita et al. 1997). In atopic dermatitis and other 
types of eczema, ICAM-1 and VCAM-1 are increased in in vitro studies (Montefort et al. 
1993). Upregulations of ICAM-1, VCAM-1 and E-selectin are found on the small vessels 
around colon neoplasms. The role of these molecules in metastatis and neovascularisation is 
supported by the elevation of E-selectin expression around metastatic sites of the 
endothelium. 
 
 
1.3.5  The Roles of Adhesion Molecule in Pathogenesis of Atherosclerosis 
 
   Leukocyte binding to the endothelium is of fundamental importance in many acute and 
chronic inflammatory disorders (Libby 2002) and this leukocyte binding has been studied 
extensively in vitro to obtain an understanding of the mechanism(s) involved. Activation of 
leukocytes, endothelial cells, or both results in increased adhesion of polymorphonuclear 
leukocytes, monocytes or lymphocytes to the endothelium. It has been found that several 
protein families with different functions trigger signals for leukocytes. These include 1) the 
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selectin family of adhesion molecules which act to recognize carbohydrate analogues (sialyl 
Lewis
x ligands) (Lasky 1993; Rosen 1993); 2) chemoattractants, some of which (classical 
chemoattractants such as N-formyl peptides, complement components, leukotriene B4 and 
platelet-activating factor) act mainly on neutrophils, eosinophils, basophils and monocytes; 
3) the immunoglobulin superfamily members on the endothelium (intercellular adhesion 
molecule 1 (ICAM-1), ICAM-2, ICAM-3 and vascular adhesion molecule 1 (VCAM-1)) 
which recognize the integrin ligands on the leukocyte surface in a model first established 
with ICAM-1 binding to leukocyte function associated antigen (LFA-1)) (Springer 1990). 
 
In the pathogenesis of atherosclerosis, increased E- and P-selectin, ICAM-1 and VCAM-1 
expression is observed. Moreover, it was found that mice deficient in these adhesion 
molecules have fewer fatty streaks even after consuming a high fat diet as compared to 
normal mice (Nageh et al. 1997). E-selectin and ICAM-1 are increased in the fatty streaks, 
but in fibrous plaques ICAM-1 and E-selectin are less well expressed which might be due to 
lack of macrophages producing IL-1 and TNF-α. In aortic hypercholesterolemic mice, 
Nakashima et al. (1998) reported that there is an increased VCAM-1 expression at the 
atherosclerotic lesion preceeding fatty streak formation. Of interest, however, studies in 
atherosclerosis show that VCAM-1 can mediate rolling, firm adhesion and migration of 
monocytes and VLA-4/VCAM-1 interactions without chemoattractants. In a model of cat 
myocardial ischemia and reperfusion, L- and P-selectin inhibitors also reduced endothelial 
dysfunction, decreased infarct size and improved myocardial function (Lefer 2000).  
 
 
1.3.6  Soluble Adhesion Molecules 
 
   The soluble forms of ICAM-1, VCAM-1 and the selectins are all present in the blood with 
similar structure to extracellular transmembrane domain of their membrane-bound 
counterparts. Soluble adhesion molecule concentration in the blood is believed to reflect the 
expression of these molecules at the cell surface and theoretically, shedding of the 
endothelial surface may also increase the concentration of the soluble forms. Thus, these 
molecules may be useful as markers of inflammation. Since ICAM-1 is expressed widely on 
different types of cells, the origin of soluble ICAM-1 (sICAM-1) is difficult to identify in 
vivo. Mononuclear cells and endothelial cells release soluble ICAM-1 (as sICAM-1) as 
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demonstrated in in vitro studies and sVCAM-1 and sE-selectin are shed by activated 
endothelial cells (Fabrega et al. 2000). P-selectin is produced from an alternatively spliced 
mRNA found in endothelial cells and megakaryocytes. Apparently, the source of sP-
selectin is from activated platelets, whereas sL-selectin is shed rapidly after leukocyte 
activation (Haught et al. 1996). It has been reported that TNF-α, IL-1 and IFN-γ stimulate 
the shedding of adhesion molecules from endothelial cells. These molecules act to regulate 
the immune response by providing alternative ligands for leukocyte adhesion. sVCAM-1 
can partly inhibit in vitro monocyte adhesion to activated human umbilical vein endothelial 
cells (Haught et al. (1996). sL-selectin retains functional activity and in high concentration, 
this molecule can suppress leukocyte adhesion to cytokine-stimulated endothelial cells 
(Haught et al. 1996).  
 
 
1.3.7  Soluble Adhesion Molecules in Pathological Conditions 
 
   In general, soluble adhesion molecule concentrations tend to be higher in men compared 
with women (Abe et al. 1998; Eschen et al. 2004).  In the elderly, Miles et al. (2001) found 
that sVCAM-1 and sICAM-1 are elevated in older compared with young subjects. sVCAM-
1 and sE-selectin are increased in all types of acute infections, although sICAM-1 is not 
affected in viral infections (Kulander et al. 2001). In chronic inflammatory diseases, for 
example rheumatoid arthritis, sICAM-1, sVCAM-1 and sE-selectin can be raised 
(Wallberg-Jonsson et al. 2002). sVCAM-1 and sICAM-1 are elevated in renal transplants 
and liver graft rejection, but not  sE-selectin (Eriksson et al. 2001; Adams et al. 1993). 
sICAM-1, sVCAM-1 and sE-selectin can also be raised in metabolic conditions, such as in 
diabetes (Bagg et al. 2001), even though patients are not obese and non-hypertensive (Chen 
et al. 1999) and in individuals with high BMI (Chen et al. 1999; Abe et al. 1998). All these 
three soluble forms are elevated in certain types of cancer including lymphoma, gastric, 
breast and hepatocellular (Gruss et al. 1993; Velikova et al. 1997; Wittig et al. 1996; 
O’Hanlon et al. 2002) and sICAM-1 and sVCAM-1 are also found to be raised in colorectal 
cancer (Velikova et al. 1998).  
 
In one study, an association has been noted between atherosclerosis and increased sICAM-
1, sVCAM-1 and sE-selectin (Hwang et al. 1997). Even though all three can be raised in 
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coronary artery disease (CHD) (Lang et al. 1994), there is debate about whether their 
concentrations can provide predictive information in CHD outcomes in comparison with 
more established risk factors (Malik et al. 2001). One study found sICAM-1 to be positively 
correlated with age, smoking, hypertension, diabetes, serum triglycerides, fibrinogen, 
homocysteine and tissue-type plasminogen activating factor which are all well established 
risk factors (Rohde et al. 1998). Interestingly, regular exercise was found to be beneficial 
whereby levels of sICAM-1 are more likely to be lowered and estrogen replacement therapy 
results in decreased serum levels of sICAM-1, sVCAM-1 and sE-selectin (Lang et al. 
1994), demonstrating a possible link to hormonal regulation. The role of sP- and sL-selectin 
in pathological conditions also has been studied. Generally, sP-selectin is elevated in 
thrombotic consumptive platelet disorder and unstable CHD, whereas sL-selectin is raised 
in acute inflammatory processes like sepsis, but is down-regulated in chronic inflammatory 
states like CHD (Haught et al. 1996). 
 
 
1.3.8  The Effects of Unsaturated Fatty Acids on Adhesion Molecule Expression 
 
   Dietary  components  such  as  micronutrients and fatty acids can influence vascular 
endothelial cell function (Cuevas & Germain 2004). Indeed, in recent years, studies have 
led to new thinking about the relationship between fatty acids, particularly unsaturated 
forms in modulating the immune system and inflammatory processes. This thinking has 
wide implications for pathogenesis of human disease, immunonutrition and therapeutics, 
with special reference to inflammation and atherosclerosis.  Fatty acids have been shown to 
affect inflammatory diseases (Calder 2006), and n-3 fatty acids in particular, are receiving 
increasing attention as potential anti-atherogenic and anti-inflammatory agents. There have 
been several investigations of the effects of fatty acids on adhesion molecule expression on 
endothelial and inflammatory cells and on sCAM concentrations. 
 
In general, in vitro studies with stimulated endothelial cells (Table 1.9) or short term human 
studies (Table 1.11) (Turpenin et al. 1998; Huang et al. 1997) showed that saturated fatty 
acids have no effect on the expression of adhesion molecules even though these fatty acids 
are commonly associated with a higher incidence of cardiovascular disease (Nordoy et al. 
 Chapter 1 Introduction                                                                                                                  76 
1990; Nordoy 1999; Kromhout et al. 2000). However, Bemelmens et al. (2003) reported 
that decreasing saturated fat intake over two years decreases the concentration of sICAM-1. 
 
 
1.3.8.1 The Effect of Monounsaturated Fatty Acids on Adhesion Molecule Expression  
 
   The monounsaturated fatty acid, oleic acid, has been demonstrated to inhibit ICAM-1 and 
VCAM-1 expression by human saphenous vein endothelial cells (HSaVECs) in vitro (De 
Caterina & Libby 1996; Carluccio et al. 1999). In contrast, Shaw et al. (2007) reported that 
oleic acid caused up-regulation of VCAM-1, but had no effect on E-selectin expression. 
Apart from oleic acid, De Caterina et al. (1998) showed that palmitoleic acid (cis16:1n-7) 
C16:1Δ7cis, elaidic acid (trans18:1n-9) C18:1Δ9trans and ricinoleic acid (cis18:1n-9-12-
OH) C18:1Δ9cis-12-OH, also suppress expression of VCAM-1. De Caterina et al. (1998) 
concluded that the configuration (cis/trans) has no effect on inhibitory potency since oleic 
acid (cis18:1n-9) and its trans stereoisomer elaidic acid (trans18:1n-9) are of similar 
potency. Increased consumption of oleic acid in the diet decreased ICAM-1 expression on 
peripheral blood mononuclear cells by 20%, even though this effect was not significant 
(Yaqoob et al. 1998). On the other hand, some studies report no effect of oleic acid on 
ICAM-1, VCAM-1 or E-selectin expression in human umbilical vein endothelial cells 
(HUVECs) (Holthe et al. 2005) or on the soluble forms in plasma (Turpeinen et al. 1998; 
Eschen et al. 2004). To date, there is no beneficial effect of oleic acid in human studies 
regarding the inhibition of adhesion molecule expression, even though in  vitro studies 
revealed that oleic acid exerts a similar effect to EPA and DHA.  
 
 
1.3.8.2 The Effect of n-6 PUFAs on Adhesion Molecule Expression 
 
   Toborek et al. (2002) found that linoleic acid enhanced messenger RNA levels of VCAM-
1 and ICAM-1 in HUVECs whereas Chen et al. (2003) reported an increase of ICAM-1 in 
human retinal vascular endothelial (hRVE) cells, but not in HUVECs. In another study with 
HUVECs, no change in the expression of these adhesion molecules was reported with 
linoleic acid after exposure to LPS (Holthe et al. 2005). For arachidonic acid, one in vitro 
study reported reduced ICAM-1, VCAM-1 and E-selectin in HUVECs (Huang et al. 1997), 
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whereas no effect was observed in other studies with either HUVECs (Sethi et al. 1996) or 
HSaVECs (De Caterina & Libby 1996; De Caterina et al. 1998). However, Shaw et al. 
(2007) reported that ARA can produce a neutral or down-regulatory effect on VCAM-1 and 
E-selectin in HUVECs. Their findings partly agree with Stuhlmeier et al. (1997) who 
reported reduced E-selectin expression with ARA in porcine AOEs and HUVECs. 
Arachidonic acid increased ICAM-1 expression in hRVE cells, but not in HUVECs (Chen 
et al. 2003) and in cultured human keratinocytes (Lu et al. 1995).    
 
n-6 PUFAs such as linoleic acid, γ-linolenic acid and arachidonic acid, generally, have no 
effect on adhesion molecule expression in vivo (Cazzola et al. 2006; Thies et al. 2001; 
Yaaqob et al. 2000).  
 
Thus the literature on n-6 PUFAs and adhesion molecules is rather contradictory. It seems 
important to try to resolve these discrepancies since they may provide information about 
these fatty acids and cardiovascular risk. Reasons for discrepancies, especially in the in 
vitro studies, may be due to different types of cell being studied and the fatty acid used and 
its concentration, as well as in methods of study (Goua & Wahle 2007). 
 
 
1.3.8.3 The Effect of CLA on Adhesion Molecule Expression 
 
Conjugated linoleic acids (CLAs), a group of positional and geometrical isomers of linoleic 
acid characterised by the presence of conjugated double bonds, can prevent and regress 
atherogenesis in several animal models of the disease (Kritchevsky et al. 2004; Toomey et 
al. 2006). The CLAs consist of two main isomers; cis-9, trans-11 CLA (CLA c9,t11) and 
trans-10, cis-12 CLA (CLA t10,c12) which is less common, but of particular interest since 
it appears to be the more biologically-active isomer in several respects (Choi et al. 2001; 
Eder et al. 2003). The cytokine-induced expression of ICAM-1, VCAM-1 and E-selectin in 
HAOECs was not reduced by either CLA isomer (Schleser et al. 2006). In contrast, 
Sneddon et al. (2006) found that attenuation of cytokine-induced ICAM-1, VCAM-1 and E-
selectin gene expression was mirrored in a reduced capacity of co-incubated monocytes to 
adhere to HUVECs and that the CLA t10,c12 isomer had the greatest efficacy. However, 
Guoa et al. (2008) reported decreased VCAM-1 and ICAM-1 protein and mRNA 
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expression by CLA (t10, c12 and c9, t11), and this attenuation was paralled with decreased 
NF-κB activy. 
 
 
1.3.8.4 The Effect of LC n-3 PUFA on Adhesion Molecule Expression 
  
   As for the LC n-3 PUFAs, many studies have been performed and most research has 
focused on EPA and DHA since it was hypothesized that n-3 PUFAs may modulate 
atherogenesis via reducing endothelial activation (De Caterina et al. 1994). Pioneering in 
vitro experiments using HSaVECs activated by cytokines showed that EPA had no effect on 
endothelial adhesion molecule expression (De Caterina et al. 1994; De Caterina & Libby 
1996; De Caterina et al. 1998); however increased ICAM-1 expression on keratinocytes 
was observed (Lu et al. 1995). It was then demonstrated that EPA, at higher concentrations 
(> 65 µM, compared with 10-25 µM on HSaVECs), did attenuate the expression of ICAM-
1, VCAM-1 and E-selectin by using HUVECs (Collie-Duguid & Wahle 1996; Khalfoun et 
al. 1996). It is not certain whether EPA at higher concentration may attenuate the 
expression of adhesion molecules on HSaVECs since there is no study investigating the 
effect of fatty acid concentrations on this.  DHA, on the other hand, was able to decrease 
ICAM-1, VCAM-1 and E-selectin expression on cytokine-stimulated HSaVECs or 
HUVECs (Collie-Duguid & Wahle 1996; Khalfoun et al. 1996; De Caterina et al. 1994; De 
Caterina & Libby 1996; De Caterina et al. 1998; Shaw et al. 2007) and again at higher 
concentration in HUVECs, and subsequently decrease leukocyte adhesion. Thus, DHA is 
determined to be the most potent fatty acid inhibitor of adhesion molecules (De Caterina et 
al. 1995). EPA and DHA separately or in combination decreased HLA-DR/DP and ICAM-1 
on stimulated monocytes (Hughes & Pinder 2000; De Caterina et al. 1999; Hughes et al. 
1996), and this may be part of the reason for fish oil’s beneficial effect seen in rheumatoid 
arthritis. The combination of EPA and DHA attenuated the expression of the three 
endothelial adhesion molecules (Nohe et al. 2002; Collie Duguid et al. 1996) and reduced 
L-selectin and LFA-1 on peripheral blood lymphocytes (Khalfoun et al. 1996). Table 1.9 
compiles in vitro studies using different type of cells (cell type) and the outcomes observed. 
Based on in vitro studies using HSaVECs, De Caterina et al. (2004) concluded that a 
minimum of a single double bond is required to inhibit adhesion molecule expression 
(therefore saturated fatty acids are inactive); the effectiveness does not depend on the chain 
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length and the degree of effectiveness increases correspondingly with unsaturation (double 
bond). 
 
In animal studies (Table 1.10), combined EPA and DHA were found to decrease expression 
of ICAM-1, CD 2/4/8/11a/18, L-selectin and LFA-1 on stimulated lymphocytes (Sanderson 
& Calder 1998; Sanderson et al. 1995) and resulted in a 50% reduction in Con A-stimulated 
lymphocyte adhesion to tumour necrosis factor-alpha (TNF-α)-stimulated endothelial cells 
(Sanderson & Calder 1998). In human studies (Table 1.11), sICAM-1, sVCAM-1, sE-
selectin were decreased with fish oil or n-3 PUFA supplementation even though the effects 
seen were not consistent between studies. Levels of sE-selectin and sVCAM-1 were 
decreased by ALA, DHA and EPA in one set of studies (Yli-Jama et al. 2002; Thies et al. 
2001), but other studies show increased sE-selectin in young men and a decrease in 
sVCAM-1 and sE-selectin in the elderly (Miles et al. 2001). Fish oil supplementation had 
no effect on PBMC adhesion molecule expression in human studies (Yaqoob et al. 2000). 
Interestingly, in patients with CHD, n-3 fatty acids (1.35 of EPA and 1.17g of DHA/ day) 
increased sE-selectin and sVCAM-1 blood concentrations after 4 weeks, although this was 
not significant (Johansen et al. 1999). Another study showed no effect of n-3 fatty acids on 
the expression of monocyte adhesion molecules in people with type 2 diabetes after 
receiving capsules containing 1.2 g of EPA and 0.8 g of DHA per day for 3 weeks 
(Sampson et al. 2001). The reason for these discrepancies is unclear, however they may due 
to several reasons such as dosage, type of fatty acids administered (either EPA, DHA or in 
combination), gender differences, physiological state (healthy or with different disease 
conditions), source of supplement (fish oil capsule or consumption of whole fish), age and 
also the genotypes of the subjects being studied. Interestingly, Grimble et al. (2002) 
reported that the effect of n-3 PUFAs on cytokine production can vary between individuals, 
and a small proportion of the population appear to have a genetic polymorphism whereby n-
3 PUFAs tend to induce inflammatory cytokine formation, in direct contract to the general 
responses observed. Therefore, a small proportion of the population may not derive anti-
inflammatory benefit from n-3 PUFAs and on the other hand could be at risk of 
exacerbating any inflammation and its consequences.  
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1.3.9 The Potential Mechanism for Fatty Acids to Alter Adhesion Molecule Expression 
 
   The potential mechanisms for these fatty acids to modulate the expression of adhesion 
molecules are thought to be related to the type of fatty acids, antioxidant/oxidant 
modulation, direct actions on gene expression and actions via the eicosanoid pathway. It 
was concluded that a progressive increase in inhibitory activity was observed for the same 
chain length but with increased numbers of double bonds (De Caterina et al. 2000). 
However, Wahle & Rotondo (1999)  suggested that double bond theory may be an 
oversimplification since probucol, a potent antioxidant, decreased the up-regulation of 
VCAM-1 and E-selectin; ICAM-1 on the other hand was unaffected, indicating the 
differential redox sensitivity of this adhesion molecule. Regulation of the expression of 
endothelial pro-atherogenic genes occurs, at least partly through controlling the activity of 
the nuclear factor-κB (NF-κB) system of transcription factors, secondary to generation of 
intracellular hydrogen peroxide (De Caterina & Massaro 2005). The NF-κB system of 
transcriptional factor controls expression of adhesion molecules and of leukocyte-specific 
chemo-attractants upon cytokine stimulation (De Caterina & Zampoli 2001). Fatty acids can 
alter the expression of genes coding for adhesion molecules, cytokines and redox enzymes. 
n-3 PUFAs can reduce the production of TNF-α and IL-1β which up-regulate adhesion 
molecules, as well as increase glutathione peroxidise activity which is known to inhibit 
ICAM-1 and VCAM-1 expression and NF-κB activation (Wahle & Rotondo 1999; Hennig 
& Toborek 2000). For example, DHA causes a reduction in reactive oxygen species, such 
as hydrogen peroxide, which are considered to be critical mediators of the NF-κB activation 
pathway. Finally, eicosanoid formation is believed to play a role in adhesion molecule 
expression, as n-6 PUFAs produce series 2 thromboxanes and prostaglandins and series 4 
leukotrienes, which are more potent inflammatory mediators compared with the 3 series 
thromboxanes and prostaglandins and 5 series leukotrienes produced by n-3 PUFAs. There 
is, however, some evidence to rule out the effects of eicosanoids since the effects on the 
endothelium are not attenuated by indomethacin, a blocker of cyclooxygenase (and 
therefore prostaglandins production). MUFA, such as oleic acid have an effect, but are not 
precursors of eicosanoids and the DHA has a larger effect than EPA, which would be 
unexpected since EPA is the direct precursor of the series 3 and 5 eicosanoids (De Caterina 
et al. 2000; Abeywardena & Head 2001). 
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As indicated above, different fatty acids have been shown to have a wide range of effects on 
adhesion molecule expression on endothelial cells, neutrophils, monocytes and 
lymphocytes. These differences may be due, in part, to variations in study design such as 
duration of incubation or type of cells used (Table 1.9), type of stimulus used and amount of 
oil consumed per day. By inhibiting leukocyte adhesion and migration of leukocytes, 
certain fatty acids, particularly oleic acid, EPA and DHA may have beneficial effects on a 
wide range of diseases in the western world including inflammatory, autoimmune and 
neoplastic disorders as well as alleviating symptoms and in the prevention of these illnesses. 
Soluble adhesion molecules may also be useful in some conditions as a marker of vascular 
endothelial dysfunction and may help in an early diagnosis of certain disease states, ie graft 
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TABLE 1.9: Effects of Unsaturated Fatty Acids on Adhesion Molecule Expression in InVitro Studies 
 
HSaVECs 
Reference 
Study design  Outcomes studied  Findings 
De Caterina et al. 
1994 
Fatty acids studied: OA, LA, ARA, EPA, DHA 
(10 μM) 
Stimuli: IL-1α, TNF-α, IL-1β (1-10 ng/mL), IL-
4 (50-100 ng/mL); LPS (1-10 μg/mL) 
Adhesion of monocytes and U937 cells. 
VCAM-1, ICAM-1, E-selectin protein 
expression  
DHA and OA (to a lesser extent) ↓ VCAM-1 
induced by IL-1α, TNF-α. 
DHA ↓ VCAM-1, ICAM-1, sE-selectin in dose-
dependent manner. 
DHA inhibited VCAM-1 for all stimuli tested. 
VCAM-1>sE-selectin>ICAM-1. 
De Caterina & Libby 
1996 
Fatty acids studied: DHA, EPA, OA, LA, ARA 
(10 μM) 
Stimuli: IL-1 (1-10 ng/mL), TNF-α (1-10 
ng/mL), IL-4 (50-100 ng/mL); LPS (1-10 
ng/mL) 
 
Adhesion of monocytes and U937 cells. 
VCAM-1, ICAM-1, E-selectin protein 
expression  
 
DHA ↓ adhesion of monocytes and U937 cells 
DHA ↓ ICAM-1, VCAM-1, E-selectin 
EPA, ARA, LA- no effect. 
 
De Caterina et al. 
1998 
Fatty acids studied: PA, SA, 20:0, ARA, 
palmitoleic, OA, elaidic, ricinoleic, LA, DGLA, 
ALA, EPA, DPA, DHA (25 μM) 
Control: HUVECs alone 
Stimuli: IL-1α (0.1-10 ng/mL), IL-1β, TNF-α 
(1-10 ng/mL), LPS (0.01-10 μg/mL) 
VCAM-1, ICAM-1, E-selectin protein 
expression, VCAM-1 mRNA expression 
 
 
↔ SFA. 
↓ expression with ↑ number of double bonds; 
chain length does not matter. 
No effect of the double bond position or 
configuration. 
Double bond is necessary for inhibition. 
 
 
 
 
 
HUVECs 
Reference 
Study design  Outcomes studied  Findings 
Sethi et al. 1996  Fatty acids studied: Oxidised PUFA, EPA, 
DHA, LA, ALA, PA, SA, ARA (200 μmol/L) 
HUVEC and SAEC.Stimuli 
: IL-1α (10 ng/mL), TNF-α (20 ng/mL), LPS 
(50 ng/mL). 
 
Adhesion of U937 cells 
VCAM-1, ELAM-1 and ICAM-1 protein 
expression 
Oxidised PUFA but not unoxidised PUFA ↓ the 
adhesion of U937 cells. 
Collie-Duguid & 
Wahle 1996 
Fatty acids studied: EPA, DHA, ARA (65 μM) 
Stimulus: IL-1β 10 U/mL). 
ICAM-1, VCAM-1, E-selectin mRNA 
expression 
DHA ↓ ICAM-1, VCAM-1, sE-selectin. 
EPA ↓ VCAM-1, sE-selectin (not ICAM-1). 
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HUVECs continued 
Reference 
Study design  Outcomes studied  Findings 
Khalfoun et al. 1996  Fatty acids studied: EPA, DHA (30 μM) 
Stimuli: TNF-α, IL-4 (100 IU/mL); LPS (1 
μg/mL) 
 
Peripheral blood lymphocyte adhesion. 
E-selectin, ICAM-1, VCAM-1 protein 
expression 
EPA and DHA ↓ VCAM-1 and DHA > potent 
inhibitor. 
Toborek et al. 2002  Fatty acids studied; OA,  LA, ALA (60-90 μΜ) 
Stimulus: LPS (1 μg/mL) 
 
NFκB and activator protein (AP-1) 
transcriptional activation. 
LA ↑ NFκB and AP-1 ta the most (↑ mRNA 
levels of TNF-α, VCAM-1, ICAM-1) (sig). 
ALA stimulated a moderate induction of the genes
encoding for these inflamm mediators. 
OA ↔/↓. 
Massaro et al. 2002  Fatty acids studied: PA, SA, OA, DHA (50 and 
100 μΜ) 
Stimuli: IL-1α, TNF-α; LPS (1 μg/mL) 
 
VCAM-1 protein expression 
 
Oleate + LPS/PMA ↓ VCAM-1, ↓ NFκB 
activation by LPS. 
Mayer et al. 2002  Fatty acids studied: EPA, DHA, ARA (10 μM) 
Stimuli: TNF-α (1 and 10 ng/mL). 
 
Leukocyte adhesion. 
VCAM-1,  ICAM-1 and P-selectin protein 
expression 
↓ adhesion monocyte to endothelial cells by EPA,
DHA (sig). 
Preincubation of HUVEC with EPA or DHA ↓ 
(sig) PAF synthesis, monocytes rolling and 
adherence, however ↔ expression of endothelial 
adhesion molecules. 
Chen et al. 2003  Fatty acids studied: LA, ARA, DHA, PA (100 
μM) 
Stimuli: TNF-α (20 ng/mL), IL-1β (5 ng/mL), 
PMA (10 ng/mL). 
 
ICAM-1 and VCAM-1 protein expression   LA and AA ↑ ICAM-1 in hRVE cells (sig); no ↑ 
in HUVEC. 
 
Holthe et al. 2005  Fatty acids studied: OA, LA, PA (100 μM) 
Stimuli: PMA (100 ng/mL), LPS (1 μg/mL) 
VCAM-1, ICAM-1, E-selectin protein 
expression  
PA ↓ VCAM-1 after 24 h (sig), but without 
change of mRNA level 
Shaw et al. 2007  Fatty acids studied: ARA, DHA, EPA, LA, OA, 
PA (10, 25, 100 μΜ) 
Stimulus: TNF-α (10 ng/mL) 
VCAM-1, E-selectin mRNA  ARA and DHA ↓/↔ expression of VCAM-1 and 
E-selectin mRNA; LA and OA ↑ VCAM mRNA 
expression. 
Schaefer et al. 2008  Fatty acids studied: ARA and DHA (10 μM) 
Stimulus: TNF-α (10 ng/mL) 
VCAM-1, ICAM-1, E-selectin protein 
expression 
No significant effects. 
Guoa et al. 2008  Fatty acids studied: CLA (t10, c12 and c9, t11), 
EPA, DHA (12.5, 25, 50 μM) 
Stimulus: TNF-α (5 ng/mL) 
VCAM-1, ICAM-1, E-selectin protein 
expression 
↓ VCAM-1 and ICAM-1 protein expression. 
↓ ICAM-1 and VCAM-1 protein expression by n-
PUFA was less dependent on the NFκB pathway 
than reduction by CLA 
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HAOECs 
Reference 
Study design  Outcomes studied  Findings 
Stuhlmeier et al. 
1997 
Note: Porcine AECs and HUVECs. 
Fatty acids studied: ETYA (synthetic analog 
of ARA), ARA (35-65 μM). 
Stimuli: LPS, PMA, TNF-α 
ICAM-1, VCAM-1, E-selectin protein and 
mRNA expression. 
ETYA and ARA ↓ E-selectin in AECs; VCAM-1 
and ICAM-1. protein expression in HUVECs. 
ETYA ↓ mRNA for E-selectin, ICAM-1, VCAM-
1. 
Schleser et al. 2006  Fatty acids studied: CLA (cis and trans), LA 
(5 or 50 μM). 
Stimulus: TNF-α (2 ng/mL) 
 
ICAM-1, VCAM-1, E-selectin protein 
expression. 
Adhesion of U937 cells 
↔ expression of adhesion molecules or U937 
adhesion. 
Stentz & Kitabchi 
2006 
Fatty acids studied: PA, OA, LA, ALA, ARA 
LA (1, 50, 500 μM) 
No stimulus used 
E-selectin protein expression  PA ↑ E-selectin protein expression (sig) 
HCAECs 
Reference 
Study design  Outcomes studied  Findings 
Reiβig et al. 2003  Fatty acids studied: LA, PA  (10 μM) 
Stimulus: IL-1α (10 ng/mL) 
ICAM-1, VCAM-1, E-selectin protein 
expression  
Adhesion of monocytes 
 
LA ↓ ICAM-1 and VCAM-1  
 
Monocytes  Study design  Outcomes studied  Outcomes 
Hughes et al. 1996  Fatty acids studied: EPA, DHA (0-140 μM) 
Stimulus: IFN-γ 
Cell surface ICAM-1 expression  EPA ↓ ICAM-1 and HLA-DR in unstimulated 
PMBCs  
EPA ↓ ICAM-1 and HLA-DR, DLA-DP with 
EPA + IFN-γ stimulated PBMCs  
Hughes et al. 2000  Fatty acids studied: EPA + DHA (3:1, 12 
μg/mL EPA + 8 μg/mL DHA) 
Stimulus: IFN-γ 
Cell surface ICAM-1 expression  ↓ ICAM-1  
 
Abbreviation: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PA, palmitic acid, OA, oleic acid, LA, linoliec acid; ALA, alpha linolenic acid; 
CLA, conjugated linoleic acid; ARA, arachidonic acid; ETYA, 5,8,11,14-eicosatetraynoic acid; IFN, interferon; VCAM-, vascular cellular adhesion 
molecule-; ICAM-, intercellular adhesion molecule; LPS, lipopolysaccarides; AOC, aortic endothelial cell; NF-κB, nuclear factor kappa B; IL- interleukin-
; TNF-, tumour necrosis factor-;  
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TABLE 1.10: Effects of Unsaturated Fatty Acids on Adhesion Molecule Expression in Animal Studies 
Reference Study  design  Outcomes  studied  Findings 
Yaqoob et al. 1995  Rats, fed for 10 wks 
1) LF 20% by wt 
2) HF 20% HCO 
3) HF 20% OO 
4) HF 20% SO 
5) HF 20% EPO 
6) HF 20% FO 
Blood leukocytes surface expression (LFA-
1, ICAM-1, CD2) 
No effect of dietary fats 
Sanderson et al. 1995  Rats, fed for 3 wks 
1) LF 2.5% wt CO 
2) HF 20% HCO 
3) HF 20% OO 
4) HF 20% SO 
5) HF 20% EPO 
6) HF 20% FO 
Spleen lymphocyte surface expression  
 
FO and OO ↓ CD-2, ICAM-1, LFA-1  . 
Sanderson et al. 1997  Rats, fed fror 6 wks  
1) LF 2.5% wt CO 
2) HF 20% SO           
3) HF 20% FO 
Dendritic cell surface expression  
 
FO  ↓ ICAM-1  
 
Sanderson & Calder 
1998 
Rats fed for 8 wks 
1) LF 2.5% wt CO 
2) HF 20% HCO 
3) HF 20% OO 
4) HF 20% SO 
5) HF 20% EPO 
6) HF 20% FO 
 
Lymphocyte surface expression of  ICAM-1 
and L-selectin 
Lymphocyte adhesion to endothelial cells 
 
 
FO ↓ ICAM-1 and L-selectin. 
OO and EPO ↓ ICAM-1 and L-selectin,but 
to a lesser extent than FO 
Miles et al. 2000  Mice fed for 12 wks: 
1) LF 2.5% wt CO 
2) HF 20% HCO 
3) HF 20% OO 
4) HF 20% SO 
5) HF 20% FO 
 
Macrophage ICAM-1 and scavenger 
reseptor mRNA expression 
FO ↓ ICAM-1  
 
Hsu et al. 2006  Mice fed FO vs soybean oil, 3 wks; 
polymicrobial sepsis induced by ceacal 
ligation and puncture (CLP) 
 
Plasma sICAM-1 concentrations. 
Leukocyte integrin expression. 
FO ↑ sICAM-1 6h CLP. 
FO ↑ leukocyte integrin 12-24 h after CLP. 
 Chapter 1 Introduction                                                                                                                  86 
 
 
 
 
   
Animal studies 
continued 
Reference 
Study design  Outcomes studied  Findings 
Kato et al. 2007  Mice fed laboratory chow with 5% EPA or 
LA, 4 wks 
mRNA expression of ICAM-1, MCP-1, 
VEGF and IL-6 in the retinal pigmen 
epithelium (RPE) 
EPA diet ↓ ICAM-1 protein and mRNA 
levels (sig) 
Matsumoto et al. 2008  ApoE deficient mice fed with 5% (w/w) 
EPA, n=5 vs. control (no EPA in diet), 13 
wks 
VCAM-1, ICAM-1, E-selectin, MCP-1 
expression 
↓ VCAM-1, ICAM-1, E-selectin, MCP-1 
protein expression in EPA group 
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TABLE 1.11: Effects of Unsaturated Fatty Acids on Adhesion Molecule Expression in Human Studies 
 
Reference Study  design  Outcomes  studied  Findings 
Hughes et al. 1996  Healthy volunteers 
0.93 g EPA + 0.63 g DHA/day (n=6) vs control 
(n=6) 
21 days 
 
Adhesion molecule surface expression on + 
stimulation ex-vivo with IFN-γ. 
FO ↓ ICAM-1, LFA-1 and MHC class II  ( in vivo
and ex-vivo 
Abe et al. 1998  4 g EPA + DHA/day (n=21) vs placebo (n=20), 
6 wks; then 7 mo (n=18) 
Plasma sICAM-1, sVCAM-1, sE-selectin 
concentrations 
None at 6 weeks 
FO ↓ sICAM-1 and sE-selectin after 7 mo , with 
greatest reduction in diabetic pt. 
Seljetfot et al. 1998 
 
Male smokers with hyperlipidemia (n=41) 
4.8 g EPA + DHA/day 
6 wks 
 
Plasma sP-selectin, sVCAM-1, sICAM-1, tPA 
ag, vWF, sTM concentrations 
FO ↓ vWF and sTM and ↑ sVCAM-1 and sE-
selectin  
Turpeinen et al. 1998  Healthy subjects (n=38), strictly controlled diet 
rich in LA (11.5% en) or OO (18% en) vs 
control (n=13);  
1
st 4 wks - diet rich SFA (normal); 2
nd 4 wks – 
LA or OO 
 
Plasma sICAM-1 concentration  None 
Johansen et al. 1999  Patients with CHD  
5.1g EPA + DHA/day (n=23) vs corn oil (n=31); 
6 months 
 
Plasma sP-selectin, sVCAM-1, sICAM-1, tPA 
ag, vWF, sTM concentrations 
FO ↓ vWF and sTM 
Placebo ↑ sE-selectin and sVCAM-1 
Yaqoob et al. 2000  Healthy subjects (n=40) 
- CO + soybean oil (3:1) as placebo 
- OO (6.5 g/d OA) 
- SO (6.5 g/d LA) 
- EPO (6.3 g/d LA + 1 g/d GLA) 
- FO (2.1 g/d EPA +1.1 g/d DHA) 
12 wk 
 
CD54, (ICAM-1) expression on PBMC  None 
Miles et al. 2001  Healthy subjects (n=140) 
Subset of 16 young males, 12 elderly (6 M, 6 F) 
1.2 g EPA + DHA/d vs placebo (PO + soybean 
oil, 80:20) 
12 wks 
 
Plasma sICAM-1, sVCAM-1, sE-selectin 
Concentrations 
FO ↓s-Eselectin and sVCAM-1 (elderly) ανδ ↑ 
sE-selectin (young) 
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Reference Study  design  Outcomes  studied  Findings 
Thies et al. 2001  Healthy subjects (n=40) 
-Placebo (80:20 PO+sunflower oil). 
-2 g/g ALA 
-0.7 g/d GLA 
-0.7 g/d ARA 
-0.7 g/d DHA 
-0.72 g/d EPA + 0.28 g/d DHA 
12 wks 
Plasma sE-selectin, sICAM-1, sVCAM-1 
concentrations 
FO and ALA↓ VCAM-1 
ALA ↓ sE-selectin  
Sampson et al. 2001  Male, non-smokers; 
FO (1.2 g/d EPA + 0.8 g/d DHA; n=29) vs 
control (n=21) 
21 days, 
Plasma sICAM-1, sE-selectin concentrations   None 
Yli-Jama et al. 2002  152 elderly men with increased risk of CHD  Relationship between EPA, DHA and AA in 
the NEFA fraction serum sCAM 
concentrations 
-ve (r): EPA and DHA vs. sVCAM-1. 
-ve (r): AA vs. sVCAM-1 and vWF 
Berstad et al. 2003  171 elderly men with increased risk of CHD 
FO (2.4 g/d EPA+DHA) vs. corn oil 
18 months 
 
Effect of the FO supplementation on the 
association between serum NEFA and sCAM 
concentrations 
+ve ™: ∆DHA vs. sVCAM-1 in FO group. 
-™(r): ∆DHA vs. sVCAM-1 in placebo group. 
Lopez-Gracia et al. 
2004 
Cross-sectional study, 727 women 43-69 y; 
validated FFQ. 
Plasma sE-selectin, sICAM-1, sVCAM-1 
concentrations 
High n-3 FA intake associated with lower sCAM 
concentrations  
Eschen et al. 2004  Healthy volunteers (n=60) 
FO (2.0 or 6.6 g EPA+DHA/day) vs. olive oil 
12 wks 
Serum sP-selectin, sICAM-1, sVCAM-1 
concentrations 
6.6 g/d n-3 PUFA ↓ sP-selectin in men 
2.0 g/d n-3 PUFA ↓ sICAM-1 in women 
6.6 g/d n-3 PUFA ↓ sVCAM-1 in women. 
Zhao et al. 2004  Moderately hypercholesterolemiac, non-smokers 
(n=23); cross-over study; 3 periods (6 
wks/period): 
-average American diet (AAD) 
-↑ PUFA 
-↑ ALA 
Serum sVCAM-1, sICAM-1, sE-selectin 
concentrations 
AAD: ∆ VCAM-1 –ve(r) with ∆EPA and ∆EPA +
DHA. 
LA diet: ∆ICAM-1 and E-selectin associated with 
∆any of  the serum n-3 FAs. 
Paschos et al. 2004  Dyslipidemic males 
8.1 g/day ALA  
2 group: 
a) Mediterranean-Cretan diet (n=21) 
b) Westernised-Greek diet (n=19) 
12 weeks 
 
Serum sICAM-1, sVCAM-1, sE-selectin 
concentrations 
Both diets ↓sVCAM-1  
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Reference Study  design  Outcomes  studied  Findings 
Seierstad et al. 2005  Patients with CHD (n=60), 6 wks. 
0.7 kg/wk of differently fed salmon (fillets): 
-100% FO, 2.9 g/d n-3 PUFAs 
-100% RO, 1.5 g/d n-3 PUFAs 
-50:50 FO/RO, 0.5 g/d n-3 PUFAs 
Plasma sVCAM-1, sICAM-1, and sE-selectin 
concentrations 
100% FO salmon ↓ sVCAM-1  
 
Hjerkinn et al. 2005  Elderly male patients with long-standing 
dyslipidemia (n=562) 
2.4 g EPA+DHA/d) 
3 y 
Plasma sVCAM-1, sICAM-1, sE-selectin, 
sTM, vWF, tPA ag concentrations  
™ 
FO ↓ sICAM-1, sTM  
. 
Cazzola et al. 2006  Healthy young 18-42 y (n=93), and elderly 53-
70y (n=62) males  
Placebo (5.5 g/d LA) 
1.35 g/d EPA + 0.27 g/d DHA 
2.7 g/d EPA + 0.54 g/d DHA 
4.05 g/d EPA + 0.81 g/d DHA 
12 wks 
 
Plasma sE-selectin, sICAM-1, and s VCAM-1 
concentrations 
High FO ↑ sE-selectin in young  
 
 
Lindqvist et al. 2008  Healthy men 35-60 y (n=35) 
Cross-over intervention study, 6 wks 
150g baked herring fillet/d, 5d/wk) vs.  
reference diet (150g baked pork/chicken/d, 
5d/wk) 
Plasma IL-6, IL-8, ICAM-1  None 
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1.4 Summary Statement and Study Objectives 
 
   The relationship between inflammation and CVD is gaining much attention because it is 
believed that inflammation plays an important role in initiation and progression of 
atherosclerosis. Upregulated expression of adhesion molecules following an inflammatory 
stimulus is one process whereby inflammation could contribute to atherosclerotic plaque 
initiation and growth. N-3 PUFAs from oily fish and fish oils reduce cardiovascular 
mortality and may have a primary role in preventing atherosclerosis. Anti-inflammatory 
effects might be part of the mechanism involved. Although there is some evidence that this 
is the case there are large discrepancies in the literature concerning the effect of these fatty 
acids on various components of the inflammatory process (Calder 2006) including adhesion 
molecule expression on cultured endothelial cells and on soluble adhesion molecule 
concentrations in human blood. Although in vitro studies have shown that EPA attenuates 
the expression of ICAM-1, VCAM-1 and E-selection in HUVECs (Collie-Duguid & Wahle 
1996; Khalfoun et al. 1996), other studies using HSaVECs reported that EPA has no effect 
(De Caterina et al. 1995). The discrepancy in in vitro studies (Table 1.9) could be due to 
differences in study design: some studies used HUVECs whereas other studies used 
HSaVECs. They also used different stimulants. There may be differences in effects on adult 
and fetal ECs. Furthermore, the cells used are venous ECs while atherosclerosis occurs 
mainly in arteries not veins. To date, there are no studies on the effects of n-3 PUFAs on 
adhesion molecule expression performed using arterial or aortic endothelial cells. 
Moreover, conclusive evidence is still lacking as to whether EPA or DHA has the greater 
role in modulation of inflammatory process. Studies of n-3 PUFA supplementation in adults 
have typically used high concentrations of the fatty acids, yet epidemiology reports 
associations with more modest dietary intakes.  Therefore there is a need to investigate the 
effects of modest doses of n-3 PUFAs on CVD risk factors, especially inflammation in 
adults.  
 
Therefore the overall objectives of the studies that I am undertaking are: 
1.  To identify the effects of fatty acids, including EPA and DHA, on inflammatory 
responses, especially adhesion molecule expression in cultured endothelial cells of 
different origin (fetal vs. adults; vein vs. artery vs. aorta). 
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2.  To investigate the effects of modest intakes of n-3 PUFAs on CVD risk factors 
especially inflammatory markers, including soluble adhesion molecules in adult 
humans with and without CVD. 
  
My aims will be to further understanding of the ability of fatty acids, especially n-3 PUFAs, 
to the modulate adhesion molecule expression in humans and to further investigate the 
possible mechanisms involved using in vitro model. Therefore, the specific objectives of 
my study will be as follows: 
 
1)  To study the effects of  fish oil supplementation on CVD risk factors in healthy and 
CVD patients; 
1a) Effects of fish oil supplementation on fatty acid incorporation in plasma lipid pools, 
1b) Effects of fish oil supplementation on lipid profile, 
1c) Effects of fish oil supplementation on soluble adhesion molecule concentrations, 
1d) The relationship between inflammatory markers and fatty acid status, particularly 
EPA and DHA. 
 
2)  To study the effects of fatty acids on adhesion molecule expression in different ECs; 
2a) Effects of different fatty acids (EPA, DHA, DPA, ARA, OA and SA) on adhesion 
molecule expression in different cell types using HSaVECs, HUVECs, HUAECs, 
HCAECs and HAOECs using the same stimulant i.e. LPS, 
2b) Effects at the gene expression level using RT-PCR. 
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Chapter 2 
 
 
The Effect of a Moderate Dose of Long Chain n-3 PUFAs 
on Cardiovascular Risk Factors, Particularly Plasma 
Lipids and Inflammatory Markers, in Middle Aged Men 
 
2.1 Introduction 
2.1.1 Background 
   Classic risk factors for atherosclerosis and cardiovascular disease include elevated plasma 
lipids, including triacylglycerols (TAGs) and total and low density lipoprotein (LDL) 
cholesterol, high blood pressure and insulin resistance (British Nutrition Foundation 2005; 
see also Section 1.1.3.1). However, it is now recognised that atherosclerosis is an 
inflammatory process involving movement of leukocytes, especially monocytes and T 
lymphocytes, from the bloodstream into the intima of the blood vessel wall and subsequent 
release of inflammatory mediators that contribute to plaque growth and development and 
ultimately to its rupture (British Nutrition Foundation 2005; Ross 1999; see Section 1.1.1). 
Prior to entry into the intima, blood leukocytes interact with the endothelial cells lining the 
vessel wall. These interactions are largely mediated by ligand-ligand interactions between 
proteins termed adhesion molecules. These interactions serve to slow and then tether the 
flowing blood leukocytes. Chief amongst the adhesion molecules involved are intercellular 
adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and E-selectin. 
The endothelial expression of these molecules is up-regulated by inflammatory stimuli and 
they may then be cleaved from the surface of the endothelial cells (Gearing & Newman 
1993). In vivo this results in non-surface bound forms of the adhesion molecules circulating 
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in the bloodstream; these are termed soluble adhesion molecules (e.g. soluble ICAM-1; 
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concentrations of soluble adhesion molecules and other inflammatory proteins such as 
interleukin-6 (IL-6) and C-reactive protein (CRP) are associated with increased 
cardiovascular risk and are higher in individuals with diagnosed cardiovascular disease 
compared with those without (Morisaki et al. 1997; Haught et 
al. 1996; Ridker et al. 1998; Blake & Ridker 2001; see Section 1.1.3.2.4). Thus, a 
reduction in plasma concentrations of these inflammatory markers, which may reflect a 
reduction in inflammatory processes at and within the vessel wall, would be interpreted 
as a lowering of cardiovascular risk.  
 
There is significant epidemiological evidence that consumption of fish, especially oily 
fish is protective against cardiovascular morbidity and mortality (Kromhout et al. 1985; 
Shekelle et al. 1985; Norell et al. 1986; Gillum et al. 1996; Daviglus et al. 1997; Albert 
et al. 1998; Iso et al. 2001; Hu et al. 2002; He et al. 2002). This is believed to be due to 
the long chain n-3 polyunsaturated fatty acids (n-3 PUFAs) found in oily fish, since 
both long chain n-3 PUFA consumption in the diet (Albert et al. 1998; Hu et al. 2002; 
Iso et al. 2001; Dolecek et al. 1982; Siscovick et al. 1995) and blood and tissue 
concentrations (Pedersen et al. 2000; Albert et al. 2002; Lemaitre et al. 2003) have been 
shown to be protective against cardiovascular disease morbidity and mortality. The long 
chain n-3 PUFAs found in oily fish, eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), are found in fish oils and similar preparations. Studies using fish oils have 
demonstrated that long chain n-3 PUFAs influence many cardiovascular risk factors, 
including blood pressure and plasma TAG concentrations, in a manner that could 
contribute to cardiovascular protection (Kris-Etherton et al. 2002; Calder 2004; von 
Schacky 2004). There is now much evidence that these fatty acids are anti-inflammatory 
(Calder 2001; Calder 2003; Calder 2006) While this is believed to be important in the 
context of cardiovascular disease (Calder 2004) many studies in humans have used very 
high doses of long chain n-3 PUFAs (e.g. > 3 g/day) which greatly exceed those that 
could be achieved through fish consumption and so have limited relevance to explaining 
the epidemiology. Furthermore, in the context of the very important adhesive 
interactions between leukocytes and the endothelium there is fairly limited information 
(see Section 1.3.3). In vitro studies have shown that EPA and DHA can inhibit 
inflammation-induced up-regulation of VCAM-1 on human endothelial cells (De 
Caterina et al. 1994; Khalfoun et al. 1996; Weber et al. 1995; Collie-Duguid et al. 1996) 
and of ICAM-1 on human monocytes (Hughes et al. 1996).  Feeding studies in 
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macrophages (Miles et al. 2000) and T lymphocytes (Sanderson & Calder 1998), while 
fish oil supplementation was shown to decrease ICAM-1 on the surface of human 
monocytes (Hughes et al. 1996). With regard to soluble forms of adhesion molecules, 
reports in the literature are mixed (Miles et al. 2001; Seljeflot et al. 1998; Abe et al. 
1998; Johansen et al. 1999; see Section 1.3.7.2). Long chain n-3 PUFA dose, duration 
of exposure, differences between the subjects studied and differences in experimental 
design might contribute to the different findings of these studies. 
 
Most studies of fish oil and inflammation have used high doses of long chain n-3 
PUFAs (Calder 2006). In the UK, the guideline range for oily fish intake among males 
and adult women not of child bearing age is one to four portions per week (SACN/COT 
2004) The long chain n-3 PUFA content of a portion of oily fish ranges from about 1.5 
to 3.5 g (British Nutrition Foundation 1999) Thus, one to four portions per week could 
provide between 1.5 and 14.0 g long chain n-3 PUFAs. This equates to an average daily 
long chain n-3 PUFA intake of 0.2 to 2 g. It is important to know the effect of 
consumption of long chain n-3 PUFAs within this guideline intake range on risk factors 
for cardiovascular disease. Thus, in this study a dose of EPA plus DHA at the upper end 
of the guideline intake range was used to investigate the effects on selected 
cardiovascular risk factors, with a focus on plasma lipid concentrations and 
inflammatory markers. The study was performed in middle-aged men, a group at risk of 
cardiovascular disease and had a double blind, randomised, placebo-controlled, parallel 
design. 
 
 
2.1.2 Aim of This Study 
 
   The aim of this study was to identify the effect of an intake of long chain n-3 PUFAs 
(EPA plus DHA) at the upper end of the UK adult guideline intake range on selected 
cardiovascular risk factors, with a focus on plasma lipid concentrations and 
inflammatory markers. To address this aim, a double blind, randomised, placebo-
controlled study of 2.1 g/d EPA plus DHA was conducted in middle-aged men, a group 
at risk of cardiovascular disease. The main outcomes were: 
•  The fatty acid composition of plasma lipid fractions 
•  The concentrations of plasma lipids 
•  The concentrations of plasma markers of inflammation Chapter 2 The Effects of Moderate Dose of LC n-3 PUFAs on CVD Risk Factors                  95                             
 
 
•  The concentrations of plasma glucose and insulin 
•  Blood pressure  
 
 
2.2 Methods 
 
2.2.1 Study Design 
 
   This was a randomised, double-blind and placebo-controlled study of eight weeks 
duration. The study ran from March until June 2006, depending on when the subject 
started. Volunteers were given a detailed written description of the study in the form of 
an information sheet before they gave their written informed consent. Subjects were 
required to attend the Welcome Trust Clinical Research Facility (WTCRF) at 
Southampton General Hospital on two occasions (at study entry (“baseline”) and end of 
the eight week intervention). On both occasions they were in the fasted state (> 12 hours 
without food and drink apart from water) and gave 20 ml blood samples. Weight, height 
(only for the first visit) and blood pressure were taken at each visit. 
 
 
2.2.2 Recruitment of the Volunteers 
 
   Ethical approval (05/Q1704/151) was obtained from the Southampton and South West 
Hampshire Joint Ethics Committee. Volunteers were recruited by a variety of means of 
advertising, including announcement in the university sussed portal system and in the 
University Bulletin, and posters around the University of Southampton and 
Southampton General Hospital. Some of them were contacted from existing databases 
(SoFIA and FINGEN studies). Volunteer’s eligibility for study entry was screened by 
using a Health and Lifestyle Questionnaire (see Section 2.2.3) and their GP was 
informed by formal letter if they were suitable to participate in the study. A total of 21 
subjects were recruited; however, one subject withdrew after 3 weeks. Figure 2.1 shows 
the recruitment and participation of the volunteers in the study 
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Advertisement       Database  searching 
 
30 volunteers                36 volunteers 
 
    Screen                    Screen 
 
11 eligible                   10 eligible 
 
 
             21 recruits (11+10 = 21) 
 
11 placebo                 10 Fish oil 
                          1 dropout 
11  complete        9  complete 
FIGURE 2.1: Summary of Subject Recruitment 
 
 
2.2.3 Inclusion Criteria 
 
   Volunteers were identified as eligible to participate in the study if they were male; 
within the age range of 35-60 years; had a body mass index (BMI) of 18.5-29.9 kg/m
2; 
were not on drug treatment for hyperlipidaemia or inflammatory conditions or a regular 
(daily) aspirin user; were not suffering from any gastrointestinal disorder, diabetes 
mellitus or other endocrine disorders; were not taking any dietary supplements 
including fatty acids and vitamins; were not vegetarian or vegan; did not consume more 
than one serving of oily fish per month; were not a heavy smoker (> 10 cigarettes per 
day); were not a vigorous exerciser (more than 3 x 30 minutes vigorous sessions per 
week); were not planning to lose weight; were not a blood donor; and had not 
participated in a clinical trial in the previous three months.  
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2.2.4 Capsules 
 
   Subjects received in random, minimization assigned group order either fish oil (66% 
of fatty acids by weight as EPA and 11% as DHA; Cardiozen
®) or placebo (97% w/w an 
oil rich in medium chain fatty acids (MCFAs)). The capsules used were a gift from 
Equazen UK Ltd. and contained 0.5 g of oil, fish flavoured and gelatine coated. Subjects 
were provided with more capsules than needed for that period of the study and they 
consumed six capsules per day. Therefore, subjects in the fish oil group consumed 3 g/d 
fish oil providing 2.1 g/d of EPA (1.8 g/d) and DHA (0.3 g/d), while subjects in the 
placebo group consumed 3 g/d placebo oil providing 2.5 g/d MCFAs. Table 2.1 shows 
the fatty acid composition of the capsules. The placebo oil used was a rich source of 
MCFAs, comprising 20.8% of fatty acids as caprylic acid (8:0) and 73.9% as capric acid 
(10:0). MCFAs were selected as placebo because these fatty acids are readily oxidised 
in the liver and are expected to have little impact on human health related biomarkers. 
 
TABLE 2.1: Fatty Acid Compositions of the Capsules Used (g/100 g Fatty Acid) 
Values are means (n = 5) and (SEM) 
 
Fatty acid 
 
Fish oil 
 
Placebo 
 
Caprylic acid, 8:0  -  20.8 (4.4) 
Capric acid, 10:0  -  73.9 (3.8) 
Lauric acid, 12:0  -  2.2 (0.3) 
Palmitic acid, 16:0  0.7 (0.0)  1.5 (0.2) 
Palmitoleic acid, 16:1n-7  0.5 (0.0)  - 
Oleic acid, 18:1n-9  2.2 (0.0)  - 
Elaidic acid, t18:1n-9 0.6  (0.0)  - 
Linoleic acid, 18:2n-6  1.1 (0.0)  - 
γ-linolenic acid, 18:3n-6  0.7 (0.0)  - 
α-linolenic acid, 18:3n-3  0.9 (0.0)  - 
Eicosanoic acid, 20:1n-9  9.2 (0.0)  - 
Arachidonic acid, 20:4n-6  4.0 (0.0)  - 
Erucic acid, 22:1n-9  2.5 (0.0)  - 
Eicosapentaenoic acid, 20:5n-3  66.8 (0.0)  1.8 (0.1) 
Docosahexaenoic acid, 22:6n-3  10.8 (0.0)  - 
 
 
2.2.5 Compliance 
 
   Subject’s compliance was measured by counting of the leftover capsules returned. If 
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final analysis of the study. No subjects were excluded on this basis. Compliance was 
also monitored by studying the plasma fatty acid profiles.  
 
 
2.2.6 Blood Samples and Measurements Made 
 
      A 20 mL venous blood sample was taken from the forearm (18 mL into tubes 
containing lithium-heparin and 2 mL into a tube containing fluoride oxalate). Blood 
samples were collected after a 12-hour overnight fast and sampling was successful in all 
subjects. Samples were put on ice and plasma was separated by centrifugation at 3000 
rpm for 10 minutes at 4
o C.  Aliquots of plasma were kept frozen at -80
o C until analysis. 
Glucose concentration was measured in plasma from blood collected into fluoride 
oxalate (to stabilize glucose). All other measurements were made on plasma from blood 
collected into heparin. 
 
Weight and height were taken to the nearest 0.1 kg and 0.1 cm, respectively. Body mass 
index (BMI) was calculated as weight (in kg) divided by standing height (in m
2). Two-
blood pressure measurements were obtained from non-dominant side arm and an 
additional reading was done if values from two consecutive measurements were more 
than 10 mm Hg apart. Subjects were lying down when blood pressure was measured 
using a blood pressure meter, Marquette®. 
 
 
2.2.7 Determination of Fatty Acid Composition of Plasma Lipids 
 
2.2.7.1 Lipid Extraction 
 
   Lipids were first extracted from plasma (0.4 mL that had been adjusted to 0.8 mL by 
addition of 0.9% NaCl), with 5.0 mL chloroform:methanol (2:1, v/v) containing 
butylated hydroxytoluene (50 mg/L) as antioxidant. Subsequently, 1.0 mL 1 M NaCl 
was added to promote partitioning of lipids into the organic phase and to facilitate 
separation of chloroform and aqueous layers. The mixture was then centrifuged at 2000 
rpm for 10 minutes at room temperature and the bottom layer (chloroform phase) 
containing lipid extract was collected and dried under nitrogen gas at 40
o C. 
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2.2.7.2 Separation of Lipid Classes 
 
   Lipid classes were separated by solid phase extraction (SPE). The total lipid extract 
was dissolved in 1.0 mL dry chloroform and then applied onto aminopropylsilica SPE 
cartridge on a SPE tank. The column was washed with 2 x 1.0 mL dry chloroform under 
vacuum. The combined washes were collected; these contained the triacylglycerol 
(TAG) and cholesteryl ester (CE) fractions and subsequently were dried under nitrogen 
gas at 40
o C. Two mL dry chloroform:methanol (60:40, v/v) was applied to the column 
and the phosphatidylcholine (PC) fraction eluted under vacuum. Then non-esterified 
fatty acids (NEFAs) were eluted from the column under vacuum after adding 2.0 mL 
chloroform:methanol:glacial acetic acid (100:2:2, v/v/v). Then, a new aminopropylsilica 
SPE cartridge was placed on the SPE tank. The column was washed with 4 x 1.0 mL 
dry hexane. The mixture of TAGs and CEs collected at the beginning was applied onto 
the column after being re-dissolved in 1.0 mL dry hexane. The column was washed with 
2 x 1.0 mL dry hexane under vacuum pump to elute the CE fraction. Subsequently, the 
TAG fraction was eluted under vacuum following the addition of 2.0 mL dry 
hexane:chloroform:ethyl acetate (100:5:5, v/v/v). All the collected fractions were dried 
under nitrogen gas at 40
o C.  
 
 
2.2.7.3 Formation of Fatty Acid Methyl Esters 
 
   Lipid fractions isolated according to the description in section 2.2.7.2 were dissolved 
in 0.5 mL dry toluene and fatty acid methyl esters (FAMEs) formed after reaction with 
1.0 mL methylation reagent (methanol containing 2% v/v H2SO4) at 50
o C for 2 hours. 
After that, samples were removed from the heating block and allowed to cool at room 
temperature before adding 1.0 mL neutralizing solution (0.25 M KHCO3, 0.5 M 
K2CO3). Subsequently, 1.0 mL of hexane was added and the mixture was centrifuged at 
1000 rpm for 2 minutes at room temperature. The upper phase containing the FAMEs 
was transferred to a new round bottom glass tube and dried under nitrogen gas at 40
o C. 
Then 2 x 75 μL dry hexane were added; the sample was vortexed and transferred into 
the insert of a gas chromatography auto-sampler vial.  
 
 
 Chapter 2 The Effects of Moderate Dose of LC n-3 PUFAs on CVD Risk Factors                  100                          
 
 
2.2.7.4 Separation of Fatty Acid Methyl Esters by Gas Chromatography 
    
   FAMEs dissolved in hexane were injected (1.0 μL) via a Hamilton syringe into a 
Hewlett Packard 6890 gas chromatograph (Hewlett Packard, Avondale, PA), fitted with 
a 30 m x 32 mm BPX 70 capillary column, film thickness 0.25 μm. Helium, at the 
initial flow of 1.0 mL/min was used as the carrier gas. The split ratios for TAGs and 
CEs, PC and NEFAs were 100:1, 50:1 and 5:1, respectively. Injector and detector 
temperatures were 275
o C and the column oven temperature was maintained at 170
o C 
for 12 minutes after samples injection. The oven temperature was programmed to 
increase from 170 to 210
o C at 5
o C/min. FAMEs were identified by comparison with 
authentic standards run previously; standards included commercially available 
menhaden oil FAMEs, and in-house IHN mix, Q3 and a MCFA mixture. Typical 
profiles for each standard mixture and for each lipid fraction are shown in Appendix 1. 
Peak areas were quantified using ChemStation software (Hewlett Packard, Avondale, 
PA). Each fatty acid is expressed as weight % of total fatty acids present. 
 
 
2.2.8 Measurement of TAG Concentrations in Plasma 
 
   Plasma TAG concentrations were measured using a commercial kit from Konelab™. 
TAGs were first hydrolysed by a lipase to yield glycerol and fatty acids. The glycerol 
was subsequently phosphorylated to glycerol-3-phosphate by the action of glycerol 
kinase, and the glycerol-3-phosphate was then oxidized to dihydroxyacetone phosphate 
and hydrogen peroxide by glycerol-3-phosphate dehydrogenase. The hydrogen peroxide 
was then reacted with 4-aminoantipyrine and 4-chlorophenol to form a quinoneimine 
dye, the absorbance of which was measured at 510 nm. The results were calculated 
automatically by the Konelab™ analyzer using a calibration curve whereby the 
absorbance was directly proportional to the TAG concentration.  
 
 
2.2.9 Measurement of Total Cholesterol Concentrations in Plasma 
 
   Total plasma cholesterol concentrations were measured using a commercial kit from 
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and free cholesterol. Then, the free cholesterol was oxidised by cholesterol oxidase to 
cholesterol-4-en-3-one and hydrogen peroxide. The hydrogen peroxide was then reacted 
with hydroxybenzoic acid and 4-aminoantipyrine to form a quinoneimine dye the 
absorbance of which was measured at 500-550 nm. The results were calculated 
automatically by the Konelab™ analyzer using a calibration curve whereby the 
absorbance was directly proportional to the cholesterol concentration.  
  
 
2.2.10 Measurement of LDL-cholesterol Concentrations in Plasma 
 
      Plasma LDL-cholesterol (LDL-c) was measured using a commercial kit from 
Konelab™. LDL-cholesterol was oxidized by cholesterol oxidase to cholesterol-4-en-3-
one and hydrogen peroxide. The hydrogen peroxide was reacted with 4-aminoantipyrine 
and n-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline  to form a quinoneimine dye the 
absorbance of which was measured at 500-550 nm. The results were calculated 
automatically by the Konelab™ analyzer using a calibration curve whereby the 
absorbance was directly proportional to the LDL-cholesterol concentration.  
 
 
2.2.11 Measurement of HDL-cholesterol Concentrations in Plasma 
 
   HDL-cholesterol (HDL-c) was measured using a commercial kit from Konelab™. The 
concentration of HDL-cholesterol was determined enzymatically by cholesterol oxidase 
to produce cholesterol-4-en-3-one and hydrogen peroxide. This hydrogen peroxide 
subsequently was combined with 4-aminoantipyrine coupled with HSDA to form a 
purple blue dye that may be quantitated at 500-550 nm. Results were calculated as 
above (Section 2.2.9).    
 
 
2.2.12 Measurement of NEFA Concentrations in Plasma 
 
   Plasma  NEFA  concentrations  were  measured using a commercial kit from Wako 
Chemicals GmBH. NEFAs were converted to CoA esters by acyl-CoA-synthetase. Then 
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peroxide. The hydrogen peroxide was reacted with 4-aminophenazone and 3-methyl-N-
ethyl-N-(β-hydroxyethyl) aniline to form a quinoneimine dye the absorbance of which 
was measured at 550 nm. The results were calculated automatically by the Konelab™ 
analyzer using a calibration curve as standard whereby the absorbance was directly 
proportional to the NEFA concentration.  
 
 
2.2.13 Measurement of Glucose Concentrations in Plasma 
 
      Plasma glucose concentrations were measured using a commercial kit from 
Konelab™.  Glucose was first reacted with hexokinase to form glucose-6-phosphate and 
adenosine-5’-diphosphate. The glucose-6-phosphate was then oxidised to 6-
phosphogluconate by glucose-6-phosphate dehydrogenase. In this reaction, an 
equimolar amount of NAD
+ was reduced to NADH, with a resulting increase in 
absorbance at 340 nm.  The results were calculated automatically by the Konelab™ 
analyzer using a calibration curve whereby the absorbance was directly proportional to 
the glucose concentration.  
 
 
2.2.14 Measurement of Insulin Concentrations in Plasma 
 
      Plasma insulin concentrations were determined using ELISA kits from Biosource 
Europe, Nivelles, Belgium. Assays were performed according to the manufacturer’s 
instructions and the absorbance was read on a plate reader at 450 nm with the reference 
filter of 650 nm. The sensitivity of the assay was < 0.15 μIU/mL. To assess insulin 
sensitivity, homeostatic model assessment (HOMA) was calculated as follows: 
[Glucose concentration (mg/dL) x Insulin concentration (μIU/mL)]/405. 
 
Analyses in Section 2.2.8 to 2.2.14 were performed by Mr. Chris, Institute of Human 
Nutrition, DoHAD. 
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2.2.15 Measurement of Inflammatory Marker Concentrations in Plasma 
 
   Plasma concentrations of IL-6, sE-selectin, sICAM-1, sVCAM-1 and high sensitivity 
C-reactive protein (hs-CRP) were measured using commercial ELISAs kits. sE-selectin, 
sICAM-1 and sVCAM-1 kits were purchased from Biosource Europe, Nivelles, 
Belgium; IL-6 kits were from R&D System Inc., Minneapolis, Minnesota; while hs-
CRP kits were  from Diagnostic System Laboratories Inc, Texas. For all assays, the 
manufacturer’s instructions were followed and the absorbance was read on a plate 
reader using 450 nm as the primary wavelength and 610-650 nm as the reference 
wavelength. The sensitivities of the assays were < 0.039 pg/mL (IL-6), < 0.5 ng/mL 
(sE-selectin), 0.5 ng/mL (sICAM-1), 0.9 ng/mL (sVCAM-1) and 1.6 ng/mL (hs-CRP), 
respectively.   
 
 
 2.2.16 Platelet Reactivity Assay 
 
   Plasma sP-selectin concentrations were measured using ELISA kits from Biosource 
Europe, Nivelles, Belgium, following the manufacturer’s instructions. The absorbance 
was read on a plate reader using 450 nm as the primary wavelength and 610-650 nm as 
the reference wavelength. The sensitivity of the assay was < 1.3 ng/mL.  
 
 
2.2.17 Statistical Analysis 
 
   Sample size was based upon previous studies indicating that a fish oil supplement 
providing about 2 g EPA/day would be expected to increase the EPA content of plasma 
phospholipids from approximately 1 to approximately 4% of total fatty acids (Yaqoob et 
al. 2000). Using standard deviations for EPA contents of plasma phospholipids from 
previous studies (Miles et al. 2001; Yaqoob et al. 2000; Wallace et al. 2003), it was 
estimated that a sample size of 7 would give 80% power of detecting this effect as 
statistically significant with P set at 0.01. To allow for drop-outs it was decided to 
recruit 10 subjects per group.  
 
The Kolmogorov-Smirnov and Shapiro-Wilk tests were applied to assess normality of 
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values and their standard errors (SEM) whilst non-normally distributed data are 
presented as medians and 10
th and 90
th percentiles. Comparison of normally distributed 
data between groups was performed using the unpaired Student’s t-test and within a 
group using the paired Student’s t-test. Not-normally distributed data were compared 
using the Wilcoxan signed ranks and Mann-Whitney U tests. Relationships between 
variables were evaluated using Pearson’s correlation coefficient. In all cases a value for 
P ≤ 0.05 was taken to indicate a significant effect. SPSS version 14.02 (SPSS Inc., 
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2.3 Results  
 
2.3.1 Characteristics of the Subjects 
 
   Of the twenty-one subjects recruited, twenty were used in the final analysis of the 
study. One subject withdrew because of time commitments and reported that he was 
unable to comply. Subject characteristics were not significantly different between the 
groups at baseline, except for HDL-c concentration, which was higher in the fish oil 
group (Table 2.2). Based on the counting of the returned capsules, compliance was high; 
90.1 ± 4.1% and 93.3 ± 2.2% for fish oil and placebo groups, respectively. Compliance 
was not significantly different between groups (P = 0.084). Compliance was also 
confirmed by an increase in the proportions of EPA and DHA in plasma lipids in the 
fish oil group (Tables 2.3 to 2.6).  
 
TABLE 2.2: Characteristics of the Subjects 
Data are mean (SEM) or median (10
th-90
th percentile) 
  Fish oil (n = 9)  Placebo (n = 11) 
Age (y) 
Weight (kg) 
Height (m) 
BMI (kg/m
2) 
Systolic BP (mm Hg)  
Diastolic BP (mm Hg) 
Total cholesterol (mmol/L) 
LDL-c (mmol/L) 
HDL-c (mmol/L) 
Triglycerides (mmol/L) 
Total cholesterol:HDL-c ratio 
LDL-c:HDL-c ratio 
Total NEFA (umol/L)  
Glucose (mmol/L) 
Insulin (uIU/mL) 
HOMA  
sICAM-1 (ng/mL) 
sVCAM-1(ng/mL)  
sE-selectin (ng/mL) 
sP-selectin (ng/mL) 
IL-6 (pg/mL)  
CRP (mg/L)  
43.7 (2.3) 
80.1 (3.4) 
1.8 (0) 
25.7 (0.8) 
122.5 (102.5 - 140.0) 
71.5 (60.0 - 90.0) 
5.2 (0.4) 
3.1 (0.3) 
1.4* (0.1) 
1.3 (0.2) 
4.1 (0.5) 
2. 5 (0.4) 
396.0 (209.0 - 458.0) 
5.9 (0.1) 
5.6 (1.3 - 28.4) 
1.3 (0.3 - 7.5) 
256.9 (27.7) 
456.4 (61.1 - 1375.2) 
85.1 (16.1) 
36.3 (10.3) 
1.4 (0.9 - 2.8) 
1.9 (1.9- 4.0) 
44.7 (2.0) 
81.6 (3.0) 
1.8 (0) 
26.5 (1.0) 
110.0 (108.7 - 143.4) 
66.5 (64.5 - 92.6) 
4.8 (0.3) 
3.0 (0.3) 
1.1 (0.1) 
1.1 (0.1) 
4.5 (0.3) 
2.8 (0.3) 
334.0 (248.6 - 601.6) 
5.7 (0.1) 
4.7 (4.1 - 6.2) 
1.2 (1.0 - 1.7) 
224.3 (16.1) 
648.7 (436.8 - 957.3) 
84.3 (13.2) 
33.5 (3.9) 
1.2 (0.8 - 3.9) 
1.9 (1.9 - 9.3) 
*Significantly different from the placebo group (P = 0.045) 
Abbreviations: BMI = Body mass index; LDL-c = low density lipoprotein-cholesterol; HDL-c = high 
density lipoprotein-cholesterol; NEFA = non-esterified fatty acid; HOMA = homeostatic model 
assessment; sICAM-1 = soluble intercellular adhesion molecule-1; sVCAM-1 = soluble vascular cellular 
adhesion molecule-1; sE = soluble endothelial; sP = soluble platelet; IL 6 = interleukin-6; CRP = C-
reactive protein. 
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2.3.2 Effect of Supplementation on the Fatty Acid Composition of Plasma TAGs  
 
   Table 2.3 shows the fatty acid composition of plasma TAGs. The most abundant fatty 
acids in this fraction were palmitic acid (16:0), oleic acid (18:1n-9) and linoleic acid 
(18:2n-6) comprising 27%, 40% and 16% of total fatty acids, respectively. Total of LC 
n-3 PUFAs were similar in the two groups at baseline (approx. 3.0% of total fatty 
acids), with EPA plus DHA contributing approx. 1.3% of total fatty acids. There were 
no significant differences between groups at baseline except for elaidic acid (t18:1n-9; P 
= 0.032). Supplementation with fish oil significantly (P = 0.025) increased EPA, with an 
average percent change from baseline of 96% (Table 2.7). At the end of intervention, 
there was a significant difference between groups for EPA (P = 0.042), but not for DHA 
(P = 0.337), ARA (P = 0.062), or any other fatty acids. 
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TABLE 2.3: Fatty Acid Composition of Plasma TAGs (g/100 g Fatty Acid) 
Values are means and SEM 
 
Fish oil (n = 9)  Placebo (n = 11) 
Baseline  After 8 weeks  Baseline  After 8 weeks 
 
Fatty acid 
Mean SEM Mean SEM Mean SEM Mean SEM 
12:0  0.06 0.06  -  -  0.02 0.02 0.10 0.07 
14:0  2.42 0.40 2.32 0.32 1.86 0.18 2.00 0.25 
16:0  28.28 1.71 25.15 3.48 26.21 0.62 24.50 2.22 
16:1n-7  3.57 0.34 3.50 0.40 3.41 0.31 6.70 2.98 
18:0  3.81 0.24 4.07 0.42 3.37 0.10 3.89 0.31 
18:1n-9  38.76 1.33 36.22 1.44 41.75 1.01 38.54 0.96 
t18:1n-9 1.90
a 0.07 1.80 0.09 2.17
b 0.09 2.13 0.14 
18:2n-6  16.24 2.03 15.88 1.57 16.10 1.07 15.03 1.19 
18:3n-6  0.33 0.08 0.31 0.08 0.27 0.09 0.35 0.06 
18:3n-3  1.19 0.11 1.72 0.49 1.38 0.22 1.21 0.13 
20:4n-6  1.09 0.17 1.41 0.18 1.03 0.14 1.30 0.13 
20:1n-9  0.21 0.06 0.34 0.15 0.21 0.06 0.45 0.14 
20:2n-6  - - - -  0.07  0.05  0.05  0.03 
20:0  0.18 0.08 0.25 0.11 0.31 0.12 0.30 0.08 
20:3n-6  0.12 0.05 0.17 0.06 0.17 0.07 0.12 0.05 
20:5n-3 0.25  0.14  1.80*
a  0.47 0.29 0.13 0.50
b 0.37 
22:5n-3  0.52 0.13 0.77 0.17 0.39 0.12 0.69 0.28 
22:6n-3  1.07 0.24 1.53 0.44 1.01 0.22 1.55 0.85 
*Significantly different from baseline (P = 0.025) 
abValues not sharing the same alphabetic superscript at baseline or after 8 weeks are significantly different between groups at this time point 
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2.3.3 Effect of Supplementation on the Fatty Acid Composition of Plasma NEFAs  
 
   Table 2.4 shows the fatty acid composition of plasma NEFAs. The most abundant 
fatty acids in this fraction were oleic acid, palmitic acid, stearic acid and linoleic acid 
comprising 31%, 24%, 20% and 12% of total fatty acids, respectively. Total LC n-3 
PUFAs were approx. 4% of total fatty acids at baseline, with most as EPA plus DHA. 
There were no significant differences between groups at baseline for any fatty acid. 
There were no changes in fatty acid composition of NEFAs in the placebo group. Table 
2.7 shows supplementation with fish oil significantly increased EPA, with an average 
percent change from baseline of 367%. There were significant differences between 
groups at the end of the intervention for EPA (P < 0.0001) and DPA (P = 0.018), but not 
for DHA (P = 0.288) (Table 2.4). The ARA:EPA ratio in plasma NEFAs was 
significantly decreased from 8.71 (at baseline) to 2.49 (after supplementation) in the fish 
oil group, but no significant change was observed in the placebo group (Figure 2.2). 
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TABLE 2.4: Fatty Acid Composition of Plasma NEFAs (g/100 g Fatty Acid) 
Values are means and SEM 
 
Fish oil (n = 9)  Placebo (n = 11) 
Baseline  After 8 weeks  Baseline  After 8 weeks 
 
Fatty acid 
Mean SEM Mean SEM Mean SEM Mean SEM 
14:0  1.06 0.09 1.10 0.08 1.01 0.16 1.00 0.09 
16:0  23.33 0.73 23.06 0.89 25.34 1.72 23.72 0.60 
16:1n-7 1.67 0.17 1.58 0.23 2.01 0.22 1.98 0.27 
18:0  20.54 1.40 20.67 1.57 19.11 2.43 18.69 1.49 
18:1n-9 30.57 1.21 30.95 1.77 31.54 3.56 32.69 2.24 
18:2n-6 12.39 0.91 12.11 1.15 12.88 0.72 12.40 0.65 
18:3n-3 1.11 0.07 1.54 0.35 1.28 0.15 1.24 0.12 
20:1n-9 0.17 0.07 0.17 0.06 0.40 0.19 0.15 0.10 
20:3n-6 0.58 0.20 0.31 0.10 0.27 0.06 0.19 0.09 
20:4n-6 3.26 0.42 3.18 0.34 2.99 0.33 2.73 0.32 
20:5n-3 0.47 0.09  1.63**
a 0.17  0.74  0.16  0.87
b 0.24 
22:5n-3 0.49 0.07  0.90*
a 0.10  0.58  0.18  0.48
b 0.16 
22:6n-3 2.19 0.43 2.77 0.19 1.81 0.24 2.01 0.56 
*Significantly different from baseline (P ≤ 0.02) 
**Significantly different from baseline (P < 0.0001) 
Values not sharing the same alphabetic superscript at baseline or after 8 weeks are significantly different between groups at this time point 
(
abP ≤  0.05)  
 
 
 Chapter 2 The Effects of Moderate Dose of LC n-3 PUFAs on CVD Risk Factors                  110                          
 
 
2.3.4 Effect of Supplementation on the Fatty Acid Composition of Plasma CEs 
 
   Table 2.5 shows the effect of supplementation on the fatty acid of plasma CEs. The 
most abundant fatty acids in this fraction were similar to those in the TAG fraction, 
namely palmitic acid (11% of total fatty acids), oleic acid (19%) and linoleic acid 
(53%). There were no significant differences between groups at baseline except for 
DHA (P = 0.034). Total LC n-3 PUFAs was approx. 2 to 2.5% of fatty acids at baseline, 
mainly as EPA plus DHA. Fatty acid composition of CEs was not changed in the 
placebo group. However supplementation with fish oil significantly increased (P < 
0.001) the EPA content of plasma CEs by 235% from baseline with a significant 
difference between groups at the end of intervention (P < 0.001) (Table 2.7). There were 
also small increases in myristic and palmitic acids and a decrease in linoleic acids after 8 
weeks supplementation with fish oil (P < 0.05). There were no significant changes in 
ARA or DHA. In terms of the ARA: EPA ratio, this was significantly decreased from 
5.0 (at baseline) to 1.35 (after supplementation) in the fish oil group, with no change in 
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TABLE 2.5: Fatty Acid Composition of Plasma CEs (g/100 g Fatty Acid) 
Values are means and SEM 
 
Fish oil (n = 9)  Placebo (n = 11) 
Baseline  After 8 weeks  Baseline  After 8 weeks 
 
Fatty acid 
Mean SEM Mean SEM Mean SEM Mean SEM 
14:0  0.73 0.07  0.95*  0.08 0.70 0.04 0.73 0.07 
16:0  11.42 0.22  12.21*  0.16 11.63 0.17 11.72 0.21 
16:1n-7  2.83 0.37 2.88 0.50 2.42 0.28 2.62 0.36 
18:0  1.03 0.08 1.04 0.07 1.06 0.06 0.90 0.06 
18:1n-9  19.13 0.65 18.62 1.10 19.56 0.41 19.44 0.51 
t18:1n-9 0.93
a 0.05 1.00 0.08 1.07
b 0.04 1.12 0.06 
18:2n-6  53.87 1.78  49.80*  1.83 52.62 1.07 52.32 1.44 
18:3n-6  1.13 0.21 0.99 0.17 1.02 0.11 1.03 0.18 
18:3n-3  0.53 0.12 0.70 0.07 0.63 0.11 0.69 0.07 
20:3n-6  0.71 0.12 0.64 0.12 0.71 0.11 0.75 0.14 
20:4n-6  6.10 0.43 6.13 0.34 6.55 0.52 6.91 0.50 
20:5n-3 1.22  0.22 4.54**
c  0.30 1.12 0.16 1.19
d 0.22 
22:6n-3 0.32
a 0.08 0.51 0.11 0.87
b 0.21 0.51 0.14 
*Significantly different from baseline (P ≤ 0.02) 
** Significantly different from baseline (P ≤ 0.001) 
Values not sharing the same alphabetic superscript at baseline or after 8 weeks are significantly different between groups at that time point 
(
abP ≤  0.05, 
cdP ≤ 0.001). 
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2.3.5 Effect of Supplementation on the Fatty Acid Composition of Plasma PC  
 
      Table 2.6 shows the fatty acid composition of the plasma PC fraction. The most 
abundant fatty acids in this fraction were palmitic acid, stearic acid, oleic acid and 
linoleic acid comprising 31%, 14%, 11% and 24% of total fatty acids, respectively. 
There were no significant differences between groups at baseline except for myristic 
acid (P = 0.029).  Supplementation with fish oil significantly increased EPA with a 
percent change from baseline of 363% (Table 2.7), and there were significant 
differences between groups at the end of the intervention for EPA and DPA (both P < 
0.001). It was also observed that the n-6 fatty acids (linoleic acid (LA) and dihomo-
gamma-linolenic acid (DGLA)) were significantly decreased with fish oil 
supplementation (P < 0.001). In the placebo group, the proportion of DHA was 
significantly reduced (P = 0.011) but there were no other significant effects in this 
group. Figure 2.3 shows the proportion of EPA in plasma PC for each subject in the fish 
oil group, indicating the reproducibility of the increase in EPA proportion. The ARA: 
EPA ratio in plasma PC was significantly decreased from 7.34 (at baseline) to 1.66 
(after supplementation) in the fish oil group, but no significant change was observed in 
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TABLE 2.6: Fatty Acid Composition of Plasma PC (g/100 g Fatty Acid) 
Values are means and SEM 
 
Fish oil (n = 9)  Placebo (n = 11) 
Baseline  After 8 weeks  Baseline  After 8 weeks 
 
Fatty acid 
Mean SEM Mean SEM Mean SEM Mean SEM 
14:0 0.40
a 0.03 0.39 0.04  0.32
b  0.02 0.3 0.04 
16:0  31.38 0.44 31.22 0.46 31.09 0.26 32.00 0.73 
16:1n-7  0.42 0.09 0.48 0.11 0.33 0.04 0.41 0.07 
18:0  13.96 0.34 14.09 0.51 13.73 0.29 14.67 0.90 
18:1n-9  10.17 0.47  9.94  0.65 10.64 0.35 10.31 0.52 
t18:1n-9  1.19 0.07 1.23 0.06 1.32 0.06 1.26 0.06 
18:2n-6  23.99 1.06  20.42**  0.80 23.42 0.78 22.15 1.26 
18:3n-6  0.04 0.03 0.08 0.05 0.02 0.01 0.08 0.04 
18:3n-3  0.20 0.07 0.27 0.05 0.21 0.04 0.25 0.04 
20:0  0.08 0.04 0.15 0.04 0.07 0.03 0.16 0.07 
20:3n-6  3.43 0.26  2.59**  0.29 3.53 0.22 3.29 0.29 
20:4n-6  8.59 0.57 7.99 0.40 8.94 0.49 9.00 0.48 
20:1n-9  0.03 0.02 0.08 0.06 0.07 0.03 0.10 0.04 
20:5n-3 1.39  0.19  5.01**
c  0.33 1.31 0.16 1.44
d 0.38 
22:5n-3 0.84  0.07  1.81**
c  0.11 0.95 0.13 0.82
d 0.09 
22:6n-3  3.64 0.34 4.10 0.25 3.79 0.28  3.30*  0.28 
22:1n-9  0.07 0.05 0.08 0.04 0.13 0.04 0.22 0.08 
24:0  0.06 0.03 0.03 0.02 0.03 0.02 0.04 0.03 
*Significantly different from baseline (P = 0.011). 
**Significantly different from baseline (P < 0.001). 
Numbers not sharing the same alphabetic superscript at baseline or after 8 weeks are significantly different between groups at that time 
point (
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Supplementation 
      PC fraction    NEFA fraction 
 
Plasma EPA concentration at baseline and after 
supplementation (PC fraction)
-2
0
2
4
6
8
123456789
Subject
E
P
A
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
g
/
1
0
0
 
g
)
Baseline
After supplementation
 
FIGURE 2.3: Effect of Fish Oil Supplementation on EPA in Plasma PC in Each 
Individual Subject 
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TABLE 2.7: Percent Change from Baseline (%∆) of EPA and DHA in the Fish Oil 
Group 
 
Fraction  %Δ EPA  P  %Δ DHA  P 
TAGs 
NEFAs 
PC 
CEs 
95.62 ± 28.37 
367.98 ± 106.80 
363.49 ± 123.64 
234.95 ± 45.03 
0.131 
0.026* 
0.011* 
< 0.0001* 
65.17 ± 38.07 
61.18 ± 37.42 
19.81 ± 36.84 
28.99 ± 19.67 
0.703 
0.885 
0.012* 
0.021* 
*Significantly different from percent change in placebo group (P < 0.05) 
Abbreviation: %∆ = percent change from baseline, TAGs = triacylglycerols, NEFAs = 
non-esterified fatty acids, PC = phosphatidylcholine, CEs = cholesteryl esters. 
 
 
2.3.6 BMI and Blood Pressure 
 
   Table 2.8 shows the BMI and blood pressure values at baseline and after 8 weeks. 
There were no significant differences in blood pressure between groups at baseline or at 
the end of intervention or within a group at either time point. For BMI, there were no 
significant differences between groups at baseline or at the end of the study. However 
supplementation with fish oil caused a significant increase in BMI (P = 0.023).  
 
Body weight was directly associated with systolic blood pressure (r = 0.556, P = 0.011), 
diastolic blood pressure (r = 0.591, P = 0.006) and BMI (r = 0.739, P < 0.001). In terms 
of inflammatory markers, only sE-selectin was found to be positively correlated with 
weight (r = 0.520, P = 0.019) and diastolic blood pressure (r = 0.488, P = 0.029). 
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TABLE 2.8: BMI and Blood Pressure at Baseline and after 8 Weeks Supplementation 
Values are means (SEM) or median (10
th- 90
th percentile) 
  *Significantly different from baseline (P = 0.023) 
Fish oil (n = 9)  Placebo (n = 11)   
Outcome  Baseline 
(0 weeks) 
8 weeks  Baseline 
(0 weeks) 
8 weeks 
BMI (kg/m
2) 
Systolic BP (mm Hg) 
 
Diastolic BP (mm Hg) 
25.7 (0.8) 
122.5 
(102.5 - 140) 
71.5 
(60 - 90) 
26.2* (0.8) 
119.5 
(101.5 - 152.5) 
72 
(59 - 100) 
26.5 (1.0) 
110 
(108.7 - 143.4) 
66.5 
(64.5 - 92.6) 
26.5 (1.0) 
118 
(100.9 - 149.6) 
72 
(58.5 - 97.4) 
 
 
 
2.3.7 Plasma Lipid Concentrations 
  
   Total, LDL-and HDL-cholesterol concentrations were significantly increased in the 
placebo group (P < 0.001) (Table 2.9). In terms of absolute change, the elevations of 
total cholesterol and LDL-c (P < 0.05) were greater than that of HDL-c (Table 2.10). 
Fish oil also increased total cholesterol concentration (P = 0.03). However, the increases 
in LDL-c and HDL-c were not significant in the fish oil group. Percent changes in total 
cholesterol, LDL-c and HDL-c were lower in the fish oil group compared with the 
placebo group. In the placebo group, the percent change in HDL-c was greater (20.8%), 
compared with total cholesterol and LDL-c (18.6% and 16.0%, respectively). 
Nevertheless this change was not significant compared with the fish oil group (P = 
0.172). Table 2.10 shows the ratio of total cholesterol: HDL-c in the placebo group was 
decreased (-0.06, -1.35%), due to a significant increase of HDL-c in plasma, but in 
contrast, this ratio was increased in the fish oil group (0.17, 5.06%). In terms of LDL-c: 
HDL-c ratio, both groups showed an increase because at the same time, LDL-c was also 
raised.   
 
 
2.3.8 Plasma Glucose and Insulin Concentrations and HOMA 
 
   There were no significant effects on plasma glucose concentration in either group 
(Table 2.9). However, in the placebo group, insulin concentration and HOMA were 
significantly increased (P < 0.05) (Table 2.9). Fish oil did not significantly affect insulin 
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TABLE 2.9: Plasma Lipid, Glucose and Insulin Concentrations and HOMA at Baseline 
and After 8 Weeks Supplementation 
Values are means (SEM) or median (10
th-90
th percentile) 
 
Fish oil (n = 9)  Placebo (n = 11)   
Outcome  Baseline 
 
8 weeks  Baseline 
 
8 weeks 
Total cholesterol 
(mmol/L) 
LDL-c (mmol/L) 
HDL-c (mmol/L) 
Triacylglycerol (mmol/L) 
Total cholesterol:HDL-c 
ratio 
LDL-c:HDL-c ratio 
Total NEFA (umol/L) 
 
Glucose (mmol/L) 
Insulin (uIU/mL) 
 
HOMA 
 
5.2 (0.4) 
 
3.1 (0.3) 
1.4 (0.1) 
1.3 (0.2) 
4.1 (0.5) 
 
2.5 (0.4) 
396 
(209 - 458) 
5.9 (0.1) 
5.6 
(1.3 - 28.4) 
1.3 
(0.3 - 7.5) 
5.6* (0.4) 
 
3.3 (0.3) 
1.5 (0.2) 
1.7 (0.3) 
4.2 (0.5) 
 
2.6 (0.4) 
388 
(227 - 822) 
6.06 (0.1) 
6.3 
(1.9 - 26.2) 
1.7 
(0.6 - 6.7) 
4.8 (0.3) 
 
3.0 (0.3) 
1.1 (0.1) 
1.1 (0.1) 
4.5 (0.3) 
 
2.8 (0.3) 
334 
(249 - 602) 
5.74 (0.13) 
4.73 
(4.1 - 6.2) 
1.2 
(1.0 - 1.7) 
5.6*** (0.3) 
 
3.5*** (0.3) 
1.3*** (0.1) 
1.4 (0.2) 
4.5 (0.3) 
 
2.8 (0.2) 
485 
(209 - 636) 
5.8 (0.1) 
6.3** 
(4.7 - 8.1) 
1.6** 
(1.1 - 2.2) 
*Significantly different between baseline and after 8 weeks (P < 0.05) 
**Significantly different between baseline and after 8 weeks (P < 0.02) 
***Significantly different between baseline and after 8 weeks (P < 0.001) 
Abbreviations: BMI = Body mass index; LDL-c = low density lipoprotein-cholesterol;    HDL-c 
= high density lipoprotein-cholesterol; NEFA = non-esterified fatty acid;           HOMA = 
homeostatic model assessment. 
 
TABLE 2.10: Changes (Absolute and Percentage) in Plasma Lipid, Glucose and Insulin 
Concentrations from Baseline 
Values are means (SEM) or median (10
th- 90
th percentile) 
 
Change 
Absolute % 
 
Outcome 
Fish  oil Placebo Fish  oil  Placebo 
Total cholesterol 
(mmol/L) 
LDL-c (mmol/L) 
 
HDL-c (mmol/L) 
Triacylglycerol 
(mmol/L) 
Total cholesterol:HDL-
c ratio 
LDL-c:HDL-c ratio 
Total NEFA (umol/L) 
Glucose (mmol/L) 
 
Insulin (uIU/mL) 
HOMA 
0.41 (0.17) 
 
0.16 (0.11) 
 
0.08 (0.09) 
0.41 (0.23) 
 
0.17 (0.22) 
 
0.15 (0.15) 
73.38 (66.02) 
0.13 
(-0.37 - 0.63) 
1.55 (1.22) 
0.45 (0.34) 
0.84* (0.11) 
 
0.49* (0.07) 
 
0.21 (0.03) 
0.26 (0.17) 
 
-0.06 (0.08) 
 
0.11 (0.10) 
93.27(51.06) 
0.05 
(-0.52 - 0.97) 
1.30 (0.36) 
0.35 (0.12) 
7.90 (4.13) 
 
6.79 
(-16.51 - 32.37) 
5.84 (6.74) 
33.18 (15.76) 
 
5.06 (5.23) 
 
6.55 (7.05) 
25.09(18.60) 
2.21 
(-5.67 - 11.69) 
40.01 (15.07) 
44.19 (16.11) 
18.62 (2.75) 
 
15.56 
(2.73 - 37.92) 
20.76 (4.02) 
27.17 (14.82) 
 
-1.35 (1.72) 
 
2.49 (4.66) 
33.74 (18.33) 
1.23 
(-7.79 - 18.81) 
27.64 (7.65) 
30.62 (9.74) 
 *Significantly different between groups (P < 0.04)  
2.3.9 Plasma Inflammatory Markers 
 
   The concentrations of plasma inflammatory markers at baseline, after 8 weeks and the 
relative changes (absolute and percent) are shown in Tables 2.11 and 2.12. There were no 
differences in plasma inflammatory marker concentrations between the two groups at study 
entry or at the end of the supplementation period. Neither placebo nor fish oil had a 
significant effect on the plasma inflammatory markers measured, although fish oil tended to 
lower sICAM-1 concentrations. When data were analysed as % change from baseline 
concentration, the two groups were significantly different for sICAM-1 (P = 0.05), with an 
approximately 10% decrease from baseline in the fish oil group (Table 2.12). Using data 
from both groups and from both time points it was observed that CRP concentration was 
directly correlated with IL-6 concentration (r = 0.740, P < 0.001). 
 
TABLE 2.11: Plasma Inflammatory Marker Concentrations at Baseline and After 8 Weeks 
Supplementation 
Values are means (SEM) or median (10
th-90
th percentile) 
 
Fish oil (n = 9)  Placebo (n = 11)   
Outcome  Baseline 
(0 weeks) 
8 weeks  Baseline 
(0 weeks) 
8 weeks 
sICAM-1 (ng/mL) 
sVCAM-1 (ng/mL) 
 
sE-selectin (ng/mL) 
sP-selectin (ng/mL) 
IL-6 (pg/mL) 
 
CRP (mg/L) 
257 (28) 
458.4 
(61.1- 1375.2) 
85.1 (16.1) 
36.3 (10.3) 
1.4  
(0.9 - 2.2) 
1.9 
(1.9 - 4.0) 
220 (20) 
447.7 
(82.5 - 1345.3) 
94.4 (20.5) 
37.6 (10.2) 
1.3  
(0.7 - 2.2) 
1.9 
(1.9 - 4.1) 
224 (16) 
648.7 
(436.8 - 957.3) 
84.3 (13.2) 
33.5 (3.9) 
1.2 
(0.8 - 3.9) 
1.9 
(1.9 - 9.3) 
240 (15) 
635.9  
(430.8 - 1023.9) 
69.3 (9.3) 
32.3 (3.8) 
1.1 
(0.8 - 1.7) 
1.9 
(1.9 - 4.1) 
Abbreviations: sICAM-1 = soluble intercellular adhesion molecule-1; sVCAM-1 = soluble vascular 
cellular adhesion molecule-1; sE  = soluble endothelial; sP = soluble platelet; IL-6 = interleukin- 6; 
CRP = C-reactive protein. 
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TABLE 2.12: Change (Absolute and Percentage) in Plasma Inflammatory Marker 
Concentrations 
Values are means (SEM) or median (10
th -90
th percentile) 
 
Change 
Absolute % 
Outcome 
Fish  oil Placebo Fish  oil  Placebo 
sICAM-1 (ng/mL) 
sVCAM-1 (ng/mL) 
sE-selectin (ng/mL) 
sP-selectin (ng/mL) 
IL-6 (pg/mL) 
 
CRP (mg/L) 
32.05 (22.55) 
39.65 (30.86) 
9.34 (18.36) 
1.31 (3.00) 
0.21 
(-1.21 - 1.30) 
0 
(-2.01 - 0.00) 
15.95 (12.02) 
3.11 (46.07) 
14.95 (14.31) 
-1.17 (2.10) 
-0.03 
(-2.30 - 0.23) 
0 
(-7.19 - 0.56) 
-9.48* (6.86) 
-2.10 (6.74) 
18.10 (17.37) 
17.17 (10.62) 
17.62 
(-44.0 - 104.44) 
0 
(-50.3 - 0) 
9.85 (6.14) 
2.30 (6.45) 
-2.49 (16.26) 
4.34 (9.04) 
-2.86 
(-65.74 - 16.33) 
0 
(-72.28 - 14.36) 
 
 *Significantly different between groups (P = 0.05) 
Abbreviations: sICAM-1 = soluble intercellular adhesion molecule-1; sVCAM-1 = soluble vascular 
cellular adhesion molecule-1; sE  = soluble endothelial; sP = soluble platelet; IL-6 = interleukin-6; 
CRP = C-reactive protein. 
 
 
2.3.10 Relationship between a Marker of Habitual Fatty Acid Intake and CVD Risk 
Factors 
 
   Adipose tissue fatty acid composition is believed to reflect the fatty acid composition of 
the habitual diet (Katan et al. 1997; Leaf et al. 1995). In the fasting state NEFAs are 
released from adipose tissue and the fatty acid composition of plasma NEFAs reflects that 
of adipose tissue. Thus, the fatty acid composition of NEFAs in the fasting state reflects that 
of the habitual diet. Here the % of individual fatty acids in the NEFA fraction at baseline 
was correlated with plasma concentrations of CVD risk factors in order to identify 
significant relationships. Table 2.13 shows the significant associations that were observed. 
In terms of inflammatory markers, it was found that sP-selectin was inversely correlated 
with myristic acid (r = -0.509, P = 0.009) and palmitic acid (r = -0.512, P = 0.02), whereas 
sE-selectin was negatively associated with palmitic acid (r =  -0.517, P = 0.02). On the 
other hand, CRP was positively associated with α-linolenic acid (r = 0.445, P = 0.049) and 
20:1n-9 (r = 0.493, P = 0.027). None of n-3 PUFAs was found to be associated with any 
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plasma lipid concentration, apart from DHA which was shown to be negatively related to 
HDL-c concentration (r = -0.492, P = 0.02). Oleic acid was negatively correlated with total 
cholesterol and LDL-c concentrations, and subsequently inversely associated with the total 
cholesterol: HDL-c ratio (r = -0.541, P = 0.014) and the total cholesterol: LDL-c ratio (r = -
0.578, P = 0.008).  
 
TABLE 2.13: Correlations between Fatty Acids in Plasma NEFAs and CVD Risk Factors 
 
CVD risk factor  Fatty acid  r  P 
Inflammatory markers 
sP-selectin 
 
 
sE-selectin 
 
sVCAM-1 
 
CRP 
 
Lipids 
Total cholesterol 
 
 
 
LDL-c 
 
 
 
HDL-c 
 
TAGs 
 
 
 
Total cholesterol: HDL-c ratio 
 
 
 
 
Total cholesterol: LDL-c ratio 
 
 
 
 
Total NEFA 
 
 
14:0 
16:0 
 
16:0 
 
16:1n-7 
 
18:3n-3 
20:1n-9 
 
16:0 
18:0 
18:1n-9 
 
16:0 
18:0 
18:1n-9 
 
22:6n-3 
 
20:4n-6 
18:1n-9 
18:0 
 
18:0 
18:1n-9 
20:1n-9 
22:6n-3 
 
18:0 
18:1n-9 
20:5n-3 
22:6n-3 
 
22:5n-3 
 
 
-0.569 
-0.512 
 
-0.517 
 
0.458 
 
0.445 
0.493 
 
0.514 
0.447 
-0.511 
 
0.474 
0.456 
-0.518 
 
-0.492 
 
0.671 
-0.462 
0.484 
 
0.488 
-0.541 
0.521 
0.449 
 
0.487 
-0.578 
0.462 
0.492 
 
-0.452 
 
 
0.009 
0.021 
 
0.020 
 
0.042 
 
0.049 
0.027 
 
0.020 
0.048 
0.021 
 
0.035 
0.043 
0.019 
 
0.028 
 
0.001 
0.040 
0.031 
 
0.029 
0.014 
0.019 
0.047 
 
0.029 
0.008 
0.040 
0.042 
 
0.045 
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2.3.11 Relationship between a Marker of Inflammatory Cell Fatty Acid Composition 
and CVD Risk Factors 
 
   The fatty acid composition of plasma PC has been shown to be highly related to that of 
inflammatory cells (Kew et al. 2003). Thus, the fatty acid composition of plasma PC at 
baseline was related to CVD risk factors (Table 2.14). Figure 2.4 shows that arachidonic 
acid in plasma PC was positively correlated with sICAM-1 (r = 0.604, P = 0.005). On the 
other hand, the proportion of DHA in plasma PC was inversely correlated with sICAM-1 (r 
= -0.710, P < 0.001) (Figure 2.5) along with 22:1n-9 (r = -0.512, P = 0.02).  
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FIGURE 2.4: Proportion of ARA in Plasma PC vs. sICAM-1 Concentration 
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FIGURE 2.5: Proportion of DHA in Plasma PC vs. sICAM-1 Concentration 
 
 
 
TABLE 2.14: Correlations between Fatty Acids in Plasma PC and CVD Risk Factors 
 
CVD risk factor  Fatty acid  r  P 
Inflammatory markers 
sE-selectin 
 
sICAM-1 
 
 
 
Lipid profile 
Total cholesterol 
 
LDL-c 
 
 
TAG 
 
 
 
LDL-c:HDL-c ratio 
 
 
Total NEFA 
 
Glucose 
 
HOMA 
 
20:0 
 
20:4n-6 
22:6n-3 
22:1n-9 
 
 
22:6n-3 
 
18:0 
18:1n-9 
 
18:0 
18:2n-6 
18:3n-6 
 
16:1n-7 
18:1n-9 
 
20:5n-3 
 
18:1n-9 
18:3n-3 
22:6n-3 
 
0.604 
 
0.604 
-0.710 
-0.512 
 
 
-0.529 
 
0.518 
-0.498 
 
0.449 
-0.494 
0.623 
 
0.484 
-0.506 
 
-0.488 
 
-0.462 
-0.450 
0.446 
 
0.005 
 
0.005 
< 0.001 
0.020 
 
 
0.016 
 
0.019 
0.026 
 
0.047 
0.027 
0.003 
 
0.030 
0.023 
 
0.029 
 
0.040 
0.047 
0.049 
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2.3.12 Correlations between Changes in Individual Fatty Acids and Changes in 
Inflammatory Markers  
 
      If fatty acids are causally associated with inflammation, as determined by plasma 
inflammatory markers, then changes in status of those fatty acids should be associated with 
changes in levels of the inflammatory markers. Therefore, the change in the proportions of 
ARA, EPA and DHA in the different plasma pools was related to the change in 
inflammatory marker concentrations; pooled subjects were used in this analysis (Tables 
2.15 to 2.17). There was an inverse relationship between the change in the level of plasma 
non-esterified ARA (NEFA fraction) and the change in sICAM-1 (r = -0.588, P = 0.006), 
and the changes in the level of plasma non-esterified EPA and the change in plasma 
sICAM-1 (r = -0.543, P = 0.013) and the change in plasma sVCAM-1 (r = -0.463, P = 
0.04). Conversely, a positive association between the change in plasma non-esterified DHA 
and the change in plasma sICAM-1 (r = 0.612, P = 0.04) was observed. There were no 
significant correlations observed using the CE fraction (data not shown), although there 
were trends for the absolute and percentage changes in EPA in plasma CEs to be inversely 
related to the change in plasma sICAM-1 concentration (r = -0.404, P = 0.077 and r = -
0.312, P = 0.087, respectively). Table 2.16 shows a negative correlation between change in 
DHA in plasma PC and change in sICAM-1 (r = -0.675, P = 0.001) and also clearly shown 
in Figure 2.6. There was a trend towards an inverse association between changes in plasma 
PC EPA and sICAM-1 (r = -0.406, P = 0.076). Surprisingly there were a significant positive 
association between changes in plasma PC EPA and IL-6 (r = 0.451, P = 0.046). An inverse 
association between percent change in ARA in plasma TAGs and percent change in sP-
selectin was observed (r = -0.455, P = 0.044) (Table 2.17).  
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TABLE 2.15: Correlation (r) between Changes in Individual PUFAs in Plasma NEFAs and 
Changes in Inflammatory Markers 
 
Absolute change  Fatty acid 
(Absolute 
change) 
sE-selectin sP-selectin  sICAM-1  sVCAM-1  IL-6  CRP 
ARA 
EPA 
DHA 
–0.086  
0.085 
-0.083  
-0.053 
-0.217 
-0.205 
-0.588* 
-0.543*  
-0.612*  
-0.009  
-0.463*  
-0.426  
0.011  
0.297 
0.045  
-0.079  
-0.093 
-0.030 
Percent change (%)  Fatty acid 
(Percent 
change) 
sE-selectin sP-selectin  sICAM-1  sVCAM-1  IL-6  CRP 
ARA 
EPA 
DHA 
0.015  
0.175 
-0.042  
-0.032 
0.118 
-0.038  
-0.580*  
-0.561* 
-0.669* 
-0.056  
-0.060 
-0.406 
-0.008 
0.208 
0.080  
0.005 
-0.126 
-0.100 
 *Significant at P < 0.05. 
 
TABLE 2.16: Correlation (r) between Changes in Individual PUFAs in Plasma PC and 
Changes in Inflammatory Markers 
 
Absolute change  Fatty acid 
(Absolute 
change) 
sE-selectin sP-selectin sICAM-1  sVCAM-1  IL-6  CRP 
AA 
EPA 
DHA 
0.170 
0.025  
-0.077  
-0.193  
-0.166  
-0.248  
-0.127  
-0.406  
-0.675*** 
-0.263  
-0.322  
-0.400  
0.108 
0.451*  
0.424  
0.188  
0.153  
0.217  
Percent change (%)  Fatty acid 
(Percent 
change) 
sE-selectin sP-selectin sICAM-1  sVCAM-1  IL-6  CRP 
AA 
EPA 
DHA 
0.252 -
0.064  
-0.068  
-0.345  
-0.125  
-0.045  
-0.192  
-0.131  
-0.474**  
-0.337  
-0.158  
-0.070  
0.132 
0.406  
0.184  
0.156  
0.190  
0.236  
 *Significant at P = 0.046 
**Significant at P = 0.008 
***Significant at P = 0.001 
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TABLE 2.17: Correlation (r) between Changes in Individual PUFAs in Plasma TAGs and 
Changes in Inflammatory Markers 
 
Absolute change  Fatty acid 
(Absolute 
change) 
sE-selectin sP-selectin  sICAM-1  sVCAM-1  IL-6  CRP 
ARA 
EPA 
DHA 
0.142  
0.179  
0.174  
-0.259  
-0.091  
-0.198  
0.100  
-0.178  
0.144  
0.168  
-0.239  
-0.255  
0.125  
0.268  
0.070  
-0.107  
0.129  
0.069  
Percent change (%)  Fatty acid 
(Percent 
change) 
sE-selectin sP-selectin  sICAM-1  sVCAM-1  IL-6  CRP 
ARA 
EPA 
DHA 
0.116  
0.436  
0.056  
-0.455*  
0.356  
-0.104  
0.088  
-0.277  
-0.351  
0.027  
-0.164  
-0.351  
0.321  
0.182  
0.265  
-0.033  
0.083  
0.088  
 *Significant at P = 0.044 
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2.4 Discussion 
 
   This double-blind placebo-controlled study on the effect of a moderate dose (3 g/day) of a 
fish oil supplement providing 2.1 g/day of EPA plus DHA, mainly as EPA (1.8 g/day) was 
carried out for the duration of 8 weeks. The subjects were healthy male volunteers and they 
gave blood samples twice, at baseline before supplementation began and at the end of the 
study (after 8 weeks). The dose of LC n-3 PUFAs given was as the upper limit of the 
recommended range based upon the guideline range for oily fish intake among UK adults 
(SACN Report 2004). A MCFA-rich oil (providing 0.56 g/day of caprylic acid (8:0) and 
1.96 g/day of capric acid (10:0)) was used as the placebo. MCFAs were used because these 
fatty acids are generally considered to be physiologically neutral and were not expected to 
change the blood (or cell) fatty acid profiles. This is because MCFAs enter the hepatic 
portal vein, rather than the systemic circulation, after absorption and so are directly targeted 
to the liver where they readily enter mitochondria and undergo rapid oxidation. Therefore 
the proportion of these fatty acids that make their way into the general circulation is very 
low. Indeed, there was no appearance of MCFAs in any of the plasma lipid fractions studied 
here. This agrees with the study by Tholstrup et al. (2004) which showed no appearance of 
8:0 or 10:0 in plasma TAGs, PC or CEs after consumption of a diet containing increased 
amounts of these fatty acids. Thus, from this perspective MCFAs make a suitable placebo to 
study the effects of LC n-3 PUFAs. 
 
The study was mainly aimed at identifying whether fish oil supplementation, providing LC 
n-3 PUFAs at the upper level of the current UK guideline range, but still achievable through 
a normal diet, has any beneficial effects on cardiovascular risk factors in apparently healthy, 
middle-aged male subjects. Thus, the main outcomes were based on the measurement of the 
blood lipid profile and inflammatory markers. In addition, the fatty acid composition in four 
plasma lipid fractions was measured. 
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2.4.1 Effect of Supplementation on Plasma Fatty Acid Composition 
 
      In this study, incorporation of EPA and DHA into plasma lipids was studied by 
investigating four different fractions, namely TAGs, NEFAs, CEs and PC. All four of these 
fractions represent transport pools for fatty acids in the bloodstream. NEFAs are released 
from adipose tissue as a result of hydrolysis of stored TAGs. Thus the fatty acid 
composition of the plasma NEFA fraction reflects the fatty acid composition in adipose 
tissue (Conquer & Holub 1998; Leaf et al. 1995) and these proportions are, in general, 
similar to the fatty acid composition of the habitual diet (Katan et al. 1997). Therefore 
analysis of this fraction can give information about the composition of dietary fatty acids. In 
addition, NEFAs are available for uptake by cells and tissues for use as fuels (Newsholme 
& Leech 1983) and may influence cell function (Kew et al. 2003). In the fasting state, fatty 
acids carried in the plasma TAGs fraction have been released from the liver and are being 
carried to peripheral cells and tissues. Plasma PC and CE fractions also represent transport 
of lipids including fatty acids. Because intact phospholipids and phospholipid fatty acids 
can exchange with cell membranes, the fatty acid composition of plasma PC is fairly similar 
to that of circulating cells (e.g. inflammatory cells; see Kew et al. 2003). Moreover, plasma 
PC originates mainly from liver, and so its composition may reflect tissue LC n-3 fatty acid 
levels, and also is a surrogate for cell membrane fatty acid composition. Plasma CEs, 
normally contain negligible amounts of LC n-3 fatty acids; thus this lipid class may also 
serve as useful marker for LC n-3 fatty acid intake (Harris 1989; Zock et al. 1997). 
 
It was found that EPA was significantly increased in all four plasma lipid fractions studied, 
with the biggest increase (mean 368%) in the NEFA fraction. Differences in incorporation 
among the lipid fractions studied probably reflect the fact that this fatty acid is not esterified 
into different lipid classes to the same extent (Harris 1989). Plasma NEFA, PC and CE 
fractions all showed an average increase in EPA of about 320%. Previous studies reported 
increased incorporation of EPA in plasma phospholipids by approximately 400% with 3.6 
to 4 g/d EPA supplementation (Woodman et al. 2002; Mori et al. 2000; Grimsgaard et al. 
1997). The observed 363% increase in EPA in plasma PC when EPA at 1.8 g/d is given is 
consistent with the findings of Rees et al. (2006) obtained using different doses of EPA, and 
suggests a fairly linear dose-response incorporation of EPA into plasma phospholipids 
(Figure 2.7) 
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FIGURE 2.7: Effect of Different Doses of EPA on % Change of EPA in Plasma PC 
Data for older and young subjects comes from Rees et al. (2006). The arrow shows a dose 
of 1.8 g/d EPA used in this study, indicating that the change in EPA seen at this dose agrees 
with that predicted by the Rees et al. (2006) data. 
 
DHA was not significantly increased in any of the fractions studied, yielding average 
increases of 20 to 60%, depending upon the fraction studied. Previous studies 
supplementing with high amounts of DHA (> 3 g/d) reported significant incorporation of 
DHA (about a 150% increase) into plasma phospholipids (Woodman et al. 2003; Woodman 
et al. 2002, Mori et al. 2000; Halvorsen et al. 1997; Grimsgaard et al. 1997; Vidgren et al. 
1997; Agren et al. 1996; Conquer & Holub 1996; Hamazaki et al. 1996). Thies et al. (2001) 
report a significant increase in plasma phospholipids DHA when DHA was given at a dose 
of 700 mg/day. However when DHA was given at a dose of 280 mg/day, as part of an EPA-
rich fish oil preparation there was no significant effect on the proportion of DHA in plasma 
phospholipids (Thies et al. 2001). In the current study DHA was provided at 300 mg/day 
and the lack of increased DHA status observed is consistent with the findings of Thies et al. 
(2001) with low dose DHA. Thus, the lack of a significant increase in DHA status observed 
here probably simply reflects the relatively low amount of DHA in the supplement used. 
 
The increase in the proportion of EPA in plasma TAGs and NEFAs was not accompanied 
by a significant decrease in proportion of any fatty acid in these fractions. However, in 
plasma CEs the proportion of LA and DGLA decreased by 7.6% and 12.4%, respectively 
(from 53.9% to 49.8% for LA and from 1.13% to 0.99% for DGLA) with the increase in 
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EPA being totally accounted for by these decreases. Likewise in plasma PC, the increase in 
EPA was accounted for by decrease in the proportion of LA (by 15%). ARA was not 
significantly affected by incorporation of EPA. In the recent study by Rees et al. (2006), 
EPA was shown to decrease the proportions of LA and DGLA in plasma phospholipids, but 
there was little effect on ARA. The findings of the current study largely agree with this. 
Thus, it seems that EPA more easily replaces LA (and DGLA), than ARA, in plasma 
phospholipids and CEs. 
 
In general, n-3 PUFAs are proposed to decrease ARA-derived eicosanoid production by 
inflammatory cells, platelets and endothelial cells, which can subsequently result in 
inhibition of platelet aggregation, smooth muscle contraction and inflammation (British 
Nutrition Foundation 1992; 1999). These mechanisms result in anti-thrombotic and anti-
inflammatory effects, which may be responsible for the protective effect of n-3 PUFAs 
against atherosclerosis and CVD (Calder & Yaqoob 2003). Indeed many fish oil 
supplementation studies reported that ARA levels in plasma and cell lipids are decreased by 
increased LC n-3 PUFA intake (Dewailly et al. 2001; Damsgaard et al. 2006; Yaqoob et al. 
2003; Sperling et al. 1993). However, in the current study no significant reduction in ARA 
in plasma lipids was observed. In a study of postmenopausal women on HRT, Ciubotaru et 
al. (2003) found that after 5-week supplementation with fish oil providing 1.2 g EPA plus 1 
g DHA/d, there was no significant effect on ARA in total plasma lipids. Thus, a modest LC 
n-3 PUFA intake, as used by Ciubotaru et al. (2003) and in the present study, may not alter 
ARA availability and subsequently influence the ARA pathway. If this is the case then 
relatively few functional effects may be observed with modest LC n-3 PUFA intakes. 
Interestingly, a study with high dose LC n-3 PUFAs (5.3 g EPA plus DHA/day) also did not 
significantly decrease the proportion of ARA in plasma phospholipids (Allard et al. 1997).  
 
The present study indicates that modest increases in LC n-3 PUFA intake alter the fatty acid 
composition of plasma lipid fractions, but that there are differences in the effects seen 
according to the lipid fraction investigated.  
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2.4.2 BMI and Blood Pressure 
 
   BMI increased by 2% in subjects taking fish oil, but not in the placebo group. Since both 
groups consumed that same amount of oil, this difference is not due to consuming more oil 
or energy from oil. The difference may be due to a variation in diet or an alteration in 
metabolism in the fish oil group. No dietary or physical activity information was collected, 
so it is not possible to identify the reason for the increase in BMI. 
 
Mean values for systolic and diastolic blood pressures were normal for both groups at 
baseline. No effect of fish oil on blood pressure was observed. In a meta-analysis of studies 
with hypertensive subjects who consumed an average 5.6 g/day of LC n-3 fatty acids, 
Morris et al. (1993) reported that there was a significant reduction in blood pressure of -3.4 
(systolic) and -2.0 (diastolic) mm Hg. Moreover, Appel et al. (1993) found that blood 
pressure was decreased -5.5 (systolic) and -3.5 (diastolic) mm Hg in trials of untreated 
hypertensive subjects when they were given more than 3 g/day of LC n-3 fatty acids. The 
lack of effect on blood pressure in the current study may be because the dose of LC n-3 
PUFAs used was too low. Furthermore, Mori et al. (2000) reported that DHA seems to be 
more effective compared with EPA in lowering blood pressure, and in the current study 
intake of DHA was low (0.3 g/d). In addition, it was also reported in a recent meta-analysis 
that the blood pressure lowering effects of fish oil tend to be greater in subjects that were 
older (> 45 years) or hypertensive (Geleijnse et al. 2002). The current study used subjects 
with a mean age < 45 y and they were mainly normotensive. 
 
 
2.4.3 Plasma Lipid Profile 
 
   In the current study, supplementation with a MCFA-rich oil (as a placebo) significantly 
raised total cholesterol (by 17%) and LDL-c (8%). These findings are contrary to early 
studies which reported that saturated fatty acids with a chain length < 12 carbons failed to 
raise serum cholesterol (Katan et al. 1995). However, it was also documented that, 
compared with oleic acid, MCFAs (8:0 plus 10:0, as used in the current study) result in 11% 
higher plasma total cholesterol, 12% higher plasma LDL-c and 22% higher plasma TAGs in 
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healthy young men (Tholstrup et al. 2004). Thus, the findings of the current study agree in 
part with those of Tholstrup et al. (2004). Previously, there was little information about the 
effects of the MCFAs caprylic (8:0) and capric (10:0) on plasma lipids and lipoproteins 
(Kris-Etherton & Yu 1997). Some studies emphasized that generally their effects are similar 
to those of carbohydrates, even though there is limited evidence to support this conclusion 
(Grundy 1994). Indeed, Cater et al. (1995) described that MCFAs act similarly to palmitic 
acid as compared to oleic acid. In the current study, the additional MCFAs given to the 
subjects was only 2.5 g/day or equivalent to 0.7% of total calorie intake, and therefore it 
was assumed that the effects would be negligible. Most studies on the effects of individual 
fatty acids on plasma lipids were carried out at more than 4% of energy exchange. Since no 
dietary intake data were gathered in the current study, the increase in lipid profile might due 
to other factors, for instance, changes in dietary fat intake which was not monitored. 
 
In terms of the effect of fish oil supplementation on the blood lipid profile, the results 
obtained were consistent with other studies showing that LC n-3 PUFAs do not lower the 
concentration of blood cholesterol, and indeed, that they have a slight cholesterol, LDL-c 
and HDL-c raising effect (Katan et al. 1995; Harris et al.1996). It was reported that at a 
dose of 4 g/day EPA plus DHA, the increases in total cholesterol and HDL-c were 5-10% 
and 1-3%, respectively (Harris 1997). In this study, total cholesterol and HDL-c were 
increased by 9% and 6%, respectively following supplementation with 2.1 g/d EPA plus 
DHA.  Recently, no beneficial effect, in terms of changes in blood lipids in healthy 
individuals classified according to different levels of lipidemia, was seen following an 
increase in LC n-3 PUFA intake (corresponding to an intake of 2.5 to 3 times fish per week) 
(Castro et al. 2007). Since, there are many factors that may influence the cholesterol level in 
plasma, it is difficult to identify the precise dose response relationship between LC n-3 
PUFAs and cholesterol concentrations. 
 
There was no significant difference in the concentrations of plasma TAG between the fish 
oil and placebo groups. Fish oil supplementation did not exhibit the favourable TAG 
lowering effect as previously shown (Roche 1999; Harris 1996). Harris (1997) reported in a 
comprehensive review of human studies that approximately 4 g/day of LC n-3 PUFAs from 
fish oil decreased serum TAG concentration by 25%-30%, with accompanying increases in 
LDL-c of 5% to 10% and in HDL-c of 1% to 3% only. Again, most published studies 
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reporting significant reductions in TAG concentration use doses in the region of 4 g/day 
(Hamazaki et al. 1996; Grimsgaard et al. 1998; Mori et al. 2000; Woodman et al. 2002; 
Buckley et al. 2004). Moreover, a lower dose of 1.8 g/day EPA was reported to be 
ineffective at lowering TAG in patients with angina and elevated TAG levels (Yamamoto et 
al. 1995). The results of the current study are consistent with this lack of effect of modest 
doses of LC n-3 PUFAs. DHA is believed to be more important in TAG lowering compared 
with EPA (Mori et al. 2000). Even so, it has been documented that studies in which TAG 
were unchanged used relatively low doses of DHA (< 2 g/day DHA) (Conquer & Holub 
1998), lower purity DHA (Conquer & Holub 1998; Hamazaki et al. 1996) and were carried 
out in subjects with normal TAG levels at baseline (Hamazaki et al. 1996). Again, reasons 
for a lack of TAG lowering in the current study may be too low an intake of LC n-3 PUFAs, 
not enough DHA or study of normotriglyceridemic subjects.  
 
There was a trend towards increased plasma TAG concentration in both the fish oil and 
placebo groups, although this was not significant and not different between the groups. The 
increase in plasma TAG in the fish oil group may be due to other potential effect modifiers, 
such as dietary changes and BMI. BMI was significantly increased in the fish oil group. It is 
possible that the beneficial TAG lowering effect of fish oil might have been prevented by 
weight gain. The TAG-increasing effect of MCFAs that was observed by others (Uzawa et 
al. 1964; Hill et al. 1990; Tholstrup et al. 2004) is supported by the results of the present 
study, although the elevation seen was not significant. It has been suggested that a 
mechanism for the TAG-increasing effect of MCFAs is stimulation of insulin secretion and 
of anabolic-related processes (Hill et al. 1990). 
 
The increased TAG level in subjects supplemented with fish oil might due to higher intake 
of carbohydrate from the diet, which subsequently can be converted to fatty acids and 
incorporated in TAGs (Becker & Hannun 2004). If this is the explanation, it can be 
hypothesized that ingestion of fish oil supplement was not responsible for the increased 
level of TAG in plasma but that this was due to unusual changes in the habitual diet of the 
subjects, particularly in carbohydrate intake. It has been reported that eucaloric low-fat and 
high-carbohydrate diet increased plasma TAG significantly (Kasim-Karakas et al. 2006).  
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Even though one of the mechanisms to explain how EPA and DHA might beneficially 
modulate cardiovascular risk has been proposed to be via TAG lowering, the role of TAGs 
in the pathogenesis of atherosclerosis is still controversial. This is due to an inconsistent 
association between circulating TAGs and coronary heart disease risk in prospective 
epidemiological studies (Stampfer et al. 1996; Kannel et al. 1985). Harris & Bulchandani 
(2006) in their review proposed that LC n-3 PUFAs reduce TAG levels via decreasing 
hepatic lipogenesis, but concluded that the mechanism of action in human remains 
unknown. Moreover, it has been suggested that the negative impact of raised TAGs in 
plasma is lower compared with elevated LDL-c: HDL-c ratios and that the risk is actually 
due to a strong inverse relationship between TAG and HDL-c concentrations.  
 
 
2.4.4 Effect of Supplementation on Glucose, Insulin and HOMA 
 
      It was found that MCFAs significantly increased insulin and subsequently HOMA. 
Because blood glucose concentration did not change, this suggests induction of insulin 
resistance with MCFAs. In general, studies show that saturated fat significantly worsens 
insulin-sensitivity, while monounsaturated and polyunsaturated fatty acids improve it 
through modification of the composition of cell membranes (Riccardi et al. 2004). Recently 
Tholstrup et al. (2006) reported that, compared with the intake of high-oleic sunflower oil, 
MCFA intake resulted in higher plasma glucose; however insulin concentration did not 
differ significantly between the diets. There are few studies on MCFAs and fasting plasma 
glucose available, and the results of the present study are in accordance with these i.e. there 
is no effect of MCFAs on fasting blood glucose concentrations (Hill et al. 1990). On the 
other hand, Feskens et al. (1994) reported that PUFA intake was inversely associated with 
plasma insulin level. In the current study, positive effects of LC n-3 PUFAs on glucose and 
insulin sensitivity markers were not observed. Reported effects of LC n-3 PUFAs on insulin 
sensitivity are equivocal (Moore et al. 2006).  
 
 
2.4.5 Inflammatory Markers 
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   In the present study, the anticipated positive effects of LC n-3 PUFAs on plasma markers 
of inflammation were not observed, except there was a significant difference between the 
fish oil and placebo groups in terms of percent change from baseline for sICAM-1. It was 
demonstrated that in the fish oil group, sICAM-1 decreased by 9.5% compared with a 9.9% 
increase in the placebo group. Previously, the effect of LC n-3 PUFAs on markers of 
activated endothelium has been studied extensively. For example, in an in vitro study, De 
Caterina et al. (2000) found reduced cytokine-induced expression of VCAM-1, ICAM-1 
and sE-selectin on cultured human endothelial cells exposed to DHA. Miles et al. (2001) 
reported no significant effects of 1.2 g EPA + DHA/day over 12 weeks on sICAM-1 or sE-
selectin concentrations in 12 elderly healthy subjects, whereas sVCAM-1 was significantly 
reduced when compared with control subjects. Abe et al. (1998) demonstrated reduction of 
sICAM-1 after > 7 months supplementation with 4 g LC n-3 PUFAs/day in 
hypertriglyceridemic men. They also found that a reduction in sE-selectin was more 
pronounced in subjects with diabetes and a reduction in sVCAM-1 was observed only in 
subjects with diabetes as well. Berstad et al. (2003) reported that supplementation of 2.4 g 
of EPA plus DHA/day decreased sICAM-1 level significantly. Hjerkinn et al. (2005) found 
that supplementation with 2.4 g LC n-3 PUFAs daily and dietary counselling for 3 years 
reduced sICAM-1 and thrombomodulin indicating decreased endothelial activation.  The 
finding of the current study with respect to sICAM-1 is in general accordance with previous 
studies (Berstad et al. 2003; Hjerkinn et al. 2005). 
 
Even though there were no significant changes in CRP and IL-6 in the current study, CRP 
was strongly associated with IL-6 (r = 0.740, P < 0.001). Geelen et al. (2004) also reported 
that fish oil supplementation does not lower CRP concentrations in healthy subjects. Since 
CRP is synthesised by the liver and is regulated mainly by the cytokine IL-6 (Baumann & 
Gauldie 1990; Heinrich et al. 1990), this association was not unexpected. Whether CRP is 
simply a marker of inflammatory processes associated with atherosclerosis, or whether it 
plays an aetiological role in atherogenesis is still under debate (Ferns 2001). Although the 
pathophysiological role of CRP is unclear, it may be involved in complement activation and 
the regulation of tissue factor expression. Zwaka et al. (2001) suggested the involvement of 
CRP in monocyte chemotaxis, adhesion molecule upregulation and LDL uptake which can 
be associated with the development of atherosclerosis. 
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Again, a lack of pronounced significant effects of 2.1 g EPA plus DHA/day on plasma 
inflammatory markers in the current study may be due to too low intake of LC n-3 PUFA, 
especially DHA. Correlation analysis suggested that DHA rather than EPA is important in 
determining inflammatory marker concentrations 
 
 
2.4.6 Does Habitual Fatty Acid Intake Influence CVD Outcomes? 
 
   The influence of habitual fatty acid intake on CVD outcomes was investigated based on 
the association between fatty acid composition in the NEFA fraction and CVD markers. 
NEFAs in plasma are mainly released from adipose tissue and subsequently used as a 
source of energy in the fasting condition (Newsholme & Leech 1983). It was assumed that 
the composition of fatty acids in adipose tissue, which can be determined in the fasting state 
using the NEFA fraction, is similar to the fatty acid composition of diet (Conquer & Holub 
1998; Leaf et al. 1995).  
 
LC n-3 PUFAs in the NEFA fraction were not found to be associated with lipid profile 
parameters, apart from DHA which was negatively associated to HDL-c concentration. 
Conquer & Holub (1998) reported that DHA supplementation, even at a high concentration 
(1.5 g DHA/day) had no significant effect on serum lipid and lipoprotein levels. It was also 
found that oleic acid (18:1n-9) was negatively correlated with total cholesterol, LDL-c and 
TAG and with the total cholesterol:LDL-c and total cholesterol: HDL-c ratios. This effect 
of oleic acid is consistent with reports from interventions with that fatty acid (Katan et al. 
1995). However, in terms of the relationship between NEFAs and inflammatory markers, 
palmitoleic acid was inversely associated with sVCAM-1. This contrasts with findings of 
Yli-Jama et al. (2002) who reported an inverse linear association between serum non-
esterified EPA, DHA and ARA and sVCAM-1 among elderly men at high risk for CHD 
(Hjerkinn et al. 2005). These authors did not report what the effect of oleic acid was. As far 
as I am aware, there are no other studies of this type, which restricts further discussion and 
comparison. There is a need for future research to determine the relationships between 
plasma NEFAs, since these are reflective of dietary fatty acid pattern, and CVD risk 
markers especially those related to inflammation. 
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2.4.7 Does Fatty Acid Composition of Inflammatory Cells Relate to CVD Outcomes? 
 
   The relationship between the fatty acids in plasma phospholipids and CVD outcomes was 
determined using the PC fraction at baseline.  Plasma PC was used as a surrogate for 
inflammatory cell phospholipids, since there is a close relationship between the fatty acid 
composition of plasma PC and of inflammatory cells (Kew et al. 2003). ARA, a potentially 
potent of pro-inflammatory factor (Dwyer et al. 2004), was shown to be positively 
correlated with sICAM-1. Inflammatory cells typically contain a high proportion of ARA 
(∼20%) which is usually the major substrate for eicosanoid synthesis. These eicosanoids are 
involved in modulating the intensity and duration of inflammatory responses (Lewis et al. 
1990; Tilley et al. 2001). Yli-Jama et al. (2002) showed that non-esterified ARA was 
inversely associated with sVCAM-1 which might indicate an anti-inflammatory effect on 
the vascular endothelium. These contradictory results are difficult to explain, except that 
free-ARA and ARA in phospholipids might have different effects.  
 
 
2.4.8 Correlation between Inflammatory Markers and Specific Fatty Acids 
 
   The role of LC n-3 PUFAs, particularly EPA and DHA on inflammatory responses have 
been studied in cell culture with results indicating that non-esterified DHA reduces the 
expression of adhesion molecules, particularly VCAM-1 (De Caterina et al. 1994; De 
Caterina et al. 1995; De Caterina et al. 2000; Weber et al. 1995). Miles et al. (2001) 
reported no significant effects of 1.2 g/day of n-3 PUFAs on sICAM-1 or sE-selectin, 
whereas sVCAM-1 was significantly decreased. In contrast, in the current study, it was 
found that there were no significant correlation between sVCAM-1 and n-3 PUFAs. Yli-
Jama et al. (2002) reported in their human studies that the inverse correlation between 
sVCAM-1 was more prominent for DHA than EPA, with no association found for sICAM-
1. Moreover, in their study there was a significant inverse linear association between serum 
non-esterified ARA and sICAM-1 level. However, after fish oil supplementation (2.1 g of 
EPA plus DHA per day for 18 months), there was a significant positive correlation between 
the change in serum non-esterified DHA and sVCAM-1 (Berstad et al. 2003). This is odd, 
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because it suggests that long term (18 months) supplementation with fish oil changed the 
relationship between the level of endothelial markers and fatty acids in the serum NEFA 
fraction.  In other studies, it was found that supplementation with n-3 PUFAs significantly 
reduced sICAM-1 (Berstad et al. 2003; Hjerkinn et al. 2005), but correlation analyses did 
not provide any clues of possible relations between changes in the fatty acid profile and the 
reduction of sICAM-1 (Hjerkinn et al. 2005). The present study is the first time an inverse 
association between the levels of sICAM-1 and plasma LC n-3 PUFAs (DHA in PC 
fraction) has been documented. This finding strengthens the hypotheses from other studies 
that LC n-3 PUFAs, particularly DHA inhibits the inflammatory response in the vascular 
endothelium.  
 
sICAM-1 concentration has been used to mark the inflammatory state (Adams et al. 1993), 
and several studies reported that patients with elevated sICAM-1 are at risk for future CVD 
events (Morisaki et al. 1997; Ridker et al. 1998). Therefore, a decrease in sICAM-1 
concentration is likely to be clinically important. Therefore, it can be concluded that an 
intake of LC n-3 PUFAs at the upper end of current UK dietary recommendations is 
beneficial in modulating the inflammatory marker of sICAM-1 and subsequently has a 
potential to reduce progression of the atherosclerotic plaque and future CVD events. 
 
 
2.5 Conclusion 
 
   The present study indicates that a dose of 2.1 g/d of EPA plus DHA is not sufficient to 
demonstrate maximal effects on CVD risk factors including inflammatory markers among 
fairly healthy young male subjects, although results show that percent change for the 
sICAM-1 decreased significantly compared with placebo. Correlation analyses showed a 
significant inverse relationship between the change in plasma DHA in PC fraction and 
change in sICAM-1 concentration. The expected positive effect of LC n-3 PUFAs on TAG 
levels was not seen. The reason for the observed trend to increased TAG among the subjects 
supplemented with fish oil remains unresolved. Results also agree with previous studies that 
non-esterified oleic acid has beneficial effect on cholesterol levels and DHA seems to be 
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more important than EPA since an inverse relationship between DHA and sICAM-1 was 
found in the present study. In healthy subjects, a higher dose of LC n-3 PUFAs will be 
needed to modify the CVD risk factor profile. 
 
 
 
 
 
 
Chapter 3 
 
 
The Effects of a Moderate Dose of Long Chain n-3 
PUFAs on Cardiovascular Risk Factors, Particularly 
Plasma Lipids and Inflammatory Markers, in Patients 
Awaiting Carotid Endarterectomy 
 
 
3.1 Introduction 
 
3.1.1 Background 
 
   It has been widely reported that consumption of long chain n-3 polyunsaturated fatty acids 
(LC n-3 PUFAs) found mainly in oily fish protects against cardiovascular disease (CVD) 
morbidity and mortality (Daviglus et al. 1997; Albert et al. 1998; Hu et al. 2002; Iso et al. 
2001; He et al. 2002).  On this basis recommendations have been made to increase oily fish 
and LC n-3 PUFA consumption (SACN 2004).  However, fish consumption is low in the 
UK population (SACN 2004) and it has proved difficult to convince people to change their 
diets to improve this (British Nutrition Foundation 2005; SACN 2004). An alternative 
source of LC n-3 PUFAs is fish oil capsules. Most fish oils contain about 35% of 
eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA). Thus a single one g 
capsule of fish oil can provide only about 300 mg EPA+DHA. A pharmaceutical 
preparation of LC n-3 PUFAs in ethyl ester form called Omacor is available and this 
contains about 90% EPA plus DHA; Omacor is produced to a pharmaceutical standard 
139   
140 
(Figure 3.1) because it is a licensed medication for secondary prevention of myocardial 
infarction (Harrison & Abhyankar 2005). The production process results in undetectable 
levels of environmental toxins (heavy metals, halogenated polycarbons and dioxins), less 
than 0.05% of trans fatty acids, < 90 mg of n-6, -7 and -9 fatty acids and markedly reduced 
potential for fishy taste or belching. Clinical studies using Omacor have demonstrated its 
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triacylglycerol (TAG) levels in various patient populations by 19% to 47% (Eritsland et 
al. 1996; Abe et al. 1996; Johansen et al. 1999; Grundt et al. 1995; Durrington et al. 
2001; Davidson et al. 2007). 
 
 
  
Crude fish oil (to 
approved specification) 
Purification step 1  Removal of pesticides, 
cholesterol, and other fatty 
acids 
N-3 fatty acids 
concentration of ∼30% 
 
 
Purification step 2 
 
N-3 fatty acids 
concentration of ∼50%   
Removal of saturated fatty 
acids 
Purification step 3 
 
N-3 fatty acids 
concentration of ∼75% 
 
 
Purification step 4  Removal of oxidized and 
other by-products   
N-3 fatty acids 
concentration of ∼90%   
 
FIGURE 3.1: The Process of Omacor Preparation 
 
In Chapter 2, the effect of a moderate dose of fish oil, providing 2.1 g/d EPA+DHA, on 
CVD risk factors, particularly plasma lipids and inflammatory markers, was investigated 
in healthy middle-aged males. The main conclusion was that moderate fish oil 
supplementation (2.1 g/d EPA plus DHA) is not sufficient to demonstrate maximal 
effects on CVD risk factors including inflammatory markers in this group. This may be 
because the total dose of LC n-3 PUFAs provided was too low, because not enough 
DHA was provided, or because relatively healthy subjects are fairly resistant to n-3 
PUFA-induced improvements in the CVD risk factor profile. Therefore, in this chapter 
the effect of moderate dose n-3 PUFA supplementation (1.8 g/day) including a 
significant amount of DHA (0.675 g/day) in patients with advanced carotid 
atherosclerosis was investigated. It was thought that patients with disease and so, most 
likely, an altered risk factor profile might be more sensitive to the effects of LC n-3 Chapter 3 The Effects of Omacor on CVD Risk Factors  in Endarterectomy Patients   141     
  
 
PUFAs than healthy subjects. It was also thought that the higher amount of DHA used, 
compared with the study described in Chapter 2, would make effects more likely to 
occur. The total dose of LC n-3 PUFA was selected to be similar to that used in Chapter 
2, to allow comparison, to be relevant to the guideline range for intake of LC n-3 PUFAs 
among UK adults (SACN Report 2004), and to allow comparison with results from a 
previous study of fish oil in carotid endarterectomy patients which used about this dose 
(Thies et al. 2003). No previous studies of Omacor in carotid endarterectomy patients 
have been performed. In accordance with the focus of the study described in Chapter 2, 
the main outcomes studied here were plasma lipid concentrations and inflammatory 
markers. 
 
 
3.1.2 Aim of the Study 
 
   The aim of this study was to identify the effects of LC n-3 PUFAs (EPA plus DHA 
from Omacor) on selected cardiovascular risk factors, with a focus on plasma lipid 
concentrations and inflammatory markers. To address this aim, a double blind, 
randomised, placebo-controlled study of 1.8 g/d EPA plus DHA was conducted in 
patients awaiting carotid endarterectomy. The main outcomes were: 
•  The fatty acid composition of plasma phosphatidylcholine (PC) 
•  The fatty acid composition of plaque phosphatidylcholine (PC) 
•  The concentrations of plasma lipids 
•  The concentrations of plasma inflammatory markers 
•  The concentrations of  plaque inflammatory markers (measured at the mRNA 
level) 
•  Blood pressure 
 
In addition, comparison was made, for the first time, between inflammatory markers 
measured in atherosclerotic plaques and in plasma. 
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3.2 Methods 
 
3.2.1 Study Design 
 
   Ethical permission for all protocols was obtained from the Southampton and South 
West Hampshire Local Research Ethics Committee. This study was carried out between 
March 2003 and December 2004 for the duration between 7 and 102 days before 
patients underwent surgical removal of the carotid plaque (Figure 3.2).  
 
FIGURE 3.2: Surgical Removal of the Carotid Plaque 
 
 
3.2.2 Recruitment of the Subjects 
 
      Patients were identified in the clinics of Professor C.P. Shearman, Southampton 
General Hospital and Mr. S. Payne, Princess Alexandra Hospital, Portsmouth. Patients 
were recruited by Mrs Jennifer Williams, Dr Abbie Cawood and Mrs Frances Knapper. 
Inclusion criteria were patients awaiting carotid endarterectomy, being > 18 y of age and 
being able to give written informed consent. Exclusion criteria were inability to give 
written informed consent, consuming fish oil supplements, eating > one oily fish meal 
per week, being pregnant or lactating, or participation in another trial. All patients gave 
their written informed consent after a detailed description of the study was provided 
prior to entering the study. Patients continued their usual medication throughout the 
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study period and they were advised not to change their current diet. A total of 121 
subjects were recruited (n = 58 and n = 63 for Omacor and placebo, respectively); 
however only one hundred patients (n = 47 and n = 53 for Omacor and placebo, 
respectively) were used in the final analysis. Figure 3.3 shows the summary of the trial 
profile in this study. Patients were excluded from the study if they went to surgery 
within 7 days, others were lost to follow-up, and others reported that they could not 
comply. A further twelve patients who completed the study were excluded from the 
analysis because they were identified as protocol violators, including consuming 
insufficient capsules. Compliance was promoted by regular contact with patients and 
was monitored using capsule count and by analysis of the plasma fatty acid profile. 
 
 
 
 
 
Placebo 
(n = 63) 
Omacor 
(n = 58) 
Completed 
n = 53 
Completed 
    n = 57 
Randomised 
Analysed 
(n = 53) 
Analysed 
(n = 47) 
       Protocol violators 
        (n = 6) 
      Dropouts (n = 6)        Dropouts (n = 5) 
       Protocol violators 
       (n = 6) 
N = 121 
 
FIGURE 3.3: Summary of Trial Profile 
 
 
3.2.3 Capsules 
 
   Capsules were provided in sealed containers and patients took two capsules/day (2 g 
of Omacor or olive oil as placebo) until surgery. The capsules were gelatine-coated and 
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respectively, which is achievable in the diet with regular, but high, oily fish 
consumption. The amount of oleic acid provided by the olive oil placebo was 1.2 g/day; 
this amount is considered negligible since the adult UK consumption of oleic acid is 20-
30 g/day (British Nutrition Foundation 1999).  
 
 
3.2.4 Blood Samples and Measurements Made 
 
   At study entry and just prior to surgery a 20 mL fasting venous blood sample was 
taken from the forearm into tubes containing lithium-heparin. Blood samples were 
collected after a 12-hour overnight fast, put on ice and plasma separated by 
centrifugation at 3000 rpm for 10 minutes at 4
o C.  Aliquots of plasma were kept frozen 
at -80
o C until analysis.  
 
Weight and height were taken to the nearest 0.1 kg and 0.1 cm, respectively. Body mass 
index (BMI) was calculated as weight (in kg) divided by the square of the standing 
height (m
2). Two-blood pressure measurements were obtained from the non-dominant 
side arm and an additional reading was done if values from two consecutive 
measurements were more than 10 mm Hg apart. Subjects were lying down when blood 
pressure was measured using a blood pressure meter, Marquette®. 
 
The plaque was collected at surgery, rinsed, sectioned and frozen at -80
o  C until 
analysis. These plaque manipulations were performed by Dr Abbie Cawood. 
 
 
3.2.5 Determination of Fatty Acid Composition of Plasma and Plaque 
Phosphatidylcholine 
 
   Plasma and plaque phosphatidylcholine (PC) fatty acid composition was determined 
as described for plasma in Section 2.2.7. This analysis was performed by Dr Abbie 
Cawood and Miss Ruth Young. 
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3.2.6 Measurement of TAG, and Total, LDL and HDL Cholesterol Concentrations 
in Plasma 
 
   Plasma TAG and total, LDL and HDL cholesterol concentrations were determined as 
described in Sections 2.2.8, 2.2.9, 2.2.10 and 2.2.11. These analyses were performed at 
the Chemical Pathology Laboratory in Southampton General Hospital by ………. 
 
 
3.2.7 Measurement of Inflammatory Marker Concentrations in Plasma 
 
   Plasma  concentrations  of  IL-6,  IL-10, sE-selectin, sICAM-1, sVCAM-1, MMP-2, 
MMP-9, CRP, TGF-β1, sCD40L, IP-10 and Mig were measured using commercial 
ELISA kits. sE-selectin, sICAM-1 and sVCAM-1 kits were from Biosource Europe, 
Nivelles, Belgium; IL-6, IL-10, MMP-2, MMP-9, sCD40L, IP-10, Mig and TGF-β1 kits 
were from R&D Systems, Minneapolis, USA; high sensitivity CRP kits were from 
Diagnostic System Laboratories, Texas, USA. For all assays, the manufacturer’s 
instructions were followed and the absorbance was read on a plate reader using 450 nm 
as the primary wavelength and 610-650 nm as the reference wavelength. The sensitivity 
of the assays were: < 0.039 pg/mL (IL-6), < 0.5 ng/mL (IL-10), 0.5 ng/mL (sE-selectin), 
< 0.5 ng/mL (sICAM-1), 0.9 ng/mL (sVCAM-1), 0.16 ng/mL (MMP-2), < 0.156 ng/mL 
(MMP-9), < 4.61 pg/mL (TGF-β1), < 10.1 pg/mL (sCD40L), < 4.46 pg/mL (IP-10), < 
11.3 pg/mL (Mig) and 1.6 ng/mL (CRP).   
 
 
3.2.8 Measurement of Plaque mRNA Expression 
 
   Total  cellular  RNA  was  extracted  from plaques using an RNAgents total RNA 
isolation system (Promega UK Ltd., Southampton). The purity and integrity of the RNA 
samples were assessed byA260/A280 spectrophotometric measurements. RNA samples 
were subsequently converted to cDNA by reverse transcription with reverse 
transcription system (Promega UK Ltd., Southampton). Real-time PCR was performed 
using an ABI prism 7700 Sequence Detection System (Applied Biosystems, Foster City, 
USA). PCR primers and probes (Table 3.1) were designed using Primer Express 
Program (version 2.0, Applied Biosystems). PCR products for the MMP1 were detected 
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reporter dye 6-carboxy-fluorescein (FAM) at the 5’ and the quencher dye 6-carboxy-
tetramethyl-rhodamine (TAMRA) at the 3’ end. The 2–ΔΔCt method was used to 
analyze the results. The expression of each target gene was normalized to 36B4 value 
and applied to the subsequent statistical analysis. These measurements were performed 
by Dr Ren Ding. 
 
 
TABLE 3.1: Primers and Probes for Real-time PCR 
Primer/probe Sequence 
MMP1  Forward primer 5’-ACAGCCCAGTACTTATTCCCTTTG-3’ reverse 
primer: 5’-GGGCTTGAAGCTGCTTACGA-3’ 
MMP3  Forward primer 5’-AAAGGATACAACAGGGACCAATTTA-3’ reverse 
primer: 5’-CAGTGTTGGCTGAGTGAAAGAGA-3’ 
MMP7  Forward primer 5’-CGGGAGGCATGAGTGAGCT-3’ reverse primer: 5’-
GCATTTTTTGTTTCTGAGTCATAGAGATA-3’  
MMP8  Forward primer 5’-CTCACAGGGAGAGGCAGATATCA-3’ reverse 
primer: 5’-GATTCCATTGGGTCCATCAAA-3’ 
MMP9  Forward primer 5’-TGGCACCACCACAACATCAC-3’ reverse primer: 5’-
GCAAAGGCGTCGTCAATCA-3’ 
MMP12  Forward primer 5’-CCCACGTTTTTATAGGACCTACTTCT-3’ reverse 
primer: 5’-GGGATAACCAGGGTCCATCAT-3’ 
MMP13  Forward primer 5’-ATGGCATTGCTGACATCATGA-3’ reverse primer: 
5’-GCCAGAGGGCCCATCAA-3’ 
TIMP1  Forward primer 5’-CCAGCGCCCAGAGAGACA-3’ reverse primer: 5-
AGCAACAACAGGATGCCAGAA-3’ 
TIMP2  Forward primer 5’-AGCCTGAACCACAGGTACCAGAT-3’ reverse 
primer: 5’-AGGAGATGTAGCACGGGATCA-3’ 
IL6  Forward primer 5’-TCCAGGAGCCCAGCTATGAA-3’ reverse primer: 5’-
CCCAGGGAGAAGGCAACTG-3’ 
IL10  Forward primer 5’-CTACGGCGCTGTCATCGATT-3’ reverse primer: 5’-
TGGAGCTTATTATTAAAGGCATTCTTCA-3’ 
TNF-α  Forward primer 5’-ATCTTCTCGAACCCCGAGTGA-3’ reverse primer: 
5’-AGCTGCCCCTCAGCTTGA-3’ 
ICAM1  Forward primer 5’-GCAGACAGTGACCATCTACAGCTT-3’ reverse 
primer: 5’-CTTCTGAGACCTCTGGCTTCGT-3’ 
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CCCATCATTAAGGAATTCATGTCA-3’ 
36B4  Forward primer 5’-CCATTCTATCATCAACGGGTACAA-3’ reverse 
primer: 5’-AGCAAGTGGGAAGGTGTAATCC-3’ 
MMP3 probe  6FAM-TGCTCATGAAATTGGCCACTCCCTG-TAMRA 
MMP7 probe  6FAM-CAGTGGGAACAGGCTCAGGACTATCTCAAGA-TAMRA 
MMP8 probe  6FAM-TTGCTTTTTACCAAAGAGATCACGGTGACAAT-TAMRA 
MMP9 probe  6FAM-ACTACTCGGAAGATTGCCGCGGG-TAMRA 
MMP12 probe  6FAM-TGTAGATAACCAGTATTGGAGGTATGATGAAAGGAGACA-
TAMRA 
MMP13 probe  6FAM-TCTTTTGGAATTAAGGAGCATGGCGACTTCTA-TAMRA 
TIMP1 probe  6FAM-AGAGAACCCACCATGGCCCCCTTT-TAMRA 
TIMP2 probe  6FAM-CTGCGAGTGCAAGATCACGCGC-TAMRA 
IL6 probe  6FAM-CCTTCTCCACAAGCGCCTTCGGT-TAMRA 
IL10 probe  6FAM-AACAAGAGCAAGGCCGTGGAGCAG-TAMRA 
ICAM1 probe  6FAM-CCGGCGCCCAACGTGATTCT-TAMRA 
PPAR-γ probe  6FAM-ACAACAGACAAATCACCATTCGTTATCT-TAMRA 
36B4 probe  6FAM-TCTCCACAGACAAGGCCAGGACTCGT-TAMRA 
 
 
 
3.2.9 Statistical Analysis 
 
   The Kolmogorov-Smirnov and Shapiro-Wilk tests were applied to assess normality of 
data. Data for continuous variables that were normally distributed are presented as mean 
values and their standard errors (SEM) whilst non-normally distributed data are presented 
as medians and 10
th and 90
th percentiles. Comparison of normally distributed data 
between groups was performed using the unpaired Student’s t-test and within a group 
using the paired Student’s t-test. Non-normally distributed data were compared using the 
Wilcoxon signed ranks and Mann-Whitney U tests. Relationships between variables were 
evaluated using Pearson’s correlation coefficient or Spearman’s rank correlation. In all 
cases a value for P ≤ 0.05 was taken to indicate a significant effect. SPSS version 14.02 
(SPSS Inc., Chicago, IL) was used for all statistical analyses. 
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3.3 Results  
 
3.3.1 Characteristics of the Subjects  
 
      Of the one hundred and twenty-one patients recruited, twenty-one patients were 
excluded for various reasons: some of them underwent surgery within 7 days, while 
some were unable to comply or were lost to follow-up. Characteristics of the included 
100 patients were not significantly different between the groups at baseline (Table 3.2). 
Table 3.2 shows that patients’ BMIs were slightly higher than normal (27.2 and 26.5 
kg/m
2, for Omacor and placebo groups, respectively). Moreover, in general, patients 
were mildly hypertensive with mean systolic blood pressure of 155 mm Hg vs < 140 
mm Hg (as normal reference), and many (> 50% of patients) had higher plasma LDL-c 
concentration than normal (< 2.6 mmol/L) whereas HDL-c concentration on the other 
hand, was slightly lower than normal (1.2-1.3 mmol/L vs > 1.6 mmol/L).  
 
The median durations of supplementation were 26 and 29 days for Omacor and placebo, 
respectively, and ranged between 7 and 102 days. Based on the counting of the returned 
capsules, compliance was very high: 95.5% and 95.1% for Omacor and placebo groups, 
respectively.  
 
Compliance amongst the 100 included patients was not significantly different between 
groups (P = 0.808). Based on the fatty acid analysis in plasma PC; EPA, DPA and DHA 
were significantly increased (P ≤ 0.001) in the Omacor group (section 3.3.2) indicating 
compliance in that group. 
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TABLE 3.2: Baseline Characteristics of the Subjects 
Unless otherwise indicated data are mean (SEM) or median (10
th-90
th percentile) 
 
  Omacor (n = 47)  Placebo (n = 53) 
Sex (n) 
   Men 
   Women 
Smoking status (n (%)) 
   Yes 
    No 
    Ex-smokers 
Medication use (n (%)) 
   Aspirin 
   Anti-coagulant 
   Beta-blocker 
   Calcium 
   ACE-inhibitor 
   Statin 
   Diuretics 
   Nitrates 
   Insulin 
Age (y) 
Duration of treatment (days) 
BMI (kg/m
2) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Total cholesterol (mmol/L) 
LDL-c (mmol/L) 
HDL-c (mmol/L) 
Triglycerides (mmol/L) 
Total cholesterol:HDL-c ratio 
LDL-c:HDL-c ratio 
sICAM-1 (ng/mL) 
sVCAM-1(ng/mL) 
sE-selectin (ng/mL) 
IL-6 (pg/mL) 
IL-10 (pg/mL) 
MMP-2 (ng/mL) 
MMP-9 (ng/mL) 
TGF-β1 (ng/mL) 
 
CRP (mg/L) 
sCD40L (pg/mL) 
 
IP-10 (pg/mL) 
 
Mig (pg/mL) 
 
32 
15 
 
8 (17.0) 
8 (17.0) 
31 (66.0) 
 
41 (87.2) 
13 (27.7) 
17 (36.2) 
18 (38.3) 
28 (59.6) 
45 (95.7) 
26 (55.3) 
13 (27.7) 
2 (4.3) 
72.8 (1.5) 
21 (8-57) 
27.2 (0.7) 
155.3 (4.1) 
80.6 (2.0) 
4.8 (0.2) 
2.5 (1.6-4.3) 
1.3 (0.9- 2.4) 
1.3 (0.7-2.2) 
3.2 (2.4-4.8) 
1.8 (1.0-3.6) 
167.1 (73.2- 425.7) 
673.3 (226.3-1578.4) 
46.0 (16.51-117.2) 
1.2 (0.4- 4.0) 
1.5 (0-5.24) 
192.2 (129.2-290.3) 
167.2 (46.6-421.1) 
9308 
 (2394-19170) 
1.0 (1.0- 31.7) 
775.8 
(243.2-2238.7) 
111.3 
(51.9-298.5) 
123.9 
(45.9-417.7) 
 
36 
17 
 
8 (15.1) 
11 (20.8) 
34 (64.2) 
 
38 (71.7) 
5 (9.4) 
16 (30.2) 
16 (30.2) 
27 (50.9) 
39( 73.6) 
25 (47.2) 
8 (15.1) 
1 (1.9) 
72.7 (1.2) 
22 (9-66) 
26.5 (0.5) 
155.2 (3.0) 
81.9 (1.8) 
4.9 (0.2) 
2.7 (1.5-4.4) 
1.2 (0.9- 1.9) 
1.3 (0.7-2.6) 
3.8 (2.6-5.0) 
2.24 (1.3-3.2) 
216.1 (64.9- 444.7) 
594.3 (271.8-1130.8) 
45.7 (7.8-145.2) 
1.2 (0.1- 4.8) 
0.5 (0-2.9) 
191.2 (129.0-293.7) 
138.0 (28.8-389.3) 
9788 
 (3356-16844) 
1.0 (1.0-9.1) 
774.0 
(212.7-3139.9) 
105.8 
(45.9-282.0) 
107.0 
(31.4-252.9) 
Abbreviations: BMI = Body mass index; LDL-c = low density lipoprotein-cholesterol; HDL-c = high 
density lipoprotein-cholesterol; sICAM-1 = soluble intercellular adhesion molecule-1; sVCAM-1 = 
soluble vascular cellular adhesion molecule-1; sE = soluble endothelial; IL-6 = interleukin-6; IL-10 = 
interleukin-10; MMP-2 = matrix metalloproteinase-2; MMP-9 = matrix metalloproteinase-9; TGF- β1 = 
transforming growth factor-β1; CR P= C-reactive protein. 
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3.3.2 Effect of Supplementation on the Fatty Acid Composition of Plasma PC 
 
      Table 3.3 shows the fatty acid composition of the plasma PC fraction. The most 
abundant fatty acids in this fraction were palmitic, linoleic, stearic and oleic comprising 
31%, 19%, 14% and 11% of total fatty acids, respectively.  There were no significant 
differences between groups at baseline for any fatty acid.  The proportions of EPA, DPA 
and DHA were significantly increased (P < 0.001) in the Omacor group (Table 3.4, 
Figure 3.4). Linoleic (LA), γ-linolenic (ALA), dihomo-γ-linolenic (DGLA) and 
arachidonic acids were significantly decreased with Omacor (Table 3.4, Figure 3.4). 
There was a small increase in DPA and DHA in the placebo group (Figure 3.4).  
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TABLE 3.3: Fatty Acid Composition of Plasma PC (g/100 g Fatty Acid) 
Values are means (SEM) or median (10
th-90
th percentile) 
 
Omacor (n = 47)  Placebo (n = 53) 
Baseline After  treatment Baseline After  treatment 
Fatty acid 
Mean or 
median 
SEM or 
10
th-90
th 
percentile 
Mean or 
median 
SEM or 
10
th-90
th 
percentile 
Mean or 
median 
SEM or 
10
th-90
th 
percentile 
Mean or 
median 
SEM or 
10
th-90
th 
percentile 
14:0  0.4  0.2 - 0.5  0.3  0.2 - 0.6  0.4  0.2 - 0.5  0.4  0.2 - 0.6 
16:0  30.8  29.0 - 34.4  31.8  29.2 - 34.4  31.0  27.9 - 34.1  31.3**  29.4 - 35.1 
16:1n-7  0.6  0.3 - 1.2  0.6  0.4 - 1.1  0.6  0.3 - 1.0  0.7  0.4 - 1.1 
18:0  14.5  12.1 - 17.4  14.5  12.2 - 16.9  14.5  12.6 - 16.6  13.9*  12.2 - 16.2 
18:1n-9  11.2  9.0 - 13.8  10.4**
a  8.2 - 12.8  11.3  9.8 - 14.5  11.4
b  9.0 - 14.5 
18:2n-6 19.1 0.5  16.5***
c  0.4 19.9 0.4  18.0
*d 0.4 
18:3n-3  0.2  0 - 0.4  0.1  0 - 0.3  0.2  0  0.2  0 
18:3n-6  0.3  0.1 - 0.6  0.2**  0.1 - 0.3  0.2  0.1 - 0.6  0.2  0.1 - 0.5 
20:3n-6  3.3  2.3 - 4.5  2.6***
e  1.7 - 3.7  3.1  2.3 - 4.5  3.3
f  2.3 - 5.1 
20:4n-6  9.9  6.3 - 14.2  9.1*  6.7 - 12.7  9.8  6.6 - 12.9  10.0  6.7 - 14.2 
20:5n-3  1.2  0.7 - 2.1  3.5***
e  2.1 - 4.4  1.2  0.8 - 1.7  1.2
f  0.8 - 2.0 
22:5n-3 1.0  0  1.3***
c  0 1.0 0  1.1*
d 0 
22:6n-3 3.7 0.2  5.8***  0.2 3.9 0.2  4.2
 * 0.2 
*Significantly different from baseline (P < 0.05) 
**Significantly different from baseline (P < 0.01)  
***Significantly different from baseline (P < 0.001) 
Values not sharing the same alphabetic superscript are significantly different between groups at this point; 
abP ≤  0.05, 
cdP ≤ 0.01, 
ef P ≤ 
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FIGURE 3.4: Effect of Supplementation on the Plasma PC n-6 and 
 n-3 Fatty Acid Composition 
*Significantly different from baseline (P < 0.05) 
***Significantly different from baseline (P < 0.001) 
 
Table 3.4 shows the percent change for the main n-6 and n-3 fatty acids present in 
plasma PC. In the Omacor group, it was found that LA, DGLA and ARA (n-6 fatty 
acids) were decreased significantly from baseline, 13%, 22% and 2%, respectively 
compared with the placebo (P < 0.01). On the other hand, the n-3 fatty acids increased 
significantly (P < 0.001) by 161% and 70% for EPA and DHA, respectively. As a result 
of these changes, the ratios of ARA: EPA and ARA:DHA in the Omacor group were 
significantly decreased from 8.98 to 3.14 and from 2.96 to 1.74, respectively (P < 0.001)  
(Figure 3.5) and no significant effect was found in the placebo group.   
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TABLE 3.4: Percent Change from Baseline for n-6 and n-3 Fatty Acids in Plasma PC 
Values are mean (SEM) or median (10
th-90
th percentile) 
% change from baseline  Fatty acid 
Omacor Placebo 
P 
 
LA, 18-2n-6 
DGLA, 18:3n-6 
ARA, 20:4n-6 
 
EPA, 20:5n-3 
DPA, 22:5n-3 
DHA, 22:5n-3 
 
-13.0 (1.8) 
-22.2 (-92.3-66.6) 
-2.1 (-21.4-14.9) 
 
160.9 (54.2-383.6) 
29.3 (5.6) 
70.1 (8.5) 
 
-2.2 (3.2) 
0 (-58.4-126.5) 
0 (-18.5-28.4) 
 
0 (-38.2-56.4) 
15.3 (5.8) 
12.9 (5.0) 
 
0.005 
0.024 
0.006 
 
< 0.001 
0.088 
< 0.001 
 
Effect of supplementation on the ARA:EPA and 
ARA:DHA ratios
0
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FIGURE 3.5: Effect of Supplementation on the ARA: EPA and ARA:DHA  
Ratios of Plasma PC 
***Significantly different from baseline (P < 0.001) 
 
 
 
3.3.3 Effect of Supplementation on the Fatty Acid Composition of Plaque PC 
 
   Table 3.5 shows the fatty acid composition of plaque PC. The most abundant fatty 
acids were palmitic, stearic and oleic comprising 36%, 23% and 11% of total fatty acids, 
respectively. Total LC n-3 PUFAs was approx. 6% of total fatty acids with most as 
DHA (about 60% of total LC n-3 PUFAs). There were no significant differences 
between groups for any fatty acid in plaque PC apart from EPA which was significantly 
higher in the Omacor group (P < 0.001). The ratio of ARA: EPA in the Omacor group 
was much lower than that in the placebo group (13.5 and 24.5, respectively). Chapter 3 The Effects of Omacor on CVD Risk Factors  in Endarterectomy Patients   154     
  
 
TABLE 3.5: Fatty Acid Composition of Plaque PC (g/100 g Fatty Acid) 
Values are means (SEM) or median (10
th-90
th percentile) 
 
Omacor (n = 47)  Placebo (n = 53)  Fatty acid 
Mean or median  SEM or 10
th-90
th 
percentile 
Mean or median  SEM or 10
th-90
th 
percentile 
14:0 0.7  0  0.7  0 
16:0  35.6  31.0 - 39.7  35.1  11.0 - 38.6 
16:1n-7  0.6  0.3 - 1.1  0.6  0.3 - 1.0 
18:0 22.7  0.8  22.4  0.8 
18:1n-9  11.4  8.7 - 14.8  11.8  9.0 - 15.1 
18:2n-6  9.6  7.0 - 12.3  9.4  6.7 - 12.8 
18:3n-3  0.1 0-  0.2 0.1 0-  0.2 
18:3n-6  0.1 0-  0.2 0.1 0-  0.2 
20:3n-3  1.8  1.1 - 2.8  1.8  1.2 - 2.8 
20:4n-6  9.6  6.7- 14.4  10.0  6.4 - 13.6 
20:5n-3  0.7***  0.3 - 1.6  0.4  0.2 - 0.7 
22:5n-3  1.0  0.7 - 1.9  1.0  0.5 - 1.5 
22:6n-3 2.6  0.1  2.3  0.1 
***Significantly different from placebo group (P < 0.001) 
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3.3.4 Effect of Supplementation on BMI, Blood Pressure and Plasma Lipid Profile 
 
   Table 3.6 shows the BMI, blood pressure and plasma lipid profile at baseline and after 
supplementation. Interestingly, it was found that there were significant reductions in 
systolic blood pressure, from 156 mm Hg to 143 mm Hg (P = 0.014) and from 155 mm 
Hg to 142 mm Hg (P = 0.001) with Omacor and placebo supplementation, respectively. 
The decrease in diastolic blood pressure was more apparent, from 81 mm Hg to 72 mm 
Hg in Omacor group and 82 mm Hg to 74 mm Hg in placebo group, respectively (both P 
< 0.001). Plasma TAG and total cholesterol concentrations were significantly decreased 
in both groups (both P < 0.001) and HDL-c was also found to decrease significantly 
(both P = 0.05). LDL-c was significantly decreased with Omacor (P = 0.015), but not in 
the placebo group. There were no significant effects on total cholesterol:HDL-c and 
LDL-c:HDL-c ratios in either group. 
 
Similar trends were also found when the data was analysed by gender (Table 3.7 and 
Table 3.8) except for LDL-c which was not significantly decreased in females in the 
Omacor group, but was significantly decreased (P = 0.022) in females in the placebo 
group.Chapter 3 The Effects of Omacor on CVD Risk Factors  in Endarterectomy Patients   156     
  
 
 
TABLE 3.6: Blood Pressure and Plasma Lipid Concentrations at Baseline and After Supplementation 
Data are means (SEM) or median (10
th-90
th percentile) 
 
Omacor  (n = 47)   Placebo (n = 53)  Outcome 
Before After  Baseline  After   
BMI (kg/m
2)  27.3 (0.7)  27.0  26.5 (0.5)  26.4 (0.5) 
Systolic blood pressure 
(mm Hg) 
155.9 (4.1)  142.7* (3.5)  155.2 (3.0)  142.0** (2.6) 
Diastolic blood pressure  
(mm Hg) 
80.6 (2.0)  72.4** (1.5)  82.0 (1.8)  73.8** (1.6) 
TAG (mmol/L)  1.3 (0.7-2.2)  1.0** (0.6-1.6)  1.3 (0.7-2.6)  1.1* (0.6-2.4) 
% change TAG  -20.0 (-52.4-19.0)  -9.1 (-52.9-60.4) 
Total cholesterol (mmol/L)  4.8 (0.2)  4.3** (0.2)  4.9 (0.2)  4.3** (0.2) 
% change TC  -12.7 (-22.0-6.8)  -8.8 (-32.3-9.0) 
HDL-c (mmol/L)  1.3 (0.9-2.4)  1.3** (0.9-2.1)  1.2 (0.9-1.9)  1.1** (0.7-1.8) 
% change HDL-c  -10.81 (-25.1-7.1)  -9.94 (-30.9-13.3) 
LDL-c (mmol/L)  2.5 (1.6-4.3)  2.5* (1.6-3.7)  2.8 (1.5-4.4)  2.5 (1.5-3.9)* 
% change LDL-c  -5.4 (-26.7-15.1) -7.1  (-42.5-28.6) 
Total cholesterol:HDL-c 
ratio 
3.2 (2.4-4.8)  3.4 (2.5-5.1)  3.8 (2.6-5.0)  3.9 (2.4-5.4) 
LDL-c:HDL-c ratio  1.8 (1.0-3.6)  2.0 (1.2-3.4)  2.2 (1.3-3.2)  2.4 (1.3-3.7) 
*Significantly different from baseline (P ≤ 0.05) 
**Significantly different from baseline (P < 0.01)  
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TABLE 3.7: Blood Pressure and Plasma Lipid Concentrations at Baseline and After Supplementation in Male Patients 
Data are means (SEM) or median (10
th-90
th percentile) 
 
Omacor  (n = 32)  Placebo (n = 36)  Outcome 
Baseline After Baseline After 
BMI (kg/m
2)  26.8 (0.8)  26.8** (0.9)  26.9 (0.6)  26.8* (0.6) 
Systolic blood pressure  
(mm Hg) 
154.7 (4.6)  135.0** (3.6)  156.8 (3.5)  143.3*** (2.8) 
Diastolic blood pressure  
(mm Hg) 
83.0 (58.2-98.0)  70.0** (56.4-86.6)  86.0 
(65.7-99.7) 
75.0 
(61.4-90.6) 
TAG (mmol/L)  1.2 (0.7-2.4)  1.0** (0.6-1.9)  1.3 (0.7-2.6)  1.1*** (0.6-2.4) 
% change TAG  -20.0 (-53.7-27.7)  -7.0 (-51.7-64.8) 
Total cholesterol (mmol/L)  4.7 (0.2)  4.2*** (0.2)  4.6 (0.2)  4.3 (0.2) 
% change TC  -12.9 (-23.93-9.1)  -8.6 (-29.7-13.2) 
HDL-c (mmol/L)  1.3 (0.9-2.3)  1.1*** (0.8-2.1)  1.1 (0.9-1.7)  1.0*** (0.7-1.4) 
% change HDL-c  -13.67 (-28.2-11.2)  -10.7 (-32.1-16.5) 
LDL-c (mmol/L)  2.5 (1.6-4.1)  2.4* (1.5-3.7)  2.4 (1.4-4.4)  2.4 (1.5-3.9) 
% change LDL-c  -5.0 (-28.6-30.6) -7.1  (-35.0-32.8) 
Total cholesterol:HDL-c 
ratio 
3.6 (0.2)  3.7 (0.2)  4.0 (0.2)  4.2 (0.2) 
LDL-c:HDL-c ratio  1.9 (1.0-3.4)  2.0 (1.2-3.4)  2.3 (1.2-3.4)  2.6* (1.4-4.0) 
*Significantly different from baseline (P ≤ 0.05) 
**Significantly different from baseline (P ≤ 0.01) 
***Significantly different from baseline (P ≤ 0.001) 
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TABLE 3.8: Blood Pressure and Plasma Lipid Concentrations at Baseline and After Supplementation in Female Patients 
Data are means (SEM) or median (10
th-90
th percentile) 
 
Omacor  (n = 15)  Placebo (n = 17)  Outcome 
Before After  Baseline  After   
BMI (kg/m
2)  28.0 (1.4)  27.5 (1.3)  25.5 (1.1)  25.5 (1.1) 
Systolic blood pressure  
(mm Hg) 
156.6 (8.5)  158.5 (6.1)  151.9 (6.0)  139.1 (5.7) 
Diastolic blood pressure  
(mm Hg) 
81  
(60.2-102.2) 
75 
(61.2-90.0) 
78 
(61.6-96.2) 
70
** 
(57.2-80.8) 
TAG (mmol/L)  1.3 (0.1)  1.0* (0.1)  1.1 (0.7-2.7)  0.9 (0.6-1.9) 
% change TAG  -20.5 (5.8)  -18.7 (7.9) 
Total cholesterol  
(mmol/L) 
5.0 
(3.7-7.5) 
4.5
** 
(3.3-6.5) 
5.2  
(4.1-7.0) 
4.7** 
 (2.9-5.7) 
% change TC  -8.9 (2.6)  -14.2 (4.3) 
HDL-c (mmol/L)  1.6 (0.1)  1.4* (0.1)  1.6 (0.1)  1.4* (0.1) 
% change HDL-c  -9.7 (-24.7-11.3)  -9.9 (-27.1-8.2) 
LDL-c (mmol/L)  3.0 (0.3)  2.7 (0.2)  3.2 (0.2)  2.64* (0.2) 
% change LDL-c  -7.01 (3.4)  -14.4 (5.7) 
Total cholesterol:HDL-c 
ratio 
3.0 (1.8-5.0)  3.3 (1.9-5.4)  3.4 (0.2)  3.2 (0.3) 
LDL-c:HDL-c ratio  1.7 (0.9-4.3)  2.0 (0.8-3.6)  2.1 (0.2)  2.0 (0.2) 
*Significantly different from baseline (P ≤ 0.05)  
**Significantly different from baseline (P < 0.01) 
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3.3.5 Plasma Inflammatory Markers  
 
   The concentrations of plasma inflammatory markers at baseline and after treatment 
(between 7 and 102 days) are shown in Table 3.9. Supplementation with Omacor 
decreased sE-selectin significantly (P = 0.006) from 46.0 ng/mL at baseline to 30.2 
ng/mL after supplementation, sVCAM-1 from 673.3 ng/mL to 544.3 ng/mL (P < 0.001) 
and MMP-2 from 192.2 ng/mL to 165.7 ng/mL (P < 0.001) by 23%, 25% and 17%, 
respectively. However, it was also found that in the placebo group, the same effect was 
observed although this was less significant for sE-selectin (P = 0.035), sVCAM-1 (P = 
0.005) and MMP-2 (P < 0.001), respectively. The anti-inflammatory mediator TGF-β1 
was found to decrease significantly (P = 0.046) in the Omacor group. In terms of percent 
change, the decrease in the Omacor group was more pronounced compared with that in 
the placebo group. Omacor supplementation had no significant effect on plasma 
sICAM-1, IL-6, MMP-9, sCD40L, IP-10 and Mig concentrations, even though trends 
toward decreases were observed.  
 
When the data were analysed by gender (Tables 3.10 and 3.11), sE-selectin, sVCAM-1 
and IL-6 concentrations were significantly decreased in male patients with Omacor 
supplementation and only MMP-2 was found to be significantly decreased in both 
supplementation groups. On the other hand, in female patients, sVCAM-1 and MMP-2 
were decreased in both groups.  
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TABLE 3.9: Plasma  Inflammatory Markers before and after Supplementation 
Data are median (10
th-90
th percentile) 
Omacor  (n = 47)  Placebo ( n = 53)  Outcome 
Baseline After Baseline After 
CRP (mg/L)  1.0 (1.0- 31.7)  1.0 (1.0-20.0)  1.0 (1.0- 9.1)  1.0 (1.0-23.0) 
Change vs % change  0  (-14.6-8.2) vs 
0 (-69.1-224.1)% 
0  (-3.3-10.6) vs 
0  (-60.9-231.1)% 
sE-selectin (ng/mL)  46.0 (16.5-117.2)  30.2* (8.7-120.3)  45.7 (7.8-145.2)  47.7* (8.2-137.5) 
Change vs % change  -12.1 (-44.8-29.8) vs 
-22.9 (-68.1-44.8)% 
-9.0 (-42.1-31.0) vs 
-18.8 (-58.1-123.1)% 
sICAM-1 (ng/mL)  167.1 (73.2-425.7)  146.3 (69.2-383.3)  216.1 (64.9-444.7)  202.0 (74.2-345.5) 
Change vs % change  -9.0 (-117.7-82.4) vs 
-5.7 (-54.9-56.1)% 
-9.14 (-120.37-92.99) vs 
-3.52 (-49.05-80.86)% 
sVCAM-1 (ng/mL)  673.3 (226.3-1578)  544.3*** (252.4-1146)  594.3 (271.8-1130.8)  488.9** (236.3-932.5) 
Change vs % change  -186.7 (-575.8-133.8) vs 
-25.4 (-46.5-28.5% 
-113.3 (-452.7-242.8) vs 
-18.7 (-48.2-76.3)% 
IL-6 (pg/mL)  1.2(0.2-4.0)  1.0 (0.2-4.1)  1.2 (0.1-4.8)  0.9 (0-3.7) 
Change vs % change  -0.2 (-1.4-1.0) vs 
-26.2 (-80.6-113.0)% 
-0.1 (-2.3-2.2) vs 
-10.9(-89.7-229.7)% 
IL-10 (pg/mL)  1.5 (0-5.2)  0.9 (0-6.2)  0.5 (0-2.9)  0.8 (0-3.5) 
Change vs % change  0 (-1.8-2.3) vs 
-18.8 (-96.4-307.1)% 
0 (-1.4-1.5) vs 
-27.0 (-100.0-138.2)% 
MMP-2 (ng/mL)  192.2 (129.2-290.3)  165.7*** (100.8-248.4)  191.2 (129.0-293.7)  155.3*** (71.8-233.2) 
Change vs % change  -29.1 (-85.6-21.8) vs 
-16.5 (-32.6-15.3)% 
-26.7 (-89.0-13.8) vs 
-14.9 (-46.7-12.4)% 
MMP-9 (ng/mL)  167.2 (46.6-421.1)  163.3 (32.0-558.3)  138.0 (28.8-389.3)  152.1 (34.2-403.2) 
Change vs % change  5.2 (-178.13-201.42) vs 
3.35 (-66.99-249.12)% 
27.6 (-212.4-203.4) vs 
21.62 (-72.80-143.94) % 
TGF-β1 (ng/mL)  9308 
(2394.40-19170.40) 
7908.00* 
(2956.00-13690.40) 
9788  
(3356-16844) 
7516 
(3484-17388) 
Change vs % change  -1640 (-9584-4728) vs 
-22.4 (-66.6-93.7)% 
-840 (-8096-6424) vs 
-9.4(-57.4-104.9)% 
sCD40-L (ng/mL)  775.8 
(243.2-2238.7) 
655.4 
(178.8-1677.4) 
774.0 
 (193.2-2905.7) 
659.3 
(247.8-2285.1) 
Change vs % change  -93.6 (-1214.2-764.2) vs 
-22.9 (-79.7-220.7)% 
-114.9 (-1056.8-688.4) vs 
-12.8 (-74.8-222.1)% 
IP-10 (pg/mL)  103.9 (51.6-273.3)  100.2 (55.4-353.1)  102.8 (47.8-289.4)  114.9 (35.9-295.9) 
Change vs % change  2.6 (-78.4-130.7) vs 
2.91 (-45.8-97.1)% 
-17.0 (-74.4-110.4) vs 
-11.1 (-55.9-158.0)% 
Mig (pg/mL)  119.3 (398-360.7)  107.2 (30.60-320.6)  107.4 (30.6-294.3)  97.40 (16.9-327.2 
Change vs % change  -20.7 (-63.18-47.8) vs 
-13.2 (-43.92-35.7)% 
-18.1 (-97.6-56.6) vs 
-19.0 (-83.1-121.6)% 
*Significantly different from baseline (P < 0.05) 
**Significantly different from baseline (P < 0.01) 
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TABLE 3.10: Plasma Inflammatory Markers before and after Supplementation in Male Patients 
Data are means (SEM) or median (10
th-90
th percentile) 
Omacor (n = 32)  Placebo (n = 36)     Outcome 
Before After Before After 
CRP (mg/L)  1.0 (1.0-24.9)  1.0 (1.0-15.7)  1.5 (1.0-13.0)  1.0 (1.0-24.5) 
Change vs % change  0 (-13.6-2.8) vs 
0 (-87.5-139.7)% 
0  (-2.8-6.8) vs 
0 0 (-64.7-193.9)% 
sE-selectin (ng/mL)  65.0 (20.4-134.3)  38.3** (16.0-128.8)  57.7 (5.8-149.2)  53.5* (9.2-148.3) 
Change vs % change -12.2 (-53.9-13.8) vs 
-23.0 (-60.4-31.8)% 
-10.7 (-44.0-30.6) vs 
-19.2 (-55.1-114.4)% 
sICAM-1 (ng/mL)  177.8 (73.15-459.1)  146.7 (63.3-386.3)  231.9 (27.2)  213.1 (25.5) 
Change vs % change  -20.0 (13.6) vs 
-5.7 (6.5)% 
-18.82 (14.0) vs 
1.21 (6.5)% 
sVCAM-1 (ng/mL)  671.1 (184.6-1633.4)  598.9** (73.5-1238.7)  665.3 (56.9)  590.3 (50.6) 
Change vs % change  -147.1 (45.6) vs 
-22.6 (-71.2-37.2)% 
-75.0 (66.3) vs 
-9.7 (-75.2-82.5)% 
IL-6 (pg/mL)  1.3 (0.2-5.0)  0.8* (0.1-4.7)  2.7 (0.7)  1.71 (0.3) 
Change vs % change  -0.3 (0.2) vs 
-27.0 (-79.5-88.5)% 
-1.0 (0.7) vs 
-24.4 (-95.1-244.7)% 
IL-10 (pg/mL)  1.59 (0.00-5.24)  1.01 (0.00-5.8)  0.4 (0-4.3)  0.5 (0-4.9) 
Change vs % change  0.00 (-6.91-2.36) vs 
-20.42 (-100.00-245.25)% 
0 (-10.4-1.6) vs 
-84.2 (-100.0-360.9)% 
MMP-2 (ng/mL)  199.4 (13.2)  168.0*** (10.4)  185.8 (11.5)  154.5** (10.5) 
Change vs % change  -31.3 (5.9) vs 
-14.5 (-38.4-10.8)% 
-31.3 (8.8) vs 
-14.0 (-57.2-16.8)% 
MMP-9 (ng/mL)  197.2 (28.7-454.9)  158.15 (0.00-545.72)  152.3 (1.5-402.2)  152.1 (22.6-410.6) 
Change vs % change  -10.2 (27.9) vs 
-9.9 (-92.1-130.4)% 
5.8 (25.3) vs 
17.7 (-83.9-135.3)% 
TGF-β1 (ng/mL)  9012  
(2949-17076) 
7636 
 (3426-13256) 
8872 
(2723 -16760) 
7612 
(193-15733) 
Change vs % change  -1680 (-11468-4512) vs 
-22.4 (-80.9-74.7)% 
-860 (-10104-6084) vs 
-14.6 (-97.7-105.3)% 
sCD40-L (ng/mL)  720.4 (155.5-2084.8)  576.0 (67.1-1230.6)  617.8 (123.5-1537.7)  633.2 (143.9-1813.8) 
Change vs % change  -176.0 (-1230.3-418.9) vs 
-36.2 (-85.0-128.6)% 
0.7 (-980.6-702.1) vs 
-2.3 (-76.0-246.4)% 
IP-10 (pg/mL)  110.4 (38.3-257.7)  98.8 (28.4-315.0)  105.8 (38.9-304.7)  103.4 (18.8-315.3) 
Change vs % change  2.2 (-74.54-102.0) vs 
2.8 (-46.8-72.1)% 
-20.9 (-86.5-52.9) vs 
-23.2 (-56.3-63.3)% 
Mig (pg/mL)  108.3 (13.1-317.2)  96.8 (6.7-317.7)  103.2 (10.1-302.4)  86.8 (2.5-424.2) 
Change vs % change  -21.3 (-54.7-93.4) vs 
-13.0 (-51.0-35.6)% 
-29.3 (-125.7-63.9) vs 
-23.4 (-86.3-156.0)% 
*Significantly different from baseline (P < 0.05) 
**Significantly different from baseline (P < 0.01) 
***Significantly different from baseline (P < 0.001) 
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TABLE 3.11: Plasma Inflammatory Markers before and after Supplementation in Female Patients 
Data are means (SEM) or median (10
th-90
th percentile) 
Omacor (n = 15)  Placebo (n = 17)  Outcome 
Before After Before After 
CRP (mg/L)  2.5 (1.0-38.0)  3.0 (1.0-24.5)  1.0 (1.0-9.1)  2.2 (1.0-30.1) 
Change vs % change  0 (-17.8-18.4) vs 
0 (-57.8-682.6)% 
0 (-3.5-26.3) vs 
0 (-55.0-2126.0)% 
sE-selectin (ng/mL)  28.5 (5.9-101.1)  21.5 (1.7-123.7)  39.1 (11.5-150.3)  35.8 (7.6-159.4) 
Change vs % change  -0.4 (6.0) vs 
-19.3 (-90.5-99.2%) 
-2.0 (8.9) vs 
-8.6 (-69.1-320.4)% 
sICAM-1 (ng/mL)  141.3 (49.9-357.7)  134.7 (52.5-373.0)  594.3 (248.8-977.2)  433.5** (203.6-669.1) 
Change vs % change  -11.7 (17.8) vs 
-4.7 (-69.6-304.3)% 
-0.8 (35.6) vs 
9.0 (-78.4-135.9)% 
sVCAM-1 (ng/mL)  734.2 
(367.0-1859.7) 
517.7** 
(296.41-1310.71) 
586.6 (62.6)  442.0** (41.4) 
Change vs % change  -233.5 (56.6) vs 
-37.8 (-47.1-18.4)% 
-144.6 (37.8) vs 
-26.6 (-47.5-44.0)% 
IL-6 (pg/mL)  1.1 (0.2-8.2)  1.3 (0-3.0)  1.1 (0.2-3.9)  1.3 (0-3.2) 
Change vs % change  0.2 (-6.1-1.2) vs 
23.8 (-88.2-184.1)% 
0.1 (-1.3-2.2) vs 
10.2 (-93.0-1352.5)% 
IL-10 (pg/mL)  0 (0-3.9)  0.4 (0-8.6)  0 (0-4.3)  0.4 (0-3.4) 
Change vs % change  0 (-1.3-5.3) vs 
-17.2 (-100.0-15.9)% 
0 (-2.3-0.7) vs 
-15.7 (-100.0-304.1)% 
MMP-2 (ng/mL)  207.2 (13.8)  172.7* (13.5)  204.1 (19.7)  166.11** (16.8) 
Change vs % change  -34.5 (12.3) vs 
-18.4 (-39.6-37.7)% 
-38.0 (8.8) vs 
-17.7 (-46.0-8.5)% 
MMP-9 (ng/mL)  129.0 (24.1-454.9)  199.4 (44.3-560.1)  129.0 (34.5-375.3)  199.4 (47.6-422.9) 
Change vs % change  69.6 (37.1) vs 
32.3 (-54.5-2728.4)% 
47.7 (34.0) vs 
38.0 (-58.88-203.7)% 
TGF-β1 (ng/mL)  11596 (496.8-54647.2)  10076 (2108-21508)  10796 
(1366-17580) 
7228 
(2294-28365) 
Change vs % change  -1120 (-9340-8331) vs 
-19.7 (-72.6-138.9)% 
-560 (-10408-12240) vs 
-7.2 (-63.2-101.7)% 
sCD401 (ng/mL)  916.7 
(198.3-2645.6) 
1118.0 
(310.7-3021.6) 
1325.2 
(334.3-5278.2) 
791.7 
(226.0-3868.3) 
Change vs % change  159.7 (-1388.04-1936.5) vs 
22.0 (9-70.5-381.6)% 
500.6 (-3993.6-2251.6) vs 
-38.4 (-85.1-274.3)% 
IP-10 (pg/mL)  94.3 (53.9-491.2)  109.5 (60.8-474.4)  97.6 (42.9-295.2)  151.4 (47.9-330.1) 
Change vs % change  8.70 (-83.8-209.9) vs 
11.2 (-50.2-193.0)% 
12.7 (-72.7-169.3) vs 
14.1 (-52.3-263.9)% 
Mig (pg/mL)  178.2 (43.8-570.8)  155.7 (37.2-428.8)  116.5 (55.5-232.1)  132.0 (38.0-347.7) 
Change vs % change  -14.6 (-154.2-33.5) vs 
-6.1 (-35.9-78.7)% 
5.30 (-80.6-95.7) vs 
-17.5 (-67.3-58.5)% 
*Significantly different from baseline (P < 0.05)  
**Significantly different from baseline (P < 0.01) 
 Chapter 3 The Effects of Omacor on CVD Risk Factors  in Endarterectomy Patients   163     
  
 
3.3.6 Relationship between a Marker of Inflammatory Cell Fatty Acid Composition 
and CVD Risk Factors  
 
   Kew et al. (2003) reported that the fatty acid composition of plasma PC was highly 
related to that of inflammatory cells. Thus, in order to see if fatty acid status was related 
to inflammation in these patients, the fatty acid composition of plasma PC at baseline 
was related to plasma inflammatory marker concentrations at that time point (Table 
3.12). It was found that oleic acid was significantly but slightly positively correlated 
with sE-selectin (r = 0.199, P = 0.047), ALA (18:3n-3) was inversely correlated with 
sVCAM-1 (r = -0.367, P < 0.001), and palmitoleic acid was negatively correlated with 
MMP-2 (r = -0.223, P = 0.026). DGLA was positively correlated with IL-6 (r = 0.340, P 
= 0.001) and an inverse association was found between sICAM-1 and myristic acid (r = 
-0.198, P = 0.049).  
 
TABLE 3.12: Correlation between Fatty Acids in Plasma PC and Plasma Inflammatory 
Markers 
 
Inflammatory marker  Fatty acid  r  P 
 
sE-selectin 
 
sICAM-1 
 
sVCAM-1 
 
IL-6 
 
MMP-2 
 
18:1n-9 
 
14:0 
 
18:3n-3 
 
20:3n-6 
 
16:1n-7 
 
 
0.199* 
 
-0.198* 
 
-0.367** 
 
0.340** 
 
-0.223* 
 
 
0.047 
 
0.049 
 
0.001 
 
0.001 
 
0.026 
 
 
 
 
  
3.3.7 Correlation between Changes in Plasma PC Fatty Acids and Changes in 
Inflammatory Markers  
 
      If fatty acids are causally associated with inflammation, as determined by plasma 
inflammatory markers, changes in status of those fatty acids should be associated with 
changes in levels of the inflammatory markers. In this analysis, pooled subjects were used 
to study whether the change in the proportion of ARA, EPA, DPA and DHA in the plasma 
PC fraction related to the change in inflammatory marker concentrations. There were no 
significant associations with ARA or EPA. Table 3.13 shows the association between 
changes in DPA and DHA in plasma PC fraction and changes in the inflammatory markers 
of sE-selectin and MMP-9. These positive associations suggest that DPA and DHA may act 
in a pro-inflammatory, not an anti-inflammatory, manner. There were no other significant 
associations with these fatty acids. 
 
TABLE 3.13: Correlation between Changes in DPA and DHA and Changes in Plasma 
Inflammatory Markers 
 
Inflammatory marker  Fatty acid  r  P 
sE-selectin 
  Change 
  % change 
 
MMP-9 
% change 
 
DPA 
 
 
 
DPA 
DHA 
 
0.213 
0.501 
 
 
0.217 
0.415 
 
0.033 
< 0.001 
 
 
0.031 
< 0.001 
 
 
3.3.8 mRNA Expression of Inflammatory Markers in Plaque 
 
   The level of mRNA encoding a range of inflammatory markers, including some of those 
measured in plasma above, in plaque is shown in Table 3.14. Expression of mRNA for 
MMP-7, MMP-9, MMP-12, TIMP-2 and IL-6 were significantly lower following Omacor 
supplementation compared with the placebo group (P < 0.05). However, ICAM-1 mRNA 
was significantly higher in the Omacor group as compared to the placebo (P =  0.014).  
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TABLE 3.14: mRNA Expression of Inflammatory Markers in Plaques from Patients 
Supplemented with Omacor or Placebo 
Values are median (10
th-90
th percentile) 
 
CT36 plaque 
fraction 
Omacor Placebo  P 
TNF-α 
PPAR-γ 
MMP-1 
MMP-3 
MMP-7 
MMP-8 
MMP-9 
MMP-12 
MMP-13 
TIMP-1 
TIMP-2 
IL-10 
IL-6 
ICAM-1 
0.009 (0-0.142) 
0.001 (0-0.005) 
0.003 (0-0.026) 
0 (0-0.002) 
0.005 (0-0.188) 
0.002 (0-0.010) 
0.033 (0.001-1.684) 
0.009 (0-0.254) 
0.001 (0-0.011) 
0.648 (0.005-9.020) 
0.044 (0-0.688) 
0.002 (0-0.011) 
0.019 (0.001-0.900) 
0.556 (0.065-2.553) 
0.030 (0.002-0.256) 
0.002 (0-0.005) 
0.005 (0.001-0.034) 
0 (0-0.002) 
0.019 (0.001-0.434) 
0.003 (0-0.024) 
0.225 (0.009-2.425) 
0.044 (0.002-0.794) 
0.001 (0-0.024) 
1.248 (0.177-11.479) 
0.151 (0.013-0.973) 
0.003 (0.001-0.019) 
0.026 (0.050-0.203) 
0.448 (0.080-1.542) 
0.145 
0.055 
0.146 
0.886 
0.005 
0.126 
0.005 
0.004 
0.149 
0.053 
0.014 
0.218 
0.039 
0.014 
 
 
3.3.9 Correlation between mRNA Expression of Plaque Inflammatory Markers and 
Fatty Acid Composition in Plaque 
 
   In section 3.3.2 it was demonstrated that Omacor treatment increases LC n-3 PUFAs in 
circulating PC while in section 3.3.3 it was demonstrated that Omacor results in higher EPA 
in plaque PC. If these fatty acids are causally related to inflammatory processes within the 
plaque, then a relationship between fatty acids in plaque and mRNA expression of 
inflammatory markers should be apparent. Table 3.15 shows correlations between 
inflammatory mRNA expression in the plaque and fatty acids in plaque PC using data from 
both groups of patients. 
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Significant inverse associations between EPA and MMP-7, MMP-9, MMP-12, TIMP-1, 
TIMP-2, IL-6 and ICAM-1 mRNAs were observed (Table 3.15), suggesting that EPA acts 
in anti-inflammatory manner in advanced plaques. Only MMP-3 mRNA was significantly 
negatively associated with DPA. There were no significant associations between mRNA 
expression of inflammatory marker and DHA in plaque PC. Surprisingly ARA in plaque PC 
was inversely correlated with PPAR-γ, MMP-1, MMP-3, MMP-7, MMP-9, MMP-12, 
TIMP-1 and ICAM-1 mRNAs (Table 3.15).  
 
TABLE 3.15: Inverse Relationship between Plaque mRNA Expression and Fatty Acids in 
Plaque PC 
 
Fatty acid  mRNA   r P 
ARA 
 
 
 
 
 
 
 
 
EPA 
 
 
 
 
 
 
 
DPA 
PPAR-γ 
MMP-1 
MMP-3 
MMP-7 
MMP-9 
MMP-12 
TIMP-1 
ICAM-1 
 
MMP-7 
MMP-9 
MMP-12 
TIMP-1 
TIMP-2 
IL-6 
ICAM-1 
 
MMP-3 
-0.254 
-0.239 
-0.242 
-0.225 
-0.247 
-0.207 
-0.257 
-0.235 
 
-0.212 
-0.237 
-0.226 
-0.252 
-0.311 
-0.240 
-0.282 
 
-0.243 
0.022 
0.018 
0.017 
0.027 
0.014 
0.043 
0.011 
0.021 
 
0.038 
0.019 
0.027 
0.012 
0.002 
0.024 
0.005 
 
0.016 
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3.4 Discussion 
 
   This  double-blind,  placebo-controlled  study  on the effect of moderate dose (2 g/day) 
Omacor (providing 1.8 g/day of EPA plus DHA) was carried out for the duration between 7 
and 102 days. The subjects were patients awaiting carotid endarterectomy and they were 
required to give their blood samples twice, at baseline before supplementation began and at 
the end of the study (before the carotid endarterectomy procedure). Omacor was used in the 
GISSI trial (GISSI 1999), one of the most important and largest studies advocating the 
beneficial effects of LC n-3 PUFAs towards cardiovascular mortality (Bays 2006). In the 
GISSI study, involving more than 11,000 high-risk patients, Omacor significantly reduced 
overall mortality, cardiovascular mortality and sudden death (GISSI 1999; Marchioli et al. 
2002).  Since Omacor is produced by an extensive purification and concentration process, 
each capsule has approximately 90% n-3 fatty acids primarily as EPA and DHA, and the 
amount of EPA and DHA used in the present study were 45% and 37.5% of fatty acids, 
respectively. In this study, olive oil was used as a placebo providing approximately 1.2 g of 
monounsaturated oleic acid and this amount is considered negligible as compared to the 
average adult UK intake.  
 
 
3.4.1 Effect of Omacor Supplementation on Plasma PC Fatty Acid Composition 
 
   In the present study, incorporation of EPA and DHA into plasma lipids was investigated 
using the PC fraction. This is because the fatty acid composition of plasma PC is similar to 
that of cells and tissues (Kew et al. 2003) and therefore may reflect a marker of functional 
significance. EPA and DHA were significantly increased in the Omacor group, by 161% 
and 70%, respectively. Previous studies reported increased EPA incorporation in plasma 
phospholipids by 390% with 3.6 to 4 g/d EPA supplementation (Woodman et al. 2002; 
Mori et al. 2000; Grimsgaard et al. 1997). In the present study, the dose of EPA provided 
was only 810 mg/d. Figure 3.6 plots the % change in EPA content of plasma PC seen in the 
current study alongside that seen in the study described in Chapter 2 as well as the data 
from Rees et al. (2006) for plasma PC. It is clear that the change in EPA observed here fits 
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well on this dose-response curve and is in accordance with what is seen in other studies 
using other doses of EPA.   
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FIGURE 3.6: Effect of Different Doses of EPA on % Change of EPA in Plasma PC 
Data for older and young subjects comes from Rees et al. (2006). The arrow shows a dose 
of 0.81 g/d EPA used in this study, indicating that the change in EPA seen at this dose 
agrees with that predicted by the Rees et al. (2006) data and also in accordance with data 
from Chapter 2. 
 
The increase in the proportion of EPA in plasma PC was accompanied by a significant 
decrease in proportion of n-6 fatty acids DGLA (22%), LA (13%) and ARA (2%). The 
present findings are in agreement with Rees et al. (2006), whereby EPA was reported to 
decrease the proportion of DGLA and LA in plasma phospholipids, but with only a small 
effect on ARA. Again, similar to the findings of my first study (Chapter 2), it seems that 
EPA consistently more easily replaces DGLA and LA, than ARA, in plasma phospholipids.  
 
Interestingly, in the present study, DHA was also significantly increased in plasma PC in 
patients taking Omacor. Previous studies supplementing with only high doses of DHA (>3 
g/d) reported significant incorporation of DHA (about a 150% increase) into plasma PC 
(Woodman et al. 2003; Woodman et al. 2002; Mori et al. 2000; Halvorsen et al. 1997; 
Vidgren et al. 1997). Figure 3.7 plots the % change in DHA content of plasma PC seen in 
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the current study alongside that seen in the study described in Chapter 2 as well as the data 
from Rees et al. (2006) for plasma PC.  
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FIGURE 3.7: Effect of Different Doses of DHA on % Change of DHA in Plasma PC 
Data for older and young subjects comes from Rees et al. (2006). The arrow shows a dose 
of 0.68 g/d DHA used in this study, indicating that the change in DHA seen at this dose was 
at a greater extent compared with that predicted by the Rees et al. (2006) data and data from 
Chapter 2. 
 
It seems that the change in DHA observed here does not fit well on this dose-response curve 
and is not in accordance with what is seen in other studies using other doses of DHA. This 
might be due to the varying ratios of EPA to DHA used in different studies. Here the ratio 
of EPA to DHA was 1.21 and the contribution of DHA to total LC n-3 PUFAs was 37.5%. 
In the study described in Chapter 2 these values were 7.69 and 10.9%, respectively, while in 
the study of Rees et al. (2006) they were 4.5 and 18%, respectively. Thus, one explanation 
for the better incorporation of DHA seen in the current study is that there is less competition 
from EPA for incorporation into plasma phospholipids than occurred in the other studies. 
To investigate this further the contribution of DHA from the supplement can be 
“normalised” as follows:  
Normalised amount of DHA = (Amount of DHA provided in g/d) x (DHA as proportion of EPA+DHA) 
This gives “normalised” amounts of DHA (in g/day) of 0.306 for the current study, 0.023 
for the study described in Chapter 2 and 0.054, 0.108 and 0.162 for the three doses used in 
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the study of Rees et al. (2006). These normalised intakes of DHA are plotted against the % 
change in DHA observed in the different studies in Figure 3.8. 
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FIGURE 3.8: Effect of DHA (Normalised Amount) on % Change of DHA in Plasma PC.  
a represents value from the study in Chapter 2, whereas b represents value from the present 
study. The other three points are calculated from Rees et al. (2006). 
 
It is clear from this figure that the change in DHA observed in the current study fits well on 
this dose-response curve and is in accordance with what is seen in other studies using other 
doses of DHA, once the competition of DHA with EPA is taken into consideration.  
 
It has been reported that statin therapy per se results in unfavourable changes in plasma 
fatty acids, whereby the ARA:EPA and ARA:DHA ratios are increased (Harris et al. 2004). 
The patients studied here were almost all taking statins. However, it was possible to 
compare the fatty acid composition of plasma PC between these patients awaiting carotid 
endarterectomy and the healthy middle aged subjects studied in Chapter 2; data at study 
entry was compared. The only difference seen was a higher proportion of ARA in the 
patients (P = 0.031).  The ARA:EPA and ARA:DHA ratios in the patients were slightly 
higher, but not significantly so (P > 0.05), than those seen in the healthier subjects studied 
in Chapter 2: 8.98 vs. 7.34 and 2.96 vs. 2.01, for patients and healthy subjects, respectively.   
 
In the present study, it was found that following Omacor supplementation, the ratios of 
ARA:EPA and  ARA:DHA were significantly reduced, from 8.42 to 2.58 and 2.68 vs. 1.58, 
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respectively; however no effect was observed in the placebo group, 8.35 vs. 8.54 and 2.48 
vs. 2.41, respectively. Thus, increased intake of LC n-3 PUFAs among patients taking 
statins induces a similar fatty acid composition change in plasma PC to that seen in subjects 
not taking statins and overrides the effect of statins on the ARA:EPA and ARA:DHA ratios.  
 
 
3.4.2 Blood Pressure and Plasma Lipid Concentrations 
 
   Systolic and diastolic blood pressures were found to decrease significantly in both groups. 
The reason for this is not clear but may involve some change in lifestyle induced by the 
knowledge that surgery was required. An antihypertensive effect of n-3 PUFAs has been 
described in the literature (Morris et al. 1993; Howe 1997), the effect being related to the 
initial extent of hypertension and being greater when a higher dose on n-3 PUFA is 
administered. However, here the effect of Omacor was similar to the effect of placebo, 
ruling out any n-3 PUFA-specific effect on blood pressure. The lack of an effect in the 
Omacor group may be because of an insufficient dose of LC n-3 PUFA. 
 
It has been reported that fish oil increases total blood cholesterol by 5-10% and decreases 
blood TAG by 20 to 30% (Harris 1997). In the current study it was shown that total 
cholesterol was significantly decreased by 13% in the Omacor group compared with 9% in 
the placebo group. HDL-c was also significantly decreased in both groups. On the other 
hand, TAG concentrations were decreased by 20% in the Omacor group as compared to that 
9% in the placebo group. Meyer et al. (2007) in their studies using high doses of DHA in 
statin-treated hyperlipidaemic subjects reported decreased TAG by 27% with 8 g/day DHA-
rich fish oil. Mori and Woodman (2006) recently confirmed the effect of a high intake 
(4g/d) of EPA vs. DHA producing convincing evidence that EPA and DHA are equally 
effective at reducing serum TAG, but only DHA may raise HDL-c, specifically HDL2 
fraction as well as LDL. Thus, in this present study, the decrease in HDL-c could be due to 
not enough DHA being present. Contrary to a general tendency towards slightly increased 
LDL-c concentration with fish oil supplementation (Katan et al. 1995; Harris et al. 1996), 
LDL-c was found to decrease significantly in the Omacor group. Even though total 
cholesterol was already well controlled by statin treatment (mean initial levels were 4.8 
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mmol/L), since 84% of the patients were on statins, there was a further reduction in total 
cholesterol with Omacor, 13% compared with 9% with olive oil-placebo treatment. 
 
In the present study, both groups exhibited significant TAG lowering. The percent reduction 
in the Omacor group was greater than in the placebo group (20% vs. 9%). N-3 PUFA 
supplementation studies typically show reductions in TAG of 25-30% in those with normal 
triglyceride levels (Harris 1997). Buckley et al. (2004) reported 7% TAG lowering with 
placebo and they also used olive oil as placebo. Thus, olive oil may also have a beneficial 
TAG-lowering effect, even though to a lesser extent compared to n-3 PUFAs. The 
hypotriglyceridaemic effect (20% lowering of fasting TAG) of n-3 PUFA supplementation 
seen in the present study suggests that it may be a useful adjunct to lipid-lowering therapy 
with statins. 
 
It is believed that the combination of Omacor and statins exhibits a greater lipid-lowering 
effect than statins alone, and this is demonstrated in this study. Omacor is indicated as an 
adjunct to diet to reduce very high (≥ 5.65 mmol/L) plasma TAG in adult patients and has 
been shown to be effective in reducing plasma TAG concentrations when used in 
combination with statins (Durrington et al. 2001). A recent study by Meyer et al. (2007) 
demonstrated that DHA-rich fish oil supplementation (2.16 g/day) can improve plasma 
lipids in a dose-dependent manner in patients taking statins. Moreover, Davidson and 
colleagues (2007) also found that combination of Omacor plus simvastatin and dietary 
counselling improved non-HDL-c and other lipid and lipoprotein parameters to a greater 
extend than simvastatin alone. Over the past decades, no other drugs have been proven to be 
as effective in cholesterol-lowering as statins. However statin therapy per se results in 
unfavourable changes in plasma fatty acids whereby it has been reported that ARA:EPA 
and ARA:DHA ratios are increased (Harris et al. 2004). Drug combinations are usually 
prescribed for treatment of hyperlipidemia and these drugs are well known for adverse side 
effects. For example, fibrates cause liver and muscle toxicity (Pierce et al. 1990; Schectman 
& Hiatt 1996) and niacin results in hepatic toxicity (Rader et al. 1992) and myopathy 
(Norman et al. 1988). Therefore it is suggested that fish oil supplementation in combination 
with statin treatment can be an alternative approach to eliminate harmful adverse effects 
due to combined therapy.   
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3.4.3 Effect of Supplementation on Plasma Inflammatory Markers 
 
   Contrary to the previous study (Chapter 2), positive effects of LC n-3 PUFAs on plasma 
inflammatory markers were observed in the present study. It was shown that in the Omacor 
group, sE-selectin and sVCAM-1 decreased significantly by 23% and 25%, respectively. In 
the study described in Chapter 2 there was no effect of fish oil supplementation in healthy 
middle-aged men on these molecules. In the present study reductions in sE-selectin and IL-
6 with Omacor were observed in male, but not female, patients.  The role of IL-6 as a better 
predictor for CVD risk in older adults has been examined (Harris 1999; Jenny et al. 2002; 
Cesari et al. 2003). Lee et al. (2006) reported no significant effect in plasma IL-6 in post-MI 
patients allocated to 1 g/day Omacor. However, cell culture studies by venous endothelial 
cells demonstrate that EPA and DHA can inhibit IL-6 production (De Caterina et al. 1994; 
Khalfoun et al. 1997). Supplementation with fish oil in healthy volunteers has been reported 
to decrease the IL-6 production by mononuclear cells (Meydani et al. 1993; Caughey et al. 
1996; Trebble et al. 2003; Wallace et al. 2003). Reduction in plasma IL-6 with increased n-
3 PUFA intake has been observed in population-based studies (Paschos et al. 2004; Lopez-
Garcia et al. 2004; Esposito et al. 2004).  
 
sVCAM-1 was significantly decreased by Omacor in both male and female patients. 
Previously, Miles et al. (2001) found no significant effects of 1.2 g EPA + DHA/day on 
plasma sICAM-1 or sE-selectin in elderly healthy subjects, although sVCAM-1 was 
significantly decreased when compared with control subjects. In the present study, sICAM-
1 was not decreased following Omacor supplementation and this finding is in accordance 
with Miles et al. (2001). However, it has been reported that supplementation with 2.4 g of 
EPA plus DHA/day decreased plasma sICAM-1 significantly (Berstad et al. 2003; Hjerkinn 
et al. 2005). Thus, a lack of effect of n-3 PUFAs on sICAM-1 seen here and by Miles et al. 
(2001) may be due to insufficient dose. The effect of n-3 PUFAs on the expression of 
sVCAM-1 is inconsistent. Thies et al. (2001) reported reduced sVCAM-1 in healthy 
subjects with 1 g EPA plus DHA daily. Eschen et al. (2004), however found that sVCAM-1 
was only reduced with high dose n-3 PUFAs (6.6 g/day) in female healthy subjects, 
whereas Cazzola et al. (2006) and Miles et al. (2001) reported this effect in older subjects 
with high dose EPA of 4.05 g and 1.2 g EPA plus DHA daily, respectively. Likewise, it was 
173  
also reported that the effects of n-3 PUFAs on sVCAM-1 may be time-dependent whereby 
in hypertriglyceridemic patients, six-week supplements with 4 g/d of n-3 PUFAs increased 
the level of sE-selectin, but had no effect on sVCAM-1 or sICAM-1 (Abe et al. 1998). 
Further continuation of supplementation for more than six months, however, led to a 
significant decrease in both sE-selectin and sICAM-1, respectively. Interestingly, in the 
present study, the effect of Omacor supplementation was more pronounced in male patients 
as compared to that of females. 
 
This study also demonstrated that no beneficial effects with Omacor supplementation on IL-
10, CRP, sCD40L, IP-10 and Mig. Balk et al. (2006) reported in their systematic review 
that the effect of n-3 PUFAs on CRP is inconsistent and non-significant. It has been argued 
that among many serum markers of CVD risk, a role for CRP is the most supported by 
research and clinical application (Ferranti & Rifai 2007).  
 
Human and animal studies, as well as tissue culture work show that there are discrepancies 
on the effects of fish oil supplementation on inflammatory markers. Characteristics of the 
subjects (normal or healthy, hyperlipidemic or patient with heart disease), dosage, duration 
of the intervention will vary the outcomes.  Several studies show that supplementation with 
fish oil (in higher dosage > 4 g/day EPA plus DHA) increases the inflammatory markers of 
TNF-α, E-selectin and VCAM-1 (Torstensen et al. 2000; Seljeflot et al. 1998; Holm 2001; 
Eschen et al. 2004) even though n-3 fatty acids are anti-inflammatory (Calder 2003; 
Yaqoob 2003) and also have been shown to decrease adhesion molecules (Hughes et al. 
1996; Miles et al. 2001). Moreover, irrespective of the previous dietary pattern (for example 
diet rich in corn oil or n-3 PUFAs), it was found that higher dosage (> 5 g n-3 PUFAs/day) 
increased sE-selectin and sVCAM-1 (Johansen et al. 1999). These unexpected results 
suggest that supplementation with highly concentrated n-3 PUFAs to patients with coronary 
heart disease may decrease the homeostatic activity of the endothelium, and subsequently 
increase the inflammatory activity. Blok et al. (1997), on the other hand reported in a 
prospective trial that fish oil supplementation did not affect the levels of plasma cytokines. 
The reason for the apparent discrepancy is not clear. It is well known, however, that PUFAs 
(especially at higher dosage) are prone to peroxidation which further generates free radicals 
and oxidised LDL which are cytotoxic to cells (Steinberg et al. 1989). Yet, in other studies 
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(Nenseter et al. 1992; Lussier-cacan et al. 1993; Bonaname et al. 1996) using moderate dose 
(< 3 g of n-3 PUFAs/day), conflicting results have been reported as well. 
 
IL-6 and TNF-α are generally considered as proinflammatory cytokines and the potent anti-
inflammatory properties of IL-10 and TGF-β are well known (Pestka et al. 2004; Wahl & 
Chen 2003). Anti-inflammatory cytokines such as TGF-β have been shown to prevent 
vascular inflammation and to promote plaque stabilization in mice models (Gourdy et al. 
2007). In the present study, however, Omacor significantly decreased TGF-β concentration. 
Thus this effect of Omacor is unlikely to be of benefit. The mechanism responsible for the 
anti-atherogenic effects of TGF-β, particularly reduction in the intimal inflammatory 
process and promotion of plaque stabilization were recently further analyzed (Tedgui & 
Mallat 2006; Singh & Ramji 2006). Fish oil supplementation has been demonstrated to 
elevate TGF-β levels in pregnant women (Krauss-Etschmann et al. 2007).  
 
IP-10 and Mig are reported to be present in arterial plaque and immunohistochemical 
staining of human atherosclerotic lesions revealed that these chemokines are expressed in 
endothelial cells overlying the plaque, suggesting that IP-10 and Mig are likely play an 
important role in T cell recruitment to sites of inflammation (Mach et al. 1999). IP-10 was 
increased in a small group of coronary artery disease patients with restenosis compared with 
other coronary artery disease patients (Kawamura et al. 2003) and a positive correlation 
between IP-10 and ICAM-1 has been observed (Rothenbacher et al. 2006). In the present 
study, no effects of Omacor on IP-10 and Mig were observed. 
 
One of the earliest events in the formation of atherosclerotic plaque is the adherence of 
circulatory monocytes to the vascular endothelium which subsequently enhances the 
secretion of a wide variety of growth factors in a series of complex cell-cell interactions 
(Hansson et al. 1989), such as inflammatory cytokines and matrix metalloproteinases 
(MMPs). MMPs are known to be expressed in human atherosclerotic plaques by both 
smooth muscle cells and foam cells, which have been demonstrated by in situ zymography 
and in situ hybridization (Henney et al. 1991; Galis et al. 1994) and may thus contribute to 
plaque vulnerability (Brown et al. 1995) as well as de novo atherosclerotic remodelling 
(Pasterkamp et al. 2000). Increased expressions of MMP-2 and MMP-9 that degrade the 
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major component of basement membrane have been demonstrated within plaque 
(Pasterkamp et al. 2000; Zaltsman et al. 1999). MMP-9, which is also known as gelatinase 
13 or 92-kDa type 10 collagenase, is one of the MMPs found to be highly expressed in the 
vulnerable regions of atherosclerotic plaque. Even though, it has been documented that 
MMP-9 is undetectable in blood of 80% of healthy individuals (Sundstrom et al. 2004), in 
this study, MMP-9 was detected in blood of all patients.  
 
Prior to the expression of adhesion molecules, CD40L on activated platelets and T-
lymphocytes activates MMPs and thereby promotes plaque rupture. On the other hand, 
sCD40L is not only as a marker of immune activation but also may be involved in 
pathogenic processes in angina patients. Indeed, sCD40L has been implicated in acute 
coronary syndrome (Aukrust et al. 1999) and elevated sCD40L predicts an increased risk of 
future CVD events in healthy subjects (Schonbech et al. 2001). In this present study, no 
beneficial effects of Omacor on MMP-2, MMP-9 and sCD40L were found. Our findings 
agree with Aarsetoey et al. (2006) which also reported the lack of benefit with Omacor 
intervention on sCD40L and MMP-9. In their studies, the placebo corn oil group also 
exhibited significant decreases in sCD40L and non-significant decreases in MMP-9. Of 
note, in the present study, MMP-2 was reduced significantly in both groups.  
 
The beneficial effects of Omacor, such as lipid-lowering, reduced platelet aggregation, 
antithrombotic and fibrolytic activities, reduced blood viscosity and anti-inflammatory 
properties have been demonstrated at high doses (Bhatnagar & Durrington 2003). In the 
present study, even though the dose administered was only 1.8 g/day EPA plus DHA, 
combination of Omacor and statins improved lipid profiles and certain inflammatory 
markers to a greater extent than statins alone, as represented in the placebo group. 
Therefore, again, the beneficial effect of Omacor as a useful adjunct to statins therapy has 
been demonstrated, not only in terms of lipid-lowering, but also in certain plasma 
inflammatory markers, particularly in male patients. 
 
 
3.4.4 The Relationship between Fatty Acid Intake and CVD Outcomes 
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      The influence of fatty acid intake and CVD outcomes was investigated based on the 
association between fatty acid composition in the PC fraction and CVD markers. Plasma PC 
represents transport of lipids in the bloodstream since exchange of phospholipids occurs 
with cell membranes (Kew et al. 2003). Moreover, plasma PC that originates mainly from 
liver may reflect tissue n-3 fatty acids levels and further may serve as a marker to document 
n-3 fatty acid intake and also is a surrogate for cell membrane fatty acid composition 
(Harris 1989).  
 
The effects of n-3 PUFAs, particularly EPA and DHA on inflammatory responses have 
been investigated in in vitro (De Caterina et al. 1994; De Caterina et al. 1995; Weber et al. 
1995; De Caterina et al. 2000) with results favouring DHA as a more potent anti-
inflammatory fatty acid. In the present study, only ALA and DHA were found to be 
inversely associated with inflammatory markers sVCAM-1 and IL-6, respectively. Yli-Jama 
et al. (2002) reported an inverse linear association between sVCAM-1 and non-esterified 
DHA. Even though ARA has been documented, and portrayed, as a potent pro-
inflammatory factor (Dwyer et al. 2004), in the present study, no associations were found. 
Yli-Jama et al. (2002) reported anti-inflammatory effect of ARA, however with sVCAM-1. 
 
 
3.4.5 Correlation between Plasma Inflammatory Markers and Specific Fatty Acids 
 
   Section 2.4.8 has further discussed the role of LC n-3 PUFAs, particularly EPA and DHA 
on inflammatory responses. In the present study, only sE-selectin and MMP-9 showed a 
relationship with DPA and DHA, however with a direct association, indicating a pro-
inflammatory response. Therefore, even though in the present study beneficial effects of 
Omacor have been demonstrated, it is difficult to state with certainty that EPA and DHA are 
causally responsible for these changes since there were no significant relations between 
these fatty acids and inflammatory markers studied. Of note, the role of fish oil 
supplementation to exert an anti-inflammatory response is well reported, even though the 
mechanism by which this action is working is still under extensive investigation. 
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3.4.6 Effect of Supplementation on the mRNA Expression of Plaque Inflammatory 
Markers 
 
   MMP-7 mRNA concentrations were significantly lower in the Omacor group than in the 
placebo group. Based on an animal study using apoE/MMP-7 double knock-out mice, it 
was found that MMP-7 has no effect on plaque growth or stability, although it is associated 
with reduced smooth muscle cell content in plaques (Johnson et al. 2005). Nilsson et al. 
(2006) reported that the plasma concentration of MMP-7 was increased in patients with 
stable and unstable CAD. Conversely, for MMP-8, the regions of advance atherosclerotic 
lesions displayed an increase of MMP-8 mRNA expression level in comparison with 
healthy tissues (Herman et al. 2001). In the present study however, there was no significant 
effect of Omacor on MMP-8 mRNA expression.  
 
It has been reported that plasma MMP-9 had significantly higher concentrations and tissue 
inhibitor of metalloproteinase (TIMP-1) levels were lower in subjects with previous acute 
myocardial infarction (AMI) (Furenes et al. 2007). On the other hand, Tuomainen et al. 
(2007) documented that TIMP-1 concentrations alone had no predictive value. Moreover, it 
was found that n-3 PUFAs supplementation did not alter the levels of MMP-9 and TIMP-1 
(Furenes et al. 2007). In the present study, MMP-9 mRNA levels were significantly lower 
in plaques in the Omacor group compared with the placebo group. 
   
The decreases in plasma IL-6 in the Omacor group was also in accordance with lower IL-6 
mRNA expression in plaque as compared to the placebo. Conversely, even though plasma 
sICAM-1 was not significantly decreased with Omacor supplementation, ICAM-1 mRNA 
expression in plaque was shown to decrease significantly. On the other hand, there was no 
significant effect on plaque VCAM-1 mRNA expression, even though plasma sVCAM-1 
showed a significant decrease. To date, no similar studies which measure ICAM-1 or 
VCAM-1 mRNA levels in plaque were found with which to make comparison. However, it 
has been reviewed and documented that expression of ICAM-1 has been consistently 
observed in atherosclerotic plaque (Blankenberg et al. 2003). Therefore, the findings in the 
present study suggest that the association between plasma inflammatory markers and 
mRNA expression of plaque inflammatory markers is not consistent. It is believed that 
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changes in gene expression levels will lead to changes in protein level as well. However, 
this may not necessarily hold true. 
 
 
3.5 Conclusion 
 
   In this study it was not possible to ascertain the positive effect of fish oil supplementation 
(Omacor) in patients awaiting carotid endarcterectomy on blood pressure and lipid profile 
since the results revealed that both placebo and Omacor groups showed significant 
decreases in TAG, total cholesterol and LDL-cholesterol. In terms of inflammatory 
markers, it was found that Omacor significantly decreased sE-selectin (23%) and sVCAM-1 
(25%); even though in the placebo group, sVCAM-1 was also reduced but to a lesser extent, 
by 19%. However, the anti-inflammatory TGF-β1 was decreased significantly by 22% in 
the Omacor group. Interestingly, when the data were analyzed by gender, it was found that 
in males receiving Omacor, sE-selectin (-23%), sVCAM-1 (-23%), IL-6 (-27%) were 
reduced significantly. In the females receiving Omacor, only sVCAM-1 was found to be 
decreased significantly (-38%). Thus, the present study supports some anti-inflammatory 
actions of moderate dose of Omacor in carotid endarterectomy patients, especially males. 
Correlation analysis was carried out to study the association between mRNA expression of 
inflammatory markers in plaque and in plasma concentrations for MMP-9, IL-10, IL-6 and 
ICAM-1. Results, however demonstrated that there were no significant relationships 
between these inflammatory markers even though it was found that in the Omacor group, 
the mRNA expression of MMP-9, IL-6 and ICAM-1 in plaque was significantly different 
(lower) than in the placebo group. ARA has been shown to exert an anti-inflammatory 
response because mRNA expression of PPAR-γ, MMP-1, MMP-3, MMP-7, MMP-9, 
MMP-12, TIMP-1 and ICAM-1 were consistently inversely correlated with ARA. The 
beneficial effect of EPA as shown in plaque inflammatory expression was demonstrated by 
mRNA expression of MMP-7, MMP-12, TIMP-1 and IL-6.  Therefore, I conclude that 
soluble inflammatory markers which are measured in blood cannot be used to reflect the 
expression of these molecules at the cell surface, i.e. in the vasculature or the plaque.  
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Chapter 4 
 
The Effects of Fatty Acids on the Expression of Adhesion 
Molecules in Cultured Human Endothelial Cells  
 
4.1 Introduction 
 
   Endothelial cells constitute the main barrier of exchange and contact between the blood 
and the tissue; they play a critical role in inflammatory events that influence the vessel wall 
(section 1.1). In relation to atherosclerosis development, adhesion of leukocytes to 
endothelial cells is a complex and crucial process involving adhesion molecules on both the 
leukocytes and endothelial cells. Important amongst these receptors are VCAM-1 (CD106), 
ICAM-1 (CD54) and E-selectin (CD62E) which play key roles in the tethering, activation, 
adhesion and transmigration of the leukocytes into the intimal space underlying the 
endothelium. As a result of the adhesion molecule mediated leukocyte-endothelium 
interactions there is an upregulation of production of inflammatory mediators. Unlike E-
selectin, ICAM-1 and VCAM-1 are reported to be constitutively expressed by endothelial 
cells (Prober et al. 1988; Bevilacqua et al. 1989). Nevertheless, endothelial expression of all 
three of these adhesion molecules can be up-regulated by cytokines or other inflammatory 
stimuli. For example, the expression of these adhesion molecules is markedly up-regulated 
by pro-inflammatory cytokines, such as IL-1β and TNF-α (Prober et al. 1988; Bevilacqua et 
al. 1989; Prober et al. 1987) and the enhanced expression is dependent on mRNA and 
protein synthesis (Bevilacqua et al. 1989; Dustin et al. 1986). 
 
180  
181 
In Chapter 2, I described findings from an intervention trial with fish oil in healthy, middle-
aged men, which identified a small reduction in soluble ICAM-1 concentration in the 
plasma in subjects consuming 2.1 g/day of eicosapentaenoic acid (EPA) plus 
docosahexaenoic acid (DHA). The small effect on sICAM-1 and the lack of effect on other Chapter 4 The Effects of Fatty Acids on Adhesion Molecule Protein Expression                           181               
 
biomarkers studied and the results of correlation analysis suggest that DHA is more 
important than EPA with regard to these outcomes. Furthermore, the findings suggest a 
need for further detailed examination of the differential effects of EPA and DHA. 
 
 In Chapter 3 I described findings from another intervention trial with n-3 fatty acids, this 
time in patients with established atherosclerotic disease. In this study, patients received 
either 1.8 g/day EPA plus DHA in the form of Omacor or 1.2 g/day oleic acid from olive oil 
as placebo. It was found that Omacor significantly decreased sE-selectin and sVCAM-1, but 
not sICAM-1, concentrations in plasma. The findings of these two studies indicate a need to 
further study effects of fatty acids on soluble adhesion molecules, in order to identify more 
clearly whether these are affected by fatty acids and, if so, the mechanisms involved. 
Correlation analyses between inflammatory markers in plaque (mRNA level) and in the 
bloodstream (circulating proteins) showed little relationship. From this, I concluded that 
soluble inflammatory markers which are measured in blood cannot be used to reflect the 
expression of these molecules at the cell surface, i.e. on the endothelium or in plaque. Thus 
studies at the cellular level are required. Thus, in this and the following chapter, I have used 
in vitro models to examine the direct effects of fatty acids on the expression of three 
adhesion molecules (VCAM-1, ICAM-1 and E-selectin) at two different levels, namely, 
protein (using ELISA) and mRNA (using real-time Reverse Transcriptase Polymerase 
Chain Reaction (PCR)), respectively. In this chapter, I will focus on findings on protein 
expression, and the mRNA expression results will be presented in Chapter 5.  
 
 
4.1.1 Background of the Study 
 
The present study is inspired by the pioneering work of De Caterina et al. (1994) using in 
vitro experiments using human saphenous vein endothelial cells (HSaVECs) activated by 
cytokines. Using these cells it was reported that EPA has no effect on endothelial adhesion 
molecule expression (De Caterina et al. 1994; De Caterina & Libby 1996; De Caterina et al. 
1998). It was then demonstrated that EPA at higher concentrations (> 65 µM, compared  
with 10-25 µM used by De Caterina and colleagues with HSaVECs), attenuated the 
expression of ICAM-1, VCAM-1 and E-selectin on human umbilical vein endothelial cells 
(HUVECs) (Collie-Duguid & Wahle 1996; Khalfoun et al. 1996). It is not clear whether 
EPA at these higher concentrations may attenuate the expression of adhesion molecules on 
HSaVECs since there are no studies investigating the effect of this fatty acid at high 
concentrations.  DHA, on the other hand, was able to decrease ICAM-1, VCAM-1 and E-
selectin expression on cytokine-stimulated HSaVECs or HUVECs (Collie-Duguid & Wahle 
1996; Khalfoun et al. 1996; De Caterina et al. 1994; De Caterina & Libby 1996; De 
Caterina et al. 1998) and subsequently decreased leukocyte adhesion. Thus, DHA has been 
determined to be the most potent fatty acid inhibitor of adhesion molecules (De Caterina et 
al. 1995). Conversely however, the combination of EPA and DHA attenuated the 
expression of these three endothelial adhesion molecules (Nohe et al. 2002; Collie-Duguid 
et al. 1996) and reduced L-selectin and LFA-1 on peripheral blood lymphocytes (Khalfoun 
et al. 1996). Based on in vitro studies using HSaVECs, De Caterina et al. (2004) concluded 
that a minimum of a single double bond is required to inhibit adhesion molecule expression 
(therefore saturated fatty acids are inactive); the effectiveness does not depend on the chain 
length and the degree of effectiveness increases correspondingly with unsaturation (double 
bond insertion). 
 
In atherosclerosis, occlusion of the blood vessels occurs mainly in the arteries, not the 
veins. To date, there were no studies on the effects of LC n-3 PUFAs on adhesion molecule 
expression performed using either arterial or aortic endothelial cells. Therefore, it is very 
important to perform such studies to enable comparison with data from the previous models 
which were using venous endothelial cells (HSaVECs and HUVECs). I have investigated 
the effects of individual fatty acids, including EPA, docosapentaenoic acid (DPA), DHA, 
arachidonic acid (ARA), oleic acid (OA) and stearic acid (SA) on adhesion molecule 
expression in different cell types (human saphenous vein endothelial cells - HSaVECs, 
human umbilical vein endothelial cells - HUVECs, human umbilical artery endothelial cells 
- HUAECs, human coronary artery endothelial cells - HCAECs and human aortic 
endothelial cells - HAOECs).  
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4.2 Aim of this Study 
 
   The aim of this study was to identify the effects of individual fatty acids on endothelial 
cells adhesion molecule expression. To investigate this aim, different endothelial cell types 
were used under similar experimental conditions. The objectives of the experiments were: 
 
• To optimize conditions for LPS stimulation in five different endothelial cell types 
(HUVECs, HUAECs, HCAECs, HSaVECs and HAOECs) of adhesion molecules 
expression (LPS concentration and incubation time); 
 
• To optimize conditions for fatty acid pre-incubation (time and concentration);  
 
• To compare the effects of individual fatty acids (EPA, DPA, DHA, ARA, OA and SA) on 
VCAM-1 protein expression in each endothelial cell type; 
 
•  To compare the effects of individual fatty acids on ICAM-1 expression in each 
endothelial cell type; 
 
• To compare the effects of individual fatty acids on E-selectin expression in each 
endothelial cell type 
 
 
4.3 Methods 
 
4.3.1 Reagents 
 
   Sodium salts of EPA, DPA, DHA, ARA, OA, and SA were from Sigma-Aldrich, Poole 
and each dissolved in ethanol to prepare 100 mM fatty acid stock solution at room 
temperature or at 37
o C, to overcome fatty acid insolubility in aqueous solution. LPS (from 
E.coli, cell culture tested) was from Sigma-Aldrich, Poole and was dissolved in growth 
media to prepare 1 mg/mL stock solution. Endothelial cell growth media were from 
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PromoCell, Heidelberg and ECACC, Salisbury (only for HAOECs). Cell detaching kit 
(HepesBSS: 30 mM Hepes, D-glucose, NaCl, KCl, Na Phosphate, Phenol red), 
trypsin/EDTA solution and soybean trypsin neutralizing solution from soybean (0.05%) 
were from PromoCell, Heidelberg. The antibiotics penicillin and streptomycin were from 
PAA Laboratories, Somerset.  
 
 
4.3.2 Endothelial Cell Culture 
 
   Endothelial cells (HUVECs, HUAECs, HSaVECs and HCAECs) were from PromoCell, 
Heidelberg. HAOECs were from European Collection of Cell Culture (ECACC), Salisbury. 
The cells were thawed and subcultured following the supplier’s instructions. Prior to use in 
experiments cells at passage four were grown in 96-well plates until confluence.  
 
 
4.3.3 Optimization of LPS Concentration and Incubation Time 
 
   Confluent  cultures  were  seeded  after 3-5 minutes exposure to trypsin-EDTA and 
neutralized by trypsin neutralizing solution (Promocell, Heidelberg). Cells were grown at 1-
2 x 10
4 cells per well in 0.2 mL culture medium in 96-well flat-bottomed plates to 
confluence. Then, cells were stimulated with LPS at different concentrations (1, 10 and 100 
µg/mL) and for different durations (6, 12, 24, 48, 72 and 96 hours). At the end of the 
incubation, cells were incubated in 100 µL fresh, cold 2% formaldehyde in PBS and 
incubated at 4
o C for 20 minutes and the excess was drained off. After drying for about 2 
hours at room temperature, plates were sealed with parafilm and frozen at -20
o C until 
analysis. 
 
 
4.3.4 Detection of Adhesion Molecule Expression 
 
   The expression of adhesion molecule expression in endothelial cells was determined by 
ELISA. Prior to ELISA assays, the plate was removed from freezer and was allowed to 
acclimatize for at least 1 hour at room temperature before removing the parafilm. The plate 
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was washed three times with wash buffer (0.05% Tween® 20 in PBS, pH 7.4). Cells were 
then fixed with 100 µL per well of biotinylated anti-human VCAM-1 (CD106) antibody 
(200 ng/mL), biotinylated anti-human ICAM-1 (CD54) antibody (100 ng/mL) and 
biotinylated anti-human E-selectin (CD62E) antibody (0.5 µg/mL), respectively for 2 hours 
at room temperature. Following aspiration and then washing steps, 100 µL of steptavidin 
horse radish peroxidase (1:200 dilution) was added to each well and further incubated for 
30 min at room temperature. After aspiration and washing steps again, 100 µL of substrate 
solution (1:1 mixture of hydrogen peroxide and tetramethylbenzidine) was added to each 
well and incubated for 20-30 min at room temperature. The development of colour was 
stopped by the addition of stop solution (1 M sulfuric acid) and the absorbance was 
determined on a microplate reader at 450 nm. 
 
 
4.3.5 Statistical Analysis 
 
Results are presented as mean ± SEM. Data were analyzed using SPSS Version 16.0 (SPSS 
Inc., Chicago). Multiple comparisons were carried out by one-way analysis of variance 
(ANOVA) and significant findings were further studied using the least significant 
difference (LSC) post-hoc comparison.  
 
 
4.4 Results 
 
4.4.1 Optimization of LPS Concentration 
 
   The influence of different LPS concentrations and of duration of LPS exposure upon 
expression of three adhesion molecules (VCAM-1, ICAM-1, E-selectin) in five endothelial 
cell types was examined. The aim was to identify optimal conditions (LPS concentration, 
duration of culture) for use in experiments with fatty acids. 
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 4.4.1.1 Optimization of LPS Concentration in HUVECs 
 
   Figures 4.1- 4.3 show the expression of VCAM-1, ICAM-1 and E-selectin in HUVECs 
following LPS stimulation for 6, 12, 24 and 48 hrs, respectively. At 6 hours incubation 
time, no significant changes were observed for E-selectin and VCAM-1 (except for 
increased VCAM-1 at the highest LPS concentration of 100 µg/mL), even though there was 
significant induction of ICAM-1 at this early time point. LPS stimulation for 12 hours 
significantly induced the expression of all three adhesion molecules studied, although 
induction of E-selectin was weaker than of VCAM-1 or ICAM-1. Expression of these 
adhesion molecules was increased by an average of 424%, 143% and 11%, respectively, by 
12 hrs exposure to 1 μg/mL LPS (compared with 12 hours incubation in the absence of 
LPS). A similar effect was observed at higher LPS concentrations and at 24 hrs LPS 
stimulation, but by 48 hrs expression of VCAM-1 and E-selectin declined. On the basis of 
these findings, 12 hours incubation at 1 µg/mL LPS was selected as the condition with 
which to study the effect of fatty acids on adhesion molecule expression by HUVECs.  
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FIGURE 4.1: Effects of LPS Stimulation on VCAM-1 Expression in HUVECs 
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Effect of LPS stimulation on ICAM-1 expression in HUVECs
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FIGURE 4.2: Effects of LPS Stimulation on ICAM-1 Expression in HUVECs 
 
 
Effect of LPS stimulation on E-selectin expression in HUVECs
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FIGURE 4.3: Effects of LPS Stimulation on E-selectin Expression in HUVECs 
 
 
 
4.4.1.2 Optimization of LPS Concentration in HUAECs 
 
   Figures 4.4-4.6 show the expression of VCAM-1, ICAM-1 and E-selectin in HUAECs 
following LPS stimulation for 6, 12, 24 and 48 hrs, respectively. Six hrs incubation time 
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was sufficient to induce significant increases in expression of all three adhesion molecules. 
However greater expression of each was observed at 12 and 24 hrs with reduced expression 
of VCAM-1 and E-selectin occurring at 48 hrs. Expression of the adhesion molecules was 
increased by an average of 359% (VCAM-1), 62% (ICAM-1) and 29% (E-selectin), 
respectively, by 12 hrs exposure to 1 μg/mL LPS (compared with 12 hours incubation in the 
absence of LPS). On the basis of these findings, 12 hours incubation at 1 µg/mL LPS was 
selected as the condition with which to study the effect of fatty acids on adhesion molecule 
expression by HUAECs.  
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FIGURE 4.4: Effects of LPS Stimulation on VCAM-1 Expression in HUAECs 
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Effect of LPS stimulation on ICAM-1 expression in HUAECs
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FIGURE 4.5: Effects of LPS Stimulation on ICAM-1 Expression in HUAECs 
 
 
Effect of LPS stimulation on E-selectin expression in HUAECs
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FIGURE 4.6: Effects of LPS Stimulation on E-selectin Expression in HUAECs 
 
 
4.4.1.3 Optimization of LPS Concentration in HCAECs  
 
   Figures 4.7-4.9 show the expression of VCAM-1, ICAM-1 and E-selectin in HCAECs 
following LPS stimulation for 6, 12, 24, 48, 72 and 96 hrs, respectively. Six hrs incubation 
time was sufficient to induce significant increases in expression of all three adhesion 
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molecules. Indeed near maximal expression was seen at this time point. The effect of LPS 
was dose-dependent at the earlier time points. Expression of the adhesion molecules was 
increased by an average of 495% (VCAM-1), 134% (ICAM-1) and 46% (E-selectin), 
respectively, by 12 hrs exposure to 1 μg/mL LPS (compared with 12 hours incubation in the 
absence of LPS). Expression of VCAM-1 and ICAM-1 was maintained up to 96 hours but 
expression of E-selectin declined at 24 hrs of culture and thereafter. On the basis of these 
findings, 12 hours incubation at 1 μg/mL LPS was selected as the condition with which to 
study the effect of fatty acids on adhesion molecule expression by HCAECs.  
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FIGURE 4.7: Effects of LPS Stimulation on VCAM-1 Expression in HCAECs 
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FIGURE 4.8: Effects of LPS Stimulation on ICAM-1 Expression in HCAECs 
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FIGURE 4.9: Effects of LPS Stimulation on E-selectin Expression in HCAECs 
 
 
4.4.1.4 Optimization of LPS Concentration in HSaVECs  
 
   Figures 4.10-4.12 show the expression of VCAM-1, ICAM-1 and E-selectin in HSaVECs 
following LPS stimulation for 6, 12, 24, 48, 72 and 96 hrs, respectively. Six hrs incubation 
time was sufficient to induce an increase in expression of VCAM-1, with smaller increases 
in ICAM-1 and E-selectin. Greater expression of VCAM-1 was seen at 12 and 24 hrs of 
culture, while longer incubation times (48 or 72 hrs) were required to observe higher 
ICAM-1 expression. E-selectin expression declined beyond 12 hrs of culture, although LPS 
was still effective. Expression of the adhesion molecules was increased by an average of 
309% (VCAM-1), 12% (ICAM-1) and 51% (E-selectin), respectively, by 12 hrs exposure to 
1 μg/mL LPS (compared with 12 hours incubation in the absence of LPS). On the basis of 
these findings, 12 hours incubation at 1 µg/mL LPS was selected as the condition with 
which to study the effect of fatty acids on adhesion molecule expression by HUAECs.  
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FIGURE 4.10: Effects of LPS Stimulation on VCAM-1 Expression in HSaVECs 
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FIGURE 4.11: Effects of LPS Stimulation on ICAM-1 Expression in HSaVECs 
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FIGURE 4.12: Effects of LPS Stimulation on E-selectin Expression in HSaVECs 
 
 
4.4.1.5 Optimization of LPS Concentration in HAOECs  
 
   Figures 4.13- 4.15 show the expression of VCAM-1, ICAM-1 and E-selectin in HAOECs 
following LPS stimulation for 6, 12, 24, 48 and 72 hrs, respectively. Six hrs incubation time 
was sufficient to induce significant, and near maximal, increases in expression of all three 
adhesion molecules, although for HAOECs LPS at 1 μg/mL was ineffective. Expression of 
the adhesion molecules was increased by an average of 202% (VCAM-1), 47% (ICAM-1) 
and 54% (E-selectin), respectively, by 12 hrs exposure to 10 μg/mL LPS (compared with 12 
hours incubation in the absence of LPS). On the basis of these findings, 12 hours incubation 
at 10 ug/mL LPS was selected as the condition with which to study the effect of fatty acids 
on adhesion molecule expression by HAOECs.  
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FIGURE 4.13: Effects of LPS Stimulation on VCAM-1 Expression in HAOECs 
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FIGURE 4.14: Effects of LPS Stimulation on ICAM-1 Expression in HAOECs 
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FIGURE 4.15: Effects of LPS Stimulation on E-selectin Expression in HAOECs 
 
 
4.4.2 Optimization of Fatty Acid Pre-incubation Time and Concentration 
 
   In this set of experiments, two endothelial cell types were used, namely HUVECs and 
HAOECs. This is because from the LPS stimulation results (section 4.4.1), similar 
conditions were found for all cell types apart from HAOECs. Therefore, for these latter 
cells specific conditions, different from those used with the other four cell types, needed to 
be used. The aim of these experiments was to identify a fatty acid concentration and pre-
incubation time to be used in experiments where several fatty acids would be compared. 
DHA was used for these studies, since it was expected to influence adhesion molecule 
expression.  
 
 
4.4.2.1 Optimization of Fatty Acid Pre-incubation in HUVECs 
 
   HUVECs were pre-incubated with DHA at 0, 25, 50 and 100 μM for 24, 48 and 80 hrs. 
Then the cells were stimulated with LPS at 1 μg/mL for 12 hrs. Figures 4.16-4.18 show the 
effects of DHA preincubation on LPS-induced expression of VCAM-1, ICAM-1 and E-
selectin. Exposure to DHA (50 or 100 μM) for 48 or 80 hrs was able to abolish the effect of 
LPS on VCAM-1 expression (Figure 4.16). Exposure to DHA (50 or 100 μM) for 48 hrs 
was able to reduce the effect of LPS on ICAM-1 expression while longer exposure to DHA 
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(80 hrs) abolished LPS-induced ICAM-1 exposure (Figure 4.17). DHA had little effect on 
LPS-induced E-selectin expression, except that this was increased at the shortest exposure 
(24 hrs) to 100 μM DHA (Figure 4.18). On the basis of this experiment, a fatty acid 
concentration of 50 μM and a pre-incubation time of 48 hrs was selected to compare the 
effects of different fatty acids.   
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FIGURE 4.16: Effect of Fatty Acid Pre-incubation on VCAM-1 Expression in HUVECs 
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FIGURE 4.17: Effect of Fatty Acid Pre-incubation on ICAM-1 Expression in HUVECs 
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Effects of DHA concentration on the LPS-induced E-selectin 
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FIGURE 4.18: Effect of Fatty Acid Pre-incubation on E-selectin Expression in HUVECs 
 
 
4.4.2.2 Optimization of Fatty Acid Pre-incubation in HAOECs 
 
   HAOECs were pre-incubated with DHA at 0, 25, 50 and 100 μM for 24, 48 and 80 hrs. 
Then the cells were stimulated with LPS at 1 μg/mL for 12 hrs. Figures 4.19-4.21 show the 
effects of DHA preincubation on LPS-induced expression of VCAM-1, ICAM-1 and E-
selectin. Exposure to DHA (50 or 100 μM) for 24, 48 or 80 hrs abolished the effect of LPS 
on VCAM-1 and ICAM-1 expression (Figures 4.19 and 4.20). DHA (50 or 100 μM) 
increased LPS-induced E-selectin expression (Figure 4.21). On the basis of this experiment, 
a fatty acid concentration of 50 μM and a pre-incubation time of 48 hrs was selected to 
compare the effects of different fatty acids.   
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FIGURE 4.19: Effect of Fatty Acid Pre-incubation on VCAM-1 Expression in HAOECs 
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FIGURE 4.20: Effect of Fatty Acid Pre-incubation on ICAM-1 Expression in HAOECs 
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Effects of DHA concentration on the LPS-induced E-selectin 
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FIGURE 4.21: Effect of Fatty Acid Pre-incubation on E-selectin Expression in HAOECs 
 
 
4.4.3 Effects of Fatty Acids on Adhesion Molecule Expression 
 
   A comparison of the effects of fatty acids on adhesion molecule expression was carried 
out under optimal conditions of 48 hrs pre-incubation with fatty acid at 50 μM and 
subsequent stimulation with 1 μg/mL  or, for HAOECs, 10 μg/mL LPS for a further 12 hrs. 
Expression of adhesion molecules was determined by ELISA as described in Section 4.3.4. 
To assess whether any fatty acid per se exhibits any effects on adhesion molecule 
expression, parallel comparative experiments without LPS stimulation were conducted. Six 
fatty acids were used: EPA, DPA, DHA, ARA, OA and SA.  
 
 
4.4.3.1 Effects of Fatty Acids on Adhesion Molecule Expression in HUVECs 
 
   Figures 4.22-4.24 show the effects of six fatty acids on VCAM-1, ICAM-1 and E-selectin 
expression on unstimulated and LPS-stimulated HUVECs. It was observed that LPS 
significantly up-regulated adhesion molecule expression in HUVECs, particularly VCAM-
1. None of the fatty acids except DHA demonstrated any significant effect on adhesion 
molecule expression in the absence of LPS stimulation (P > 0.05). DHA induced expression 
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of ICAM-1 by 73% (P = 0.01) and of E-selectin by 22% (P < 0.001) on unstimulated 
HUVECs.  
 
Under the optimized experimental conditions, all fatty acids studied significantly attenuated 
VCAM-1 expression in HUVECs (P < 0.05) (Figure 4.22). DHA exerted the greatest 
inhibitory effect (average 85%), followed by ARA (71%), EPA (63%) and DPA (54%). OA 
and SA exhibited a similar degree of inhibition (34%) of LPS-induced expression of 
VCAM-1. 
 
The observed effects of fatty acids on LPS-induced ICAM-1 and E-selectin expression were 
less marked than the effects on VCAM-1 expression (Figure 4.23 and 4.24, respectively). 
ARA, DHA, EPA, and DPA inhibited ICAM-1 expression significantly (P < 0.05) by an 
average of 30%, 23%, 23% and 12%, respectively. Neither OA nor SA showed any 
significant effects for ICAM-1 expression (P > 0.05). EPA, ARA and DHA significantly 
attenuated LPS-induced E-selectin expression by 16%, 15% and 6%, respectively. DPA did 
not affect E-selectin expression while both OA and SA significantly increased E-selectin 
expression in HUVECs (P < 0.001), by 13% and 16%, respectively.  
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FIGURE 4.22: Comparative Effects of Fatty Acids on VCAM-1 Expression in HUVECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, **P < 
0.005, ***P < 0.001. 
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Effects of Fatty acids on ICAM-1expression in HUVECs
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FIGURE 4.23: Comparative Effects of Fatty Acids on ICAM-1 Expression in HUVECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, * P < 0.05, 
***P < 0.001, NS = non-significant. 
 
 
Effects of fatty acids on E-selectin expression in HUVECs
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Control EPA DPA DHA ARA OA SA
E
-
s
e
l
e
c
t
i
n
 
 
e
x
p
r
e
s
s
i
o
n
(
O
D
 
4
5
0
 
n
m
)
Stimulated with LPS Unstimulated
 
  ***     *** 
   NS 
    * 
   ***     *** 
FIGURE 4.24: Comparative Effects of Fatty Acids on E-selectin Expression in HUVECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, * P < 0.05, 
***P < 0.001, NS = non-significant. 
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Thus certain fatty acids were able to inhibit LPS-induced expression of VCAM-1, ICAM-1 
and E-selectin in HUVECs, although the magnitude of VCAM-1 inhibition was the greatest, 
followed by ICAM-1 and E-selectin. Figure 4.25 attempts to summarise the pattern of 
inhibition seen across all fatty acids and all three adhesion molecules; this figure 
demonstrates that a very similar pattern of effects of fatty acids was seen, although the 
extent of the effect of a given fatty acid was different according to the adhesion molecule 
studied.   
 
Effect of fatty acids on the LPS-induced adhesion molecule expression in 
HUVECs
-100
-80
-60
-40
-20
0
20
40
%
 
o
f
 
c
o
n
t
r
o
l
VCAM-1 ICAM-1 E-selectin
 
EPA  DPA DHA ARA OA  SA
FIGURE 4.25: Comparative Effects of Fatty Acids on Adhesion Molecules Expression in 
HUVECs 
 
 
4.4.3.2 Effects of Fatty Acids on Adhesion Molecule Expression in HUAECs 
 
   Figures 4.26-4.28 show the effects of six fatty acids on VCAM-1, ICAM-1 and E-selectin 
expression on unstimulated and LPS-stimulated HUAECs; this is the first time that the 
effects of fatty acids on these cells has been reported. It was observed that LPS significantly 
up-regulated adhesion molecule expression in HUAECs, particularly VCAM-1 and ICAM-
1. None of the fatty acids demonstrated any significant effect on VCAM-1 expression in the 
absence of LPS stimulation (P > 0.05). However, ICAM-1 was induced by EPA (P = 
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0.001), OA (P = 0.001) and SA (P = 0.025) and E-selectin was induced by DHA and SA 
(both P < 0.001).   
 
Under the optimized experimental conditions, all fatty acids studied significantly attenuated 
VCAM-1 expression in HUAECs (all P < 0.001) (Figure 4.26). DHA exerted the greatest 
inhibitory effect (average 95%), followed by ARA (85%), DPA (84%), SA (81%), EPA 
(77%) and OA (60%).  
 
The effects of fatty acids on LPS-induced ICAM-1 and particularly E-selectin expression 
were less marked than the effects on VCAM-1 expression (Figures 4.27 and 4.28). DHA, 
DPA, EPA and SA inhibited ICAM-1 expression significantly (P < 0.05) by an average of 
43%, 41%, 22% and 38%, respectively. Neither ARA nor OA showed any significant 
effects on ICAM-1 expression (P > 0.05). EPA and DPA significantly attenuated LPS-
induced E-selectin expression by 21% and 19%, respectively. In contrast, DHA 
significantly enhanced LPS-induced E-selectin expression in HUAECs. ARA, OA and SA 
did not affect E-selectin expression.  
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FIGURE 4.26: Comparative Effects of Fatty Acids on VCAM-1 Expression in HUAECs. 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, ***P < 
0.001. 
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FIGURE 4.27: Comparative Effects of Fatty Acids on ICAM-1 Expression in HUAECs  
Data are expressed as mean ± SEM (n = 3). Significantly different from control, * P < 0.05, 
**P < 0.005, ***P < 0.001, NS = non-significant. 
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FIGURE 4.28: Comparative Effects of Fatty Acids on E-selectin Expression in HUAECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, **P < 
0.005, ***P < 0.001, NS = non-significant. 
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Thus certain fatty acids were able to modulate LPS-induced expression of VCAM-1, 
ICAM-1 and E-selectin in HUAECs (Figure 4.29). Several fatty acids inhibited VCAM-1 
and ICAM-1 expression with a greater effect on the former and DHA had the greatest 
effect. Effects of fatty acids on E-selectin included both inhibition and enhancement, 
although the magnitude of effects seen was smaller than those seen with VCAM-1 and 
ICAM-1 (Figure 4.29). 
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FIGURE 4.29: Comparative Effects of Fatty Acids on Adhesion Molecules Expression in 
HUAECs 
 
 
4.4.3.3 Effects of Fatty Acids on Adhesion Molecule Expression in HCAECs 
 
   Figures 4.30-4.32 show the effects of six fatty acids on VCAM-1, ICAM-1 and E-selectin 
expression on unstimulated and LPS-stimulated HCAECs; this is the first time that the 
effects of fatty acids on these cells has been reported, apart from Reissig et al. (2003) in 
their study in respect to only linoleic acid. It was observed that LPS significantly up-
regulated adhesion molecule expression in HCAECs, particularly VCAM-1. None of the 
fatty acids demonstrated any significant effect on VCAM-1 expression in the absence of 
LPS stimulation (P > 0.05). However, ICAM-1 was induced by DHA (P = 0.005), OA (P = 
0.035) and SA (P < 0.001) and E-selectin was induced by ARA, OA and SA (all P < 0.001).   
 
206  
Under the optimized experimental conditions, ARA and DHA significantly attenuated 
VCAM-1 expression in HCAECs (P = 0.014 and P < 0.001, respectively) (Figure 4.31). 
ARA exerted the greatest inhibitory effect (average 40%), followed by DHA (13%). SA 
enhanced LPS-stimulated VCAM-1 expression by 40%.   
None of the tested fatty acids affected LPS-induced ICAM-1 in HCAECs (Figure 4.31). 
Likewise no fatty acid inhibited LPS-induced E-selectin expression, but both OA and SA 
enhanced this by about 20% (P < 0.05).  
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FIGURE 4.30: Comparative Effects of Fatty Acids on VCAM-1 Expression in HCAECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, * P < 0.05, 
***P < 0.001, NS = non-significant. 
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Effects of fatty acids on ICAM-1 expression in HCAECs 
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FIGURE 4.31: Comparative Effects of Fatty Acids on ICAM-1 Expression in HCAECs 
Data are expressed as mean ± SEM (n = 3). NS = non-significant. 
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FIGURE 4.32: Comparative Effects of Fatty Acids on E-selectin Expression in HCAECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, ***P < 
0.001, NS = non-significant. 
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Thus the extent of modulation of LPS-induced adhesion molecule expression in HCAECs 
by fatty acids was limited (Figure 4.33).  
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FIGURE 4.33: Comparative Effects of Fatty Acids on Adhesion Molecules Expression in 
HCAECs 
 
 
 
4.4.3.4 Effects of Fatty Acids on Adhesion Molecule Expression in HSaVECs 
 
   Figures 4.34-4.36 show the effect of six fatty acids on VCAM-1, ICAM-1 and E-selectin 
expression on unstimulated and LPS-stimulated HSaVECs. It was observed that LPS 
significantly up-regulated adhesion molecule expression in HSaVECs, particularly VCAM-
1. None of the fatty acids demonstrated any significant effect on VCAM-1 or E-selectin 
expression in the absence of LPS stimulation (P > 0.05). However, ICAM-1 was induced by 
DHA (P = 0.001), ARA (P = 0.004), OA (P < 0.001) and SA (P = 0.001).   
 
Under the optimized experimental conditions, DHA, ARA, DPA and EPA significantly 
attenuated VCAM-1 expression in HSaVECs (all P < 0.001 except for EPA [P = 0.006])  
(Figure 4.34). DHA exerted the greatest inhibitory effect (average 81%), with the other 
three fatty acids causing 23 to 29% inhibition. OA and SA both significantly enhanced 
LPS-stimulated VCAM-1 expression by 52% and 78% respectively (both P < 0.001).   
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None of the tested fatty acids affected LPS-induced ICAM-1 in HSaVECs (Figure 4.35). 
Only DHA affected LPS-induced E-selectin expression, an inhibition of 29% (P < 0.05) 
(Figure 4.36).   
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FIGURE 4.34: Comparative Effects of Fatty Acids on VCAM-1 Expression in HSaVECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control * P < 0.05, 
***P < 0.001. 
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FIGURE 4.35: Comparative Effects of Fatty Acids on ICAM-1 Expression in HSaVECs 
Data are expressed as mean ± SEM (n = 3). NS = non-significant. 
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FIGURE 4.36: Comparative Effects of Fatty Acids on E-selectin Expression in HSaVECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, * P < 0.05, 
NS = non-significant. 
 
 
Figure 4.37 summarises the effects of the different fatty acids on LPS-induced adhesion 
molecule expression in HSaVECs. Clearly the nature of the effects on VCAM-1 expression 
is different from those on the other two adhesion molecules.  
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FIGURE 4.37: Comparative Effects of Fatty Acids on Adhesion Molecules Expression in 
HSaVECs 
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4.4.3.5 Effects of Fatty Acids on Adhesion Molecule Expression in HAOECs 
 
   Figures 4.38-4.40 show the effect of five fatty acids on VCAM-1, ICAM-1 and E-selectin 
expression on unstimulated and LPS-stimulated HAOECs; this is the first time that the 
effects of these selected fatty acids on these cells has been reported. Previous studies on the 
effects of fatty acids on adhesion molecule expression used α-linolenic acid, arachidonic 
acid analogs and linoleic acid (Stuhlmeier et al. 1997; Schleser et al. 2006). It was observed 
that LPS significantly up-regulated VCAM-1 and ICAM-1, but not E-selectin expression in 
HAOECs. None of the fatty acids demonstrated any significant effect on VCAM-1 or E-
selectin expression in the absence of LPS stimulation (P > 0.05). However, ICAM-1 was 
inhibited by DPA (P = 0.001) and DHA (P = 0.001).     
 
Under the optimized experimental conditions, DPA and DHA significantly attenuated 
VCAM-1 expression in HAOECs by almost 90% (both P < 0.001) (Figure 4.38). In addition 
SA significantly enhanced VCAM-1 expression in these cells (314%; P < 0.001).   
 
DPA and DHA also significantly inhibited LPS-induced ICAM-1 in HAOECs, while EPA, 
ARA and SA significantly enhanced the effect of LPS on ICAM-1 in these cells (Figure 
4.39). This stimulatory effect was approx. 20 to 25%.  
 
EPA and SA significantly inhibited LPS-induced E-selectin expression by 31% (P = 0.001) 
and 36% (P < 0.001), respectively whilst DHA enhanced the effect of LPS on E-selectin by 
38% (P < 0.05).  
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FIGURE 4.38: Comparative Effects of Fatty Acids on VCAM-1 Expression in HAOECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, ***P < 
0.001, NS = non-significant. 
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FIGURE 4.39: Comparative Effects of Fatty Acids on ICAM-1 Expression in HAOECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, ***P < 
0.001. 
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FIGURE 4.40: Comparative Effects of Fatty Acids on E-selectin Expression in HAOECs 
Data are expressed as mean ± SEM (n = 3). Significantly different from control, * P < 0.05, 
**P < 0.005, NS = non-significant. 
 
 
Figure 4.41 summarises the effects of the different fatty acids on LPS-induced adhesion 
molecule expression in HAOECs. Clearly there are fatty acid and adhesion molecule 
specific effects in these cells. 
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FIGURE 4.41: Comparative Effects of Fatty Acids on Adhesion Molecules Expression in 
HAOECs 
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4.5 Discussion 
 
   The protective role of LC n-3 PUFAs towards cardiovascular diseases has been known for 
many years (Iso et al. 2001; He et al. 2002; Hu et al. 2002; Albert et al. 1998). Part of this 
protective role may relate to an anti-inflammatory effect at the level of the vessel wall. 
However, support for such a role in vivo is not clear due to conflicting findings on the 
association between plasma inflammatory markers and LC n-3 PUFA exposure. Indeed in 
the studies described in Chapters 2 and 3 of this thesis I found that LC n-3 PUFAs could 
slightly decrease plasma sICAM-1 with no effect on sVCAM-1 or sE-selectin in healthy 
volunteers and in contrast, there were significant decreases in sVCAM-1 and sE-selectin in 
patients with advanced carotid atherosclerosis. In vitro experiments are useful in identifying 
potential effects and for undertaking mechanistic studies and a number of cell culture 
experiments using endothelial cells have investigated the potential anti-inflammatory effect 
of LC n-3 PUFAs on these cells, focusing upon adhesion molecule expression. The 
pioneering work of De Caterina et al. (1994) demonstrated that DHA could decrease 
cytokine-stimulated upregulation of the adhesion molecule VCAM-1 in cultured HSaVECs. 
Further work of this type has focused upon venous endothelial cells, including HSaVECs 
(De Caterina et al. 1996; De Caterina & Libby 1998; De Caterina et al. 1998) and HUVECs 
(Khoulfon et al. 1996; Collie-Duguid & Wahle 1996). Even in the highly controlled in vitro 
environment, conflicting effects of fatty acids have been reported (see Section 1.3.8). In 
addition no studies have examined the effect of fatty acids on adhesion  molecule 
expression in arterial endothelial cells, which is surprising since cardiovascular diseases is 
mainly arterial in its location. Therefore, the aim of the study described in this chapter was 
to identify the effects of individual fatty acids on adhesion molecule expression in a range 
of human venous and arterial endothelial cells. In order to address this aim the conditions of 
endothelial cell culture were first optimized. 
 
 
4.5.1 Optimized Condition for LPS Stimulation 
 
   Prior to the studying the effects of different fatty acids on adhesion molecule expression 
in vitro, endothelial cells were stimulated with LPS at different concentrations and for 
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different incubation times. Initially attempts were made to use flow cytometry to measure 
the expression of adhesion molecules. However this technique was unable to detect 
significant expression perhaps because flow cytometry requires that cells be detached from 
the culture plates and the use of proteases like trypsin to achieve this most likely cleaves 
surface adhesion molecules. Thus, ELISA was used instead to quantify adhesion molecules 
in endothelial cells that were still adherent to tissue culture plates. The work by De Caterina 
et al. used a similar assay (EIA) to measure endothelial adhesion molecules. In the present 
study, the optimum conditions for the expression of VCAM-1, ICAM-1 and E-selectin in 
five endothelial cell types (HUVECs, HUAECs, HCAECs, HSaVECs and HAOECs) were 
determined. For HUVECs, HUAECs, HCAECs and HSaVECs, the optimum conditions for 
LPS stimulation were 1 μg/mL for 12 hours; whereas for HAOECs, LPS concentration at 
10 μg/mL for 12 hours stimulation time was optimal. 
 
For HUVECs, the identified conditions partly agree with those used in several previous 
studies (Khalfoun et al. 1996; Massaro et al. 2002; Carluccio et al. 2003; Holthe et al. 2005) 
in which LPS was used at 1 µg/mL but cells were incubated with LPS for 4 hrs (Massaro et 
al. 2002; Carluccio et al. 2003), 6 hrs (Holthe et al. 2005) or 8 hrs (Khalfoun et al. 1996) 
after pre-incubation with fatty acids. On the other hand, Kalogeris et al. (1999) reported that 
no effect of 1 µg/mL LPS on VCAM-1 expression in HUAECs for 4 hours. However, the 
present study clearly shows that LPS does stimulate VCAM-1 expression and to a lesser 
extent of ICAM-1 and E-selectin on HUAECs after 12 hrs. For HCAECs, my results partly 
agree with Zouki et al. (2000) which used LPS at 1 µg/mL to stimulate ICAM-1 and E-
selectin expression, however these cells were stimulated for 4 hours. Studies with HAOECs 
used much lower LPS concentrations than used here including 0.1 µg/mL (Tummala et al. 
2000) and 0.01 µg/mL (Tsao et al. 1996).  
 
 
4.5.2 Optimized Conditions for Fatty Acid Studies 
 
   In the present study, the optimal conditions for studying the effects of fatty acids were 
identified by preliminary studies using DHA in HUVECs and HAOECs. Inhibitory effects 
were observed at 48 hours pre-incubation with 50 μM DHA followed by stimulation with 
LPS for another 12 hours. These conditions are in general accordance with De Caterina et 
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al. (1994; 1995) who reported that in order to achieve an inhibitory effect of fatty acids, a 
relatively prolonged fatty acid incubation time ranging from 48 to 72 hours before the 
addition of the stimulating cytokines was required. The prolonged incubation time with 
fatty acids is presumably to allow their incorporation into the endothelial cell membranes. 
Indeed De Caterina et al. (1994) found that the incorporation of DHA and ARA reached 
plateau at about 72 hours of incubation at 25 μM concentration. Under the conditions of a 
prolonged fatty acid pre-exposure followed by six hrs stimulation with an inflammatory 
cytokine, DHA in particular exhibited inhibition of VCAM-1 expression. These results 
suggested that fatty acids at a concentration of 50 μM should be used in further 
experiments. 
 
 
4.5.3 Effects of Stearic Acid on Adhesion Molecule Expression 
 
      De Caterina et al. (1998) are the only researchers to have reported the influence of 
saturated fatty acids on adhesion molecule protein expression in cultured endothelial cells; 
they found no effects of palmitic acid or stearic acid on VCAM-1 expression in HSaVECs.  
On this basis they concluded that only unsaturated fatty acids affected adhesion molecule 
expression. In contrast, the current study found that stearic acid did affect adhesion 
molecule expression, and that it had different effects on different cell types and on different 
adhesion molecules. Table 4.1 summarises the effects of all fatty acids tested on all three 
adhesion molecules in all five endothelial cell types. Stearic acid affected VCAM-1 
expression in all five cell types. It attenuated VCAM-1 expression in HUVECs and 
HUAECs, but enhanced VCAM-1 expression in HCAECs, HSaVECs and HAOECs. SA 
affected ICAM-1 expression in only two endothelial cell types: it decreased expression in 
HUAECs and increased expression in HAOECs. Stearic acid increased E-selectin 
expression in HUVECs, HUAECs and HCAECs; and decreased expression in HAOECs. In 
the current study, cells were pre-incubated with stearic acid at 50 μM for 48 hours before 
stimulation with LPS for 12 hours, while De Caterina et al. (1998) used 25 μM stearic acid 
for 72 hours and then stimulated with IL-1α for 12 hours. It is possible that the difference 
between the current findings and those of De Caterina et al. (1998) relate to the higher 
stearic acid concentration used here.  
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The present study is the first to compare fatty acid effects among different types of 
endothelial cells. Table 4.1 indicates that fatty acids have different effects on different cell 
types, despite the generally similar functional characteristics of those cell types.  
 
 
TABLE 4.1: Summary of the Significant Effects of Fatty Acids on LPS-stimulated 
Adhesion Molecule Expression in Endothelial Cells 
 
 Cell  EPA  DPA  DHA  ARA  OA  SA 
1  ↓↓  ↓↓  ↓↓↓  ↓↓  ↓  ↓ 
2  ↓  ↓  ↓↓↓  ↓  ↑  ↑ 
3  ↓↓  ↓↓  ↓↓↓  ↓↓  ↓↓  ↓↓ 
4 -  -  ↓  ↓↓  -  ↑ 
VCAM-1 
5 -  ↓↓↓  ↓↓↓  - NA  ↑↑↑ 
 
1  ↓  ↓  ↓  ↓  - - 
2  - - - - - - 
3  ↓  ↓↓  ↓↓  - - ↓ 
4  - - - - - - 
ICAM-1 
5  ↑  ↓↓↓  ↓↓↓  ↑  NA  ↑ 
 
1  ↓  -  ↓  ↓  ↑  ↑ 
2 -  -  ↓  - - - 
3  ↓  ↓  ↑↑  -  ↑  ↑↑ 
4  - - - - ↑  ↑ 
E-selectin 
5  ↓  -  ↑  - NA ↓ 
1 = HUVECs; 2 = HSaVECs; 3 = HUAECs; 4 = HCAECs; 5 = HAOECs 
NA = not available; ↓↓↓/↑↑↑ = extremely significant; ↓↓/↑↑ = highly significant;  
↓/↑ = significant (P < 0.05) 
 
 
4.5.4 Effects of Oleic Acid on Adhesion Molecule Expression 
 
   In the present study, OA did not affect ICAM-1 expression on any of the four endothelial 
cell types studied (Table 4.1). OA increased E-selectin expression in HUVECs, HUAECs 
and HCAECs, increased VCAM-1 expression in HSaVECs and decreased VCAM-1 
expression ion HUVECs and HUAECs. De Caterina et al. (1998) in their HSaVECs study 
reported that pre-incubation with 50 μM OA for 72 hours and then stimulation with IL-1α 
(1 ng/mL) resulted in modest VCAM-1 inhibition. Carluccio et al. (1999) also demonstrated 
that OA at a higher concentration (100 μM) pre-incubated for 72 hrs followed by 
stimulation with LPS at 1 μg/mL inhibited VCAM-1 and E-selectin expression to a similar 
extent and ICAM-1 to a lesser extent in HSaVECs. Clearly the current study reporting that 
OA increases VCAM-1 and E-selectin in HSaVECs contradicts these earlier findings. 
Holthe et al. (2005) reported no significant effects on the expression of VCAM-1, ICAM-1 
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and E-selectin following 100 μM OA incubated together with LPS (1 μg/mL), either at 6 or 
24 hours in HUVECs. This may due to shorter pre-incubation time as compared to previous 
studies and to the lack of a fatty acid pre-incubation prior to stimulating the cells.  
 
 
4.5.5 Effects of Arachidonic Acid on Adhesion Molecule Expression 
 
   In the present study, ARA attenuated VCAM-1 expression in four endothelial cell types, 
with no effect seen in HAOECs (Table 4.1). However, few effects of ARA were seen for 
ICAM-1 and E-selectin, apart from a reduction in ICAM-1 and E-selectin expression in 
HUVECs (Table 4.1). Using HSaVECs, De Caterina et al. (1998) reported that ARA 
produced significant inhibition of VCAM-1 expression. The current study is in accordance 
with this. Mayer et al. (2002) reported no significant effects of ARA on VCAM-1, ICAM-1 
and E-selectin expression in TNF-α-stimulated HUVECs. In their study, the concentration 
of ARA used was much lower than used here (10 μM) and there was a shorter pre-
incubation time (6 hrs) but a longer exposure to TNF-α (20 hrs). The lower concentration 
and shorter pre-incubation time may account for the differences in results seen.  
 
 
4.5.6 Effects of n-3 PUFAs on Adhesion Molecule Expression 
 
   Three n-3 PUFAs were used in this study: EPA, DPA and DHA. They were found to have 
a different range of effects (Table 4.1) and different potencies. DHA consistently resulted in 
a highly significant reduction in VCAM-1 expression in all endothelial cell types studied, 
and in ICAM-1 in three endothelial cell types and in E-selectin in two endothelial cell types 
(Table 4.1). DPA and EPA also inhibited VCAM-1, ICAM-1 and E-selectin in some of the 
endothelial cell types, but the results clearly showed that among the three n-3 PUFAs 
compared, DHA is the most potent inhibitor of endothelial activation. The effects of EPA 
and DPA were very similar. EPA and DPA contain the same number of double bonds (five) 
but are different chain lengths (20 vs. 22), while DPA and DHA are the same chain length 
(22 carbons) but have different numbers of double bonds (5 vs. 6). Thus, the findings of the 
current study support the contention of De Caterina et al. (1998) that the degree of 
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unsaturation, but not the chain length alone, is important in influencing the inhibition of 
endothelial activation.  
 
Previously, it has been reported that DHA, but not EPA, reduced cytokine-induced adhesion 
molecule expression in HSaVECs (De Caterina et al. 1995). In the current study both EPA 
and DHA inhibited VCAM-1 expression in HSaVECs, but DHA was much more potent. 
This discrepancy in the effect of EPA seen may due to the fatty acid concentration used: 50 
μM in the current study and 10-25 μM in De Caterina et al. (1995).  In support of this, other 
studies have demonstrated a reduction in adhesion molecules in HUVECs by EPA at 65 μM 
(Collie-Duguid et al., 1996) or 30 μM (Khalfoun et al. 1996). Kim et al. (1995) reported 
that EPA at 50-100 μM reduced the expression of VCAM-1, ICAM-1 and E-selectin in 
HUVECs.  
 
Unexpectedly DHA increased E-selectin expression in HUAECs and HAOECs. This may 
suggest a different effect on signaling processes leading to E-selectin expression in these 
particular cells.   
 
In general n-3 PUFAs inhibited LPS-stimulated adhesion molecule expression. This is 
indicative of an anti-inflammatory effect that might come about as a result of inhibiting cell 
signaling processes that result in enhanced gene expression. It is likely that inhibition of 
signaling leading to NF-κB activation is involved (Wahle & Rotondo 1999; Hennig & 
Toborek 2000; De Caterina & Massaro 2005).  
 
 
4.6 Conclusion 
 
   The current study has identified that fatty acids can influence expression of adhesion 
molecules in endothelial cells of venous, arterial and aortic origin. By studying the effects 
of six different fatty acids on expression of three adhesion molecules on five endothelial 
cell types, it has been possible to identify that effects are fatty acid, adhesion molecule and 
endothelial cell specific. VCAM-1 is affected by fatty acids to a greater extent than ICAM-
1 or E-selectin. Cells of venous, arterial and aortic origin can all be affected by fatty acids. 
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Amongst the fatty acids, DHA has the greatest and the most consistent effects, at least 
under the conditions of concentration and timing used here. Differences in findings reported 
in the literature most likely relate to fatty acid concentration and exposure time used, rather 
than cell type. If n-3 fatty acids, particularly DHA behave in vivo in a similar manner to the 
effects seen here in vitro, then a significant anti-inflammatory effect may occur at the 
vascular wall and this might contribute to the protective effect of these fatty acids on CVD. 
The greater potency of DHA than EPA or DPA seen in this study suggests that DHA is a 
very important functional component of fish and of fish oils. Thus functional effects of fish 
oil may not be seen if the amount of DHA provided is insufficient. The identification of an 
important role for DHA is consistent with the conclusion of Chapter 2 in relation to the 
limited impact of the fish oil used in the study described therein.   
 
 
 
 
 
Chapter 5 
 
The Effects of Fatty Acids on the Expression of Adhesion 
Molecule mRNA Levels in Cultured Endothelial Cells 
 
5.1 Introduction 
 
5.1.1 Background of the study 
 
   In Chapter 4, I described the effects of fatty acids on the expression of adhesion molecule 
proteins in cultured human endothelial cells. It was found that fatty acids can affect 
expression of adhesion molecules in endothelial cells and that effects are fatty acid, 
adhesion molecule and endothelial cell specific. My results demonstrated that VCAM-1 is 
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affected by fatty acids to a greater extent than ICAM-1 or E-selectin. Amongst the fatty 
acids studied, DHA had the greatest and the most consistent effects, under the conditions of 
concentration and timing used. The greater potency of DHA rather than EPA or DPA seen 
in this study suggests that DHA is an important functional component of fish and of fish oil 
in the diet. Therefore, functional effects of fish oil in vivo may not be seen if the amount of 
DHA provided is insufficient. The identification of an important role for DHA is consistent 
with the conclusion of Chapter 2 in relation to the limited impact of the fish oil used in the 
study described therein.   
 
 
Evidence illustrates that selected fatty acids can stimulate inflammatory responses through 
the transcriptional regulation of inflammatory genes, for example, genes encoding for 
adhesion molecules and inflammatory cytokines (Toborek et al. 1998). Since fatty acids 
may be released by triacylglycerol hydrolysis at the vascular endothelium by the action of  
lipoprotein lipase, endothelial cells can be directly exposed to high concentrations of free 
fatty acids (Zilversmit et al. 1973). It has been reported that n-3 PUFAs, particularly EPA 
and DHA inhibit migration of inflammatory cells into local tissue by down regulating 
adhesion molecule expression (VCAM-1, ICAM-1, E-selectin) and monocyte adherence to 
the vascular endothelium (Hughes et al. 1996). The effects of these fatty acids involve 
several mechanisms including actions on signal transduction and on gene expression 
(Grimm et al. 2002; De Caterina et al. 1994; Collie-Duguid et al. 1996; Wahle et al. 1999).  
 
The present study is an extension of the previous work on the effects of fatty acids on 
endothelial inflammatory protein expression as described in Chapter 4. Previously, in vitro 
work of this sort has mostly focused on protein expression (De Caterina et al. 1995; Holthe 
et al. 2005; ReiBig et al. 2003; Khalfoun et al. 1996), although there have been a limited 
number of studies which have investigated the effect of fatty acids on pro-inflammatory 
gene expression (De Caterina et al. 1996; Huang et al. 1997; Holthe et al. 2005; Shaw et al. 
2007). The outcomes however, were reported to be inconsistent. This may due to many 
experimental variables, such as the type and concentration of fatty acid used and incubation 
time with fatty acid, type of stimulus used and its concentration, duration of exposure to 
stimulant, and type of endothelial cell studied. These factors differ considerably between 
studies, making comparisons between them difficult. Moreover, the methods used were also 
varied, from flow cytometry for determination at the protein level to polymerase chain 
reaction (PCR), for assessing the expression at the genomic level. Based on the pioneering 
in vitro studies using HSaVECs, it has been concluded that a minimum of single double 
bond is required for fatty acids to inhibit adhesion molecule expression (therefore saturated 
fatty acids are inactive); it was also concluded that the effectiveness does not depend on the 
chain length and the degree of effectiveness increases correspondingly with unsaturation 
(double bond insertion) (De Caterina et al. 1998). However, some of my findings in Chapter 
4 dispute this conclusion. Therefore, in order to further explore the inhibition
 of adhesion 
molecules production by selected fatty acids at the transcriptional level, I
 studied mRNA 
expression using real-time reverse transcriptase PCR. The main aim of the present study 
was to provide a systematic investigation of the comparative effects of fatty acids on 
adhesion molecule expression at the mRNA level using different types of endothelial cells. 
 
 5.2 Aim of this Study 
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   The aim of this study was to identify the effects of individual fatty acids on endothelial 
cell adhesion molecule mRNA levels and to compare this with results on protein expression 
(as described in Chapter 4). To investigate this aim, different endothelial cell types were 
used under similar experimental conditions and the expression of genes encoding a number 
of inflammatory proteins was assessed by reverse transcription and quantitative real time 
polymerase chain reaction (real-time-PCR). The objectives of the experiments were: 
 
• To compare the effect of individual fatty acids (EPA, DPA, DHA, arachidonic acid 
(ARA), oleic acid (OA) and stearic acid (SA)) on VCAM-1 mRNA levels in five different 
endothelial cell types (HUVECs, HUAECs, HCAECs, HSaVECs and HAOECs); 
 
•  To compare the effect of individual fatty acids on ICAM-1 mRNA levels in five different 
endothelial cell types; 
 
• To compare the effect of individual fatty acids on E-selectin mRNA levels in five 
different endothelial cell types. 
 
 
5.3 Methods 
 
5.3.1 Reagents 
 
   Sodium salts of EPA, DPA, DHA, ARA, OA and SA were from Sigma-Aldrich, Poole 
and each was dissolved in ethanol to prepare 100 mM fatty acid stock solutions at room 
temperature or at 37
o C, to overcome fatty acid insolubility in aqueous solution. Endothelial 
cell growth media were from PromoCell, Heidelberg and ECACC, Salisbury (only for 
HAOECs). Cell detaching solution (HepesBSS: 30 mM Hepes, D-glucose, NaCl, KCl, 
NaPhosphate, Phenol red), trypsin/EDTA solution and soybean trypsin neutralizing solution 
from soybean (0.05%) were from PromoCell, Heidelberg.  The antibiotics penicillin and 
streptomycin were from PAA Laboratories, Somerset, UK. Trizol was from Invitrogen, 
Paisley. Chloroform and ethanol were from BDH Laboratory, Poole and isopropanol was 
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from Sigma, Dorset. RT-PCR reagents were from Promega, Madison and PCR reagents 
were from PrimerDesign, Southampton. 
 
 
5.3.2 Experimental Design 
 
   In order to determine a possible stimulatory effect of fatty acids at the mRNA level, 
endothelial cells were pre-incubated with fatty acids at 50 μM for 48 hours. Then the cells 
were stimulated with LPS at 1 μg/mL for 12 hours. This optimum experimental condition 
was chosen based on my previous preliminary results (See Section 4.3.3). Endothelial cells 
of HUVECs, HUAECs, HSaVECs and HCAECs were purchased from PromoCell, 
Heidelberg, whereas HAOECs were from European Collection of Cell Culture (ECACC), 
Salisbury. The cells were thawed and subcultured following the supplier’s instructions. 
Prior to use in experiments, cells at passage four were grown in 6-well plates until 
confluence.  
 
 
5.3.3 Isolation of RNA 
 
   Following manufacturer’s instructions, endothelial cell cultures were lysed by the direct 
addition of 1 mL trizol reagent and the cell lysate was passed several times with a pipette to 
form a homogenous lysate. Then the phases were separated by adding 0.2 mL chloroform 
per 1 mL trizol and RNA was precipitated from the top aqueous layer by adding to 0.5 mL 
isopropanol before washing with 70% ethanol. At the end of the procedure, the RNA was 
redissolved in RNase-free water. The concentration and purity of total RNA were 
determined by measuring the absorbance at 260 nm (one absorbance unit at 260 nm equals 
40 μg RNA/mL) and 280 nm using a Nano Drop 1000 Spectrophotometer (Thermo Fisher 
Scientific, USA). The ratio between the absorbance at 260 and 280 nm reflects RNA purity 
and value should be more than 1.7.  
 
 
5.3.4 Synthesis of cDNA 
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   cDNA was generated from isolated RNA by heating to 70 
oC for 5 min (reaction volume 
15  μL) in the presence of random primers (400 ng) and subsequently was reverse 
transcribed using mixture reagents of 5 μL RT Buffer (5 x concentration), 1.25 μL dNTPs 
(PCR MIX 10 mM, Promega), 0.625 μL RNAsin (40 u/µL) and 1 μL M-MLV 
Transcriptase (200 u/µL) (reaction volume 10 μL). The samples were loaded into a Hybaid 
Thermal Reactor and the program used was 1 hour at 37 
oC, followed by 10 min at 42 
oC 
and 10 min at 75 
oC.   
 
 
5.3.5 Real Time RT-PCR 
 
   The sequences of primers are as follows:  
VCAM-1 forward primer: 5’-CAGGCTAAGTTACATATTGATGACAT-3’  
VCAM-1 reverse primer: 5’-GAGGAAGGGCTGACCAAGAC-3’  
ICAM-1 forward primer: 5’-CCTATGGCAACGACTCCTTC-3’  
ICAM-1 reverse primer: 5’-TCTCCTGGCTCTGGTTCC-3’ 
E-selectin forward primer: 5’-TTCTTGCCTACTATGCCAGATG-3’  
E-selectin reverse primer: 5’-AGGAAAGGGAACACTGAGTCT-3’  
with the accession numbers NM_001078, NM_000201 and NM_000450, respectively. The 
following primers were then obtained from PrimerDesign Ltd (Southampton, UK): VCAM-
1 PerfectProbe CGAACCCAAACAAAGGCAGAGTACGCAAACACggttcg 
ICAM-1 PerfectProbe CTGGGTGCCCTCGTCCTCTCGGGccag  
E-selectin PerfectProbe AACCGCAACACCCATCACCACTTCAATAAgcggtt.  
 
Real time RT-PCR was performed using Absolute QPCR SYBR Green PCR Master Mix 
(ABgene, Epsom, UK) for β-actin and PerfectProbe for VCAM-1, ICAM-1 and E-selectin 
using a 7500 Fast Real time PCR system (Applied Biosystems, Foster City, CA). The PCR 
was run for 10 min at 95 
oC followed by 50 cycles of 15 sec at 95 
oC, 30 sec at 50 
oC and 15 
sec at 72 
oC (for VCAM-1, ICAM-1 and E-selectin), whereas the program for β-actin: 2 
min at 50 
oC followed by 40 cycles of 10 min at 95 
oC, 15 sec at 95 
oC and 1 min at 60 
oC. 
After amplification, melting curve analysis was performed to verify specificity of the 
reactions with SYBR Green. The end point used in the real time RT-PCR quantification, Ct, 
was defined as the PCR cycle number at which threshold fluorescence was reached. A 
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standard curve was constructed using stock cDNA from HCAECs in a series of dilutions. 
The expression of β-actin and of each target gene of cDNA in each sample was quantified 
against a standard curve by allowing the software to determine the sample units accurately.  
Then the expression of each target gene was normalized to β-actin expression, whereby 
relative adhesion molecule production units were expressed as arbitrary units, calculating 
according to the following formula:  
relative adhesion molecule production units = sample adhesion units/sample β-actin units. 
 
 
5.3.6 Statistical Analysis 
 
   Data were analyzed using SPSS Version 16.0 (SPSS Inc., Chicago, IL) and results were 
presented as means ± SEM. The statistical significance of differences (P < 0.05) was 
determined using unpaired two-tailed Student t-test with GraphPad Software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 Results 
 
5.4.1 Effects of Fatty Acids on Adhesion Molecule mRNA Levels in HUVECs   
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   Figures 5.1-5.3 show the effects of five fatty acids (50 μM) on VCAM-1, ICAM-1 and E-
selectin expression on unstimulated and LPS-stimulated HUVECs; no data are shown for 
DHA because it was not possible to recover mRNA from HUVECs after exposure to DHA. 
HUVECs were cultured with the fatty acids for 48 hrs and then with LPS for a further 12 
hrs. Adhesion molecule mRNA was hardly detectable
 in unstimulated endothelial cells. 
However, LPS significantly up-regulated adhesion molecule mRNA levels in HUVECs (P 
< 0.05 vs. unstimulated cells).  
 
Under the experimental conditions used EPA, OA (both at P < 0.01) and SA (P < 0.001) 
significantly attenuated VCAM-1 mRNA levels in HUVECs, indicating possible regulation 
by these fatty acids at the transcriptional level.
 Interestingly, SA was found to exert the 
greatest inhibitory effect (average 62%), followed by EPA (40%) and OA (31%).  DPA and 
ARA had no significant effect on VCAM-1 mRNA levels in HUVECs. 
 
EPA (P < 0.01), OA and SA (both at P < 0.05) significantly inhibited LPS-induced ICAM-1 
mRNA levels by 56%, 55% and 46%, respectively (Figure 5.2). As seen for VCAM-1 
mRNA, DPA and ARA showed no significant effects on ICAM-1 mRNA levels (P > 0.05).  
 
EPA, DPA, ARA and SA all significantly inhibited LPS-stimulated E-selectin mRNA 
levels in HUVECs (all P < 0.001); inhibition was by 62%, 20%, 62% and 53%, respectively 
(Figure 5.3). Only OA was without effect. 
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FIGURE 5.1: Effects of Fatty Acids on VCAM-1 mRNA Levels in HUVECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, **P < 
0.005, ***P < 0.001, NS = non-significant. 
 
 
 
Effects of fatty acids on the ICAM-1 mRNA levels in 
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FIGURE 5.2: Effects of Fatty Acids on ICAM-1 mRNA Levels in HUVECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, * P < 0.05, 
**P < 0.005, NS = non-significant. 
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Effects of fatty acids on the E-selectin mRNA levels in 
HUVECs
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Control EPA DPA ARA OA SA
E
-
s
e
l
e
c
t
i
n
 
m
R
N
A
 
l
e
v
e
l
(
r
e
l
a
t
i
v
e
 
t
o
 
b
-
a
c
t
i
n
)
Stimulated with LPS Unstimulated
 
***
***
***
*** 
NS
FIGURE 5.3: Effects of Fatty Acids on E-selectin mRNA Levels in HUVECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, ***P < 
0.001, NS = non-significant. 
 
Thus certain fatty acids were able to inhibit LPS-induced expression of VCAM-1, ICAM-1 
and E-selectin at the mRNA levels in HUVECs. Figure 5.4 attempts to summarise the 
pattern of inhibition seen across all fatty acids and all three adhesion molecules; this figure 
demonstrates that a similar pattern of effects of fatty acids was seen, although the extent of 
the effect of a given fatty acid was different according to the adhesion molecule mRNA 
studied. EPA and SA were consistently shown to be the most potent fatty acid inhibitors for 
the three adhesion molecules studied.  
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Effects of fatty acids on the LPS-induced adhesion molecule mRNA levels 
in HUVECs
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FIGURE 5.4: Comparative Effects of Fatty Acids on Adhesion Molecules mRNA Levels in 
HUVECs (Relative to Control) 
 
 
5.4.2 Effects of Fatty Acids on Adhesion Molecule mRNA Levels in HUAECs 
 
  Figures 5.5-5.7 show the effects of five fatty acids (50 μM) on VCAM-1, ICAM-1 and E-
selectin mRNA levels on unstimulated and LPS-stimulated HUAECs; no data are shown for 
DHA because it was not possible to recover mRNA from HUAECs after exposure to DHA. 
HUAECs were cultured with the fatty acids for 48 hrs and then with LPS for a further 12 
hrs. Adhesion molecule mRNA was hardly detectable
 in unstimulated endothelial cells. 
However, LPS significantly up-regulated adhesion molecule mRNA levels in HUAECs (P 
< 0.05 vs. unstimulated cells).  
 
Under the experimental conditions used EPA, DPA (both at P < 0.01) and SA (P = 0.05) 
significantly attenuated VCAM-1 mRNA levels in HUAECs, indicating regulation by these 
fatty acids at the transcriptional level (Figure 5.5).
 EPA was found to exert the greatest 
inhibitory effect (average 80%), followed by DPA (72%) and SA (47%).  ARA and OA had 
no significant effect on VCAM-1 mRNA evels in HUAECs. 
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EPA, DPA (both at P < 0.01) and OA (P < 0.001) significantly inhibited LPS-induced 
ICAM-1 mRNA levels in HUAECs by 52%, 66% and 53%, respectively (Figure 5.6). As 
seen for VCAM-1 mRNA, ARA showed no significant effect on ICAM-1 mRNA levels (P 
> 0.05). SA tended to increase LPS-induced ICAM-1 mRNA levels (by 78%) but the effect 
did not reach statistical significance. 
 
Only EPA and ARA significantly inhibited LPS-stimulated E-selectin mRNA levels in 
HUAECs (both P < 0.001); inhibition was by 60% and 46%, respectively (Figure 5.7).  
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FIGURE 5.5:  Effects of Fatty Acids on VCAM-1 mRNA Levels in HUAECs. 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, * P < 0.05, 
**P < 0.005, NS = non-significant. 
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Effects of fatty acids on the ICAM-1 mRNA levels in 
HUAECs
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FIGURE 5.6: Effects of Fatty Acids on ICAM-1 mRNA Levels in HUAECs  
Data are expressed as mean ± SEM (n = 2). Significantly different from control, **P < 
0.005, ***P < 0.001, NS = non-significant. 
 
 
Effects of fatty acids on the E-selectin mRNA levels in 
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FIGURE 5.7: Effects of Fatty Acids on E-selectin mRNA Levels in HUAECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, ***P < 
0.001, NS = non-significant. 
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Thus only EPA inhibited mRNA levels of all three adhesion molecules in HUAECs (Figure 
5.8). 
 
Effects of fatty acids on the LPS-induced adhesion molecule mRNA levels 
in HUAECs
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FIGURE 5.8: Comparative Effects of Fatty Acids on Adhesion Molecules mRNA Levels in 
HUAECs (Relative to Control) 
 
 
5.4.3 Effects of Fatty Acids on Adhesion Molecule mRNA Levels in HCAECs 
 
  Figures 5.9-5.11 show the effects of six fatty acids (50 μM) on VCAM-1, ICAM-1 and E-
selectin mRNA levels on unstimulated and LPS-stimulated HCAECs. HCAECs were 
cultured with the fatty acids for 48 hrs and then with LPS for a further 12 hrs. Low levels of 
adhesion molecule mRNA were detectable
 in unstimulated HCAECs but these were not 
affected by any of the fatty acids. LPS significantly up-regulated adhesion molecule mRNA 
levels in HCAECs (P < 0.05 vs. unstimulated cells).  
 
Under the experimental conditions used none of the fatty acids significantly affected 
VCAM-1 mRNA levels in HCAECs, although EPA and DHA tended to decrease (by 83% 
and 68%, respectively) and ARA tended to increase it. A similar set of findings was made 
for ICAM-1 mRNA in HCAECs as seen for VCAM-1 mRNA (Figure 5.10). Once again, 
EPA and DHA, and also SA, tended to decrease mRNA levels (by 93%, 89% and 67%, 
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respectively) and ARA tended to increase it, but these effects were not significant. 
However, the inhibition of E-selectin mRNA levels seen for EPA, DPA and OA in 
HCAECs was significant (Figure 5.11). Reductions were by 94% (P = 0.0018), 78% (P = 
0.0033) and 73% (P = 0.0488), respectively. 
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FIGURE 5.9: Effects of Fatty Acids on VCAM-1 mRNA Levels in HCAECs 
          Data are expressed as mean ± SEM (n = 2). NS = non-significant. 
 
Effects of fatty acids on the ICAM-1 mRNA levels in 
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FIGURE 5.10: Effects of Fatty Acids on ICAM-1 mRNA Levels in HCAECs 
Data are expressed as mean ± SEM (n = 2). NS = non-significant. 
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Effects of fatty acids on the E-selectin mRNA levels in 
HCAECs
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FIGURE 5.11: Effects of Fatty Acids on E-selectin mRNA Levels in HCAECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, * P < 0.05, 
**P < 0.005, NS = non-significant. 
 
   Figure 5.12 indicates that EPA and DPA caused a similar degree of inhibition of LPS-
induced mRNA for all three adhesion molecules and that the effects of these two fatty acids 
were near identical. The figure also shows the limited impact of DHA and of the other fatty 
acids studied.  
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FIGURE 5.12: Comparative Effects of Fatty Acids on Adhesion Molecules mRNA Levels 
in HCAECs (Relative to Control) 
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5.4.4 Effects of Fatty Acids on Adhesion Molecule mRNA Levels in HSaVECs 
 
  Figures 5.13-5.15 show the effects of six fatty acids (50 μM) on VCAM-1, ICAM-1 and 
E-selectin mRNA levels on unstimulated and LPS-stimulated HSaVECs. HSaVECs were 
cultured with the fatty acids for 48 hrs and then with LPS for a further 12 hrs. Low levels of 
adhesion molecule mRNA were detectable
 in unstimulated HSaVECs but these were not 
affected by any of the fatty acids. LPS significantly up-regulated adhesion molecule mRNA 
levels in HUAECs (P < 0.05 vs. unstimulated cells).  
 
Under the experimental conditions used EPA, DPA, DHA and ARA all significantly 
inhibited LPS-induced VCAM-1 mRNA levels in HSaVECs (Figure 5.13). DHA was found 
to exert the greatest inhibitory effect (average 86%; P = 0.0011), followed by ARA (72%; P 
= 0.0019), EPA (68%; P = 0.0013) and DPA (52%; P = 0.0131).  OA and SA had no 
significant effect on VCAM-1 mRNA levels in HSaVECs. 
 
Only EPA and DHA inhibited ICAM-1 mRNA levels in HSaVECs (Figure 5.14). Inhibition 
was by 54% (P = 0.0042) and 61% (P = 0.0064), respectively. SA significantly enhanced 
the effect of LPS on ICAM-1 in HSaVECs, increasing mRNA levels by 262% (P = 0.0002).   
 
EPA, DPA, DHA and ARA all inhibited LPS-induced E-selectin mRNA levels with 
decreases of 43% (P = 0.0123), 23% (P = 0.0313), 28% (P = 0.0678) and 48% (P = 0.0012), 
respectively. Once again, SA tended to enhance mRNA levels in this case by 37%, though 
this was not significant. 
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Effects of fatty acids on the VCAM-1 mRNA levels in 
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FIGURE 5.13: Effects of Fatty Acids on VCAM-1 mRNA Levels in HSaVECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, * P < 0.05, 
**P < 0.005, NS = non-significant. 
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FIGURE 5.14: Effects of Fatty Acids on ICAM-1 mRNA Levels in HSaVECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, **P < 
0.005, NS = non-significant. 
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Effects of fatty acids on the E-selectin mRNA levels in 
HSaVECs
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FIGURE 5.15: Effects of Fatty Acids on E-selectin mRNA Levels in HSaVECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control * P < 0.05, 
**P < 0.005, NS = non-significant. 
 
   Figure  5.16  indicates  that DHA, EPA and DPA all caused a fairly similar degree of 
inhibition of LPS-induced mRNA for all three adhesion molecules, with DHA being 
slightly more potent. The figure also shows the adhesion molecule specific effects of the 
other fatty acids.   
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  FIGURE 5.16: Comparative Effects of Fatty Acids on Adhesion Molecules mRNA 
Levels in HSaVECs (Relative to Control) 
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5.4.5 Effects of Fatty Acids on Adhesion Molecule mRNA Levels in HAOECs 
 
  Figures 5.17-5.19 show the effects of four fatty acids (50 μM) on VCAM-1, ICAM-1 and 
E-selectin mRNA levels on unstimulated and LPS-stimulated HAOECs; no data are shown 
for DPA and DHA because no mRNA could be isolated from these cells after culture with 
these two fatty acids. HAOECs were cultured with the fatty acids for 48 hrs and then with 
LPS for a further 12 hrs. Low levels of adhesion molecule mRNA were detectable
  in 
unstimulated HAOECs. These were not affected by EPA, ARA or SA, but OA induced 
expression of mRNA for all three adhesion molecules. LPS significantly up-regulated 
adhesion molecule mRNA levels in HAOECs (P < 0.05 vs. unstimulated cells).  
 
Under the experimental conditions used none of the four fatty acids for which data are 
available inhibited levels of mRNA for any of the three adhesion molecules, although EPA 
and ARA showed a strong tendency to decrease VCAM-1, ICAM-1 and E-selectin. In 
contrast SA significantly increased LPS-induced ICAM-1 mRNA and had a tendency to 
increase E-selectin 
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FIGURE 5.17: Effects of Fatty Acids on VCAM-1 mRNA Levels in HAOECs 
         Data are expressed as mean ± SEM (n = 2). NS = non-significant. 
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Effects of fatty acids on the ICAM-1 mRNA levels in 
HAOECs
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FIGURE 5.18: Effects of Fatty Acids on ICAM-1 mRNA Levels in HAOECs 
Data are expressed as mean ± SEM (n = 2). Significantly different from control, * P < 0.05, 
NS = non-significant. 
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FIGURE 5.19: Effects of Fatty Acids on E-selectin mRNA Levels in HAOECs 
Data are expressed as mean ± SEM (n = 2). NS = non-significant. 
 
Figure 5.20 indicates a general lack of effect of the fatty acids tested on adhesion molecule 
mRNA levels in HAOECs.  
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Effects of fatty acids on the LPS-induced adhesion molecule mRNA levels 
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FIGURE 5.20: Comparative Effects of Fatty Acids on Adhesion Molecules mRNA Levels 
in HAOECs (Relative to Control) 
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5.5 Discussion 
 
      Long chain fatty acids, particularly mono- and polyunsaturated 18-carbon fatty acids, 
provide a unique model for studying the cellular effects of fatty acids that differ in 
unsaturation whilst retaining the same carbon length (Toborek & Hennig 1994). Almost all 
of the currently available data on the effects of fatty acids on adhesion molecule expression 
has been obtained with venous endothelial cells. Apparent differences in leukocyte 
adhesiveness to the arterial and the venous endothelium under inflammatory conditions in 
vivo, suggest that the venous enodothelium is more adhesive for leukocytes (particularly 
neutrophils) than arterial endothelium (Granger & Kubes 1994). Thus there may be 
different components to the leukocyte-endothelium interaction within veins and arteries and 
these may be regulated differently. Therefore it is important to study potential regulators at 
both sites and to do this under similar experimental conditions.  
 
In the present study, similar conditions were used for studying the effects of fatty acids as 
those that had been identified as optimal for the previous study of protein expression (as 
described in Chapter 4). Endothelial cells were pre-incubated with fatty acids at 50 μM for 
48 hours and then stimulated for 12 hours with LPS at a concentration of 1 μg/mL. Even 
though the expression of E-selectin occurred much earlier and to a greater extent than 
VCAM-1 and ICAM-1, Sawa and Tsuruga (2008) showed that increased mRNA expression 
in LPS stimulated endothelial cells only reached a plateau after 48 hours of stimulation. My 
study clearly shows markedly enhanced expression of all three adhesion molecule mRNAs 
in all five endothelial cells by LPS under the conditions used here.  
 
 
5.5.1 Effects of Saturated Stearic Acid on Adhesion Molecule mRNA Levels 
 
   Until recently, De Caterina et al. (1998) were the only researchers to have reported the 
influence of saturated fatty acids on adhesion molecule expression in cultured endothelial 
cells; they found no effects of palmitic acid or SA on VCAM-1 mRNA expression in 
HSaVECs stimulated with IL-1α.  In contrast, in the present study, I found that SA can 
affect adhesion molecule mRNA expression, but that it had different effects on different cell 
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types and on different adhesion molecules.  Table 5.1 shows that the effects of SA on 
endothelial cells adhesion molecule mRNA expression were varied. I found that SA has an 
inhibitory effect on LPS-induced VCAM-1, ICAM-1 and E-selectin expression at the 
mRNA level in HUVECs. However, SA attenuated only VCAM-1 mRNA expression in 
HUAECs by 47% whereas in contrast, SA increased ICAM-1 (by 262%) and E-selectin (by 
37%) mRNA levels in HSaVECs. No effects of SA on adhesion molecule mRNA 
expression in HCAECs and HAOECs were observed.  
 
Apart from De Caterina et al. (1998) who studied SA and VCAM-1 mRNA in HSaVECs, 
this is the first study to investigate the effects of SA on adhesion molecule mRNA levels in 
endothelial cells. Shaw et al. (2007) in their study of comparative effects of fatty acids 
reported that the saturated fatty acid palmitate enhanced E-selectin mRNA levels in 
HUVECs. Their findings were consistent with those of Stentz et al. (2006) who found that 
palmitic acid increased E-selectin cell surface expression in HAOECs even though other 
studies demonstrated no effect (Holthe et al. 2005; ReiBig et al. 2003). None of these more 
recent studies examined the effect of SA. 
 
My findings do not support the theory that the presence of a double bond within the 
structure of a fatty acid is a necessary requirement for alteration in endothelial function as 
suggested by De Caterina et al. (1998) which was further supported by Carluccio et al. 
(1999). Indeed, I observed that SA exerted anti-inflammatory effects in HUVECs and, to a 
lesser extent in HUAECs, but was associated with pro-inflammatory effects in HSaVECs. 
Dichtl et al. (2002) reported that palmitic acid induced VCAM-1 and MCP-1 gene 
expression in HUVECs.  
 
Importantly, since the present study is the first one using different types of endothelial cells, 
I found that fatty acids do not necessarily influence endothelial inflammatory gene 
expression in a similar direction.  Furthermore, although previous work has suggested the 
degree of fatty acid unsaturation was positively associated with inhibition of cytokine-
induced endothelial activation as assessed by cell surface protein expression, my findings 
on the effects on endothelial mRNA levels do not accord with this paradigm.  In terms of 
the effect of saturated fatty acids on the expression of adhesion molecule mRNA, the 
present work shows that SA can have down-regulatory effects on the expression of some 
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inflammatory genes in some cells, while having neutral (no significant effect) or up-
regulatory effects on genes associated with inflammation in other cells.   
 
 
TABLE 5.1: Summary of the Significant Effects of Fatty Acids on LPS-stimulated mRNA 
Adhesion Molecule Levels in Endothelial Cells 
 
 Cell  EPA  DPA  DHA  ARA  OA  SA 
1  ↓  ↔ NA ↔  ↓  ↓↓ 
2  ↓  ↔  ↓  ↔  ↔  ↔ 
3  ↓↓  ↓  NA  ↓  ↔  ↓ 
4  ↔  ↓↓  ↔  ↔  ↔  ↔ 
VCAM-1 
5  ↔ NA  NA ↔  ↔  ↔ 
 
1  ↓  ↔ - ↔  ↓  ↓ 
2  ↓  ↔  ↓  ↔  ↔  ↑ 
3  ↓  ↓  -  ↔  ↓  ↔ 
4  ↔  ↓↓  ↔  ↔  ↔  ↔ 
ICAM-1 
5  ↔ NA  NA ↔  ↔  ↑ 
 
1  ↓  ↓  -  ↓  ↔  ↓ 
2  ↓  ↓  ↓  ↓  ↔  ↑ 
3  ↓  ↔ -  ↓  ↔  ↔ 
4  ↓↓  ↓↓  ↔  ↔  ↓  ↔ 
E-selectin 
5  ↔ NA  NA ↔  ↔  ↔ 
1 = HUVECs; 2 = HSaVECs; 3 = HUAECs; 4 = HCAECs; 5 = HAOECs 
NA = not available; ↓↓↓/ ↑↑↑ = extremely significant; ↓↓/ ↑↑ = highly significant; ↓/ ↑ = 
significant (P < 0.05). Student’s T-test between control and fatty acid treatment was used to 
determine any significant level (P < 0.05). NA = data not available. 
 
 
 
5.5.2 Effects of Monounsaturated Oleic Acid on Adhesion Molecule mRNA Levels 
 
   In the present study, I found that OA can affect adhesion molecule expression, but that it 
has different effects on different cell types and on different adhesion molecules as shown in 
Table 5.1. I found that VCAM-1 and ICAM-1 mRNA levels were inhibited significantly by 
OA in HUVECs. In HUAECs, attenuation was only significant on ICAM-1 mRNA 
expression. OA did not have significant effects on other endothelial cells.  De Caterina et al. 
(1998) reported that treatment of HSaVECs with OA resulted in pronounced reduction (> 
50%, as assessed by Northern analysis) in VCAM-1 mRNA, suggesting that the effect of 
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OA on VCAM-1 is not only seen at the protein level, but also involves a pre-translational 
process. Carluccio et al. (1999) also reported reduced VCAM-1 mRNA expression with OA 
(10, 50, 100 μM) in HUVECs, whereas decreased ICAM-1 mRNA level was demonstrated 
in HUVECs (incubated with 60 and 90 μM OA for 24 hours)  (Toborek et al. 2002). 
However, Shaw et al. (2007) indicated that OA (at 10, 25, 100 μM and incubated for 6 and 
24 hours) caused increased expression of VCAM-1 mRNA in TNF-α-stimulated HUVECs. 
Their findings were further supported by the observed up-regulation of NF-κB expression 
after incubation with this fatty acid. This is in agreement with Park et al. (2003) who used 
much higher concentrations of 150, 300 and 450 μM OA (incubated for 24 hours) in 
HAOECs. In my study using HAOECs, VCAM-1, ICAM-1 and E-selectin were induced 
significantly by OA in unstimulated cells. The present work is the first to report the 
inhibitory effect of OA on E-selectin mRNA expression which was only shown in 
HCAECs.  
 
Upregulation of adhesion molecules on endothelial cells is considered to be a key part of 
inflammatory conditions including atherosclerosis (Ross 1999). The Mediterranean diet is 
believed to protect against atherosclerosis and other inflammatory conditions (de Lorgeril & 
Salen 2008; Carluccio et al. 2007; Perona et al. 2006; Massaro & De Caterina 2002).  Olive 
oil, which contains OA, is the major culinary fat used in the Mediterranean diet and is 
believed to contribute to the protective effect of that diet. It is possible part of the benefits 
of the Mediterranean diet are mediated by the anti-inflammatory effects of OA seen here 
with respect to down-regulating inflammation-triggered adhesion molecule gene 
expression. 
 
 
5.5.3 Effects of n-6 Arachidonic Acid on Adhesion Molecule mRNA Levels 
 
   Table 5.1 shows that exposure of endothelial cells to ARA attenuated E-selectin mRNA 
expression in HUVECs, HUAECS and HSaVECs. No significant effect of ARA on ICAM-
1 mRNA expression was found, whereas VCAM-1 mRNA expression was inhibited in 
HUAECs. These findings are in accordance with Stuhlmeier et al. (1996) which reported 
that ARA attenuated ICAM-1 and E-selectin mRNA expression, but not VCAM-1 mRNA, 
in porcine aortic endothelial cells. Khalfoun et al. (1996) reported no effect on adhesion 
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molecule (VCAM-1, ICAM-1 and E-selectin) expression in HUVECs with 150-300 μM 
ARA. De Caterina et al. (1998) demonstrated that ARA decreased VCAM-1 protein 
expression (mRNA data was not available) in HSaVECs and that the effect was much 
greater compared with OA. I also demonstrated that ARA consistently attenuated VCAM-1 
protein expression (as assessed by ELISA) (see Section 4.5.5), but it appears that the effect 
does not involve a change in transcription. 
 
 
5.5.4 Effects of n-3 PUFAs on Adhesion Molecule mRNA Levels 
 
   n-3 Fatty acids, particularly EPA and DHA, are currently receiving remarkable attention 
as potential anti-atherogenic and anti-inflammatory substances. In Chapter 4, I reported that 
n-3 fatty acids exhibited pronounced inhibitory effects on the surface adhesion molecule 
protein expression as determine by ELISA. In the present study, treatment of endothelial 
cells with EPA consistently resulted in a pronounced inhibition of VCAM-1, ICAM-1 and 
E-selectin mRNA in HUVECs, HUAECs and HSaVECs (Table 5.1). Furthermore 
inhibitory effects of EPA were seen in HCAECs and HAOECs, but these results were not 
significant, except for E-selectin mRNA expression in HCAECs. This lack of significance 
is most likely due to having too few samples; thus this experiment should be repeated with 
more samples to confirm the precise effect of EPA. Figure 5.21 shows the percent of 
inhibition seen with EPA on LPS-stimulated endothelial cells (only significant results). It is 
clear that EPA has a fairly similar inhibitory effect (approx. 50%) on all three adhesion 
molecules (at the mRNA level) in all three cell types shown. This effect is consistent with 
what was seen in Chapter 4 for the effect of EPA on adhesion molecule proteins.  
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FIGURE 5.21: Comparison of % Inhibitory Effects of EPA on Adhesion Molecule mRNA 
Levels 
 
In HSaVECs, VCAM-1, ICAM-1 and E-selectin mRNA expression were attenuated by 
DHA but no significant effect of this fatty acid was observed on HCAECs. DPA, decreased 
VCAM-1 and ICAM-1 mRNA expression in HUAECs, whereas E-selectin mRNA 
expression was inhibited in HUVECs and HSaVECs. Unfortunately, I was not able to 
obtain complete data for the effects of DHA on all five different types of endothelial cells. 
It is not clear why sufficient mRNA was not obtained from HUVECs, HUAECs and 
HAOECs following DHA treatment. In the experiments described in Chapter 4, I was able 
to gather protein data (as assessed by ELISA) on the effect of fatty acids, including DHA on 
adhesion molecule expression in all cell types. Thus the cells were viable. The fatty acid 
concentration used in the present study was 50 μM, compared with 20, 25 and 65 μM used 
by others (Weber et al. 1995; De Caterina et al. 1998; Collie-Duguid & Wahle 1996). Thus 
the DHA concentration I used is not likely to have been responsible. Future work should try 
to understand what is happening when these cells are exposed to DHA.  
 
Among the three n-3 PUFAs studied, EPA appears to be the most potent inhibitor of 
endothelial activation. De Caterina’s group first reported the effects of n-3 fatty acids on 
adhesion molecule expression, both at the protein (flow cytometry) and gene expression 
levels (Northern analysis). Using HUVECs, they found that inhibition of adhesion molecule 
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expression occurred in a range of DHA concentrations that they said were achievable by 
normal dietary intake. Furthermore, the extent of inhibitory effects was paralleled with 
DHA incorporation into the cells and was inversely associated with the amount of n-6 fatty 
acids. In the present work, compared with other fatty acids studied, n-3 fatty acids 
demonstrated remarkable inhibition on adhesion molecule mRNA expression and my 
findings are in agreement with previous studies (De Caterina et al. 1999; Collie-Duguid & 
Wahle 1996; Weber et al. 1995), although they extend these studies by comparing effects 
on different endothelial cell types.  
 
All three n-3 fatty acids I studied (EPA, DPA, DHA reduced mRNA levels induced by LPS. 
High intakes of these fatty acids are associated with protection against cardiovascular 
disease (Nordoy et al. 2001; von Schacky 2003; Harris 2005) and can be used to treat some 
inflammatory conditions (Calder 2006; Sijben & Calder 2007; Calder 2008). Thus, the 
observed inhibitory actions of these fatty acids as observed here, may provide part of the 
explanation for their benefits in vivo.  
 
The present study demonstrates that the effects of fatty acids on adhesion molecule 
expression at the protein level is not always consistent with the effects seen at the 
transcriptional level. These observed differences in the inhibitory effects of fatty acids on 
specific adhesion molecule expression might vary according to endothelial types and also 
could relate to the method used.  
 
Most of the data previously available for the effects of n-3 fatty acids on adhesion molecule 
expression at the transcriptional level were obtained by Northern analysis. This method uses 
agarose gels for detection of PCR amplification at the end stage (plateau) of the PCR 
reaction. Real-time RT-PCR, on the other hand, as used here, is a much more precise 
quantification method allowing quantification of relative gene expression at a particular 
time. Moreover, to ensure accuracy in the quantification, data is normalized by the amount 
of RNA from a housekeeping gene measured in the same sample. Since I used a real-time 
RT-PCR method to assess differences of adhesion molecule expression at the 
transcriptional level, my results are likely to be more precise. The only limitation in the 
present study is sample size. Thus further work is highly recommended to confirm my 
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findings and subsequently to gain clearer picture of the effects of different fatty acids on 
inflammatory markers in relation to atherogenesis. 
 
5.6 Conclusion 
 
   n-3 Fatty acids, particularly EPA and DHA have become a focus of interest, and recent 
research and trial evidence have highlighted their effects, including as anti-inflammatory 
agents. Despite this progress, to date, the precise mechanisms by which n-3 fatty acids act 
remain poorly understood. In the present study, with the limitation of DHA data, EPA 
appears to be the most potent fatty acid inhibitor of adhesion molecule expression at the 
mRNA level as assessed by reverse transcription and real-time PCR. However, the 
mechanisms involved have not been extensively investigated (i.e. mRNA stability, 
transcription regulation, etc.).  Previous studies documented that this effect (anti-
inflammatory) may occur via the attenuation of the activated NF-κB transcription factor 
pathway (Wahle & Rotondo 1999; Hennig & Toborek 2000; Calder 2002). Studies that 
report effects of n-3 PUFAs on the NF-κB pathway will be described further in Chapter 6. 
My results also do not support the theory that the presence simply of a double bond within 
the structure of a fatty acid is a necessary requirement for alteration in endothelial function 
as suggested by De Caterina et al. (1998). Interestingly, SA (a saturated fatty acid), can act 
as both anti- and pro-inflammatory depending on the cell type. I also showed that both OA 
(a monounsaturated fatty acid) and arachidonic acid (an n-6 fatty acid) appear to inhibit 
some of the adhesion molecule expression at the transcriptional level. n-3 PUFAs were 
generally inhibitory and of all fatty acids tested EPA was the most potent. 
 
As I had seen in Chapter 4 for adhesion molecule protein expression, the effects of fatty 
acids on the adhesion molecule expression at the transcriptional level are fatty acid, 
adhesion molecule and endothelial cell specific. In general, the inhibitory effects of fatty 
acids are more pronounced in vein endothelial cells (i.e. HUVECs and HSaVECs) than 
arterial endothelial cells. More needs to be understood about the mechanisms by which fatty 
acids affect adhesion molecule gene and protein expression and to examine whether these 
effects seen in cell culture also occur in vivo.  
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Chapter 6 
 
General Discussion 
 
6.1 Overview 
 
  The present thesis was primarily aimed at examining the effects of long chain n-3 fatty 
acids, particularly EPA and DHA, on processes and outcomes relevant to cardiovascular 
disease (CVD). The focus of the human studies conducted was the most widely recognised 
conventional risk factor, namely the blood lipid profile and the newly recognised 
(emerging) risk factor inflammation. With regard to markers of inflammation I was 
especially interested in blood adhesion molecules. This is because leukocyte-endothelial 
adhesive interaction is amongst the earliest events in the atherosclerotic process, yet 
remains important throughout the progression of atherosclerosis. It has been reported that 
supplementation with fish oil results in reduced atherosclerosis in animal models (Weiner et 
al. 1986; Davis et al. 1987; Mortensen et al. 1998). Furthermore, large studies in humans 
(GISSI 2001; Yokoyama et al. 2007) reveal a cardio-protective effect of long chain n-3 
PUFAs which might be attributable to a combination of lipid-lowering and decreased 
inflammation (Calder 2002). Having studied inflammatory markers in healthy volunteers 
and in patients with advanced carotid atherosclerosis and observed some effects on soluble 
adhesion molecules suggesting an effect of the endothelium, I moved my focus to in vitro 
studies of human endothelial cells in order to identify whether individual fatty acids have 
different effects and whether cells of different origin respond differently to fatty acids. 
Thus, overall I conducted four separate but related studies: 
 
1) the effects of moderate dose of long-chain n-3 PUFAs (about 2.1 g/day of EPA plus 
DHA) on risk factors for cardiovascular disease in particular blood lipids and inflammatory 
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2) the effects of 1.8 g/day EPA plus DHA in the form of ethyl esters (Omacor) on blood 
lipids and inflammatory markers in patients awaiting carotid endarterectomy; 
 
3) the effects of selected fatty acids on adhesion molecule expression (at the protein level) 
in cultured human endothelial cells of different origins;  
 
4) the effects of selected fatty acids on adhesion molecule mRNA expression (at the 
transcriptional level) in cultured human endothelial cells of different origins.  
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6.2 The effects of Fish Oil Supplementation in vivo 
 
6.2.1 Fatty Acid Incorporation into Plasma or Plaque Phosphatidylcholine 
 
  In order for long chain n-3 fatty acids from fish oil to affect the plasma lipid profile and 
inflammatory markers, those fatty acids must appear in relevant pools such as plasma lipids. 
My findings from human studies showed that EPA and DHA were incorporated into plasma 
phosphatidylcholine (PC), whereby remarkably increased levels of these fatty acids at the 
end of supplementation were revealed. In the first study, 2.1 g/day EPA plus DHA resulted 
in a 363% increase in EPA and only a 13% increase in DHA. In this study, DHA was not 
significantly increased in any of the lipid fractions studied probably because the dose of 
DHA was only 300 mg/day compared with 1800 mg/day of EPA administered. In the 
second study, a dose of 1.8 g/day of EPA plus DHA (818 mg of EPA plus 675 mg of DHA) 
resulted in significantly increased EPA and DHA in plasma PC by 161% and 70%, 
respectively. Using the data from Rees et al. (2006) I plotted the percent change in EPA and 
DHA content of plasma PC as a function of supplemental EPA observed in both studies and 
found that the change in EPA I observed fits well on the dose-response curve. The increase 
in the proportion of EPA in plasma PC was accompanied by a significant decrease in 
proportion of n-6 fatty acids and it seems that EPA consistently more easily replaces 
dihomo-γ-linolenic acid (DGLA) and linoleic acid (LA) than arachidonic acid (ARA), in 
plasma phospholipids. It has been reported that increased dietary intake of LA leads to 
oxidation of low-density lipoprotein (LDL), and platelet aggregation, and interferes with the 
incorporation of essential fatty acids (EFA) in cell membrane phospholipids (Simopoulos 
2008). Thus the decrease in the proportion of LA is most likely of importance. For DHA 
incorporation, the data obtained did not fit well onto the dose-response curve from Rees et 
al. (2006). However if supplemental DHA was normalised according to EPA, then a dose-
response incorporation of DHA was observed. I also analysed the incorporation of PUFAs 
into atherosclerotic plaques since it is believed that if PUFAs are to affect plaque stability 
(Thies et al., 2005), they must be first incorporated into the plaque. It was found that there 
were no significant differences between groups for any fatty acid in plaque PC apart from 
EPA which was demonstrated to be significantly higher in the Omacor (n-3 fatty acid) 
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in the Omacor group was enough to enable incorporation into plaque PC. It appears that the 
dose of DHA however, is insufficient, since successful incorporation was not demonstrated. 
 
 
6.2.2 The Effects of Fish Oil Supplementation on Blood Pressure and Lipid Profile 
 
  In my first study involving normotensive, healthy subjects, there was no effect of fish oil 
supplementation on blood pressure. This is in agreement with a meta-analysis that identified 
that the blood pressure lowering effects of long chain n-3 fatty acids were greater in 
subjects that were older or hypertensive than those who were younger or normotensive 
(Geleijnse et al. 2002). In addition, Mori et al. (2000) reported that DHA was more 
effective compared with EPA in lowering blood pressure. Thus, the lack of blood pressure-
lowering in my study might due to insufficient dose of DHA. On the other hand, in the 
second study in which subjects were hypertensive and also on anti-hypertensive medication, 
both control and Omacor groups exhibited significant decreases in systolic and diastolic 
blood pressures. The effect of Omacor was similar to the effect of placebo, therefore ruling 
out any specific effect of EPA plus DHA on blood pressure.  
 
In terms of the blood lipid profile, results from my study in healthy subjects were consistent 
with other studies demonstrating that fish oil supplementation does not lower the 
concentration of blood cholesterol, and indeed may have slight total cholesterol, LDL-c and 
HDL-c raising effects (Katan et al. 1995; Harris et al. 1996). However, in the Omacor group 
whereby subjects also taking statins and lipid-lowering drugs, total cholesterol and TAG 
were significantly decreased by 13% and 20%, respectively. These effects were much more 
apparent in the Omacor group as compared to those seen in the placebo group. The 
reduction in total cholesterol with long chain n-3 PUFAs as demonstrated in my second 
study in carotid endarterectomy patients suggests that it may be a useful adjunct to lipid-
lowering therapy even though fish oil supplementation has been reported by others to 
increase total cholesterol by 5-10% (Harris 1997). My findings also in accordance with 
previous studies showing the beneficial effects of co-administration of statins and fish oil 
on the lipid profile (Durrington et al. 2001; Davidson et al. 2007; Mayer et al. 2007). Hence Chapter 6 General Discussion     254                             
 
 
it is suggested that fish oil supplementation be used in combination with statin treatment as 
an optimal lipid lowering strategy.  
 
 
6.2.3 The Effects of Fish Oil Supplementation on Plasma Inflammatory Markers 
 
    In terms of plasma inflammatory markers, again the anticipated effects of fish oil in 
healthy subjects were not as apparent as in carotid endarterectomy patients. The only 
beneficial effect of long chain n-3 fatty acids in the first study in healthy subjects was a 
significant difference between the fish oil and placebo groups in percent change from 
baseline for sICAM-1, with a reduction (about 10% from baseline) in the fish oil group. 
There was an inverse association between the levels of sICAM-1 and plasma PC DHA. This 
is the first time this relationship has been reported and it suggests that long chain n-3 
PUFAs, particularly DHA, are of importance in controlling inflammatory responses at the 
level of the vascular endothelium. The recent study of Paulo et al. (2008) on the effects of 
1.4 g/day n-3 PUFAs in young, healthy subjects also reported no significant effects on 
sICAM-1. In contrast, following Omacor supplementation, sE-selectin and sVCAM-1 were 
decreased significantly by 23% and 25%, respectively. Interestingly, the beneficial effect of 
Omacor was more pronounced in male subjects whereby IL-6 was also decreased compared 
to what was seen in of females. Based on correlation analysis between mRNA expression of 
inflammatory markers in plaque and plasma concentrations, it seems that soluble 
inflammatory markers cannot be used to reflect the expression of these molecules at the cell 
surface, i.e. in the vasculature or in the plaque. Integrating the findings of these two studies 
indicates that supplementation with the long chain n-3 PUFAs EPA and DHA reduces 
sICAM-1 (in healthy subjects), and sVCAM-1 and sE-selectin (both in carotid 
endarterectomy patients). Further in vitro experiments were performed using several fatty 
acids and different cell types in order to progress mechanistic understanding of the effects 
of long chain n-3 fatty acids. 
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6.3 The Effects of Fatty Acids on Adhesion Molecule Expression on 
Cultured Human Endothelial Cells 
 
  In order to systematically evaluate the effects of a range of fatty acids on endothelial 
adhesion molecules studies were conducted on five different cell lines. This was done in 
order to establish whether fatty acids behaved differently with arterial and venous cells; 
CVD is an arterial disease but most studies of fatty acids and adhesion molecules have used 
venous cells as models. Also it was thought possible that some of the discrepancies in the 
literature might be due to use of different cell lines. This is the first study comparing the 
effects of fatty acids on adhesion molecule expression using different endothelial cell types. 
Previously, work of this type focused upon human venous endothelial cells, including 
saphenous (De Caterina et al. 1994; De Caterina 1996; De Caterina & Libby 1998) or 
umbilical (Khalfoun et al. 1996; Collie-Duguid & Wahle 1996; Carluccio et al.1999). To 
date, there were no studies on the effects of long chain fatty acids on adhesion molecule 
expression performed using either arterial or aortic endothelial cells.  Hence, this is the first 
comparative study of the effects of fatty acids on adhesion molecule expression (at protein 
and mRNA levels) under similar experimental conditions using several types of endothelial 
cells. 
 
De Caterina et al. (1998) reported that the saturated fatty acids palmitate and stearate have 
no effects on endothelial activation. In relation to inflammation, in vitro and animal feeding 
studies also suggest that saturated fatty acids have limited impact on T lymphocyte 
proliferation, Th1-type and Th2-type cytokine production and NK cell activity (Calder 
1998). The lack of effect of dietary saturated fatty acids on NK cell activity is supported by 
human studies (Hebert et al. 1990; Rasmussen et al. 1994). In this study, however, I found 
that stearic acid can affect adhesion molecule expression, but it had different effects on 
different cell types and on different adhesion molecules. The effects seen at the protein 
level were not always consistent with the effects seen at the transcriptional level. In 
HUVECs and HUAECs, I found that the effect of stearic acid on VCAM-1 expression was 
consistent, at both protein and transcriptional levels. On the other hand, my results revealed 
that in the other endothelial cells studied, stearic acid significantly enhanced VCAM-1 
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analysed by real-time RT-PCR for gene expression. This is because the outcomes from real-
time RT-PCR are more accurate compared with ELISA due to method sensitivity, and in 
the real-time technique, data were also normalised to a housekeeping gene. Of note, 
consistent results (at protein and at mRNA levels) were obtained from endothelial cells that 
are from umbilical cord, irrespective of whether the cells were from vein or artery. 
Moreover, for ICAM-1 expression, only HAOECs exhibited similar results for both protein 
and gene expression. Therefore, saturated stearic acid can have down-regulatory effects on 
the expression of some inflammatory genes in some cells, while having neutral effects or 
even up-regulatory effects on genes associated with inflammation in other cells.  
 
For oleic acid which represents monounsaturated fatty acids, the present study also showed 
inconsistent results. Results revealed that the inhibitory effect was almost similar to that of 
stearic acid. In addition, not only VCAM-1 attenuation effects with oleic acid as 
demonstrated in HUVECs and HUAECs were observed, but decreased ICAM-1 mRNA 
expression was also demonstrated in both endothelial cell lines. Interestingly, my results 
also showed that the effects of stearic and oleic acid on E-selectin expression were similar 
amongst the endothelial cells studied, whereby in HUVECs, HUAECs and HCAECs, both 
these fatty acids resulted in increased E-selectin expression at protein levels.  
 
It has been known that in inflammatory conditions, 20-carbon PUFAs present in cellular 
membranes are converted to eicosanoids and the activity of these molecules depends on the 
nature of their precursors: when arachidonic acid (n-6) is present, strongly pro-
inflammatory molecules are released, meanwhile EPA-derived eicosanoids are weakly 
inflammatory. In relation to this, n-3 PUFAs increase the content of EPA-eicosanoids and 
decrease arachidonic acid in immune and endothelial cells leading to a decrease 
inflammatory activity. Likewise, oleic acid exhibits anti-inflammatory effects by preventing 
the release of particular chemotactic molecules (Garcia et al. 2006). Previously, Massaro & 
De Caterina (2002) reported decreased expression of a number of major pro-inflammatory 
proteins, such as endothelial leukocyte adhesion molecules by incorporation of oleic acid 
into total cell lipids. The mechanisms by which the effects of oleic acid on vascular 
dysfunction occur are believed through modulation of the endothelial activity that involves 
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molecules, and indeed in most cases by activation of nuclear factor κB (NFκB) by reactive 
oxygen species (Perona et al. 2006). 
 
My study revealed that the effect of n-6 arachidonic acid (ARA) on adhesion molecule 
expression, particularly on VCAM-1 was more pronounced as compared to that of stearic 
and oleic acids. VCAM-1 expression at the protein level was decreased significantly in all 
endothelial cells studied apart from HAOECs, even though no significant effect was 
observed using real-time RT-PCR for mRNA expression except from HUAECs. The 
decreased ICAM-1 expression at the protein level was only demonstrated in HUVECs, 
whereas E-selectin was attenuated at both protein and mRNA levels. 
 
Interest in the effects of ARA in modulating inflammation is based upon the roles of 
mediators derived from ARA which can be inhibited by the long chain n-3 PUFAs found in 
fish oils (Calder et al. 2002). It has been documented that n-6 fatty acids influence gene 
expression and tend to be pro-inflammatory. However, contrary to the pro-atherosclerotic 
effects of ARA and LA, there is also broad evidence that 15-LOX  metabolites of these 
fatty acids have anti-inflammatory effects. The 15-LOX arachidonic acid metabolite 15-
HETE inhibits superoxide production and polymorphonuclear neutrophil (PMN) migration 
across cytokine-activated endothelium and subsequently can be further metabolized to the 
anti-inflammatory lipoxins. These lipoxins promote vasorelaxation in the aorta and 
counteract the action of most other pro-inflammatory factors like leukotrienes and 
prostanoids (Wittwer & Hersberger 2007). 
  
Amongst the fatty acids studied in the present study, n-3 PUFAs are of great interest 
particularly EPA and DHA. These fatty acids are the major bioactive n-3 fatty acids that 
have long been recognized to modulate inflammatory responses (Calder 2001). In the 
present study, DHA had the greatest and the most consistent effects on adhesion molecule 
expression at the protein level. However, interpretation of this study at the mRNA level was 
hindered by limited DHA data available, leading to a conclusion from the data available 
that EPA is the most potent fatty acid inhibitor. Because inflammation is believed to be the 
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n-3 fatty acids, particularly EPA and DHA has been recommended (Ruxton et al 2004; 
Simopoulos 2008).  
 
The mechanism by which n-3 PUFAs affect the expression of inflammatory genes could be 
through direct actions on the intracellular signaling pathways that lead to inactivation of one 
or more transcription factors such as NF-κB (Ross et al. 1999; von Schacky et al. 2007). 
NF-κB is composed of homo- or heterodimeric complexes of at least five distinct subunits, 
such as p50, p52, p65 (RelA), c-Rel and Rel-B; however, the p50/p65 heterodimer is the 
predominant form of this transcription factor (Baeuerele 1998). NF-κB binding sites were 
identified in the promoter regions of genes encoding for adhesion molecules VCAM-1 
(Wang et al. 2008; Massaro et al. 2008), ICAM-1, and E-selectin (Massaro et al. 2008) and 
inflammatory cytokines (such as TNF-α, IL-1β, IL-6 or IL-8), growth factors and 
chemokines. Although other transcription factors are also required for expression of these 
genes, NF-κB constitutes an important component of their transcriptional regulation. 
Berliner et al. (1995) demonstrated that generation of inflammatory cytokines is dependent 
on activated NF-κB, and in turn, these cytokines can stimulate activation of this 
transcription factor. In relation to this, fish oil has been reported to decrease endotoxin 
induced activation of NF-κB in human monocytes (Lo et al. 1999), and this was linked with 
decreased IκB phosphorylation (Novak et al. 2003). The inhibition of NF-κB activation can 
be caused by mechanisms that produce the activation of PPAR or inhibition of Toll-like 
receptors (Torrejon et al. 2007). Evidence from in vitro studies (De Caterina & Massaro, 
2005) indicates that both EPA and DHA decrease agonist-induced activation of NF-κB and 
increase PPAR. In contrast, Goua et al. (2008) reported that reduction of ICAM-1 and 
VCAM-1 protein expression by n-3 PUFA was less dependent on the NF-κB pathway than 
reduction by conjugated linoleic acid which reflected the parallel attenuation of NF-κB 
activity. However, they suggested involvement of other transcription factors (i.e. activator 
protein-1, AP-1) in the fatty acid regulation of adhesion molecule expression. 
 
Besides the transcription factor NF-κB, AP-1 also appears to be most important in 
regulating the inflammatory process. Activation of AP-1 enhances the expression of 
inflammatory genes. AP-1 binding sites were identified in the promoter regions of genes 
encoding for VCAM-1 (Ahmad et al. 1998; Goua et al. 2008), ICAM-1 (Stade et al. 1990; Chapter 6 General Discussion     259                             
 
 
Goua et al. 2008) and E-selectin (Lee et al. 2004). The schematic diagram is proposed 
(Figure 6.1), in which n-3 fatty acids particularly EPA and DHA would act downstream to 
receptors and likely at the level of reactive oxygen species (ROS). This ROS appears to be a 
critical mediator of NF-κB activation and would activate the NF-κB system transcription 
factors, and most likely via IκB degradation and subsequent translocation of free active NF-
κB heterodimer (relA-p50) into the nucleus and further binding to specific consensus 
sequences in a number of NF-κB-responsive genes, including genes for VCAM-1, ICAM-1 
and E-selectin (De Caterina & Massaro 2005). 
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  Various receptors for various 
pro-atherogenic stimuli 
(cytokines, LDL, etc) 
 
 
FIGURE 6.1: Schematic Diagram of Anti-inflammatory Pathway Induced by n-3 Fatty 
Acids 
 
In the present work both in vivo and in vitro studies demonstrated that the beneficial effects 
of EPA and DHA are more pronounced in inflammatory conditions than in normal or 
‘healthy’ conditions. This is not surprising since fish oil supplementation has been shown to 
be more effective in those who already manifested the disease outcomes. However, even 
though no significant enhancement of immune function in relation to adhesion molecule 
expression has been shown in normal cells, still it is very difficult to conclude whether any 
enhancement when cells are healthy is a good sign. Based on these in vivo and in vitro 
studies, I conclude that fish oil supplementation is likely to be more beneficial for patients 
who already have developed a disease involving inflammation than for healthy individuals. 
Therefore I do not think that there is a need to increase the current recommendation of EPA 
and DHA intake to a higher level especially to those who are healthy.  
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6.4 Study Limitations and Suggestions for Further Work 
   
   Based on the current studies, it is important to further examine whether the beneficial 
effects seen in vitro also occur in vivo and if so, what the minimum dose of EPA or DHA 
required to induce these effects is. One of the limitations of my in vitro experiments is 
sample size. Therefore, future work is warranted to increase the sample size to improve 
confidence in the findings. There is an opportunity to study more fatty acids than studied 
here.  Moreover, further work can be carried out in order to investigate whether the effect of 
fatty acids on adhesion molecule expression is mediated via an effect on the NF-κB 
pathway or on other pathways. The precise underlying mechanisms remain to be clarified, 
and it has been proposed that these might involve PPAR, NF-κB ,  A P - 1  a n d / o r  t h e  
eicosanoid system.  
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